Patent Publication Number: US-2023149535-A1

Title: Vaccines for coronavirus and methods of using the same

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application claims priority to U.S. Provisional Application No. 63/008,733 filed Apr. 11, 2020, the entire content of which is hereby incorporated by reference in its entirety into the present application. 
    
    
     SUBMISSION OF SEQUENCE LISTING 
     The Sequence Listing associated with this application is filed in electronic format as a text file and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is 37925_0008_SL_ST25 and the size of the text file is 675 KB. 
     BACKGROUND 
     Vaccination is an extremely important public health measure that has demonstrated prophylactic and therapeutic utility against many infectious diseases [1-3] , and impacted some forms of cancer [4] . In the past decade, advances in material engineering has allowed for the development and study of a new generation of vaccines, such as nanoparticle vaccines [5-7] . Hepatitis B and human papillomavirus (HPV) vaccines are examples of such self-assembling virus-like particles which have impacted millions of people [8, 9] . Nanoparticles may come in several shapes and forms. Inorganic materials [10, 11] , nontoxic phospholipids [12] , virus-like particles (VLPs) or self-assembling protein nanoparticles (SAPN) [13-16]  can all scaffold and present antigens in repetitive multimeric manners to robustly stimulate immunity in animal models [16-18] . An exemplary disclosure on compositions comprising such self-assembling vaccines and methods of preparing and using the same was provided in PCT application No. PCT/US2019/68444 filed on Dec. 23, 2019 based on U.S. Provisional Application No. 62/784,318 filed Dec. 21, 2018, each of which is incorporated by reference in its entirety. 
     Another example of such new generation of vaccines are recombinant native-like viral trimer vaccines [70-72] . An exemplary disclosure on compositions comprising nucleic acids encoding such structural trimers and methods of preparing and using the same was provided in PCT application No. PCT/US2020/26948 filed on Apr. 6, 2020 based on U.S. Provisional Application No. 62/829,629 filed on Apr. 4, 2019, each of which is incorporated by reference in its entirety. 
     Coronaviruses are a group of viruses that cause diseases in mammals and birds. Coronaviruses were first discovered in the 1960s. The earliest virus from the family of Coronaviridae discovered were infectious bronchitis virus in chickens and two viruses from the nasal cavities of human patients with the common cold that were subsequently named human coronavirus 229E (HCoV-229E) and human coronavirus OC43 (HCoV-OC43). Other members of this family have since been identified, including SARS-CoV in 2003, HCoV NL63 in 2004, HKU1 in 2005, MERS-CoV in 2012, and SARS-CoV-2 (formerly known as 2019-nCoV or novel coronavirus 2019, which caused the global COVID-19 pandemic). Most of these have involved serious respiratory tract infections. 
     Symptoms of coronavirus infection vary in species. In chicken, for instance, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. In humans, coronaviruses cause respiratory tract infections that are typically mild, such as some cases of the common cold (among other possible causes, predominantly rhinoviruses), though rarer forms can be lethal, such as SARS, MERS, and COVID-19. 
     Coronaviruses vary significantly in risk factor. Some can kill more than 30% of those infected (such as MERS-CoV), and some are relatively harmless, such as the common cold. Coronaviruses cause flu-like symptoms, such as fever and sore throat from swollen adenoids, primarily in the winter and early spring seasons. Coronaviruses can cause pneumonia—either direct viral pneumonia or a secondary bacterial pneumonia—and may cause bronchitis—either direct viral bronchitis or a secondary bacterial bronchitis. The much publicized human coronavirus discovered in 2003, SARS-CoV, which causes severe acute respiratory syndrome (SARS), has a unique pathogenesis because it causes both upper and lower respiratory tract infections. The novel human coronavirus discovered in 2019, SARS-CoV-2, causes mild symptoms, most often fever, dry cough, and shortness of breath, to complications including pneumonia and acute respiratory distress syndrome. 
     SUMMARY OF EMBODIMENTS 
     Since it was emerged in late 2019, SARS-CoV-2 was rapidly characterized as a new member of the betacoronavirus genus, closely related to several bat coronaviruses and to severe acute respiratory syndrome coronavirus (SARS-CoV). Compared to SARS-CoV, however, SARS-CoV-2 appears to be more readily transmitted from human to human. 
     SARS-CoV-2 makes use of a densely glycosylated Spike (S) protein to gain entry into host cells. The S protein is a trimeric class I fusion protein that exists in a metastable prefusion conformation that undergoes a substantial structural rearrangement to fuse the viral membrane with the host cell membrane [73, 74] . This process is triggered when the S1 subunit of the S protein binds to a host cell receptor. Receptor binding destabilizes the prefusion trimer, resulting in shedding of the S1 subunit and transition of the S2 subunit to a stable postfusion conformation [75] . To engage a host cell receptor, the receptor-binding domain (RBD) of S1 undergoes hinge-like conformational movements that transiently hide or expose the determinants of receptor binding. These two states are referred to as the “down” conformation and the “up” conformation, where down corresponds to the receptor-inaccessible state and up corresponds to the receptor-accessible state, which is thought to be less stabler [76-79] . Because of the indispensable function of the S protein, it represents a target for vaccine design and development. See Wrapp et al., Science, 2020, 367, 1260-1263. 
     In one aspect, the disclosure relates to a composition comprising an expressible nucleic acid sequence. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide and a second nucleic acid sequence encoding a viral antigen from a virus of the family Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a third nucleic acid sequence encoding a leader sequence. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding a linker, said nucleic acid sequence positioned between the first nucleic acid sequence and the second nucleic acid sequence in the 5′ to 3′ orientation. 
     In other embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence and a second nucleic acid sequence encoding a soluble viral trimer or a soluble monomer thereof, wherein the soluble viral trimer or the soluble monomer thereof is from a virus of the family Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a third nucleic acid sequence encoding a linker. In some embodiments, the soluble viral trimer or the soluble monomer thereof comprises at least a portion of SARS-CoV-2 spike protein. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding a self-assembling polypeptide or a functional fragment or variant thereof. 
     In some embodiments, the disclosure relates to a vaccine comprising a polypeptide. In some embodiments, the polypeptide comprises a scaffold domain comprising a self-assembling polypeptide and an antigen domain comprising a viral antigen from a virus of the family Coronaviridae. In some embodiments, the polypeptide further comprises a leader sequence. In some embodiments, the polypeptide further comprises a linker domain comprising a linker peptide located between the scaffold domain and the antigen domain. In some embodiments, the polypeptide comprises at least 70% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88 or SEQ ID NO: 91, or a functional fragment or variant thereof. 
     In some embodiments, the polypeptide comprises a leader sequence and an antigen domain comprising a soluble viral trimer or a soluble monomer thereof, wherein the soluble viral trimer or the soluble monomer thereof is from a virus of the family Coronaviridae. In some embodiments, the polypeptide further comprises one or a plurality of linker. In some embodiments, the soluble viral trimer or the soluble monomer thereof comprises at least a portion of SARS-CoV-2 spike protein. In some embodiments, the polypeptide further comprises a self-assembling polypeptide or a functional fragment or variant thereof. In some embodiments, the polypeptide comprises at least 70% sequence identity to SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. 
     In a further aspect, the disclosure relates to a cell comprising an expressible nucleic acid sequence. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide and a second nucleic acid sequence encoding a viral antigen from a virus of the family Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a third nucleic acid sequence encoding a leader sequence. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding a linker, said nucleic acid sequence positioned between the first nucleic acid sequence and the second nucleic acid sequence in the 5′ to 3′ orientation. In some embodiments, the expressible nucleic acid sequence comprises a nucleic acid sequence encoding a leader sequence, a nucleic acid sequence encoding a scaffold domain, a nucleic acid sequence encoding a linker, and a nucleic acid sequence encoding a viral antigen from Coronaviridae, in the 5′ to 3′ orientation. 
     In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence and a second nucleic acid sequence encoding a soluble viral trimer or a soluble monomer thereof, wherein the soluble viral trimer or the soluble monomer thereof is from a virus of the family Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a third nucleic acid sequence encoding a linker. In some embodiments, the soluble viral trimer or the soluble monomer thereof comprises at least a portion of SARS-CoV-2 spike protein. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding a self-assembling polypeptide or a functional fragment or variant thereof. 
     In some embodiments, the self-assembling polypeptide of the disclosure is from  Aquifex aeolicus, Helicobacter pylori, Pyrococcus furiosus  or  Thermotoga maritima . In some embodiments, the self-assembling polypeptide of the disclosure comprises at least 70% sequence identity to SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20, or a functional fragment or variant thereof. 
     In some embodiments, the viral antigen of the disclosure is an antigen from a coronavirus. In some embodiments, the viral antigen is an antigen from SARS-CoV-2. In some embodiments, the viral antigen comprises at least 70% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. 
     In some embodiments, the leader sequence of the disclosure comprises at least 70% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof. 
     In some embodiments, the linker of the disclosure comprises at least 70% sequence identity to SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. 
     In some embodiments, the expressible nucleic acid sequence of the disclosure comprises at least 70% sequence identity to SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89 or SEQ ID NO: 90, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence of the disclosure encodes a polypeptide comprising at least 70% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88 or SEQ ID NO: 91, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence of the disclosure comprises at least 70% sequence identity to SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence of the disclosure encodes a polypeptide comprising at least 70% sequence identity to SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. 
     In some embodiments, the expressible nucleic acid sequence of the disclosure is operably linked to one or a plurality of regulatory sequences. In some embodiments, the expressible nucleic acid sequence of the disclosure is comprised in a nucleic acid molecule. In some embodiments, the expressible nucleic acid sequence of the disclosure is comprised in a nucleic acid molecule which is a plasmid. 
     In some embodiments, the disclosure relates to a pharmaceutical composition comprising a pharmaceutically effective amount of any of the composition disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises any of the disclosed composition from about 1 to about 100 micrograms. In some embodiments, the pharmaceutical composition comprises any of the disclosed composition from about 1 to about 20 micrograms. 
     In some embodiments, the disclosure relates to a method of vaccinating a subject comprising administering a therapeutically effective amount of any of the disclosed pharmaceutical composition to the subject. 
     In other aspects, the disclosure relates to a method of inducing an immune response in a subject comprising administering to the subject any of the disclosed pharmaceutical composition. In some embodiments, the immune response is an antigen-specific immune response against SARS-CoV-2. In some embodiments, the subject is diagnosed with or suspected of having a SARS-CoV-2 infection. In some embodiments, the immune response is an antigen-specific immune response against a SARS-CoV-2 antigen. In some embodiments, the immune response is an antigen-specific immune response against a SARS-CoV-2 spike antigen. 
     In some embodiments, the disclosure relates to a method of neutralizing one or a plurality of viruses in a subject comprising administering to the subject any of the disclosed pharmaceutical composition. 
     In some embodiments, the disclosure relates to a method of stimulating a therapeutically effective antigen-specific immune response against a virus in a mammal infected with a virus comprising administering a therapeutically effective amount of any of the disclosed pharmaceutical composition. In some embodiments, the subject is infected with SARS-CoV-2. 
     In some embodiments, the disclosure relates to a method of inducing expression of a self-assembling vaccine in a subject comprising administering any of the disclosed pharmaceutical composition. In some embodiments, the method is free of administering any polypeptide directly to the subject. 
     In some embodiments, the administering in any of the disclosed methods is accomplished by oral administration, parenteral administration, sublingual administration, transdermal administration, rectal administration, transmucosal administration, topical administration, inhalation, buccal administration, intrapleural administration, intravenous administration, intraarterial administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, intranasal administration, intrathecal administration, and intraarticular administration, or a combination thereof. In some embodiments, the therapeutically effective amount used in any of the disclosed methods is from about 1 to about 2000 micrograms of the expressible nucleic acid sequence. In some embodiments, the therapeutically effective amount used in any of the disclosed methods is from about 1 to about 30 micrograms of the expressible nucleic acid sequence. In some embodiments, the disclosed method is free of activating any mannose-binding lectin or complement process. In some embodiments, the subject is a human. In some embodiments, the therapeutically effective dose used in any of the disclosed method is from about 0.3 microgram of the composition per kilogram of the subject to about 30 micrograms per kilogram of the subject. In some embodiments, the therapeutically effective dose used in any of the disclosed method is from about 0.001 microgram of composition per kilogram of the subject to about 0.05 microgram per kilogram of the subject. 
     The disclosure further relates to a DNA vaccine comprising an expressible nucleic acid sequence encoding a polypeptide comprising at least about 70% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88 or SEQ ID NO: 91, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence of the disclosed DNA vaccine comprises at least about 70% sequence identity to SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83, SEQ ID NO: 86, SEQ ID NO: 89, SEQ ID NO: 92, SEQ ID NO: 95, SEQ ID NO: 98, SEQ ID NO: 101, SEQ ID NO: 104, SEQ ID NO: 107, SEQ ID NO: 110, SEQ ID NO: 113, SEQ ID NO: 116, SEQ ID NO: 119, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 128, SEQ ID NO: 131, SEQ ID NO: 134, SEQ ID NO: 137, SEQ ID NO: 140, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 149, SEQ ID NO: 152, SEQ ID NO: 155 or SEQ ID NO: 158, or a functional fragment or variant thereof. In some embodiments, the disclosed DNA vaccine further comprises a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient further comprises an adjuvant. 
     The disclosure also relates to a RNA vaccine comprising an expressible nucleic acid sequence encoding a polypeptide comprising at least about 70% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88 or SEQ ID NO: 91, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence of the disclosed RNA vaccine comprises at least about 70% sequence identity to SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 84, SEQ ID NO: 87, SEQ ID NO: 90, SEQ ID NO: 93, SEQ ID NO: 96, SEQ ID NO: 99, SEQ ID NO: 102, SEQ ID NO: 105, SEQ ID NO: 108, SEQ ID NO: 111, SEQ ID NO: 114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO: 123, SEQ ID NO: 126, SEQ ID NO: 129, SEQ ID NO: 132, SEQ ID NO: 135, SEQ ID NO: 138, SEQ ID NO: 141, SEQ ID NO: 144, SEQ ID NO: 147, SEQ ID NO: 150, SEQ ID NO: 153, SEQ ID NO: 156 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the disclosed RNA vaccine further comprises a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient further comprises an adjuvant. 
     The disclosure relates to a viral particle or a self-assemblying particle comprising either a pharmaceutically effective amount of antigen from Coronaviridae in a trimer configuration and/or a viral particle comprising a pharmaceutically effective amount of any nuclec acid sequence disclosed herein. In some embodiments, the viral particle is an adeno-associated vector (AAV) or lentiviral vector. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed method and compositions. 
         FIG.  1 A- 1 B  show the structure of SARS-CoV-2 in the prefusion conformation.  FIG.  1 A  is a schematic of SARS-CoV-2 S primary structure grayscaled by domain. Domains that could not be visualized in the final map are colored white. SS: signal sequence; S2′: S2′ protease cleavage site; FP: fusion peptide; HR1: heptad repeat 1; CH: central helix; CD: connector domain; HR2: heptad repeat 2; TM: transmembrane domain; CT: cytoplasmic tail. Arrows denote protease cleavage sites.  FIG.  1 B  shows the side and top views of the prefusion structure of the SARS-CoV-2 protein with a single RBD in the up conformation. The two RBD down protomers are shown as cryo-EM density in either white or gray and the RBD up protomer is shown in ribbons grayscaled corresponding to the schematic in (A). Source: Wrapp et al., Science, 2020, 367, 1260-1263. 
         FIG.  2    shows that the fusion peptide from SARS-CoV2 was scaffolded onto a modified version of Lumazine Synthase (60mer) with an expression domain as a genetic fusion. SARS-CoV-2 fusion peptide nanoparticle shown on the left is decorated by sixty copies of the fusion peptide. 
         FIG.  3 A- 3 B  depict the expression of 2 SARS-CoV-2 fusion peptide nanoparticle designs.  FIG.  3 A  depicts the expression of construct WuhanS_FP_L9GT60_pVax.  FIG.  3 B  depicts the expression of construct WuhanS_FP12_L9GT60_pVax. For SARS-Cov2 fusion peptide purification, DNA was maxiprepped and transfected into Expi293 cells with PEI. Constructs were harvested on day 6. Constructs were purified by lectin chromatography and run on a size-exclusion column (GE Superdex S6 increase). Control nanoparticles elute at ˜12.5 ml using the same protocols. 
         FIG.  4 A- 4 E  show the results of SARS-CoV-2 fusion peptide binding ELISA.  FIG.  4 A : Week 1 post vaccination;  FIG.  4 B : Week 2 post vaccination;  FIG.  4 C : Week 3 post vaccination;  FIG.  4 D : Week 4 post vaccination;  FIG.  4 E : Comparison of endpoint titers to WuFuse1 between WuhanS_FP12_L9GT60_pVax (“S_FP12_L9GT60”) and WuhanS_FP_L9GT60_pVax (“S_FP_L9GT60”). ELISA plates were coated with 2 μg/mL streptavidin at room temperature for 8 hours and then blocked overnight at 4° C. The next day, the plates were incubated with fusion peptide at 2 μg/mL at room temp for 2 hours and then with sera at 37° C. for 2 hours, followed by addition of anti-mouse IgG (H+L)-HRP to the plates. The plates were developed with TMB substrates for 5 minutes, absorbances at 450 nm and 570 nm were recorded. 
         FIG.  5 A- 5 E  show the results of SARS-CoV-2 full-length spike protein binding ELISA.  FIG.  5 A : Week 1 post vaccination;  FIG.  5 B : Week 2 post vaccination;  FIG.  5 C : Week 3 post vaccination;  FIG.  5 D : Week 4 post vaccination;  FIG.  5 E : Comparison of endpoint titers to SARS-CoV-2 full-length spike protein (“FL SARS2 Spike”) between WuhanS_FP12_L9GT60_pVax (“S_FP12_L9GT60”) and WuhanS_FP_L9GT60_pVax (“S_FP_L9GT60”). ELISA plates were coated with 1 μg/mL anti-histine antibody at room temp for 8 hours and then blocked overnight at 4° C. The next day, the plates were incubated with His-tagged SARS-CoV-2 spike protein at 2 μg/mL at room temperature for 2 hours and then with sera at 37° C. for 2 hours, followed by addition of anti-mouse IgG (H+L)-HRP to the plates. The plates were developed with TMB substrates for 5 minutes, absorbances at 450 nm and 570 nm were recorded. 
     
    
    
     DETAILED DESCRIPTION 
     The disclosed method and compositions may be understood more readily by reference to the following detailed description of particular embodiments and the examples included therein and to the figures and their previous and following description. It is to be understood that the disclosed method and compositions are not limited to specific synthetic methods, specific analytical techniques, or to particular reagents unless otherwise specified, and, as such, may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure which will be limited only by the appended claims. 
     Definitions 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. 
     It must be noted that as used herein and in the appended claims, the singular forms “a”, “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a nucleic acid sequence” includes a plurality of nucleotides that are formed, reference to “the nucleic acid sequence” is a reference to one or more nucleic acid sequences and equivalents thereof known to those skilled in the art, and so forth. 
     Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, also specifically contemplated and considered disclosed is the range from the one particular value and/or to the other particular value unless the context specifically indicates otherwise. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another, specifically contemplated embodiment that should be considered disclosed unless the context specifically indicates otherwise. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint unless the context specifically indicates otherwise. The term “about” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. 
     As used herein, the terms “activate,” “stimulate,” “enhance” “increase” and/or “induce” (and like terms) are used interchangeably to generally refer to the act of improving or increasing, either directly or indirectly, a concentration, level, function, activity, or behavior relative to the natural, expected, or average, or relative to a control condition. “Activate” in context of an immunotherapy refers to a primary response induced by ligation of a cell surface moiety. For example, in the context of receptors, such stimulation entails the ligation of a receptor and a subsequent signal transduction event. Further, the stimulation event may activate a cell and upregulate or downregulate expression or secretion of a molecule. Thus, indirect or direct ligation of cell surface moieties, even in the absence of a direct signal transduction event, may result in the reorganization of cytoskeletal structures, or in the coalescing of cell surface moieties, each of which could serve to enhance, modify, or alter subsequent cellular responses. As used herein, the terms “activating CD8+ T cells” or “CD8+ T cell activation” refer to a process (e.g., a signaling event) causing or resulting in one or more cellular responses of a CD8+ T cell (CTL), selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. As used herein, an “activated CD8+ T cell” refers to a CD8+ T cell that has received an activating signal, and thus demonstrates one or more cellular responses, selected from proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. Suitable assays to measure CD8+ T cell activation are known in the art and are described herein. 
     The term “combination therapy” as used herein is meant to refer to administration of one or more therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time; as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. In some embodiments, the therapeutic agents are administered within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes within each other. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dose having a fixed ratio of each therapeutic agent or in multiple, individual doses for each of the therapeutic agents. For example, one combination of the present disclosure may comprise a pooled sample of one or more nucleic acid molecules comprising one or a plurality of expressible nucleic acid sequences and an adjuvant and/or an anti-viral agent administered at the same or different times. In some embodiments, the pharmaceutical composition of the disclosure can be formulated as a single, co-formulated pharmaceutical composition comprising one or more nucleic acid molecules comprising one or a plurality of expressible nucleic acid sequences and one or more adjuvants and/or one or more anti-viral agents. As another example, a combination of the present disclosure (e.g., DNA or RNA vaccines and anti-viral agent) may be formulated as separate pharmaceutical compositions that can be administered at the same or different time. As used herein, the term “simultaneously” is meant to refer to administration of one or more agents at the same time. For example, in certain embodiments, antiviral vaccine or immunogenic composition and antiviral agents are administered simultaneously). Simultaneously includes administration contemporaneously or immediately sequentially, that is during the same period of time. In certain embodiments, the one or more agents are administered simultaneously in the same hour, or simultaneously in the same day. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, sub-cutaneous routes, intramuscular routes, direct absorption through mucous membrane tissues (e.g., nasal, mouth, vaginal, and rectal), and ocular routes (e.g., intravitreal, intraocular, etc.). The therapeutic agents can be administered by the same route or by different routes. For example, one component of a particular combination may be administered by intravenous injection while the other component(s) of the combination may be administered intramuscularly only. The components may be administered in any therapeutically effective sequence. A “combination” embraces groups of compounds or non-small chemical compound therapies useful as part of a combination therapy. In some embodiments, the therapeutic agent is an anti-retroviral therapy, (such as one or a combination of efavirenz, lamivudine and tenofovir disoproxil fumarate) or anti-flu therapy (such as TamiFlu®). In some embodiments, the therapeutic agent is one or a combiantion of: abacavir/dolutegravir/lamivudine (Triumeq), dolutegravir/rilpivirine (Juluca), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild), elvitegravir/cobicistat/emtricitabine/tenofovir alafenami de (Genvoya), efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera), emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey), bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy). In some embodiments, the therapeutic agent is one or a combination of a reverse transcrioptase inhibitor of a retrovirus such as efavirenz (Sustiva), etravirine (Intelence), nevirapine (Viramune), nevirapine extended-release (Viramune XR), rilpivirine (Edurant), delavirdine mesylate (Rescriptor). In some embodiments, the therapeutic agent is one or a combination of a protease inhibitor of a retrovirus, such as: atazanavir/cobicistat (Evotaz), darunavir/cobicistat (Prezcobix), lopinavir/ritonavir (Kaletra), ritonavir (Norvir), atazanavir (Reyataz), darunavir (Prezista), fosamprenavir (Lexiva), tipranavir (Aptivus). 
     As used herein, “expression” refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA (or administered mRNA) is translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as “gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell. In some embodiments, the at least one expressible nucleic acid sequence comprises only DNA nucleotides, RNA nucleotides or comprises both RNA and DNA nucleotides. In some embodiments, the at least one expressible nucleic acid consist of RNA. In some embodiments, the at least one expressible nucleic acid consist of DNA. 
     The terms “functional fragment” means any portion of a polypeptide or nucleic acid sequence from which the respective full-length polypeptide or nucleic acid relates that is of a sufficient length and has a sufficient structure to confer a biological affect that is at least similar or substantially similar to the full-length polypeptide or nucleic acid upon which the fragment is based. In some embodiments, a functional fragment is a portion of a full-length or wild-type nucleic acid sequence that encodes any one of the nucleic acid sequences disclosed herein, and said portion encodes a polypeptide of a certain length and/or structure that is less than full-length but encodes a domain that still biologically functional as compared to the full-length or wild-type protein. In some embodiments, the functional fragment may have a reduced biological activity, about equivalent biological activity, or an enhanced biological activity as compared to the wild-type or full-length polypeptide sequence upon which the fragment is based (such wild-type or full length sequences “reference sequences” or each individually a “reference sequence”). In some embodiments, the functional fragment is derived from the sequence of an organism, such as a human. In such embodiments, the functional fragment may retain about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity to the wild-type human sequence upon which the sequence is derived. In some embodiments, the functional fragment may retain about 85%, 80%, 75%, 70%, 65%, or 60% sequence identity to the wild-type sequence upon which the sequence is derived. 
     By “fragment” is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or about 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more nucleotides or amino acids. 
     “Optional” or “optionally” means that the subsequently described event, circumstance, or material may or may not occur or be present, and that the description includes instances where the event, circumstance, or material occurs or is present and instances where it does not occur or is not present. 
     The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified unless clearly indicated to the contrary. Thus, as a non-limiting example, a reference to “A and/or B,” when used in conjunction with open-ended language such as “comprising” can refer, in some embodiments, to A without B (optionally including elements other than B); in another embodiments, to B without A (optionally including elements other than A); in yet another embodiments, to both A and B (optionally including other elements); etc. 
     As used herein in the specification and in the claims, “or” should he understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e. “one or the other but not both”) when preceded by terms of exclusivity, “either,” “one of,” “only one of,” or “exactly one of” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law. 
     As used herein an “antigen” is meant to refer to any substance that elicits an immune response. 
     As used herein, the term “electroporation,” “electro-permeabilization,” or “electro-kinetic enhancement” (“EP”), are used interchangeably and are meant to refer to the use of a transmembrane electric field pulse to induce microscopic pathways (pores) in a bio-membrane; their presence allows biomolecules such as plasmids, oligonucleotides, siRNA, drugs, ions, and/or water to pass from one side of the cellular membrane to the other. In some of the disclosed methods of treatment or prevention, the method comprises a step of electroporation of a subject&#39;s tissue for a sufficient time and with a sufficient electrical field capable of inducing uptake of the pharmaceutical compositions disclosed herein into the antigen-presenting cells. In some embodiments, the cells are antigen presenting cells. 
     The term “pharmaceutically acceptable excipient,” “pharmaceutically acceptable carrier” or “pharmaceutically acceptable diluent” as used herein is meant to refer to an excipient, carrier or diluent that can be administered to a subject, together with an agent or the pharmaceutical compositions disclosed herein, and which is inert or fails to eliminate the pharmacological activity of the active agent of the pharmaceutical composition. In some embodiments, the pharmaceutically acceptable carrier does fails to destroy or is incapable of eliminating the pharmacological activity of an active agent/vaccine and and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the active agent. The term “pharmaceutically acceptable salt” of nucleic acids as used herein may be an acid or base salt that is generally considered in the art to be suitable for use in contact with the tissues of human beings or animals without excessive toxicity, irritation, allergic response, or other problem or complication. Such salts include mineral and organic acid salts of basic residues such as amines, as well as alkali or organic salts of acidic residues such as carboxylic acids. Specific pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, suifanilic, formic, toluenesulfonie, methanesulfonic, benzene sulfonic, ethane disulfonic, 2-hydroxyethyl sulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenyiacetic, alkanoic such as acetic, HOOC—(CH 2 )n-COOH where n is 0-4, and the like. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. Those of ordinary skill in the art will recognize from this disclosure and the knowledge in the art that further pharmaceutically acceptable salts for the pooled viral specific antigens or polynucleotides provided herein, including those listed by Remington&#39;s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985). In general, a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in an appropriate solvent. 
     As used herein, the terms “prevent,” “preventing,” “prevention,” “prophylactic treatment,” and the like, are meant to refer to reducing the probability of developing a disease or condition in a subject, who does not have, but is at risk of or susceptible to developing a disease or condition. 
     As used herein, the term “purified” means that the polynucleotide or polypeptide or fragment, variant, or derivative thereof is substantially free of other biological material with which it is naturally associated, or free from other biological materials derived, e.g., from a recombinant host cell that has been genetically engineered to express the polypeptide of the present disclosure. That is, e.g., a purified polypeptide of the present disclosure is a polypeptide that is at least from about 70 to 100% pure, i.e., the polypeptide is present in a composition wherein the polypeptide constitutes from about 70 to about 100% by weight of the total composition. In some embodiments, the purified polypeptide of the present disclosure is from about 75% to about 99% by weight pure, from about 80% to about 99% by weight pure, from about 90 to about 99% by weight pure, or from about 95% to about 99% by weight pure. 
     The terms “subject,” “individual,” and “patient” are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murine, simians, humans, farm animals, cows, pigs, goats, sheep, horses, dogs, sport animals, and pets. Tissues, cells and their progeny obtained in vivo or cultured in vitro are also encompassed by the definition of the term “subject.” The term “subject” is also used throughout the specification in some embodiments to describe an animal from which a cell sample is taken or an animal to which a disclosed cell or nucleic acid sequences have been administered. In some embodiment, the subject is a human. For treatment of those conditions which are specific for a specific subject, such as a human being, the term “patient” may be interchangeably used. In some instances in the description of the present disclosure, the term “patient” will refer to human patients suffering from a particular disease or disorder. In some embodiments, the subject may be a non-human animal. The term “mammal” encompasses both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murine, bovines, equines, caprine, and porcines. 
     The term “therapeutic effect” as used herein is meant to refer to some extent of relief of one or more of the symptoms of a disorder (e.g., SARS-CoV-2 infection) or its associated pathology. A “therapeutically effective amount” as used herein is meant to refer to an amount of an agent which is effective, upon single or multiple dose administration (such as a first, second and/or third booster) to the cell or subject, in prolonging the survivability of the patient with such a disorder, reducing one or more signs or symptoms of the disorder, preventing or delaying, and the like beyond that expected in the absence of such treatment. A “therapeutically effective amount” is intended to qualify the amount required to achieve a therapeutic effect. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the “therapeutically effective amount” (e.g., ED50) of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the present disclosure employed in a pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. 
     The terms “treat,” “treated,” “treating,” “treatment,” and the like as used herein are meant to refer to reducing or ameliorating a disorder and/or symptoms associated therewith (e.g., a viral infection). “Treating” can refer to administration of the DNA and/or RNA vaccines described herein to a subject after the onset, or suspected onset, of a viral infection. “Treating” includes the concepts of “alleviating,” which refers to lessening the frequency of occurrence or recurrence, or the severity, of any symptoms or other ill effects related to a virus and/or the side effects associated with viral therapy. The term “treating” also encompasses the concept of “managing” which refers to reducing the severity of a particular disease or disorder in a patient or delaying its recurrence, e.g., lengthening the period of remission in a patient who had suffered from the disease. It is appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition, or symptoms associated therewith be completely eliminated. 
     For any therapeutic agent described herein the therapeutically effective amount may be initially determined from preliminary in vitro studies and/or animal models. A therapeutically effective dose may also be determined from human data. The applied dose can be adjusted based on the relative bioavailability and potency of the administered agent. Adjusting the dose to achieve maximal efficacy based on the methods described above and other well-known methods is within the capabilities of the ordinarily skilled artisan. General principles for determining therapeutic effectiveness, which may be found in Chapter 1 of Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill (New York) (2001), incorporated herein by reference, are summarized below. Pharmacokinetic principles provide a basis for modifying a dosage regimen to obtain a desired degree of therapeutic efficacy with a minimum of unacceptable adverse effects. In situations where the drug&#39;s plasma concentration can be measured and related to the therapeutic window, additional guidance for dosage modification can be obtained. Drug products are considered to be pharmaceutical equivalents if they contain the same active ingredients and are identical in strength or concentration, dosage form, and route of administration. Two pharmaceutically equivalent drug products are considered to be bioequivalent when the rates and extents of bioavailability of the active ingredient in the two products are not significantly different under suitable test conditions. 
     The terms “polynucleotide,” “oligonucleotide” and “nucleic acid” are used interchangeably throughout and include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs (e.g., peptide nucleic acids and non-naturally occurring nucleotide analogs), and hybrids thereof. The nucleic acid molecule can be single-stranded or double-stranded. In some embodiments, the nucleic acid molecules of the disclosure comprise a contiguous open reading frame encoding an antibody, or a fragment thereof, as described herein. “Nucleic acid” or “oligonucleotide” or “polynucleotide” as used herein may mean at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of a depicted single strand. Many variants of a nucleic acid may be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and complements thereof. A single strand provides a probe that may hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions. Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods. A nucleic acid will generally contain phosphodiester bonds, although nucleic acid analogs maybe included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or 0-methylphosphoroamidite linkages and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, which are incorporated by reference in their entireties. 
     Nucleic acids containing one or more non-naturally occurring or modified nucleotides are also included within one definition of nucleic acids. The modified nucleotide analog may he located for example at the 5′-end and/or the 3′-end of the nucleic acid molecule. Representative examples of nucleotide analogs may be selected from sugar- or backbone-modified ribonucleotides. It should be noted, however, that also nucleobase-modified ribonucleotides, i.e. ribonucleotides, containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase such as uridines or cytidines modified at the 5-position, e.g. 5-(2-amino)propyl uridine, 5-bromo uridine; adenosines and guanosines modified at the 8-position, e.g. 8-bromo guanosine; deaza nucleotides, e.g. 7-deaza-adenosine; 0- and N-alkylated nucleotides, e.g. N6-methyl adenosine are suitable. The 2′-OH-group may be replaced by a group selected from H, OR, R, halo, SH, SR, NH 2 , NHR, N 2  or CN, wherein R is C 1 -C 6  alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I. Modified nucleotides also include nucleotides conjugated with cholesterol through, e.g., a hydroxyprolinol linkage as described in Krutzfeldt et al., Nature (Oct. 30, 2005), Soutschek et al., Nature 432:173-178 (2004), and U.S. Patent Publication No. 20050107325, which are incorporated herein by reference in their entireties. Modified nucleotides and nucleic acids may also include locked nucleic acids (LNA), as described in U.S. Pat. No. 20020115080, which is incorporated herein by reference. Additional modified nucleotides and nucleic acids are described in U.S. Patent Publication No. 20050182005, which is incorporated herein by reference in its entirety. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments, to enhance diffusion across cell membranes, or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs may be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. In some embodiments, the expressible nucleic acid sequence is in the form of DNA. In some embodiments, the expressible nucleic acid is in the form of RNA with a sequence that encodes the polypeptide sequences disclosed herein and, in some embodiments, the expressible nucleic acid sequence is an RNA/DNA hybrid molecule that encodes any one or plurality of polypeptide sequences disclosed herein. 
     As used herein, the term “nucleic acid molecule” is a molecule that comprises one or more nucleotide sequences that encode one or more proteins. In some embodiments, a nucleic acid molecule comprises initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of the individual to whom the nucleic acid molecule is administered. In some embodiments, the nucleic acid molecule also includes a plasmid containing one or more nucleotide sequences that encode one or a plurality of viral antigens. In some embodiments, the disclosure relates to a pharmaceutical composition comprising a first, second, third or more nucleic acid molecule, each of which encoding one or a plurality of viral antigens and at least one of each plasmid comprising one or more of the compositions disclosed herein. 
     The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-natural amino acids or chemical groups that are not amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term “amino acid” includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. 
     The “percent identity” or “percent homology” of two polynucleotide or two polypeptide sequences is determined by comparing the sequences using the GAP computer program (a part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters. “Identical” or “identity” as used herein in the context of two or more nucleic acids or amino acid sequences, may mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent. Identity may he performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0. Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length Win the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension for the word hits in each direction are halted when: 1) the cumulative alignment score falls off by the quantity X from its maximum achieved value; 2) the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or 3) the end of either sequence is reached. The Blast algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The Blast program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 10915-10919, which is incorporated herein by reference in its entirety) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands. The BLAST algorithm (Karlin et al., Proc. Natl. Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity between two sequences. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide sequences would occur by chance. For example, a nucleic acid is considered similar to another if the smallest sum probability in comparison of the test nucleic acid to the other nucleic acid is less than about 1, less than about 0.1, less than about 0.01, and less than about 0.001. Two single-stranded polynucleotides are “the complement” of each other if their sequences can be aligned in an anti-parallel orientation such that every nucleotide in one polynucleotide is opposite its complementary nucleotide in the other polynucleotide, without the introduction of gaps, and without unpaired nucleotides at the 5′ or the 3′ end of either sequence. A polynucleotide is “complementary” to another polynucleotide if the two polynucleotides can hybridize to one another under moderately stringent conditions. Thus, a polynucleotide can be complementary to another polynucleotide without being its complement. 
     The term “hybridization” or “hybridizes” as used herein refers to the formation of a duplex between nucleotide sequences that are sufficiently complementary to form duplexes via Watson-Crick base pairing. Two nucleotide sequences are “complementary” to one another when those molecules share base pair organization homology. “Complementary” nucleotide sequences will combine with specificity to form a stable duplex under appropriate hybridization conditions. For instance, two sequences are complementary when a section of a first sequence can bind to a section of a second sequence in an anti-parallel sense wherein the 3′-end of each sequence binds to the 5′-end of the other sequence and each A, T(U), G and C of one sequence is then aligned with a T(U), A, C and G, respectively, of the other sequence. RNA sequences can also include complementary G=U or U=G base pairs. Thus, two sequences need not have perfect homology to be “complementary.” Usually two sequences are sufficiently complementary when at least about 90% (preferably at least about 95%) of the nucleotides share base pair organization over a defined length of the molecule. 
     By “substantially identical” is meant nucleic acid molecule (or polypeptide) exhibiting at least about 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein). In some embodiments, such a sequence is at least about 60%, 70%, 80% or 85%, 90%, 95% or even 99% identical at the amino acid level or nucleic acid to the sequence used for comparison. 
     A nucleotide sequence is “operably linked” to a regulatory sequence if the regulatory sequence affects the expression (e.g., the level, timing, or location of expression) of the nucleotide sequence. A “regulatory sequence” is a nucleic acid that affects the expression (e.g., the level, timing, or location of expression) of a nucleic acid to which it is operably linked. The regulatory sequence can, for example, exert its effects directly on the regulated nucleic acid, or through the action of one or more other molecules (e.g., polypeptides that bind to the regulatory sequence and/or the nucleic acid). Examples of regulatory sequences include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Further examples of regulatory sequences are described in, for example, Goeddel, 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. and Baron et al., 1995, Nucleic Acids Res. 23:3605-06. 
     A “vector” is a nucleic acid that can be used to introduce another nucleic acid linked to it into a cell. One type of vector is a “plasmid,” which refers to a linear or circular double stranded DNA molecule into which additional nucleic acid segments can be ligated. Another type of vector is a viral vector (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), comprising additional, exogenous DNA, RNA or hybrid DNA or RNA molecules that can be introduced into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors comprising a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. An “expression vector” is a type of vector that can direct the expression of a chosen polynucleotide. The disclosure relates to any one or plurality of vectors that comprise nucleic acid sequences encoding any one or plurality of amino acid sequence disclosed herein. In some embodiments, the expression vector includes from about 30 to about 100,000 nucleotides (e.g., from about 30 to about 50, from about 30 to about 100, from about 30 to about 250, from about 30 to about 500, from about 30 to about 1,000, from about 30 to about 1,500, from about 30 to about 3,000, from about 30 to about 5,000, from about 30 to about 7,000, from about 30 to about 10,000, from about 30 to about 25,000, from about 30 to about 50,000, from about 30 to about 70,000, from about 100 to about 250, from about 100 to about 500, from about 100 to about 1,000, from about 100 to about 1,500, from about 100 to about 3,000, from about 100 to about 5,000, from about 100 to about 7,000, from about 100 to about 10,000, from about 100 to about 25,000, from about 100 to about 50,000, from about 100 to about 70,000, from about 100 to about 100,000, from about 500 to about 1,000, from about 500 to about 1,500, from about 500 to about 2,000, from about 500 to about 3,000, from about 500 to about 5,000, from about 500 to about 7,000, from about 500 to about 10,000, from about 500 to about 25,000, from about 500 to about 50,000, from about 500 to about 70,000, from about 500 to about 100,000, from about 1,000 to about 1,500, from about 1,000 to about 2,000, from about 1,000 to about 3,000, from about 1,000 to about 5,000, from about 1,000 to about 7,000, from about 1,000 to about 10,000, from about 1,000 to about 25,000, from about 1,000 to about 50,000, from about 1,000 to about 70,000, from about 1,000 to about 100,000, from about 1,500 to about 3,000, from about 1,500 to about 5,000, from about 1,500 to about 7,000, from about 1,500 to about 10,000, from about 1,500 to about 25,000, from about 1,500 to about 50,000, from about 1,500 to about 70,000, from about 1,500 to about 100,000, from about 2,000 to about 3,000, from about 2,000 to about 5,000, from about 2,000 to about 7,000, from about 2,000 to about 10,000, from about 2,000 to about 25,000, from about 2,000 to about 50,000, from about 2,000 to about 70,000, and from about 2,000 to about 100,000 nucleotides). 
     The term “vaccine” as used herein is meant to refer to a composition capable of generating immunity for the prophylaxis and/or treatment of diseases (e.g., viral infections). In some embodiments, the vaccine is a composition capable of generating therapeutically effective immunity for the prophylaxis or treatment of Coronaviridae infection or propagation in a subject. Accordingly, vaccines are medicaments which comprise antigens in protein and/or nucleic acid forms and are in animals for generating specific defense and protective substance by vaccination. A “vaccine composition” can include a pharmaceutically acceptable excipient, carrier or diluent. A “vaccine composition” or “nucleic acid vaccine composition” as used herein can comprise a DNA vaccine, a RNA vaccine or a combination thereof. 
     “Variants” are intended to mean substantially similar sequences. For nucleic acid molecules, a variant comprises a nucleic acid molecule having deletions (i.e., truncations) at the 5′ and/or 3′ end; deletion and/or addition of one or more nucleotides at one or more internal sites in the native polynucleotide; and/or substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a “native” nucleic acid molecule or polypeptide comprises a naturally occurring or endogenous nucleotide sequence or amino acid sequence, respectively. For nucleic acid molecules, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the disclosure. Variant nucleic acid molecules also include synthetically derived nucleic acid molecules, such as those generated, for example, by using site-directed mutagenesis but which still encode a protein of the disclosure. Generally, variants of a particular nucleic acid molecule of the disclosure will have at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters as described elsewhere herein. Variants of a particular nucleic acid molecule of the disclosure (i.e., the reference DNA sequence) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant nucleic acid molecule and the polypeptide encoded by the reference nucleic acid molecule. Percent sequence identity between any two polypeptides can be calculated using sequence alignment programs and parameters described elsewhere herein. Where any given pair of nucleic acid molecule of the disclosure is evaluated by comparison of the percent sequence identity shared by the two polypeptides that they encode, the percent sequence identity between the two encoded polypeptides is at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity. In some embodiments, the term “variant” protein is intended to mean a protein derived from the native protein by deletion (so-called truncation) of one or more amino acids at the N-terminal and/or C-terminal end of the native protein; deletion and/or addition of one or more amino acids at one or more internal sites in the native protein; or substitution of one or more amino acids at one or more sites in the native or wild-type protein upon which the variant structure is based. Variant proteins encompassed by the present disclosure are biologically active, that is they continue to possess the desired biological activity of the native protein as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a protein of the disclosure will have at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a protein of the disclosure may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue. The proteins or polypeptides of the disclosure may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants and fragments of the proteins can be prepared by mutations in the nucleic acid sequence that encode the amino acid sequence recombinantly. In some embodiments, the nucleic acid molecules or the nucleic acid sequences comprise conservative mutations of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides. 
     As used herein, “SARS-CoV-2” refers to severe acute respiratory syndrome-related coronavirus-2 or a subtype or variant thereof. Non-limiting examples of the SARS-CoV-2 virus, variants and subtypes thereof are described, for example, in Morais et al. (Sci. Rep., 2020, 10(1):18289), Zhao et al. (PLoS Comput Biol., 2020, 16(9):e1008269), Forster et al. (PNAS, 2020, 117(17):9241-9243), and Tang et al. (National Science Review, 2020, 7(6):1012-1023), all of which are incorporated by reference herein. In some embodiments, the SARS-CoV-2 is one of the 6 subtypes and 10 tentative subtypes identified in Morais et al. (Sci. Rep., 2020, 10(1):18289). In some embodiments, the SARS-CoV-2 is one of the 3 SARS-CoV-2 variants identified in Foster et al. (PNAS, 2020, 117(17):9241-9243). In some embodiments, the SARS-CoV-2 is one of the two SARS-CoV-2 subtypes identified in Tang et al. (National Science Review, 2020, 7(6):1012-1023). In some embodiments, the SARS-CoV-2 is SARS-CoV-2 hCoV-19/Australia/VIC01/2020 or a variant thereof. In some embodiments, SARS-COV-2 comprises the sequences as described in NCBI Reference Sequence: NC 045512.2 or a variant thereof. In some embodiments, SARS-CoV-2 comprises the sequence as described in GenBank: MN908947.3 or a variant thereof. In some embodiments, the SARS-Cov-2 variant is the B.1.1.7 varian, also referred to as lineage B.1.1.7, VOC 202012/01 or 20I/501Y.V1. In some embodiments, the SARS-Cov-2 variant is the B.1.351 variant, also referred to as B.1.351 lineage. In some embodiments, the SARS-Cov-2 variant is the B.1.1.28 subclade (renamed “P.1”). In some embodiments, the SARS-Cov-2 variant is the B.1.1.7 variant, also referred to as B.1.1.7 lineage or 20I/501Y.V1. 
     As used herein, a “scaffold domain” refers to a region of a polypeptide that structurally facilitates, or acts as a scaffold for, presentation of one or a plurality of viral antigens. In some embodiments, a scaffold domain of the disclosure comprises a self-assembling polypeptide which, when expressed, forms an inner scaffold or core upon which one or a plurality of viral antigens are displayed. In some embodiments, the self-assemblying peptide forms a three dimensional shape with identical single polypeptide surfaces. In some embodiments, the scaffold doman forms a secondary and/or tertiary structure that is a polyhedron. In some embodiments, the scaffold domain encodes a monomer or series of monomers that form a 7, 14, 20, 28 or 60 faces of a polyhedron upon which antigens are encoded or displayed. 
     As used herein, the term “trimer” refers to a protein complex formed by three individual monomers. In some embodiments, the monomer subunits of the trimer are bound together to form a trimer by non-covalent protein-protein interactions. 
     Finally, it should be understood that all of the individual values and sub-ranges of values contained within an explicitly disclosed range are also specifically contemplated and should be considered disclosed unless the context specifically indicates otherwise. The foregoing applies regardless of whether in particular cases some or all of these embodiments are explicitly disclosed. 
     Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed method and compositions belong. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present method and compositions, the particularly useful methods, devices, and materials are as described. Publications cited herein and the material for which they are cited are hereby specifically incorporated by reference. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such disclosure by virtue of prior disclosure. No admission is made that any reference constitutes prior art. The discussion of references states what their authors assert, and applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of publications are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art. 
     Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps. In particular, in methods stated as comprising one or more steps or operations it is specifically contemplated that each step comprises what is listed (unless that step includes a limiting term such as “consisting of”), meaning that each step is not intended to exclude, for example, other additives, components, integers or steps that are not listed in the step. 
     A. Nucleic Acid Compositions 
     Disclosed are compositions and pharmaceutical compositions comprising one or plurality of expressible nucleic acid sequences. In some embodiments, the expressible nucleic acid sequence is a DNA. In other embodiments, the expressible nucleic acid sequence is a RNA. In some embodiments, the expressible nucleic acid is operably linked to one or a plurality of regulatory sequences. In some embodiments, the expressible nucleic acid sequence is comprised and forms a part of a nucleic acid molecule, such as a vector or plasmid. 
     In one aspect, the expressible nucleic acid sequence of the disclosure comprises a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide or a pharmaceutically acceptable salt thereof, and a second nucleic acid sequence encoding an antigen domain comprising a viral antigen or a pharmaceutically acceptable salt thereof. The self-assembling polypeptide is a self-assembling peptide that is expressed to facilitate presentation of the viral antigen. Transformed or transfected cells exposed to such expressible nucleic acid sequences can produce the self-assembling peptide which is enveloped by the viral antigens, thereby stimulating the viral antigen-specific immune response against the antigen. In some embodiments, the antigen-specific immune response is a therapeutically effective immune response against the virus from which the antigen amino acid sequence is obtained. In some embodiments, the viral antigen encoded by the expressible nucleic acid of the disclosure comprises a coronaviral antigen. In some embodiments, the expressible nucleic acid sequence further comprises a third nucleic acid sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof. In some embodiments, the leader sequence is an IgE or IgG leader sequence. In some embodiments, the expressible nucleic acid sequence further comprises a fourth nucleic acid sequence encoding a linker peptide or a pharmaceutically acceptable salt thereof, wherein the fourth nucleic acid sequence is positioned between the first nucleic acid sequence and the second nucleic acid sequence in the 5′ to 3′ orientation. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide or a pharmaceutically acceptable salt thereof, a second nucleic acid sequence encoding an antigen domain comprising a viral antigen or a pharmaceutically acceptable salt thereof, and a third nucleic acid sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide or a pharmaceutically acceptable salt thereof, a second nucleic acid sequence encoding an antigen domain comprising a viral antigen or a pharmaceutically acceptable salt thereof, a third nucleic acid sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof, and a fourth nucleic acid sequence encoding a linker peptide or a pharmaceutically acceptable salt thereof, wherein the fourth nucleic acid sequence is positioned between the first nucleic acid sequence and the second nucleic acid sequence in the 5′ to 3′ orientation. 
     In some embodiments, the expressible nucleic acid sequence of the disclosure comprises a nucleic acid sequence encoding a viral trimer polypeptide, a functional fragment thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence comprises, in a 5′ to 3′ orientation, a first nucleic acid sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof, and a second nucleic acid sequence encoding a viral trimer polypeptide, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the leader sequence is an IgE or IgG leader sequence. In some embodiments, the expressible nucleic acid sequence comprises, in a 5′ to 3′ orientation, a first nucleic acid sequence encoding a leader sequence or a pharmaceutically acceptable salt thereof, and a second nucleic acid sequence encoding a viral polypeptide that is a component of a viral trimer, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the viral polypeptide that is a component of a viral trimer is a monomer of a viral trimer, such that, upon expression, the monomers spontaneously aggregate to form a trimeric viral polypeptide. In some embodiments, the viral trimer encoded by the expressible nucleic acid of the disclosure comprises a coronaviral trimer. In some embodiments, the viral trimer comprises the spike protein of SARS-CoV-2, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. 
     In some embodiments, the nucleic acid sequences encoding the viral antigens or viral trimers comprised in the expressible nucleic acid of the disclosure comprise one or a plurality of mutations so to tailor the vaccine induced responses. Such mutations result in creating glycan sites in the encoded polypeptide so that glycosylation events can be obtained. In some embodiments, such glycan modifications or mutations decrease the bottom reactivity. In some embodiments, such glycan modifications or mutations increase antigen activity. 
     1. Leader Sequence 
     The expressible nucleic acid sequence of the present disclosure optionally comprises a nucleic acid sequence encoding a leader sequence, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. A “leader sequence” may from time to time refer to a “signal peptide” and thus, the terms “leader sequence” and “signal peptide” are used interchangeably herein and refer to an amino acid sequence that can be linked at the amino terminus of a protein set forth herein. Signal peptides/leader sequences typically direct localization of a protein. Signal peptides/leader sequences used herein preferably facilitate secretion of the protein from the cell in which it is produced. Signal peptides/leader sequences are often cleaved from the remainder of the protein, often referred to as the mature protein, upon secretion from the cell. Signal peptides/leader sequences, when present, are linked at the N terminus of the protein. The presence of a leader sequence may be required for proper secretion of the viral antigen or trimer encoded by the expressible nucleic acid sequence of the disclosure. 
     A non-limiting example of the leader sequence is the IgE leader sequence comprising the amino acid sequence of MDWTWILFLVAAATRVHS (SEQ ID NO: 1; also named “MD39”) encoded by one of the following nucleic acid sequences: 
     
       
         
           
               
            
               
                 (SEQ ID NO: 2; “MD39”) 
               
               
                 atggactggacatggattctgttcctggtcgctgccgctacaagagtgca 
               
               
                   
               
               
                 ttcc; 
               
               
                   
               
               
                 (SEQ ID NO: 3; “CPG9.2”) 
               
               
                 atggattggacttggattctgttcctggtcgcagcagccacacgagtgca 
               
               
                   
               
               
                 tagc; 
               
               
                 and 
               
               
                   
               
               
                 (SEQ ID NO: 4) 
               
               
                 atggactggacctggattctgttcctggtggccgccgccacaagggtgca 
               
               
                   
               
               
                 cagc. 
               
            
           
         
       
     
     Another non-limiting example of the leader sequence is the amino acid sequence of MDWTWRILFLVAAATGTHA (SEQ ID NO: 5) encoded by the nucleic acid sequence of atggactggacctggagaatcctgttcctggtggccgccgccaccggcacacacgccgatacacacttccccatctgcatcttttgctg tggctgttgccataggtccaagtgtgggatgtgctgcaaaact (SEQ ID NO: 6). 
     Thus, in some embodiments when the leader sequence is present, the leader sequence comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof. In some embodiments, the leader sequence comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof. In some embodiments, the leader sequence is encoded by a nucleic acid sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof. In some embodiments, the leader sequence is encoded by the nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof. In other embodiments, the leader sequence is encoded by a nucleic acid sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a nucleic acid sequence that is complementary to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof. In some embodiments, the leader sequence is encoded by a nucleic acid sequence that is complementary to the nucleic acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof 
     2. Self-Assembling Polypeptide 
     The disclosure relates to an expressible nucleic acid sequence comprising at least one nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. Self-assembling polypeptide are polypeptides capable of undergoing spontaneous assembling into ordered nanostructures. Effectively self-assembling polypeptides can act as building blocks to form the scaffold domain of the present disclosure. In some embodiments, the self-assembling polypeptides encoded by the expressible nucleic acid sequence of the disclosure are monomeric forms of viral trimers or variants thereof. In some embodiments, the self-assembling polypeptides are monomers of nanoparticle structural proteins that self-assemble into nanoparticles upon expression. Any self-assembling polypeptide can be used. In some embodiments, the self assembling polypeptide is from  Aquifex aeolicus, Helicobacter pylori, Pyrococcus furiosus  or  Thermotoga maritima.    
     A non-limiting example of a self-assembling polypeptide is the lumazine synthase of hyperthermophilic bacterium  Aquifex  aeolicus having the amino acid sequence of SEQ ID NO: 8 (LS scaffold) encoded by the nucleic acid sequence of SEQ ID NO: 7. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 7) 
               
               
                 atgcagatctacgaaggaaaactgaccgctgagggactgaggttcggaat 
               
               
                   
               
               
                 tgtcgcaagccgcgcgaatcacgcactggtggataggctggtggaaggcg 
               
               
                   
               
               
                 ctatcgacgcaattgtccggcacggcgggagagaggaagacatcacactg 
               
               
                   
               
               
                 gtgagagtctgcggcagctgggagattcccgtggcagctggagaactggc 
               
               
                   
               
               
                 tcgaaaggaggacatcgatgccgtgatcgctattggggtcctgtgccgag 
               
               
                   
               
               
                 gagcaactcccagcttcgactacatcgcctcagaagtgagcaaggggctg 
               
               
                   
               
               
                 gctgatctgtccctggagctgaggaaacctatcacttttggcgtgattac 
               
               
                   
               
               
                 tgccgacaccctggaacaggcaatcgaggcggccggcacctgccatggaa 
               
               
                   
               
               
                 acaaaggctgggaagcagccctgtgcgctattgagatggcaaatctgttc 
               
               
                   
               
               
                 aaatctctgcga 
               
               
                   
               
               
                 (SEQ ID NO: 8) 
               
               
                 MQIYEGKLTAEGLRFGIVASRANHALVDRLVEGAIDAIVRHGGREEDITL 
               
               
                   
               
               
                 VRVCGSWEIPVAAGELARKEDIDAVIAIGVLCRGATPSFDYIASEVSKGL 
               
               
                   
               
               
                 ADLSLELRKPITFGVITADTLEQAIEAAGTCHGNKGWEAALCAIEMANLF 
               
               
                   
               
               
                 KSLR 
               
            
           
         
       
     
     Another non-limiting example of a self-assembling polypeptide is ferritin from  Helicobacter pylori  having the amino acid sequence of SEQ ID NO: 10 (3BVE scaffold) encoded by the nucleic acid sequence of SEQ ID NO: 9. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 9) 
               
               
                 gggctgagtaaggacattatcaagctgctgaacgaacaggtgaacaaaga 
               
               
                   
               
               
                 gatgcagtctagcaacctgtacatgtccatgagctcctggtgctataccc 
               
               
                   
               
               
                 actctctggacggagcaggcctgttcctgtttgatcacgccgccgaggag 
               
               
                   
               
               
                 tacgagcacgccaagaagctgatcatcttcctgaatgagaacaatgtgcc 
               
               
                   
               
               
                 cgtgcagctgacctctatcagcgcccctgagcacaagttcgagggcctga 
               
               
                   
               
               
                 cacagatctttcagaaggcctacgagcacgagcagcacatctccgagtct 
               
               
                   
               
               
                 atcaacaatatcgtggaccacgccatcaagtccaaggatcacgccacatt 
               
               
                   
               
               
                 caactttctgcagtggtacgtggccgagcagcacgaggaggaggtgctgt 
               
               
                   
               
               
                 ttaaggacatcctggataagatcgagctgatcggcaatgagaaccacggg 
               
               
                   
               
               
                 ctgtacctggcagatcagtatgtcaagggcatcgctaagtcaaggaaaag 
               
               
                   
               
               
                 c 
               
               
                   
               
               
                 (SEQ ID NO: 10) 
               
               
                 GLSKDIIKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEE 
               
               
                   
               
               
                 YEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISES 
               
               
                   
               
               
                 INNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHG 
               
               
                   
               
               
                 LYLADQYVKGIAKSRKS 
               
            
           
         
       
     
     A yet another non-limiting example of a self-assembling polypeptide is PfV viral cage from  Pyrococcus furiosus  (2e0z) having the amino acid sequence of SEQ ID NO: 12 (RBE scaffold) encoded by the nucleic acid sequence of SEQ ID NO: 11. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 11) 
               
               
                 ctgagcattgcccccacactgattaaccgggacaaaccctacaccaaaga 
               
               
                   
               
               
                 ggaactgatggagattctgagactggctattatcgctgagctggacgcca 
               
               
                   
               
               
                 tcaacctgtacgagcagatggcccggtattctgaggacgagaatgtgcgc 
               
               
                   
               
               
                 aagatcctgctggatgtggccagggaggagaaggcacacgtgggagagtt 
               
               
                   
               
               
                 catggccctgctgctgaacctggaccccgagcaggtgaccgagctgaagg 
               
               
                   
               
               
                 gcggctttgaggaggtgaaggagctgacaggcatcgaggcccacatcaac 
               
               
                   
               
               
                 gacaataagaaggaggagagcaacgtggagtatttcgagaagctgagatc 
               
               
                   
               
               
                 cgccctgctggatggcgtgaataagggcaggagcctgctgaagcacctgc 
               
               
                   
               
               
                 ctgtgaccaggatcgagggccagagcttcagagtggacatcatcaagttt 
               
               
                   
               
               
                 gaggatggcgtgcgcgtggtgaagcaggagtacaagcccatccctctgct 
               
               
                   
               
               
                 gaagaagaagttctacgtgggcatcagggagctgaacgacggcacctacg 
               
               
                   
               
               
                 atgtgagcatcgccacaaaggccggcgagctgctggtgaaggacgaggag 
               
               
                   
               
               
                 tccctggtcatccgcgagatcctgtctacagagggcatcaagaagatgaa 
               
               
                   
               
               
                 gctgagctcctgggacaatccagaggaggccctgaacgatctgatgaatg 
               
               
                   
               
               
                 ccctgcaggaggcatctaacgcaagcgccggaccattcggcctgatcatc 
               
               
                   
               
               
                 aatcccaagagatacgccaagctgctgaagatctatgagaagtccggcaa 
               
               
                   
               
               
                 gatgctggtggaggtgctgaaggagatcttccggggcggcatcatcgtga 
               
               
                   
               
               
                 ccctgaacatcgatgagaacaaagtgatcatctttgccaacacccctgcc 
               
               
                   
               
               
                 gtgctggacgtggtggtgggacaggatgtgacactgcaggagctgggacc 
               
               
                   
               
               
                 agagggcgacgatgtggcctttctggtgtccgaggccatcggcatcagga 
               
               
                   
               
               
                 tcaagaatccagaggcaatcgtggtgctggag 
               
               
                   
               
               
                 (SEQ ID NO: 12) 
               
               
                 LSIAPTLINRDKPYTKEELMEILRLAIIAELDAINLYEQMARYSEDENVR 
               
               
                   
               
               
                 KILLDVAREEKAHVGEFMALLLNLDPEQVTELKGGFEEVKELTGIEAHIN 
               
               
                   
               
               
                 DNKKEESNVEYFEKLRSALLDGVNKGRSLLKHLPVTRIEGQSFRVDIIKF 
               
               
                   
               
               
                 EDGVRVVKQEYKPIPLLKKKFYVGIRELNDGTYDVSIATKAGELLVKDEE 
               
               
                   
               
               
                 SLVIREILSTEGIKKMKLSSWDNPEEALNDLMNALQEASNASAGPFGLII 
               
               
                   
               
               
                 NPKRYAKLLKIYEKSGKMLVEVLKEIFRGGIIVTLNIDENKVIIFANTPA 
               
               
                   
               
               
                 VLDVVVGQDVTLQELGPEGDDVAFLVSEAIGIRIKNPEAIVVLE 
               
            
           
         
       
     
     A further non-limiting example of a self-assembling polypeptide is the self-assembling polypeptide from  Thermotoga maritima  having the amino acid sequence of SEQ ID NO: 14 (13 scaffold) encoded by the nucleic acid sequence of SEQ ID NO: 13. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 13) 
               
               
                 atgaagatggaagaactgttcaagaagcacaagatcgtggccgtgctgag 
               
               
                   
               
               
                 ggccaactccgtggaggaggccaagaagaaggccctggccgtgttcctgg 
               
               
                   
               
               
                 gcggcgtgcacctgatcgagatcacctttacagtgcccgacgccgatacc 
               
               
                   
               
               
                 gtgatcaaggagctgtctttcctgaaggagatgggagcaatcatcggagc 
               
               
                   
               
               
                 aggaaccgtgacaagcgtggagcagtgcagaaaggccgtggagagcggcg 
               
               
                   
               
               
                 ccgagtttatcgtgtcccctcacctggacgaggagatctctcagttctgt 
               
               
                   
               
               
                 aaggagaagggcgtgttttacatgccaggcgtgatgacccccacagagct 
               
               
                   
               
               
                 ggtgaaggccatgaagctgggccacacaatcctgaagctgttccctggcg 
               
               
                   
               
               
                 aggtggtgggcccacagtttgtgaaggccatgaagggccccttccctaat 
               
               
                   
               
               
                 gtgaagtttgtgcccaccggcggcgtgaacctggataacgtgtgcgagtg 
               
               
                   
               
               
                 gttcaaggcaggcgtgctggcagtgggcgtgggcagcgccctggtgaagg 
               
               
                   
               
               
                 gcacacccgtggaagtcgctgagaaggcaaaggcattcgtggaaaagatt 
               
               
                   
               
               
                 agggggtgtactgag 
               
               
                   
               
               
                 (SEQ ID NO: 14) 
               
               
                 MKMEELFKKHKIVAVLRANSVEEAKKKALAVFLGGVHLIEITFTVPDADT 
               
               
                   
               
               
                 VIKELSFLKEMGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFC 
               
               
                   
               
               
                 KEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPN 
               
               
                   
               
               
                 VKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPVEVAEKAKAFVEKI 
               
               
                   
               
               
                 RGCTE 
               
            
           
         
       
     
     Additional non-limiting examples of self-assembling polypeptides include: QB scaffold (SEQ ID NO: 16) encoded by the nucleic acid sequence of SEQ ID NO: 15; 
     
       
         
           
               
            
               
                 (SEQ ID NO: 15) 
               
               
                 gcaaagctggagacagtgacactgggcaacatcggcaaggacggcaagca 
               
               
                   
               
               
                 gacactggtgctgaatcccaggggcgtgaaccctaccaatggagtggcat 
               
               
                   
               
               
                 ctctgagccaggcaggagcagtgcctgccctggagaagagagtgaccgtg 
               
               
                   
               
               
                 tccgtgtctcagcccagcaggaacagaaagaattataaggtgcaggtgaa 
               
               
                   
               
               
                 gatccagaacccaaccgcctgcacagccaatggcagctgtgacccatccg 
               
               
                   
               
               
                 tgacaaggcaggcatacgcagatgtgaccttctcttttacacagtatagc 
               
               
                   
               
               
                 accgatgaggagagggccttcgtgcgcaccgagctggccgccctgctggc 
               
               
                   
               
               
                 atcccctctgctgattgacgctattgaccagctgaaccctgcttac 
               
               
                   
               
               
                 (SEQ ID NO: 16) 
               
               
                 AKLETVTLGNIGKDGKQTLVLNPRGVNPTNGVASLSQAGAVPALEKRVTV 
               
               
                   
               
               
                 SVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQAYADVTFSFTQYS 
               
               
                   
               
               
                 TDEERAFVRTELAALLASPLLIDAIDQLNPAY 
               
               
                   
               
               
                 ICI scaffold (SEQ ID NO: 18) encoded by the 
               
               
                 nucleic acid sequence of SEQ ID NO: 17; 
               
               
                   
               
               
                 (SEQ ID NO: 17) 
               
               
                 gaccctgagtttaccaaaaatgctctgaatgtcgtcaaaaatgatctgat 
               
               
                   
               
               
                 tgctaaggtggaccagctgagcggagagcaggaggtgctgaggggcgagc 
               
               
                   
               
               
                 tggaggccgccaagcaggcaaaggtgaaactggaaaaccgaatcaaggaa 
               
               
                   
               
               
                 ctggaagaagaactgaaaagagtc 
               
               
                   
               
               
                 (SEQ ID NO: 18) 
               
               
                 DPEFTKNALNVVKNDLIAKVDQLSGEQEVLRGELEAAKQAKVKLENRIKE 
               
               
                   
               
               
                 LEEELKRV 
               
               
                   
               
               
                 and IC2 scaffold (SEQ ID NO: 20) encoded by the 
               
               
                 nucleic acid sequence of SEQ ID NO: 19. 
               
               
                   
               
               
                 (SEQ ID NO: 19) 
               
               
                 gccgaccccaagaaggtgctggataaagccaaagatcaggcagaaaatag 
               
               
                   
               
               
                 agtcagggaactgaagcagaagctggaggagctgtacaaggaggcccgga 
               
               
                   
               
               
                 agctggacctgacccaggagatgaggagaaagctggagctgcgctacatc 
               
               
                   
               
               
                 gccgccatgctgatggccatcggcgacatctataacgccatcaggcaggc 
               
               
                   
               
               
                 caagcaggaggccgataagctgaagaaggccggcctggtgaatagccagc 
               
               
                   
               
               
                 agctggacgagctgaagcggcgcctggaggagctgaaggaggaggccagc 
               
               
                   
               
               
                 aggaaggccagagattacggcagggagttccagctgaagctggagtatgg 
               
               
                   
               
               
                 cggcggcagcggctccggctctggcggcaagatcgagcagatcctgcaga 
               
               
                   
               
               
                 agatcgaaaagatcctgcagaagattgagtggattctgcagaagattgaa 
               
               
                   
               
               
                 cagatcctgcagggg 
               
               
                   
               
               
                 (SEQ ID NO: 20) 
               
               
                 ADPKKVLDKAKDQAENRVRELKQKLEELYKEARKLDLTQEMRRKLELRYI 
               
               
                   
               
               
                 AAMLMAIGDIYNAIRQAKQEADKLKKAGLVNSQQLDELKRRLEELKEEAS 
               
               
                   
               
               
                 RKARDYGREFQLKLEYGGGSGSGSGGKIEQILQKIEKILQKIEWILQKIE 
               
               
                   
               
               
                 QILQG 
               
            
           
         
       
     
     Accordingly, in some embodiments, the self-assembling polypeptide encoded by the expressible nucleic acid sequence of the present disclosure comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20, or a functional fragment or variant thereof. In some embodiments, the self-assembling polypeptide comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20, or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding the self-assembling polypeptide comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding the self-assembling polypeptide comprises the nucleotide sequence of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment or variant thereof. In other embodiments, the nucleic acid sequence encoding the self-assembling polypeptide comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a nucleic acid sequence that is complementary to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment thereof. In some embodiments, the nucleic acid sequence encoding the self-assembling polypeptide comprises a nucleic acid sequence that is complementary to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment thereof. 
     In some embodiments, the composition or pharmaceutical composition of the disclosure comprises a vector or a nucleic acid molecule comprising an expressible RNA sequence that encodes a self-assembling polypeptide that is optionally in sequence with one or more additional expressible RNA sequences that encode a viral antigen. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 300 to about 500 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 350 to about 480 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 350 to about 460 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 300 to about 500 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 400 to about 500 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 390 to about 410 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 300 to about 410 nucleotides in length. In some embodiments, the expressible DNA or RNA sequence that encodes a self-assembling polypeptide is from about 300 to about 500 nucleotides in length. 
     3. Linker 
     The expressible nucleic acid sequence of the present disclosure optionally comprises a nucleic acid sequence encoding a linker peptide, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. Any type of linker or linker peptide can be used. The term “linker” or “linker peptide” is used interchangeable herein. 
     In some embodiments, each linker or linker peptide is independently selectable from about 0 to about 25, about 1 to about 25, about 2 to about 25, about 3 to about 25, about 4 to about 25, about 5 to about 25, about 6 to about 25, about 7 to about 25, about 8 to about 25, about 9 to about 25, about 10 to about 25, about 11 to about 25, about 12 to about 25, about 13 to about 25, about 14 to about 25, about 15 to about 25, about 16 to about 25, about 17 to about 25, about 18 to about 25, about 19 to about 25, about 20 to about 25, about 21 to about 25, about 22 to about 25, about 23 to about 25, about 24 to about 25 natural or non-natural amino acids in length. 
     In some embodiments, each linker or linker peptide is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length. In some embodiments, each linker or linker peptide is independently selectable from a linker or linker peptide that is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length. In some embodiments, each linker or linker peptide is about 21 natural or non-natural amino acids in length. 
     In some embodiments, the length of each linker or linker peptide is different. For example, in some embodiments, the length of a first linker or linker peptide is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length, and the length of a second linker is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length, where the length of the first linker is different from the length of the second linker. Various configurations can be envisioned by the present disclosure, where the linker domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more linkers or linker peptides wherein the linkers or linker peptides are of similar or different lengths. 
     In some embodiments, two linkers or linker peptides can be used together. Accordingly, in some embodiments, the first linker or linker peptide is independently selectable from about 0 to about 25 natural or non-natural amino acids in length, about 0 to about 25, about 1 to about 25, about 2 to about 25, about 3 to about 25, about 4 to about 25, about 5 to about 25, about 6 to about 25, about 7 to about 25, about 8 to about 25, about 9 to about 25, about 10 to about 25, about 11 to about 25, about 12 to about 25, about 13 to about 25, about 14 to about 25, about 15 to about 25, about 16 to about 25, about 17 to about 25, about 18 to about 25, about 19 to about 25, about 20 to about 25, about 21 to about 25, about 22 to about 25, about 23 to about 25, about 24 to about 25 natural or non-natural amino acids in length. In some embodiments, the second linker or linker peptide is independently selectable from about 0 to about 25, about 1 to about 25, about 2 to about 25, about 3 to about 25, about 4 to about 25, about 5 to about 25, about 6 to about 25, about 7 to about 25, about 8 to about 25, about 9 to about 25, about 10 to about 25, about 11 to about 25, about 12 to about 25, about 13 to about 25, about 14 to about 25, about 15 to about 25, about 16 to about 25, about 17 to about 25, about 18 to about 25, about 19 to about 25, about 20 to about 25, about 21 to about 25, about 22 to about 25, about 23 to about 25, about 24 to about 25 natural or non-natural amino acids in length. In some embodiments, the first linker or linker peptide is independently selectable from a linker or linker peptide that is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length. In some embodiments, the second linker or linker peptide is independently selectable from a linker or linker peptide that is about 0, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 natural or non-natural amino acids in length. 
     A non-limiting example of a linker peptide may comprise the amino acid sequence of GGSGGSGGSGGSGGG (SEQ ID NO: 22) encoded by the nucleic acid sequence of ggaggctccggaggatctggagggagtggaggctcaggaggaggc (SEQ ID NO: 21). 
     A linker or linker peptide can be either flexible or rigid or a combination thereof. An example of a flexible linker is a GGS repeat. In some embodiments, the GGS can be repeated about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times. Non-limiting examples of such linker peptides may comprise the amino acid sequence of GGSGGSGGS (SEQ ID NO: 23), GGSGGSGGSGGS (SEQ ID NO: 24), or GGSGGSGGSGGSGGGGSGGGSGGG (SEQ ID NO: 25). An example of a rigid linker is 4QTL-115 Angstroms, single chain 3-helix bundle represented by the sequence: 
     
       
         
           
               
               
            
               
                 (SEQ ID NO: 26) 
                   
               
               
                 NEDDMKKLYKQMVQELEKARDRMEKLYKEMVELIQKAIELMRKIFQEVKQEVEKA 
                   
               
               
                   
               
               
                 IEEMKKLYDEAKKKIEQMIQQIKQGGDKQKMEELLKRAKEEMKKVKDKMEKLLEK 
               
               
                   
               
               
                 LKQIMQEAKQKMEKLLKQLKEEMKKMKEKMEKLLKEMKQRMEEVKKKMDGDDE 
               
               
                   
               
               
                 LLEKIKKNIDDLKKIAEDLIKKAEENIKEAKKIAEQLVKRAKQLIEKAKQVAEELIKKI 
               
               
                   
               
               
                 LQLIEKAKEIAEKVLKGLE. 
               
               
                   
               
               
                 Other non-limiting examples of linker peptides may be encoded by the nucleic 
               
               
                 acid sequence of 
               
               
                 (SEQ ID NO: 27) 
                   
               
               
                 ggcggctctggcggaagtggcggaagtgggggaagtggaggcggcggaagcgggggaggcagcgggggaggg, 
                   
               
               
                   
               
               
                 (SEQ ID NO: 28) 
                   
               
               
                 ggcggaagcggcggaagcggcgggtct, 
                   
               
               
                   
               
               
                 (SEQ ID NO: 29) 
                   
               
               
                 ggcggcagcggcggcagcggcgggagcggaggaagt, 
                   
               
               
                 or 
               
               
                   
               
               
                 (SEQ ID NO: 30) 
                   
               
               
                 ggcggctctggcggaagtggcggaagtgggggaagtggaggcggcggaagcgggggaggcagcgggggaggg. 
                   
               
               
                   
               
               
                 Additional non-limiting examples of linker peptides include Link 14 linker (SEQ 
               
               
                 ID NO: 32) encoded by the nucleic acid sequence of SEQ ID NO: 31; 
               
               
                 (SEQ ID NO: 31) 
                   
               
               
                 tctcacagcggctccggcggctctggcagcggcggccacgcc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 32) 
                   
               
               
                 SHSGSGGSGSGGHA 
                   
               
               
                   
               
               
                 CPG9.2 linker 1 (SEQ ID NO: 34) encoded by the nucleic acid sequence of SEQ ID NO: 33; 
               
               
                 (SEQ ID NO: 33) 
                   
               
               
                 gggggaaatagtagcggc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 34) 
                   
               
               
                 GGNSSG 
                   
               
               
                   
               
               
                 CPG9.2 linker 2 (SEQ ID NO: 36) encoded by the nucleic acid sequence of SEQ ID NO: 35; 
               
               
                 (SEQ ID NO: 35) 
                   
               
               
                 ggcggcaacggcagcggcggcggcagcggctccggcggcaacggctctagcggc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 36) 
                   
               
               
                 GGNGSGGGSGSGGNGSSG 
                   
               
               
                   
               
               
                 PDGFR linker (between tri mer or TSI and PDGFR; SEQ ID NO: 38) encoded by the nucleic 
               
               
                 acid sequence of SEQ ID NO: 37; 
               
               
                 (SEQ ID NO: 37) 
                   
               
               
                 ggaggaggaagcgggggaagcgggggaagcggaggaagcgggggaagcgggggaagc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 38) 
                   
               
               
                 GGGSGGSGGSGGSGGSGGS 
                   
               
               
                   
               
               
                 Foldon PDGFR linker 1 (SEQ ID NO: 40) encoded by the nucleic acid sequence of SEQ ID 
               
               
                 NO: 39; 
               
               
                 (SEQ ID NO: 39) 
                   
               
               
                 ggaggaggaagcgggggaagcggcggcggc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 40) 
                   
               
               
                 GGGSGGSGGG 
                   
               
               
                   
               
               
                 Foldon PDGFR linker 2 (SEQ ID NO: 42) encoded by the nucleic acid sequence of SEQ ID 
               
               
                 NO: 41; 
               
               
                 (SEQ ID NO: 41) 
                   
               
               
                 gggggaagcggaggaagcgggggaagcgggggaagc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 42) 
                   
               
               
                 GGSGGSGGSGGS 
                   
               
               
                   
               
               
                 3BVE linker (SEQ ID NO: 44) encoded by the nucleic acid sequence of SEQ ID NO: 43; 
               
               
                 (SEQ ID NO: 43) 
                   
               
               
                 ggaagcggc 
                   
               
               
                   
               
               
                 (SEQ ID NO: 44) 
                   
               
               
                 GSG 
                   
               
               
                   
               
               
                 13_1 linker (SEQ ID NO: 46) encoded by the nucleic acid sequence of SEQ ID NO: 45; 
               
               
                 (SEQ ID NO: 45) 
                   
               
               
                 ggcggcagcggcagcggcgggagcggagga 
                   
               
               
                   
               
               
                 (SEQ ID NO: 46) 
                   
               
               
                 GGSGSGGSGG 
                   
               
               
                   
               
               
                 13_2 linker (SEQ ID NO: 48) encoded by the nucleic acid sequence of SEQ ID NO: 47; 
               
               
                 (SEQ ID NO: 47) 
                   
               
               
                 ggagggagcgatatgagaaaggacgccgagagacggtttgataagttcgtggaggctgctaagaataagtttgacaagtttaaggct 
                   
               
               
                   
               
               
                 gccctgcggaagggcgacatcaaggaggagaggagaaaggatatgaagaagctggcaaggaaggaggcagagcaggcaagga 
               
               
                   
               
               
                 gggccgtgaggaacagactgagcgagctgctgtccaagatcaacgacatgcccatcaccaatgatcagaagaagctgatgtctaatg 
               
               
                   
               
               
                 acgtgctgaagttcgccgcagaagccgaaaagaagattgaagccctggcagcagacgccgaaggaggaagcgggagc 
               
               
                   
               
               
                 (SEQ ID NO: 48) 
                   
               
               
                 GGSDMRKDAERRFDKFVEAAKNKFDKFKAALRKGDIKEERRKDMKKLARKEAEQA 
                   
               
               
                   
               
               
                 RRAVRNRLSELLSKINDMPITNDQKKLMSNDVLKFAAEAEKKIEALAADAEGGSGS 
               
               
                   
               
               
                 LS_1 linker (SEQ ID NO: 50) encoded by the nucleic acid sequence of SEQ ID NO: 49; 
               
               
                 (SEQ ID NO: 49) 
                   
               
               
                 gggggctctagcgggaaaagtctggtggataccgtctatgctctgaaagatgaggtgcaggaactgaggcaggacaacaaaaagat 
                   
               
               
                   
               
               
                 gaagaagagcctggaggaggagcagagggccagaaaggacctggaaaaactggtgcggaaagtgctgaaaaacatgaatgacg 
               
               
                   
               
               
                 gagggagtagcggg 
               
               
                   
               
               
                 (SEQ ID NO: 50) 
                   
               
               
                 GGSSGKSLVDTVYALKDEVQELRQDNKKMKKSLEEEQRARKDLEKLVRKVLKNMN 
                   
               
               
                   
               
               
                 DGGSSG 
               
               
                   
               
               
                 LS_2 linker (SEQ ID NO: 52) encoded by the nucleic acid sequence of SEQ ID NO: 51; 
               
               
                 (SEQ ID NO: 51) 
                   
               
               
                 gggggctctagcggggcagacccaaagaaagtgctggataaggcaaaggatcaggcagagaatagagtgagagaactgaaacag 
                   
               
               
                   
               
               
                 aaactggaggaactgtataaggaggcccggaagctggacctgacccaggagatgaggagaaagctggagctgcgctacatcgccg 
               
               
                   
               
               
                 ccatgctgatggccatcggcgacatctataacgccatcaggcaggccaagcaggaggccgataagctgaagaaggccggcctggt 
               
               
                   
               
               
                 gaatagccagcagctggacgagctgaagcggcgcctggaggagctgaaggaggaggcctccaggaaggccagagattatgggc 
               
               
                   
               
               
                 gggaatttcagctgaaactggagtatggcggcggaagcggaagcgggagcggg 
               
               
                   
               
               
                 (SEQ ID NO: 52) 
                   
               
               
                 GGSSGADPKKVLDKAKDQAENRVRELKQKLEELYKEARKLDLTQEMRRKLELRYIA 
                   
               
               
                   
               
               
                 AMLMAIGDIYNAIRQAKQEADKLKKAGLVNSQQLDELKRRLEELKEEASRKARDYG 
               
               
                   
               
               
                 REFQLKLEYGGGSGSGSG 
               
               
                   
               
               
                 QB_1 linker (SEQ ID NO: 54) encoded by the nucleic acid sequence of SEQ ID NO: 53; 
               
               
                 (SEQ ID NO: 53) 
                   
               
               
                 ggaggctcttcaggcggcacagacgtgggggcaatcgctggaaaggctaacgaggctggacagggggcttatgatgctcaggtca 
                   
               
               
                   
               
               
                 aaaacgacgagcaggatgtggagctggccgaccacgaggccaggatcaagcagctgagaatcgatgtggacgatcacgagtctcg 
               
               
                   
               
               
                 gatcaccgccaacacaaaggccatcacagccctgaatgtgcgcgtgaccacagcagagggagagatcgcatccctgcagaccaac 
               
               
                   
               
               
                 gtgagcgccctggacggaagggtgaccacagcagagaacaatatctccgccctgcaggcagattacgtgagcggcggcagctccg 
               
               
                   
               
               
                 gctccgga 
               
               
                   
               
               
                 (SEQ ID NO: 54) 
                   
               
               
                 GGSSGGTDVGAIAGKANEAGQGAYDAQVKNDEQDVELADHEARIKQLRIDVDDHE 
                   
               
               
                   
               
               
                 SRITANTKAITALNVRVTTAEGEIASLQTNVSALDGRVTTAENNISALQADYVSGGSS 
               
               
                   
               
               
                 GSG 
               
               
                   
               
               
                 QB 2 linker (SEQ ID NO: 56) encoded by the nucleic acid sequence of SEQ ID NO: 55; 
               
               
                 and 
               
               
                   
               
               
                 (SEQ ID NO: 55) 
                   
               
               
                 ggaggctctggaagcgggggaagtagcggacctcacatgattgctccaggacatcgggacgagtttgaccctaagctgccaacagg 
                   
               
               
                   
               
               
                 cgagaaagaagaggtgccaggcaagcccggcatcaagaaccctgagacaggcgacgtggtgaggccccctgtggattctgtgaca 
               
               
                   
               
               
                 aagtacggcccagtgaagggcgacagcatcgtggagaaggaggagatccccttcgagaaggagaggaagtttaaccctgatctgg 
               
               
                   
               
               
                 ccccaggcaccgagaaggtgacaagagagggccagaagggcgagaagaccatcaccacacccacactgaagaatcctctgaccg 
               
               
                   
               
               
                 gcgagatcatcagcaagggcgagtccaaggaggagatcacaaaggaccccatcaacgaactgaccgaatggggaccagagacag 
               
               
                   
               
               
                 gaggaagcggcagcggcggaagcagc 
               
               
                   
               
               
                 (SEQ ID NO: 56) 
                   
               
               
                 GGSGSGGSSGPHMIAPGHRDEFDPKLPTGEKEEVPGKPGIKNPETGDVVRPPVDSVT 
                   
               
               
                   
               
               
                 KYGPVKGDSIVEKEEIPFEKERKFNPDLAPGTEKVTREGQKGEKTITTPTLKNPLTGEI 
               
               
                   
               
               
                 ISKGESKEEITKDPINELTEWGPETGGSGSGGSS 
               
               
                   
               
               
                 IC1/IC2 linker (SEQ ID NO: 58) encoded by the nucleic acid sequence of SEQ ID NO: 57 
               
               
                 (SEQ ID NO: 57) 
                   
               
               
                 ggaggcagcggcagcggcagcggg 
                   
               
               
                   
               
               
                 (SEQ ID NO: 58) 
                   
               
               
                 GGSGSGSG 
                   
               
            
           
         
       
     
     Accordingly, in some embodiments, the linker peptide encoded by the expressible nucleic acid sequence of the present disclosure comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. In some embodiments, the linker peptide comprises the amino acid sequence of SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding the linker peptide comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding the linker peptide comprises the nucleotide sequence of SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. In other embodiments, the nucleic acid sequence encoding the linker peptide comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a nucleic acid sequence that is complementary to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding the linker peptide comprises a nucleic acid sequence that is complementary to the nucleotide sequence of SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof 
     4. Viral Antigens 
     The expressible nucleic acid sequence of the present disclosure comprises a nucleic acid sequence encoding an antigen domain comprising a viral antigen, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the viral antigen comprises an antigen from a virus from the family of Coronaviridae. In some embodiments, the viral antigen comprises an antigen from a coronavirus. In some embodiments, the viral antigen comprises an antigen from SARS-CoV. In some embodiments, the viral antigen comprises an antigen from SARS-CoV-2. In some embodiments, the viral antigen comprises the spike protein of SARS-CoV-2, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the viral antigen comprises a viral trimer polypeptide, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the viral trimer comprises a trimer from a virus from the family of Coronaviridae. In some embodiments, the viral trimer comprises a trimer from a coronavirus. In some embodiments, the viral trimer comprises a trimer from SARS-CoV. In some embodiments, the viral trimer comprises a trimer from SARS-CoV-2. In some embodiments, the viral trimer comprises the spike protein of SARS-CoV-2, a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. 
     A non-limiting example of a viral antigen is a fragment of the surface glycoprotein (or spike protein or S protein) of SARS-CoV-2 having the amino acid sequence of SEQ ID NO: 60 encoded by the nucleic acid sequence of SEQ ID NO: 59 (GenBank Accession No. QHD43416). 
     
       
         
           
               
               
            
               
                 (SEQ ID NO: 59) 
                   
               
               
                 atgtttgtttttcttgttttattgccactagtctctagtcagtgtgttaatcttacaaccagaactcaattaccccctgcatacactaattctttcac 
                   
               
               
                   
               
               
                 acgtggtgtttattaccctgacaaagttttcagatcctcagttttacattcaactcaggacttgttcttacctttcttttccaatgttacttggttcc 
               
               
                   
               
               
                 atgctatacatgtctctgggaccaatggtactaagaggtttgataaccctgtcctaccatttaatgatggtgtttattttgcttccactgagaa 
               
               
                   
               
               
                 gtctaacataataagaggctggatttttggtactactttagattcgaagacccagtccctacttattgttaataacgctactaatgttgttatta 
               
               
                   
               
               
                 aagtctgtgaatttcaattttgtaatgatccatttttgggtgtttattaccacaaaaacaacaaaagttggatggaaagtgagttcagagtttat 
               
               
                   
               
               
                 tctagtgcgaataattgcacttttgaatatgtctctcagccttttcttatggaccttgaaggaaaacagggtaatttcaaaaatcttagggaat 
               
               
                   
               
               
                 ttgtgtttaagaatattgatggttattttaaaatatattctaagcacacgcctattaatttagtgcgtgatctccctcagggtttttcggctttaga 
               
               
                   
               
               
                 accattggtagatttgccaataggtattaacatcactaggtttcaaactttacttgctttacatagaagttatttgactcctggtgattcttcttca 
               
               
                   
               
               
                 ggttggacagctggtgctgcagcttattatgtgggttatcttcaacctaggacttttctattaaaatataatgaaaatggaaccattacagat 
               
               
                   
               
               
                 gctgtagactgtgcacttgaccctctctcagaaacaaagtgtacgttgaaatccttcactgtagaaaaaggaatctatcaaacttctaactt 
               
               
                   
               
               
                 tagagtccaaccaacagaatctattgttagatttcctaatattacaaacttgtgcccttttggtgaagtttttaacgccaccagatttgcatctg 
               
               
                   
               
               
                 tttatgcttggaacaggaagagaatcagcaactgtgttgctgattattctgtcctatataattccgcatcattttccacttttaagtgttatgga 
               
               
                   
               
               
                 gtgtctcctactaaattaaatgatctctgctttactaatgtctatgcagattcatttgtaattagaggtgatgaagtcagacaaatcgctccag 
               
               
                   
               
               
                 ggcaaactggaaagattgctgattataattataaattaccagatgattttacaggctgcgttatagcttggaattctaacaatcttgattctaa 
               
               
                   
               
               
                 ggttggtggtaattataattacctgtatagattgtttaggaagtctaatctcaaaccttttgagagagatatttcaactgaaatctatcaggcc 
               
               
                   
               
               
                 ggtagcacaccttgtaatggtgttgaaggttttaattgttactttcctttacaatcatatggtttccaacccactaatggtgttggttaccaacc 
               
               
                   
               
               
                 atacagagtagtagtactttcttttgaacttctacatgcaccagcaactgtttgtggacctaaaaagtctactaatttggttaaaaacaaatgt 
               
               
                   
               
               
                 gtcaatttcaacttcaatggtttaacaggcacaggtgttcttactgagtctaacaaaaagtttctgcctttccaacaatttggcagagacatt 
               
               
                   
               
               
                 gctgacactactgatgctgtccgtgatccacagacacttgagattcttgacattacaccatgttcttttggtggtgtcagtgttataacacca 
               
               
                   
               
               
                 ggaacaaatacttctaaccaggttgctgttctttatcaggatgttaactgcacagaagtccctgttgctattcatgcagatcaacttactcct 
               
               
                   
               
               
                 acttggcgtgtttattctacaggttctaatgtttttcaaacacgtgcaggctgtttaataggggctgaacatgtcaacaactcatatgagtgt 
               
               
                   
               
               
                 gacatacccattggtgcaggtatatgcgctagttatcagactcagactaattctcctcggcgggcacgtagtgtagctagtcaatccatca 
               
               
                   
               
               
                 ttgcctacactatgtcacttggtgcagaaaattcagttgcttactctaataactctattgccatacccacaaattttactattagtgttaccaca 
               
               
                   
               
               
                 gaaattctaccagtgtctatgaccaagacatcagtagattgtacaatgtacatttgtggtgattcaactgaatgcagcaatcttttgttgcaat 
               
               
                   
               
               
                 atggcagtttttgtacacaattaaaccgtgctttaactggaatagctgttgaacaagacaaaaacacccaagaagtttttgcacaagtcaa 
               
               
                   
               
               
                 acaaatttacaaaacaccaccaattaaagattttggtggttttaatttttcacaaatattaccagatccatcaaaaccaagcaagaggtcatt 
               
               
                   
               
               
                 tattgaagatctacttttcaacaaagtgacacttgcagatgctggcttcatcaaacaatatggtgattgccttggtgatattgctgctagaga 
               
               
                   
               
               
                 cctcatttgtgcacaaaagtttaacggccttactgttttgccacctttgctcacagatgaaatgattgctcaatacacttctgcactgttagcg 
               
               
                   
               
               
                 ggtacaatcacttctggttggacctttggtgcaggtgctgcattacaaataccatttgctatgcaaatggcttataggtttaatggtattgga 
               
               
                   
               
               
                 gttacacagaatgttctctatgagaaccaaaaattgattgccaaccaatttaatagtgctattggcaaaattcaagactcactttcttccaca 
               
               
                   
               
               
                 gcaagtgcacttggaaaacttcaagatgtggtcaaccaaaatgcacaagctttaaacacgcttgttaaacaacttagctccaattttggtg 
               
               
                   
               
               
                 caatttcaagtgttttaaatgatatcctttcacgtcttgacaaagttgaggctgaagtgcaaattgataggttgatcacaggcagacttcaaa 
               
               
                   
               
               
                 gtttgcagacatatgtgactcaacaattaattagagctgcagaaatcagagcttctgctaatcttgctgctactaaaatgtcagagtgtgta 
               
               
                   
               
               
                 cttggacaatcaaaaagagttgatttttgtggaaagggctatcatcttatgtccttccctcagtcagcacctcatggtgtagtcttcttgcatg 
               
               
                   
               
               
                 tgacttatgtccctgcacaagaaaagaacttcacaactgctcctgccatttgtcatgatggaaaagcacactttcctcgtgaaggtgtcttt 
               
               
                   
               
               
                 gtttcaaatggcacacactggtttgtaacacaaaggaatttttatgaaccacaaatcattactacagacaacacatttgtgtctggtaactgt 
               
               
                   
               
               
                 gatgttgtaataggaattgtcaacaacacagtttatgatcctttgcaacctgaattagactcattcaaggaggagttagataaatattttaag 
               
               
                   
               
               
                 aatcatacatcaccagatgttgatttaggtgacatctctggcattaatgcttcagttgtaaacattcaaaaagaaattgaccgcctcaatga 
               
               
                   
               
               
                 ggttgccaagaatttaaatgaatctctcatcgatctccaagaacttggaaagtatgagcagtatataaaatggccatggtacatttggcta 
               
               
                   
               
               
                 ggttttatagctggcttgattgccatagtaatggtgacaattatgctttgctgtatgaccagttgctgtagttgtctcaagggctgttgttcttgt 
               
               
                   
               
               
                 ggatcctgctgcaaatttgatgaagacgactctgagccagtgctcaaaggagtcaaattacattacacataa 
               
               
                   
               
               
                 (SEQ ID NO: 60) 
                   
               
               
                 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPF 
                   
               
               
                   
               
               
                 FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQS 
               
               
                   
               
               
                 LLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS 
               
               
                   
               
               
                 QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPI 
               
               
                   
               
               
                 GINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDA 
               
               
                   
               
               
                 VDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRF 
               
               
                   
               
               
                 ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG 
               
               
                   
               
               
                 DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN 
               
               
                   
               
               
                 LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL 
               
               
                   
               
               
                 HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA 
               
               
                   
               
               
                 VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTW 
               
               
                   
               
               
                 RVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSI 
               
               
                   
               
               
                 IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSN 
               
               
                   
               
               
                 LLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPS 
               
               
                   
               
               
                 KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDE 
               
               
                   
               
               
                 MIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIA 
               
               
                   
               
               
                 NQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS 
               
               
                   
               
               
                 RLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKR 
               
               
                   
               
               
                 VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVF 
               
               
                   
               
               
                 VSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD 
               
               
                   
               
               
                 KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK 
               
               
                   
               
               
                 WPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGV 
               
               
                   
               
               
                 KLHYT 
               
            
           
         
       
     
     Non-limiting examples of fragments of the S protein of SARS-CoV-2 comprises the following sequences: 
     
       
         
           
               
               
            
               
                 (SEQ ID NO: 171) 
                   
               
               
                 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPF 
                   
               
               
                   
               
               
                 FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQS 
               
               
                   
               
               
                 LLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS 
               
               
                   
               
               
                 QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPI 
               
               
                   
               
               
                 GINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDA 
               
               
                   
               
               
                 VDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRF 
               
               
                   
               
               
                 ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG 
               
               
                   
               
               
                 DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN 
               
               
                   
               
               
                 LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL 
               
               
                   
               
               
                 HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA 
               
               
                   
               
               
                 VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTW 
               
               
                   
               
               
                 RVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSI 
               
               
                   
               
               
                 IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSN 
               
               
                   
               
               
                 LLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPS 
               
               
                   
               
               
                 KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDE 
               
               
                   
               
               
                 MIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIA 
               
               
                   
               
               
                 NQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS 
               
               
                   
               
               
                 RLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKR 
               
               
                   
               
               
                 VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVF 
               
               
                   
               
               
                 VSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD 
               
               
                   
               
               
                 KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK 
               
               
                   
               
               
                 WPW 
               
               
                   
               
               
                 (SEQ ID NO: 172) 
                   
               
               
                 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPF 
                   
               
               
                   
               
               
                 FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQS 
               
               
                   
               
               
                 LLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS 
               
               
                   
               
               
                 QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPI 
               
               
                   
               
               
                 GINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDA 
               
               
                   
               
               
                 VDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRF 
               
               
                   
               
               
                 ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG 
               
               
                   
               
               
                 DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN 
               
               
                   
               
               
                 LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL 
               
               
                   
               
               
                 HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA 
               
               
                   
               
               
                 VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTW 
               
               
                   
               
               
                 RVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSI 
               
               
                   
               
               
                 IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSN 
               
               
                   
               
               
                 LLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPS 
               
               
                   
               
               
                 KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDE 
               
               
                   
               
               
                 MIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIA 
               
               
                   
               
               
                 NQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS 
               
               
                   
               
               
                 RLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKR 
               
               
                   
               
               
                 VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVF 
               
               
                   
               
               
                 VSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD 
               
               
                   
               
               
                 KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK 
               
               
                   
               
               
                 WP 
               
               
                   
               
               
                 (SEQ ID NO: 173) 
                   
               
               
                 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPF 
                   
               
               
                   
               
               
                 FSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQS 
               
               
                   
               
               
                 LLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVS 
               
               
                   
               
               
                 QPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPI 
               
               
                   
               
               
                 GINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDA 
               
               
                   
               
               
                 VDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRF 
               
               
                   
               
               
                 ASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRG 
               
               
                   
               
               
                 DEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSN 
               
               
                   
               
               
                 LKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL 
               
               
                   
               
               
                 HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA 
               
               
                   
               
               
                 VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTW 
               
               
                   
               
               
                 RVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSI 
               
               
                   
               
               
                 IAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSN 
               
               
                   
               
               
                 LLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPS 
               
               
                   
               
               
                 KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDE 
               
               
                   
               
               
                 MIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIA 
               
               
                   
               
               
                 NQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILS 
               
               
                   
               
               
                 RLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKR 
               
               
                   
               
               
                 VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVF 
               
               
                   
               
               
                 VSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD 
               
               
                   
               
               
                 KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ 
               
               
                   
               
               
                 (SEQ ID NO: 174) 
                   
               
               
                 SQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHV 
                   
               
               
                   
               
               
                 SGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIK 
               
               
                   
               
               
                 VCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGN 
               
               
                   
               
               
                 FKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALH 
               
               
                   
               
               
                 RSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCT 
               
               
                   
               
               
                 LKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNC 
               
               
                   
               
               
                 VADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIA 
               
               
                   
               
               
                 DYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG 
               
               
                   
               
               
                 STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNL 
               
               
                   
               
               
                 VKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCS 
               
               
                   
               
               
                 FGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA 
               
               
                   
               
               
                 GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVA 
               
               
                   
               
               
                 YSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNR 
               
               
                   
               
               
                 ALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFN 
               
               
                   
               
               
                 KVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTI 
               
               
                   
               
               
                 TSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLS 
               
               
                   
               
               
                 STASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLI 
               
               
                   
               
               
                 TGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP 
               
               
                   
               
               
                 QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNF 
               
               
                   
               
               
                 YEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLG 
               
               
                   
               
               
                 DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ 
               
               
                   
               
               
                 (SEQ ID NO: 175) 
                   
               
               
                 NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDL 
                   
               
               
                   
               
               
                 CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGG 
               
               
                   
               
               
                 NYNYLYRLFRKSNLKPFERDIST 
               
               
                   
               
               
                 (SEQ ID NO: 176) 
                   
               
               
                 SFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKF 
                   
               
               
                   
               
               
                 (SEQ ID NO: 177) 
                   
               
               
                 PSKRSFIEDLLFNKV 
                   
               
            
           
         
       
     
     A further non-limiting example of a viral antigen is a fragment of the envelop protein (or E protein) of SARS-CoV-2 having the amino acid sequence of SEQ ID NO: 62 encoded by the nucleic acid sequence of SEQ ID NO: 61 (GenBank Accession No. QHD43418). 
     
       
         
           
               
            
               
                 (SEQ ID NO: 61) 
               
               
                 atgtactcattcgtttcggaagagacaggtacgttaatagttaatagcgt 
               
               
                   
               
               
                 acttctttttcttgctttcgtggtattcttgctagttacactagccatcc 
               
               
                   
               
               
                 ttactgcgcttcgattgtgtgcgtactgctgcaatattgttaacgtgagt 
               
               
                   
               
               
                 cttgtaaaaccttctttttacgtttactctcgtgttaaaaatctgaattc 
               
               
                   
               
               
                 ttctagagttcctgatcttctggtctaa 
               
               
                   
               
               
                 (SEQ ID NO: 62) 
               
               
                 MYSFVSEETGTLIVNSVLLFLAFVVFLLVTLAILTALRLCAYCCNIVNVS 
               
               
                   
               
               
                 LVKPSFYVYSRVKNLNSSRVPDLLV 
               
            
           
         
       
     
     Another non-limiting example of a viral antigen is a fragment of the membrane glycoprotein (or M protein) of SARS-CoV-2 having the amino acid sequence of SEQ ID NO: 64 encoded by the nucleic acid sequence of SEQ ID NO: 63 (GenBank Accession No. QHD43419). 
     
       
         
           
               
            
               
                 (SEQ ID NO: 63) 
               
               
                 ccatggcagattccaacggtactattaccgttgaagagcttaaaaagctc 
               
               
                   
               
               
                 cttgaacaatggaacctagtaataggtttcctattccttacatggatttg 
               
               
                   
               
               
                 tcttctacaatttgcctatgccaacaggaataggtttttgtatataatta 
               
               
                   
               
               
                 agttaattttcctctggctgttatggccagtaactttagcttgttttgtg 
               
               
                   
               
               
                 cttgctgctgtttacagaataaattggatcaccggtggaattgctatcgc 
               
               
                   
               
               
                 aatggcttgtcttgtaggcttgatgtggctcagctacttcattgcttctt 
               
               
                   
               
               
                 tcagactgtttgcgcgtacgcgttccatgtggtcattcaatccagaaact 
               
               
                   
               
               
                 aacattcttctcaacgtgccactccatggcactattctgaccagaccgct 
               
               
                   
               
               
                 tctagaaagtgaactcgtaatcggagctgtgatccttcgtggacatcttc 
               
               
                   
               
               
                 gtattgctggacaccatctaggacgctgtgacatcaaggacctgcctaaa 
               
               
                   
               
               
                 gaaatcactgttgctacatcacgaacgctttcttattacaaattgggagc 
               
               
                   
               
               
                 ttcgcagcgtgtagcaggtgactcaggttttgctgcatacagtcgctaca 
               
               
                   
               
               
                 ggattggcaactataaattaaacacagaccattccagtagcagtgacaat 
               
               
                   
               
               
                 attgctttgcttgtacagtaa 
               
               
                   
               
               
                 (SEQ ID NO: 64) 
               
               
                 MADSNGTITVEELKKLLEQWNLVIGFLFLTWICLLQFAYANRNRFLYIIK 
               
               
                   
               
               
                 LIFLWLLWPVTLACFVLAAVYRINWITGGIAIAMACLVGLMWLSYFIASF 
               
               
                   
               
               
                 RLFARTRSMWSFNPETNILLNVPLHGTILTRPLLESELVIGAVILRGHLR 
               
               
                   
               
               
                 IAGHHLGRCDIKDLPKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYR 
               
               
                   
               
               
                 IGNYKLNTDHSSSSDNIALLVQ 
               
            
           
         
       
     
     A yet another non-limiting example of a viral antigen is a fragment of the nucleocapsid phosphoprotein (or N protein) of SARS-CoV-2 having the amino acid sequence of SEQ ID NO: 66 encoded by the nucleic acid sequence of SEQ ID NO: 65 (GenBank Accession No. QHD43423). 
     
       
         
           
               
            
               
                 (SEQ ID NO: 65) 
               
               
                 atgtctgataatggaccccaaaatcagcgaaatgcaccccgcattacgtt 
               
               
                   
               
               
                 tggtggaccctcagattcaactggcagtaaccagaatggagaacgcagtg 
               
               
                   
               
               
                 gggcgcgatcaaaacaacgtcggccccaaggtttacccaataatactgcg 
               
               
                   
               
               
                 tcttggttcaccgctctcactcaacatggcaaggaagaccttaaattccc 
               
               
                   
               
               
                 tcgaggacaaggcgttccaattaacaccaatagcagtccagatgaccaaa 
               
               
                   
               
               
                 ttggctactaccgaagagctaccagacgaattcgtggtggtgacggtaaa 
               
               
                   
               
               
                 atgaaagatctcagtccaagatggtatttctactacctaggaactgggcc 
               
               
                   
               
               
                 agaagctggacttccctatggtgctaacaaagacggcatcatatgggttg 
               
               
                   
               
               
                 caactgagggagccttgaatacaccaaaagatcacattggcacccgcaat 
               
               
                   
               
               
                 cctgctaacaatgctgcaatcgtgctacaacttcctcaaggaacaacatt 
               
               
                   
               
               
                 gccaaaaggcttctacgcagaagggagcagaggcggcagtcaagcctctt 
               
               
                   
               
               
                 ctcgttcctcatcacgtagtcgcaacagttcaagaaattcaactccaggc 
               
               
                   
               
               
                 agcagtaggggaacttctcctgctagaatggctggcaatggcggtgatgc 
               
               
                   
               
               
                 tgctcttgctttgctgctgcttgacagattgaaccagcttgagagcaaaa 
               
               
                   
               
               
                 tgtctggtaaaggccaacaacaacaaggccaaactgtcactaagaaatct 
               
               
                   
               
               
                 gctgctgaggcttctaagaagcctcggcaaaaacgtactgccactaaagc 
               
               
                   
               
               
                 atacaatgtaacacaagctttcggcagacgtggtccagaacaaacccaag 
               
               
                   
               
               
                 gaaattttggggaccaggaactaatcagacaaggaactgattacaaacat 
               
               
                   
               
               
                 tggccgcaaattgcacaatttgcccccagcgcttcagcgttcttcggaat 
               
               
                   
               
               
                 gtcgcgcattggcatggaagtcacaccttcgggaacgtggttgacctaca 
               
               
                   
               
               
                 caggtgccatcaaattggatgacaaagatccaaatttcaaagatcaagtc 
               
               
                   
               
               
                 attttgctgaataagcatattgacgcatacaaaacattcccaccaacaga 
               
               
                   
               
               
                 gcctaaaaaggacaaaaagaagaaggctgatgaaactcaagccttaccgc 
               
               
                   
               
               
                 agagacagaagaaacagcaaactgtgactcttcttcctgctgcagatttg 
               
               
                   
               
               
                 gatgatttctccaaacaattgcaacaatccatgagcagtgctgactcaac 
               
               
                   
               
               
                 tcaggcctaa 
               
               
                   
               
               
                 (SEQ ID NO: 66) 
               
               
                 MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTA 
               
               
                   
               
               
                 SWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGK 
               
               
                   
               
               
                 MKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRN 
               
               
                   
               
               
                 PANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPG 
               
               
                   
               
               
                 SSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKS 
               
               
                   
               
               
                 AAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKH 
               
               
                   
               
               
                 WPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQV 
               
               
                   
               
               
                 ILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADL 
               
               
                   
               
               
                 DDFSKQLQQSMSSADSTQA 
               
            
           
         
       
     
     Accordingly, in some embodiments, the viral antigen encoded by the expressible nucleic acid sequence of the present disclosure comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the viral antigen comprises the amino acid sequence of SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the nucleic acid sequence encoding the viral antigen comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the nucleic acid sequence encoding the viral antigen comprises the nucleotide sequence of SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the nucleic acid sequence encoding the viral antigen comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a nucleic acid sequence that is complementary to SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the nucleic acid sequence encoding the viral antigen comprises a nucleic acid sequence that is complementary to the nucleotide sequence of SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. 
     In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1100 to about 1300 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1100 to about 1200 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1100 to about 1300 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1200 to about 1210 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1180 to about 1220 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1180 to about 1215 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1180 to about 1210 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1180 to about 1200 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1220 to about 1230 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1100 to about 1300 nucletides in length. In some embodiments, the composition or pharmaceutical composition of the disclosure comprises an expressible DNA or RNA sequence that encodes a viral antigen and is from about 1100 to about 1300 nucletides in length. 
     In some embodiments, the expressible nucleic acid sequence encodes a fusion protein comprising one or a plurality of coronaviral envelope polypeptides or functional fragments thereof. In some embodiments, the fusion protein comprise a furin cleavage site. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding, in a 5′ to 3′ orientation, at least three monomers of coronaviral envelope proteins. In some embodiments, the at least three monomers of coronaviral envelope proteins are separated by a furin cleavage site. In some embodiments, the furin cleavage site comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to RRRRRR (SEQ ID NO: 67), or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the furin cleavage site comprises the amino acid sequence of SEQ ID NO: 67, or a functional fragment or variant thereof or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence encodes a polypeptide free of carbohydrate proximate to at least 30 amino acids from the carboxy end of the polypeptide. In some embodiments, the expressible nucleic acid sequence encodes a polypeptide free of carbohydrate proximate to at least 20 amino acids from the carboxy end of the polypeptide. In some embodiments, the expressible nucleic acid sequence encodes a polypeptide free of carbohydrate proximate to at least 10 amino acids from the carboxy end of the polypeptide. In some embodiments, the expressible nucleic acid sequence encodes a polypeptide free of carbohydrate proximate to at least 50 amino acids from the carboxy end of the polypeptide. 
     In some embodiments, the expressible nucleic acid sequence of the disclosure comprises at least a first nucleic acid sequence encoding a first, a second and/or a third polypeptides, each first, second or third polypeptide comprising a viral antigen. In some embodiments, the expressible nucleic acid sequence encodes one or a plurality of fusion proteins, each fusion protein comprising at least a first, a second, and/or a third polypeptide contiguously linked by a linker sequence. In some embodiments, the expressible nucleic acid sequence of the disclosure comprises at least a first nucleic acid sequence encoding at least one self-assembling polypeptide. In some embodiments, the self-assembling polypeptide is at least one self-assembling component of a nanoparticle or at least one coronaviral monomer, the coronaviral monomer capable of assembling into a coronaviral trimer upon expression in a cell. In some embodiments, the expressible nucleic acid sequence comprises a nucleic acid sequence encoding a coronaviral antigen, but free of a nucleic acid sequence encoding a self-assembling polypeptide. In some embodiments, the expressible nucleic acid sequence of the disclosure comprises a nucleic acid sequence operably linked to a regulatory sequence and encodes a fusion peptide comprising one or a plurality of self-assembling polypeptides, wherein at least one of the self-assembling polypeptides is a self-assembling coronaviral antigen. 
     In some embodiments, upon administration to a subject a composition comprising the expressible nucleic acid sequence of the disclosure, the expressible nucleic acid sequence is transfected or transduced into an antigen presenting cell. After a plurality of expressible nucleic acid sequences are expressed, the self-assembling polypeptides assemble with into a non-native form of a viral antigen. In some embodiments, the non-native form of a viral antigen comprises a coronaviral trimer exposing an amino acid sequence that is not naturally exposed or free of carbohydrate as compared to its corresponding native form or variants thereof. Expression and presentation of the one or plurality of self-assembling polypeptides elicits an immune response against an epitope. In some embodiments, the epitope comprises a non-native secondary structure of the one or plurality of self-assembling polypeptides. 
     In some embodiments, the comopsitions comprise a nucleic acid seqeunce encoding any combination of nucleic acid sequences disclosed herein or vairants thereof. In some embodiments, the comopsitions comprise a viral particle that comprises an expressible nucleic acid seqeunce encoding any combination of nucleic acid sequences disclosed herein or variants thereof. The component of the self-assemblying peptide can be any monomer that, upon expression, self-assembles into a particle comprising 7, 14, 27 or 60 peptides sided particle, each peptide side fused to at least one antigen from the Coronoviridae family. In some embodiments, the composition comprises a particle comprising 7, 14, 27 or 60 peptides sided particle, each peptide side is fused to at least one antigen from the Coronoviridae family, wherein the antigen is positioned in an energetically stable state as compared to the unassociated energy state. In some emboidments, the disclosure relates to a cell comprising a particle comprising 7, 14, 27 or 60 peptides sided particle, each peptide side is fused to at least one antigen from the Coronoviridae family, wherein the antigen is positioned in an energetically stable state as compared to the unassociated energy state. In some embodiments, the particle is able to display the at least one viral antigen in a conformationally stable state that is more immunologically active, such activity elicting a more therapeutically effective immune response as compared to eh immune response elicited from administration of the DNA or RNA. In some embodiments, the energetically stable state is identified by association of the peptide to an antibody through surface plasmon resonance (SPR). In some embodiments, the energetically stable state is measured by absorbance units when either a ligand for the antigen or the antigen is immobilized to a surface, and the other binding partner is then passed over the surface as analyte. In some embodiments, the association can be measured through SPR on a BIACORE® system. 
     A detailed discussion of the technical aspects of the BIACORE® instruments and the phenomenon of SPR may be found in U.S. Pat. No. 5,313,264 (the full disclosure of which is incorporated by reference herein in its entirety). In the BIACORE® system, the SPR response values are expressed in resonance units (RU). One RU represents a change of 0.0001° in the angle of minimum reflected light intensity. For an SPR based sensor system like the BIACORE® system, a difference in refractive index between the two guiding fluids of, say, about 100 RU may be convenient, and the fluid interface position may be determined by means of per se conventional sensorgrams. 
     In some embodiments, it may be preferred to keep the total flow rate constant when introducing the sample flow. In such a case, the flow rates of the two guiding fluids are reduced while maintaining the flow rate ratio between them. Assume, for example, that the flow rate of one guiding fluid is 70 μl/min and the flow rate of the other guiding fluid is 30 μl/min, the total flow rate being 100 μl/min, and that a sample fluid flow of 20 μl/min is introduced between the guiding fluids. To maintain the total fluid flow rate at 100 μl/min, the flow rates of the guiding fluids will have to be reduced to 60 and 20 μl/min, respectively. The position of a sample fluid flow on a surface may be presented in various ways. A non-limiting example of a experiment indicating the relative responses obtained at different detector rows as the sample flow is guided laterally across the sensing surface of a flow cell by two guiding buffers in a BIACORE® system equipped with a ψ-cell (BIACORE® S51 is a SPR-based biosensor instrument, normally equipped with two Y-type flow cells, each allowing a dual flow over the a sensor surface for hydrodynamic addressing; Biacore AB, Uppsala, Sweden). Total buffer flow can be set to 100 μl/min, and the flow rates of the two buffer flows can be changed in steps of 2 μl/min, starting with 2 μl/min for one buffer and 98 μl/min for the other. Sample fluid flow can be 20 μl/min all the time. Relative responses&gt;0.1 (i.e. 10% coverage of the detector row) are represented are measured as absorbance over time. This approach thus permits convenient visual monitoring of the sample fluid flow. 
     In some embodiments, the stability of an antigen secondary structure with an elevated stability as compared to a native antigen or antigen not fused to self-assemblying peptide is from about 10 to about 10,000 RU more than the RU from a control as measured by SPR. In some embodiments, the stability of an antigen secondary structure with an elevated stability as compared to a native antigen or antigen not fused to self-assemblying peptide is from about 5 to about 1,000 RU more than the RU from a control as measured by SPR. In some embodiments, the stability of an antigen secondary structure with an elevated stability as compared to a native antigen or antigen not fused to self-assemblying peptide is from about 100 to about 10,000 RU more than the RU from a control as measured by SPR. In some embodiments, the stability of an antigen secondary structure with an elevated stability as compared to a native antigen or antigen not fused to self-assemblying peptide is from about 100 to about 500 RU more than the RU from a control as measured by SPR. In some embodiments, the stability of an antigen secondary structure with an elevated stability as compared to a native antigen or antigen not fused to self-assemblying peptide is from about 100 to about 200 RU more than the RU from a control as measured by SPR. 
     5. Regulatory Sequences 
     In some embodiments, the expressible nucleic acid sequence can be operably linked to one or a plurality of regulatory sequences. The term “regulatory sequence” as used herein refer to DNA sequences which are necessary to effect expression of sequences to which they are ligated. The term “regulatory sequence” is intended to include, as a minimum, all components necessary for expression and optionally additional advantageous components. Examples of regulatory sequences include, but not limited to, promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Further examples of regulatory sequences are described in, for example, Goeddel, 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. and Baron et al., 1995, Nucleic Acids Res. 23:3605-06. In some embodiments, the regulatory sequence is a promoter sequence. As used herein, a “promoter” means a region of DNA upstream from the transcription start and which is involved in binding RNA polymerase and other proteins to start transcription. Reference herein to a “promoter” is to be taken in its broadest context and includes the transcriptional regulatory sequences derived from a classical eukaryotic genomic gene, including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner. Consequently, a repressible promoter&#39;s rate of transcription decreases in response to a repressing agent. An inducible promoter&#39;s rate of transcription increases in response to an inducing agent. A constitutive promoter&#39;s rate of transcription is not specifically regulated, though it can vary under the influence of general metabolic conditions. The term “promoter” also includes the transcriptional regulatory sequences of a classical prokaryotic gene, in which case it may include a −35 box sequence and/or a −10 box transcriptional regulatory sequences. The term “promoter” is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of a nucleic acid molecule in a cell, tissue or organ. 
     6. Expressible Nucleic Acid Sequences 
     The expressible nucleic acid sequence comprised in the composition of the present disclosure can be in form of a DNA molecule, a RNA molecule or transcript, or a DNA/RNA hybrid. In some embodiments, the expressible nucleic acid sequence is in form of a DNA molecule. In some embodiments, the expressible nucleic acid sequence is in form of a RNA molecule or transcript. In some embodiments, the expressible nucleic acid sequence is in form of a DNA/RNA hybrid. 
     In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 10, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 12, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 14, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 16, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 18, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 20, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. 
     In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 175. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 176. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 177. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 12, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 175. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 12, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 176. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a self-assembling polypeptide comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 12, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 177. 
     In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. 
     In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 171. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 172. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 173. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 174. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 175. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 176. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 177. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 171. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 172. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 173. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 174. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 175. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 176. In some embodiments, the expressible nucleic acid sequence comprises a first nucleic acid sequence encoding a leader sequence comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral antigen comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 177. 
     Exemplary expressible nucleic acid sequences include, but not limited to those provided in TABLE 1. 
     
       
         
           
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Exemplary Expressible Nucleic Acid Sequences (DNA and RNA) of the 
               
               
                 Disclosure and the corresponding coding polypeptide sequences (underlined amino acid 
               
               
                 residues are glycan sites). 
               
               
                   
               
             
            
               
                 I. CoV2 Nanoparticle Constructs 
               
               
                 WuhanS_FP12_L9GT60_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcatgcagatctacgaaggaaaa 
               
               
                 ctgaccgctgagggactgaggttcggaattgtcgcaagccgcgcgaatcacgcactggtggataggctggtggaaggcgctatcga 
               
               
                 cgcaattgtccggcacggcgggagagaggaagacatcacactggtgagagtctgcggcagctgggagattcccgtggcagctgga 
               
               
                 gaactggctcgaaaggaggacatcgatgccgtgatcgctattggggtcctgtgccgaggagcaactcccagcttcgactacatcgcct 
               
               
                 cagaagtgagcaaggggctggctgatctgtccctggagctgaggaaacctatcacttttggcgtgattactgccgacaccctggaaca 
               
               
                 ggcaatcgaggcggccggcacctgccatggaaacaaaggctgggaagcagccctgtgcgctattgagatggcaaatctgttcaaat 
               
               
                 ctctgcgaggaggctccggaggatctggagggagtggaggctcaggaggaggcgacaccatcacactgccatgccgccctgcac 
               
               
                 cacctccacattgtagctccaacatcaccggcctgattctgacaagacaggggggatatagtaacgataataccgtgattttcaggccct 
               
               
                 caggaggggactggagggacatcgcacgatgccagattgctggaacagtggtctctactcagctgtttctgaacggcagtctggctga 
               
               
                 ggaagaggtggtcatccgatctgaagactggcgggataatgcaaagtcaatttgtgtgcagctgaacacaagcgtcgagatcaattgc 
               
               
                 actggcgcagggcactgtaacatttctcgggccaaatgggataataccctgaagcagatcgccagtaaactgagagagcagtacggc 
               
               
                 aataagacaatcatcttcaagccttctagtggaggcgacccagagttcgtgaaccatagctttaattgcgggggagagttcttttattgtg 
               
               
                 attccacacagctgttcgatagcacttggtttgattccaccggtgggagcggaagtggcggttccggatcattcattgaagaccttctcttt 
               
               
                 aacaaggtgaccctcgccgatgcaggtttcattaagcaatatggtgattgcctgggagacatcgcggctcgtgatcttatttgtgcgcag 
               
               
                 aaattttaatga (SEQ ID NO: 68) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaugcagaucuacg 
               
               
                 aaggaaaacugaccgcugagggacugagguucggaauugucgcaagccgcgcgaaucacgcacugguggauaggcuggu 
               
               
                 ggaaggcgcuaucgacgcaauuguccggcacggcgggagagaggaagacaucacacuggugagagucugcggcagcugg 
               
               
                 gagauucccguggcagcuggagaacuggcucgaaaggaggacaucgaugccgugaucgcuauugggguccugugccgag 
               
               
                 gagcaacucccagcuucgacuacaucgccucagaagugagcaaggggcuggcugaucugucccuggagcugaggaaacc 
               
               
                 uaucacuuuuggcgugauuacugccgacacccuggaacaggcaaucgaggcggccggcaccugccauggaaacaaaggcu 
               
               
                 gggaagcagcccugugcgcuauugagauggcaaaucuguucaaaucucugcgaggaggcuccggaggaucuggagggag 
               
               
                 uggaggcucaggaggaggcgacaccaucacacugccaugccgcccugcaccaccuccacauuguagcuccaacaucaccg 
               
               
                 gccugauucugacaagacaggggggauauaguaacgauaauaccgugauuuucaggcccucaggaggggacuggaggga 
               
               
                 caucgcacgaugccagauugcuggaacaguggucucuacucagcuguuucugaacggcagucuggcugaggaagaggug 
               
               
                 gucauccgaucugaagacuggcgggauaaugcaaagucaauuugugugcagcugaacacaagcgucgagaucaauugca 
               
               
                 cuggcgcagggcacuguaacauuucucgggccaaaugggauaauacccugaagcagaucgccaguaaacugagagagcag 
               
               
                 uacggcaauaagacaaucaucuucaagccuucuaguggaggcgacccagaguucgugaaccauagcuuuaauugcgggg 
               
               
                 gagaguucuuuuauugugauuccacacagcuguucgauagcacuugguuugauuccaccggugggagcggaaguggcg 
               
               
                 guuccggaucauucauugaagaccuucucuuuaacaaggugacccucgccgaugcagguuucauuaagcaauaugguga 
               
               
                 uugccugggagacaucgcggcucgugaucuuauuugugcgcagaaauuuuaauga (SEQ ID NO: 69) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMQIYEGKLTAEGLRFGIVASRANHALVDRLVEGAIDAI 
               
               
                 VRHGGREEDITLVRVCGSWEIPVAAGELARKEDIDAVIAIGVLCRGATPSFDYIASEV 
               
               
                 SKGLADLSLELRKPITFGVITADTLEQAIEAAGTCHGNKGWEAALCAIEMANLFKSLR 
               
               
                 GGSGGSGGSGGSGGGDTITLPCRPAPPPHCSSNITGLILTRQGGYSNDNTVIFRPSGGD 
               
               
                 WRDIARCQIAGTVVSTQLFLNGSLAEEEVVIRSEDWRDNAKSICVQLNTSVEINCTGA 
               
               
                 GHCNISRAKW  LKQIASKLREQYGNKTIIFKPSSGGDPEFVNHSFNCGGEFFYCDS 
               
               
                 TQLF  WF  GGSGSGGSGSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICA 
               
               
                 QKF** (SEQ ID NO: 70) 
               
               
                   
               
               
                 WuhanS_FP_L9GT60_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcatgcagatctacgaaggaaaa 
               
               
                 ctgaccgctgagggactgaggttcggaattgtcgcaagccgcgcgaatcacgcactggtggataggctggtggaaggcgctatcga 
               
               
                 cgcaattgtccggcacggcgggagagaggaagacatcacactggtgagagtctgcggcagctgggagattcccgtggcagctgga 
               
               
                 gaactggctcgaaaggaggacatcgatgccgtgatcgctattggggtcctgtgccgaggagcaactcccagcttcgactacatcgcct 
               
               
                 cagaagtgagcaaggggctggctgatctgtccctggagctgaggaaacctatcacttttggcgtgattactgccgacaccctggaaca 
               
               
                 ggcaatcgaggcggccggcacctgccatggaaacaaaggctgggaagcagccctgtgcgctattgagatggcaaatctgttcaaat 
               
               
                 ctctgcgaggaggctccggaggatctggagggagtggaggctcaggaggaggcgacaccatcacactgccatgccgccctgcac 
               
               
                 cacctccacattgtagctccaacatcaccggcctgattctgacaagacaggggggatatagtaacgataataccgtgattttcaggccct 
               
               
                 caggaggggactggagggacatcgcacgatgccagattgctggaacagtggtctctactcagctgtttctgaacggcagtctggctga 
               
               
                 ggaagaggtggtcatccgatctgaagactggcgggataatgcaaagtcaatttgtgtgcagctgaacacaagcgtcgagatcaattgc 
               
               
                 actggcgcagggcactgtaacatttctcgggccaaatgggataataccctgaagcagatcgccagtaaactgagagagcagtacggc 
               
               
                 aataagacaatcatcttcaagccttctagtggaggcgacccagagttcgtgaaccatagctttaattgcgggggagagttcttttattgtg 
               
               
                 attccacacagctgttcgatagcacttggtttgattccaccggtgggagcggaagtggcggttccggaccttcaaagagatctttcattg 
               
               
                 aagacctgcttttcaacaaggtctaatga (SEQ ID NO: 71) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaugcagaucuacg 
               
               
                 aaggaaaacugaccgcugagggacugagguucggaauugucgcaagccgcgcgaaucacgcacugguggauaggcuggu 
               
               
                 ggaaggcgcuaucgacgcaauuguccggcacggcgggagagaggaagacaucacacuggugagagucugcggcagcugg 
               
               
                 gagauucccguggcagcuggagaacuggcucgaaaggaggacaucgaugccgugaucgcuauugggguccugugccgag 
               
               
                 gagcaacucccagcuucgacuacaucgccucagaagugagcaaggggcuggcugaucugucccuggagcugaggaaacc 
               
               
                 uaucacuuuuggcgugauuacugccgacacccuggaacaggcaaucgaggcggccggcaccugccauggaaacaaaggcu 
               
               
                 gggaagcagcccugugcgcuauugagauggcaaaucuguucaaaucucugcgaggaggcuccggaggaucuggagggag 
               
               
                 uggaggcucaggaggaggcgacaccaucacacugccaugccgcccugcaccaccuccacauuguagcuccaacaucaccg 
               
               
                 gccugauucugacaagacaggggggauauaguaacgauaauaccgugauuuucaggcccucaggaggggacuggaggga 
               
               
                 caucgcacgaugccagauugcuggaacaguggucucuacucagcuguuucugaacggcagucuggcugaggaagaggug 
               
               
                 gucauccgaucugaagacuggcgggauaaugcaaagucaauuugugugcagcugaacacaagcgucgagaucaauugca 
               
               
                 cuggcgcagggcacuguaacauuucucgggccaaaugggauaauacccugaagcagaucgccaguaaacugagagagcag 
               
               
                 uacggcaauaagacaaucaucuucaagccuucuaguggaggcgacccagaguucgugaaccauagcuuuaauugcgggg 
               
               
                 gagaguucuuuuauugugauuccacacagcuguucgauagcacuugguuugauuccaccggugggagcggaaguggcg 
               
               
                 guuccggaccuucaaagagaucuuucauugaagaccugcuuuucaacaaggucuaauga (SEQ ID NO: 72) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMQIYEGKLTAEGLRFGIVASRANHALVDRLVEGAIDAI 
               
               
                 VRHGGREEDITLVRVCGSWEIPVAAGELARKEDIDAVIAIGVLCRGATPSFDYIASEV 
               
               
                 SKGLADLSLELRKPITFGVITADTLEQAIEAAGTCHGNKGWEAALCAIEMANLFKSLR 
               
               
                 GGSGGSGGSGGSGGGDTITLPCRPAPPPHCSSNITGLILTRQGGYSNDNTVIFRPSGGD 
               
               
                 WRDIARCQIAGTVVSTQLFLNGSLAEEEVVIRSEDWRDNAKSICVQLNTSVEINCTGA 
               
               
                 GHCNISRAKW  LKQIASKLREQYGNKTIIFKPSSGGDPEFVNHSFNCGGEFFYCDS 
               
               
                 TQLF  WF  GGSGSGGSGPSKRSFIEDLLFNKV** (SEQ ID NO: 73) 
               
               
                   
               
               
                 WuhanS_RBD_gmax_180_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcctctcaattgccccaacgttga 
               
               
                 tcaaccgggacaagccatacacgaaagaggaacttatggagatattgcggttggccattatagctgaactcgatgcaattaatctctatg 
               
               
                 aacaaatggcccgctatagcgaagacgaaaatgtgagaaagatcttgttggacgtcgctagggaagagaaagcacacgtaggagag 
               
               
                 ttcatggctttgttgcttaacctcgaccctgagcaagtcacagagctgaagggcgggttcgaggaagttaaagaattgaccggtataga 
               
               
                 agctcacattaatgacaacaagaaagaggaaagtaatgtagagtatttcgagaagctcagatctgccttgttggatggagtcaacaagg 
               
               
                 gtcgcagcttgctcaaacatctgcccgttacaagaatagaagggcagtcttttcgagtagacatcatcaaatttgaggacggcgtccga 
               
               
                 gtggttaaacaagagtataagcctataccccttcttaagaagaagttctacgtcggcattcgagaactgaatgacgggacatatgatgtc 
               
               
                 agcattgctactaaagccggtgagctgctggttaaagacgaagaaagtcttgtgatccgggaaattttgtcaacggaaggcatcaagaa 
               
               
                 aatgaaattgtcatcctgggacaatccagaagaagccctgaatgatttgatgaatgcgctccaagaagctagcaatgctagtgctggcc 
               
               
                 ccttcggccttattatcaatccaaagcggtacgccaaactgctgaagatctatgaaaagtcaggtaagatgctcgtagaagtactcaagg 
               
               
                 aaatcttccggggtggaataatcgtaactcttaatatcgacgaaaacaaagtgattatcttcgctaatacgcccgccgttctggacgtggt 
               
               
                 ggtgggtcaagacgttacgctccaggagcttggtccggaaggggatgatgtcgcattcctggtcagtgaagccattggtataagaatc 
               
               
                 aagaacccggaagctatagttgttctcgaaggcgggtctggtgggagcggtggtagtggtggttctggtggtggtgggtcaggtggc 
               
               
                 ggctcaggcggcggcaatctgtgccctttcggtgaggtctttaatgcaacaagatttgcaagtgtttacgcctggaaccgtaagcgcatt 
               
               
                 agcaactgcactgccgattactctgtgctgtacaacagcacaagcttttccacatttaaatgttacggggtttcccctaccaacctcagcg 
               
               
                 acctctgctttactaatgtttacgcagattccttcgttatccgaggcgatgaagtccggcagatagctcccggacagaccggcaaaatcg 
               
               
                 ctgactacaactataaactgccgaacgacagcacagggtgtgtaattgcttggaacagcaataacctcgattcaaaggttggcggaaat 
               
               
                 tacaattatctttaccgtctgttccggaaaagcaatctgaaaccctttgagagagacatcagcacggaaatttatcaagccggttcaacac 
               
               
                 catgtaacggagttgaaggctttaattgctattttcccctgcaatcttacggatttcaacctacgaacggggtcggttaccaaccttaccgg 
               
               
                 gtggtcgtgctgagcttcgaattgcttcatgccccagccaccgtgtgtgggccataatga (SEQ ID NO: 74) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagccucucaauugccc 
               
               
                 caacguugaucaaccgggacaagccauacacgaaagaggaacuuauggagauauugcgguuggccauuauagcugaacuc 
               
               
                 gaugcaauuaaucucuaugaacaaauggcccgcuauagcgaagacgaaaaugugagaaagaucuuguuggacgucgcua 
               
               
                 gggaagagaaagcacacguaggagaguucauggcuuuguugcuuaaccucgacccugagcaagucacagagcugaaggg 
               
               
                 cggguucgaggaaguuaaagaauugaccgguauagaagcucacauuaaugacaacaagaaagaggaaaguaauguagag 
               
               
                 uauuucgagaagcucagaucugccuuguuggauggagucaacaagggucgcagcuugcucaaacaucugcccguuacaa 
               
               
                 gaauagaagggcagucuuuucgaguagacaucaucaaauuugaggacggcguccgagugguuaaacaagaguauaagcc 
               
               
                 uauaccccuucuuaagaagaaguucuacgucggcauucgagaacugaaugacgggacauaugaugucagcauugcuacu 
               
               
                 aaagccggugagcugcugguuaaagacgaagaaagucuugugauccgggaaauuuugucaacggaaggcaucaagaaaa 
               
               
                 ugaaauugucauccugggacaauccagaagaagcccugaaugauuugaugaaugcgcuccaagaagcuagcaaugcuag 
               
               
                 ugcuggccccuucggccuuauuaucaauccaaagcgguacgccaaacugcugaagaucuaugaaaagucagguaagaugc 
               
               
                 ucguagaaguacucaaggaaaucuuccgggguggaauaaucguaacucuuaauaucgacgaaaacaaagugauuaucuu 
               
               
                 cgcuaauacgcccgccguucuggacgugguggugggucaagacguuacgcuccaggagcuugguccggaaggggauga 
               
               
                 ugucgcauuccuggucagugaagccauugguauaagaaucaagaacccggaagcuauaguuguucucgaaggcgggucu 
               
               
                 ggugggagcggugguaguggugguucuggugguggugggucagguggcggcucaggcggcggcaaucugugcccuuu 
               
               
                 cggugaggucuuuaaugcaacaagauuugcaaguguuuacgccuggaaccguaagcgcauuagcaacugcacugccgau 
               
               
                 uacucugugcuguacaacagcacaagcuuuuccacauuuaaauguuacgggguuuccccuaccaaccucagcgaccucug 
               
               
                 cuuuacuaauguuuacgcagauuccuucguuauccgaggcgaugaaguccggcagauagcucccggacagaccggcaaa 
               
               
                 aucgcugacuacaacuauaaacugccgaacgacagcacaggguguguaauugcuuggaacagcaauaaccucgauucaaa 
               
               
                 gguuggcggaaauuacaauuaucuuuaccgucuguuccggaaaagcaaucugaaacccuuugagagagacaucagcacg 
               
               
                 gaaauuuaucaagccgguucaacaccauguaacggaguugaaggcuuuaauugcuauuuuccccugcaaucuuacggau 
               
               
                 uucaaccuacgaacggggucgguuaccaaccuuaccggguggucgugcugagcuucgaauugcuucaugccccagccac 
               
               
                 cgugugugggccauaauga (SEQ ID NO: 75) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSLSIAPTLINRDKPYTKEELMEILRLAIIAELDAINLYEQM 
               
               
                 ARYSEDENVRKILLDVAREEKAHVGEFMALLLNLDPEQVTELKGGFEEVKELTGIEA 
               
               
                 HINDNKKEESNVEYFEKLRSALLDGVNKGRSLLKHLPVTRIEGQSFRVDIIKFEDGVR 
               
               
                 VVKQEYKPIPLLKKKFYVGIRELNDGTYDVSIATKAGELLVKDEESLVIREILSTEGIK 
               
               
                 KMKLSSWDNPEEALNDLMNALQEASNASAGPFGLIINPKRYAKLLKIYEKSGKMLV 
               
               
                 EVLKEIFRGGIIVTLNIDENKVIIFANTPAVLDVVVGQDVTLQELGPEGDDVAFLVSEA 
               
               
                 IGIRIKNPEAIVVLEGGSGGSGGSGGSGGGGSGGGSGGGNLCPFGEVFNATRFASVYA 
               
               
                 WNRKRIS NCT ADYSVLY NST SFSTFKCYGVSPT NLS DLCFTNVYADSFVIRGDEVRQI 
               
               
                 APGQTGKIADYNYKLP NDS TGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFER 
               
               
                 DISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV 
               
               
                 CGP** (SEQ ID NO: 76) 
               
               
                   
               
               
                 WuhanS_RBD_gmax_LS_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcatgcagatctacgaaggaaaa 
               
               
                 ctgaccgctgagggactgaggttcggaattgtcgcaagccgcgcgaatcacgcactggtggataggctggtggaaggcgctatcga 
               
               
                 cgcaattgtccggcacggcgggagagaggaagacatcacactggtgagagtctgcggcagctgggagattcccgtggcagctgga 
               
               
                 gaactggctcgaaaggaggacatcgatgccgtgatcgctattggggtcctgtgccgaggagcaactcccagcttcgactacatcgcct 
               
               
                 cagaagtgagcaaggggctggctgatctgtccctggagctgaggaaacctatcacttttggcgtgattactgccgacaccctggaaca 
               
               
                 ggcaatcgaggcggccggcacctgccatggaaacaaaggctgggaagcagccctgtgcgctattgagatggcaaatctgttcaaat 
               
               
                 ctctgcgaggaggctccggaggatctggagggagtggaggctcaggaggaggcaatctgtgccctttcggtgaggtctttaatgcaa 
               
               
                 caagatttgcaagtgtttacgcctggaaccgtaagcgcattagcaactgcactgccgattactctgtgctgtacaacagcacaagcttttc 
               
               
                 cacatttaaatgttacggggtttcccctaccaacctcagcgacctctgctttactaatgtttacgcagattccttcgttatccgaggcgatga 
               
               
                 agtccggcagatagctcccggacagaccggcaaaatcgctgactacaactataaactgccgaacgacagcacagggtgtgtaattgc 
               
               
                 ttggaacagcaataacctcgattcaaaggttggcggaaattacaattatctttaccgtctgttccggaaaagcaatctgaaaccctttgag 
               
               
                 agagacatcagcacggaaatttatcaagccggttcaacaccatgtaacggagttgaaggctttaattgctattttcccctgcaatcttacg 
               
               
                 gatttcaacctacgaacggggtcggttaccaaccttaccgggtggtcgtgctgagcttcgaattgcttcatgccccagccaccgtgtgtg 
               
               
                 ggccataatga (SEQ ID NO: 77) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaugcagaucuacg 
               
               
                 aaggaaaacugaccgcugagggacugagguucggaauugucgcaagccgcgcgaaucacgcacugguggauaggcuggu 
               
               
                 ggaaggcgcuaucgacgcaauuguccggcacggcgggagagaggaagacaucacacuggugagagucugcggcagcugg 
               
               
                 gagauucccguggcagcuggagaacuggcucgaaaggaggacaucgaugccgugaucgcuauugggguccugugccgag 
               
               
                 gagcaacucccagcuucgacuacaucgccucagaagugagcaaggggcuggcugaucugucccuggagcugaggaaacc 
               
               
                 uaucacuuuuggcgugauuacugccgacacccuggaacaggcaaucgaggcggccggcaccugccauggaaacaaaggcu 
               
               
                 gggaagcagcccugugcgcuauugagauggcaaaucuguucaaaucucugcgaggaggcuccggaggaucuggagggag 
               
               
                 uggaggcucaggaggaggcaaucugugcccuuucggugaggucuuuaaugcaacaagauuugcaaguguuuacgccug 
               
               
                 gaaccguaagcgcauuagcaacugcacugccgauuacucugugcuguacaacagcacaagcuuuuccacauuuaaauguu 
               
               
                 acgggguuuccccuaccaaccucagcgaccucugcuuuacuaauguuuacgcagauuccuucguuauccgaggcgauga 
               
               
                 aguccggcagauagcucccggacagaccggcaaaaucgcugacuacaacuauaaacugccgaacgacagcacagggugug 
               
               
                 uaauugcuuggaacagcaauaaccucgauucaaagguuggcggaaauuacaauuaucuuuaccgucuguuccggaaaag 
               
               
                 caaucugaaacccuuugagagagacaucagcacggaaauuuaucaagccgguucaacaccauguaacggaguugaaggcu 
               
               
                 uuaauugcuauuuuccccugcaaucuuacggauuucaaccuacgaacggggucgguuaccaaccuuaccggguggucgu 
               
               
                 gcugagcuucgaauugcuucaugccccagccaccgugugugggccauaauga (SEQ ID NO: 78) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMQIYEGKLTAEGLRFGIVASRANHALVDRLVEGAIDAI 
               
               
                 VRHGGREEDITLVRVCGSWEIPVAAGELARKEDIDAVIAIGVLCRGATPSFDYIASEV 
               
               
                 SKGLADLSLELRKPITFGVITADTLEQAIEAAGTCHGNKGWEAALCAIEMANLFKSLR 
               
               
                 GGSGGSGGSGGSGGGNLCPFGEVFNATRFASVYAWNRKRISNCTADYSVLYNSTSFS 
               
               
                 TFKCYGVSPTNLSDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPNDSTGC 
               
               
                 VIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY 
               
               
                 FPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGP** (SEQ ID NO: 79) 
               
               
                   
               
               
                 CoV2-RBD_7 mer_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcaatctctgtccattcggagagg 
               
               
                 ttttcaacgcgacgagattcgcctcagtttatgcctggaaccgtaaacggatatcaaactgcgtggctgactactctgttttatacaactcc 
               
               
                 gcctctttcagtaccttcaagtgttacggtgtcagccctaccaaattgaatgatctctgctttacaaatgtttacgcagattcttttgtcataag 
               
               
                 gggcgatgaggttcggcaaatcgcccccgggcagacaggcaaaattgcggactataattataagttgccagacgatttcacgggctg 
               
               
                 cgtcatcgcctggaacagtaataatctcgattcaaaagtgggtgggaactacaattatctctacaggttattccggaagtcaaatctgaag 
               
               
                 cccttcgaacgcgacatcagtacggagatttaccaggctggaagcactccgtgcaacggggtggaggggttcaactgttattttcctct 
               
               
                 gcagtcttatgggtttcagcccactaatggtgtgggataccagccgtacagagtcgtggtgctgtccttcgaacttctccacgctcccgc 
               
               
                 caccgtctgtggtcccgggggatctggcggatcagggggtagtggaggtagcggcggcgggaagaaacagggagacgctgacgt 
               
               
                 ctgtggggaagtggcttacatccagagcgtggtgtctgattgccatgtaccaaccgcggagctcaggactcttttagagattcggaaac 
               
               
                 tgtttctggagatccaaaagctgaaggtcgaactccagggcctgtcaaaagaatgataa (SEQ ID NO: 80) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaaucucuguccau 
               
               
                 ucggagagguuuucaacgcgacgagauucgccucaguuuaugccuggaaccguaaacggauaucaaacugcguggcuga 
               
               
                 cuacucuguuuuauacaacuccgccucuuucaguaccuucaaguguuacggugucagcccuaccaaauugaaugaucuc 
               
               
                 ugcuuuacaaauguuuacgcagauucuuuugucauaaggggcgaugagguucggcaaaucgcccccgggcagacaggca 
               
               
                 aaauugcggacuauaauuauaaguugccagacgauuucacgggcugcgucaucgccuggaacaguaauaaucucgauuc 
               
               
                 aaaagugggugggaacuacaauuaucucuacagguuauuccggaagucaaaucugaagcccuucgaacgcgacaucagua 
               
               
                 cggagauuuaccaggcuggaagcacuccgugcaacgggguggagggguucaacuguuauuuuccucugcagucuuaug 
               
               
                 gguuucagcccacuaauggugugggauaccagccguacagagucguggugcuguccuucgaacuucuccacgcucccgc 
               
               
                 caccgucuguggucccgggggaucuggcggaucaggggguaguggagguagcggcggcgggaagaaacagggagacgc 
               
               
                 ugacgucuguggggaaguggcuuacauccagagcguggugucugauugccauguaccaaccgcggagcucaggacucuu 
               
               
                 uuagagauucggaaacuguuucuggagauccaaaagcugaaggucgaacuccagggccugucaaaagaaugauaa 
               
               
                 (SEQ ID NO: 81) 
               
               
                   
               
               
                 NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDL 
               
               
                 CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGG 
               
               
                 NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY 
               
               
                 QPYRVVVLSFELLHAPATVCGPGGSGGSGGSGGSGGGKKQGDADVCGEVAYIQSVV 
               
               
                 SDCHVPTAELRTLLEIRKLFLEIQKLKVELQGLSKE** (SEQ ID NO: 82) 
               
               
                   
               
               
                 CoV2-RBD_gmax_14 mer_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcaatctgtgtcccttcggggag 
               
               
                 gttttcaatgctaccagatttgccagtgtgtatgcttggaatcggaagagaatctccaattgcacagcagattattcagttctctacaactct 
               
               
                 acatcttttagtacctttaagtgttacggggtgagtcccactaacctttcagatttatgtttcaccaatgtctacgctgactccttcgtgatccg 
               
               
                 gggggatgaggtgagacagattgcacctggacaaactggcaaaatcgccgactacaattacaaacttccaaacgactctacagggtg 
               
               
                 tgtaatcgcttggaacagcaataatctggatagcaaagtaggcggcaattataattacctctacagactgtttaggaagtccaacctgaa 
               
               
                 accatttgagagggacatcagcactgaaatctaccaggcggggagcaccccttgtaatggagtcgagggtttcaactgttacttcccac 
               
               
                 tgcagagctacgggttccagcctaccaatggtgtcggttaccagccctatcgagttgtggtgttgtcattcgaactgttacatgcacctgc 
               
               
                 aacggtctgtggacccgggggttcagggggtagtggggggtccggtgggagcggtgggggcaagaaacaggggatgaatccgct 
               
               
                 catcgccgccgcctctgtgatagctgctggcctggccgtgggcctggcatcaatcgggcccggggtgggccaaggcaccgccgcc 
               
               
                 ggccaggccgtcgagggtattgcaaggcagccggaggcagaaggcaaaattagagggaccctgttgttgtctttagcgttcatggaa 
               
               
                 gccctcactatttacggactggttgtggccttagcccttctgtttgccaatcctttcgtgtaatga (SEQ ID NO: 83) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaaucugugucccu 
               
               
                 ucggggagguuuucaaugcuaccagauuugccaguguguaugcuuggaaucggaagagaaucuccaauugcacagcaga 
               
               
                 uuauucaguucucuacaacucuacaucuuuuaguaccuuuaaguguuacggggugagucccacuaaccuuucagauuua 
               
               
                 uguuucaccaaugucuacgcugacuccuucgugauccggggggaugaggugagacagauugcaccuggacaaacuggca 
               
               
                 aaaucgccgacuacaauuacaaacuuccaaacgacucuacaggguguguaaucgcuuggaacagcaauaaucuggauagc 
               
               
                 aaaguaggcggcaauuauaauuaccucuacagacuguuuaggaaguccaaccugaaaccauuugagagggacaucagcac 
               
               
                 ugaaaucuaccaggcggggagcaccccuuguaauggagucgaggguuucaacuguuacuucccacugcagagcuacggg 
               
               
                 uuccagccuaccaauggugucgguuaccagcccuaucgaguugugguguugucauucgaacuguuacaugcaccugcaa 
               
               
                 cggucuguggacccggggguucaggggguagugggggguccggugggagcggugggggcaagaaacaggggaugaauc 
               
               
                 cgcucaucgccgccgccucugugauagcugcuggccuggccgugggccuggcaucaaucgggcccggggugggccaagg 
               
               
                 caccgccgccggccaggccgucgaggguauugcaaggcagccggaggcagaaggcaaaauuagagggacccuguuguug 
               
               
                 ucuuuagcguucauggaagcccucacuauuuacggacugguuguggccuuagcccuucuguuugccaauccuuucgug 
               
               
                 uaauga (SEQ ID NO: 84) 
               
               
                   
               
               
                 NLCPFGEVFNATRFASVYAWNRKRIS NCT ADYSVLY NST SFSTFKCYGVSPT NLS DL 
               
               
                 CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP NDS TGCVIAWNSNNLDSKVGG 
               
               
                 NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY 
               
               
                 QPYRVVVLSFELLHAPATVCGPGGSGGSGGSGGSGGGKKQGMNPLIAAASVIAAGL 
               
               
                 AVGLASIGPGVGQGTAAGQAVEGIARQPEAEGKIRGTLLLSLAFMEALTIYGLVVAL 
               
               
                 ALLFANPFV** (SEQ ID NO: 85) 
               
               
                   
               
               
                 CoV2-RBD_gmax_24 mer_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcaacctgtgccccttcggggaa 
               
               
                 gtttttaatgccactcggtttgcctccgtttacgcctggaacaggaagcgcatttccaactgcaccgccgactatagcgtcctttataacag 
               
               
                 cacatccttttcaactttcaagtgttacggggtttcccctacaaatctctctgacctgtgttttacaaatgtgtatgcagactctttcgtgattag 
               
               
                 gggagatgaggtgcgccagatcgcccctggacagaccggaaaaatcgccgattataattataagcttcccaacgactccacaggctg 
               
               
                 tgtaattgcctggaattctaataacctggactctaaagtgggcggtaactacaattatctgtatagactcttcagaaagtctaacctcaaac 
               
               
                 catttgaacgggacatctcaaccgagatctaccaagccgggtccaccccctgtaacggcgtggaaggcttcaactgttatttccccctc 
               
               
                 cagtcctatggcttccaacccacaaatggagtcggctaccagccttacagggtggttgtgctgtcatttgagctcctccacgctcctgcc 
               
               
                 actgtatgtgggccaggcgggtccggaggttcaggcggtagcggcggctcaggtggaggaggactgtctaaagatattataaaactg 
               
               
                 ctgaacgaacaagtgaacaaggagatgcagagcagcaacctttacatgtctatgagcagttggtgttacactcactctctcgacggcgc 
               
               
                 cggcctgttcctgtttgatcacgccgcggaggagtatgaacatgctaaaaagcttatcatcttcctcaacgaaaataacgtgccagtgca 
               
               
                 gttgacctctatttccgctcccgaacataagttcgaaggcctcacacagatctttcagaaggcttacgagcatgaacaacacatttcaga 
               
               
                 gagcatcaacaacatcgtggaccatgcgatcaagtctaaggaccacgcgacttttaacttcctccagtggtatgtcgccgaacagcatg 
               
               
                 aggaggaagtgttgttcaaagacatcctggacaagattgaacttattggcaacgaaaaccacggcctctacctggccgatcagtacgt 
               
               
                 gaaaggtatcgcgaagtcacgaaagagttaatga (SEQ ID NO: 86) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaaccugugccccu 
               
               
                 ucggggaaguuuuuaaugccacucgguuugccuccguuuacgccuggaacaggaagcgcauuuccaacugcaccgccga 
               
               
                 cuauagcguccuuuauaacagcacauccuuuucaacuuucaaguguuacgggguuuccccuacaaaucucucugaccug 
               
               
                 uguuuuacaaauguguaugcagacucuuucgugauuaggggagaugaggugcgccagaucgccccuggacagaccggaa 
               
               
                 aaaucgccgauuauaauuauaagcuucccaacgacuccacaggcuguguaauugccuggaauucuaauaaccuggacucu 
               
               
                 aaagugggcgguaacuacaauuaucuguauagacucuucagaaagucuaaccucaaaccauuugaacgggacaucucaac 
               
               
                 cgagaucuaccaagccggguccacccccuguaacggcguggaaggcuucaacuguuauuucccccuccaguccuauggcu 
               
               
                 uccaacccacaaauggagucggcuaccagccuuacagggugguugugcugucauuugagcuccuccacgcuccugccac 
               
               
                 uguaugugggccaggcggguccggagguucaggcgguagcggcggcucagguggaggaggacugucuaaagauauuau 
               
               
                 aaaacugcugaacgaacaagugaacaaggagaugcagagcagcaaccuuuacaugucuaugagcaguugguguuacacuc 
               
               
                 acucucucgacggcgccggccuguuccuguuugaucacgccgcggaggaguaugaacaugcuaaaaagcuuaucaucuu 
               
               
                 ccucaacgaaaauaacgugccagugcaguugaccucuauuuccgcucccgaacauaaguucgaaggccucacacagaucu 
               
               
                 uucagaaggcuuacgagcaugaacaacacauuucagagagcaucaacaacaucguggaccaugcgaucaagucuaaggac 
               
               
                 cacgcgacuuuuaacuuccuccagugguaugucgccgaacagcaugaggaggaaguguuguucaaagacauccuggaca 
               
               
                 agauugaacuuauuggcaacgaaaaccacggccucuaccuggccgaucaguacgugaaagguaucgcgaagucacgaaag 
               
               
                 aguuaauga (SEQ ID NO: 87) 
               
               
                   
               
               
                 NLCPFGEVFNATRFASVYAWNRKRIS NCT ADYSVLY NST SFSTFKCYGVSPT NLS DL 
               
               
                 CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP NDS TGCVIAWNSNNLDSKVGG 
               
               
                 NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY 
               
               
                 QPYRVVVLSFELLHAPATVCGPGGSGGSGGSGGSGGGGLSKDIIKLLNEQVNKEMQS 
               
               
                 SNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPE 
               
               
                 HKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFK 
               
               
                 DILDKIELIGNENHGLYLADQYVKGIAKSRKS** (SEQ ID NO: 88) 
               
               
                   
               
               
                 CoV2-RBD_gmax_7 mer_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcaatctttgtccattcggggaag 
               
               
                 tgtttaacgccactaggttcgctagtgtgtacgcctggaatcggaagcggatttcaaattgtaccgccgattattctgtcctttacaacagt 
               
               
                 accagcttttccacttttaaatgctacggagtatctcctacaaacttgagtgacctgtgttttacgaacgtctacgctgactctttcgttattag 
               
               
                 gggagacgaagttagacaaatcgctccaggccagactggcaaaatagccgactataactataaactcccaaacgattccacaggctg 
               
               
                 cgttattgcctggaacagcaataacctggactctaaagtcggaggtaactataactacttgtacaggctcttccgcaagagcaaccttaa 
               
               
                 gccatttgagcgagatatctccaccgagatttatcaggcagggagcaccccatgcaacggagtggaggggtttaattgctattttccact 
               
               
                 gcagtcctatggctttcaaccaacaaacggagtaggctaccaaccgtatcgcgttgtcgtcctgagtttcgaactgttgcacgcccctgc 
               
               
                 gaccgtatgtggccccggcggctcaggggggagtggtgggagcgggggctctgggggggggaaaaaacagggggacgccgat 
               
               
                 gtttgcggcgaggtggcctatatacagtcagtggtctccgactgtcatgtaccaactgccgaactcaggactcttctggagataaggaa 
               
               
                 gttgttcctggagatacagaagctcaaggtcgagttacagggtctctcaaaggaatgatga (SEQ ID NO: 89) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcaaucuuuguccau 
               
               
                 ucggggaaguguuuaacgccacuagguucgcuaguguguacgccuggaaucggaagcggauuucaaauuguaccgccga 
               
               
                 uuauucuguccuuuacaacaguaccagcuuuuccacuuuuaaaugcuacggaguaucuccuacaaacuugagugaccug 
               
               
                 uguuuuacgaacgucuacgcugacucuuucguuauuaggggagacgaaguuagacaaaucgcuccaggccagacuggca 
               
               
                 aaauagccgacuauaacuauaaacucccaaacgauuccacaggcugcguuauugccuggaacagcaauaaccuggacucu 
               
               
                 aaagucggagguaacuauaacuacuuguacaggcucuuccgcaagagcaaccuuaagccauuugagcgagauaucuccac 
               
               
                 cgagauuuaucaggcagggagcaccccaugcaacggaguggagggguuuaauugcuauuuuccacugcaguccuauggc 
               
               
                 uuucaaccaacaaacggaguaggcuaccaaccguaucgcguugucguccugaguuucgaacuguugcacgccccugcgac 
               
               
                 cguauguggccccggcggcucaggggggaguggugggagcgggggcucugggggggggaaaaaacagggggacgccga 
               
               
                 uguuugcggcgagguggccuauauacagucaguggucuccgacugucauguaccaacugccgaacucaggacucuucug 
               
               
                 gagauaaggaaguuguuccuggagauacagaagcucaaggucgaguuacagggucucucaaaggaaugauga (SEQ 
               
               
                 ID NO: 90) 
               
               
                   
               
               
                 NLCPFGEVFNATRFASVYAWNRKRIS NCT ADYSVLY NST SFSTFKCYGVSPT NLS DL 
               
               
                 CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP NDS TGCVIAWNSNNLDSKVGG 
               
               
                 NYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY 
               
               
                 QPYRVVVLSFELLHAPATVCGPGGSGGSGGSGGSGGGKKQGDADVCGEVAYIQSVV 
               
               
                 SDCHVPTAELRTLLEIRKLFLEIQKLKVELQGLSKE** (SEQ ID NO: 91) 
               
               
                   
               
               
                 II. CoV2 Trimer Constructs 
               
               
                 WuhanS_SolTri_FS1_pVax 
               
               
                 ggatccgccaccatggactggacctggattctgttcctggtggccgccgccacaagggtgcacagcatgtttgttttcctcgtcctcttg 
               
               
                 cccctcgtctctagtcaatgtgttaatttgaccacacgaacccaactgccacctgcctacaccaacagttttaccagaggagtttattaccc 
               
               
                 cgacaaagtattcaggtcatcagtgctgcatagtacccaagacttgtttctccccttctttagtaacgttacatggttccacgccattcacgt 
               
               
                 gagtgggacaaatggaacaaaacgcttcgacaaccctgtgctccccttcaacgatggtgtatactttgctagtaccgagaagagcgga 
               
               
                 attatccgcgggtggatctttggaacaacactggacagcaaaacccaaagcctgcttatcgttaacaatgctactaacgttgtgatcaaa 
               
               
                 gtgtgtgaattccaattttgtaatgatccgtttctcggagtttactaccacaagaacaacaaaagttggatggaaagcgaattccgggtgta 
               
               
                 ctcctcagcaaataattgtacctttgagtacgtgagtcaaccctttctcatggacctggaaggaaaacaaggcaatttcaagaacctgcg 
               
               
                 ggagtttgtgttcaagaatattgatggctattttaaaatttattctaagcatactccaatcaacctggtaagggacctgccccaaggcttttca 
               
               
                 gccctcgaaccgcttgtagatttgcctatcgggataaacattacgcgatttcaaacgctgttggcgctccaccggagctacttgactcctg 
               
               
                 gcgatagcagctccggttggaccgctggagcggccgcttattacgtcggctatctgcaacccaggacgttcctgctcaagtataatga 
               
               
                 gaacgggacgattacagatgcagtggattgtgcgcttgatcctctctctgaaaccaagtgcactctcaagtctttcacggtggagaaag 
               
               
                 gcatttatcaaactagtaactttcgagtacagcctactgagagtatcgttaggttcccaaacattacgaacctctgtccctttggagaagtat 
               
               
                 tcaatgctactcgctttgcaagcgtttatgcctggaatcgcaaacgcatcagcaattgcgtcgccgattattctgtcctttataatagcgcat 
               
               
                 cattttcaacatttaagtgttatggggtgagtccgactaagctcaatgatttgtgcttcacaaacgtctacgcggacagctttgtgataagg 
               
               
                 ggcgacgaagttcgccaaatcgctcccggccaaactgggaaaatcgcggattacaactataaattgcccgatgacttcaccggctgtg 
               
               
                 tcattgcctggaactctaataacctcgatagcaaggtgggcgggaactataattatttgtaccgcctgtttcgaaagtccaatctcaaacc 
               
               
                 ctttgagcgggacatttccactgagatctatcaggcagggagtacaccttgtaacggcgtggaaggctttaactgttattttcccctgcaa 
               
               
                 agttacggttttcaacctaccaacggagttggctatcaaccttatcgagtcgtcgtgctgagttttgagttgctgcatgccccagccaccgt 
               
               
                 ctgtggacctaagaaatccaccaacctcgtgaagaacaagtgcgtcaattttaattttaacggcctgactgggaccggtgtcctcaccga 
               
               
                 atctaataagaagttcctgccatttcaacaattcggacgggacatcgctggaacgacagatgctgtccgtgatcctcagacactggaga 
               
               
                 ttctggacatcactccttgcagctttggcggagtctctgttattactcccggaactaacacttctaaccaagttgctgtcctctatcaggacg 
               
               
                 tgaactgcactgaagtgcccgtggcaatccatgcaggccaactgacccccacttggagagtctacagcacggggagcaatgtcttcc 
               
               
                 aaacaagggccggatgccttattggagcggagcacgttaataactcatacgagtgtgatataccaattggagcaggaatttgtgcttcct 
               
               
                 accagacccaaactaacagtcccaggcgggctaggagtgtcgctagccagagcatcatcgcgtacacaatgtctctcggcgcagaa 
               
               
                 aactcagtcgcctatagcaacaactcaattgccattcccaccaacttcacaatttccgtaaccactgaaattctgcctgttagcatgacaaa 
               
               
                 gacatcagttgattgtacaatgtacatatgtggagacagcaccgaatgcagcaaccttttgcttcaatatggctccttttgtacccaactca 
               
               
                 acagggcactcactgggatagcagtcgaacaagataagaacacccaagaggtgtttgcacaagtcaaacaaatctataaaacgccgc 
               
               
                 ccataaaagactttggcggattcaatttcagccagatcttgcctgacccatccaagccttcaaagaggagctttattgaggatcttctcttc 
               
               
                 aataaagtgacactggcggacgccggttttatcaagcaatatggtgattgtctcggtgacatagcagctagagatctgatttgcgctcag 
               
               
                 aaatttaatggccttactgtgcttcccccactgctgaccgatgaaatgattgcacaatatacaagcgcccttttggccgggactattacttc 
               
               
                 cgggtggaccttcggcgccggcgccgctctgcaaattcctttcgcaatgcagatggcctaccggttcaatggcataggtgtcactcag 
               
               
                 aacgttctttatgagaatcagaaactcatcgcgaaccagtttaattcagcgatcggcaagattcaggactccttgtcctcaactgcgtcag 
               
               
                 ctttgggaaaacttcaagacgtcgtgaaccagaatgctcaggcgctcaataccctggtgaaacaacttagcagtaactttggggctattt 
               
               
                 ctagcggtccaaacgatatactgtcccgactcccgaaagtcgaggccgaagtccaaattgatcgtcttattacagggagactccaatct 
               
               
                 cttcaaacatatgtcactcaacagctcattagggctgcggagatccgggcttccgcaaatcttgccgcgacaaagatgagtgaatgcgt 
               
               
                 cttgggacaatctaagagggtggacttttgtggaaaaggttaccatctcatgtccttccctcagtcagcgccccacggagtcgttttcctg 
               
               
                 cacgtaacgtatgtcccggctcaagagaagaacttcactactgcaccagcgatttgccatgacggtaaagcccattttccccgcgagg 
               
               
                 gcgtatttgtgtccaacggtacccactggttcgtaacccaacggaatttctatgagccccaaatcattacaacagataatacagatgtttcc 
               
               
                 gggaattgcgacgttgttattggcatcgttaacaacaccgtttacgatcccttgcaaccggaactggactcctttaaagaagaactcgac 
               
               
                 aagtattttaagaaccacacatcaccagatgtcgatcttggcgacatttccggcattaacgcttcagttgtaaatattcagaaagagatag 
               
               
                 atcgcctgaatgaggtggctaagaacctgaacgaatctctcattgatctccaagagctgggaaagtacgaacaatacatcaaatggcct 
               
               
                 tctgggcgtcgccgaagacgacgagggtccggcggctcagggagcggctatatccctgaggcgcctcgggacggacaagcttatg 
               
               
                 tgaggaaagatggagaatgggtattgctgtcaaccttcctgggataatga (SEQ ID NO: 92) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauucuguuccugguggccgccgccacaagggugcacagcauguuuguuuucc 
               
               
                 ucguccucuugccccucgucucuagucaauguguuaauuugaccacacgaacccaacugccaccugccuacaccaacagu 
               
               
                 uuuaccagaggaguuuauuaccccgacaaaguauucaggucaucagugcugcauaguacccaagacuuguuucuccccu 
               
               
                 ucuuuaguaacguuacaugguuccacgccauucacgugagugggacaaauggaacaaaacgcuucgacaacccugugcuc 
               
               
                 cccuucaacgaugguguauacuuugcuaguaccgagaagagcggaauuauccgcggguggaucuuuggaacaacacugg 
               
               
                 acagcaaaacccaaagccugcuuaucguuaacaaugcuacuaacguugugaucaaagugugugaauuccaauuuuguaau 
               
               
                 gauccguuucucggaguuuacuaccacaagaacaacaaaaguuggauggaaagcgaauuccggguguacuccucagcaaa 
               
               
                 uaauuguaccuuugaguacgugagucaacccuuucucauggaccuggaaggaaaacaaggcaauuucaagaaccugcgg 
               
               
                 gaguuuguguucaagaauauugauggcuauuuuaaaauuuauucuaagcauacuccaaucaaccugguaagggaccugc 
               
               
                 cccaaggcuuuucagcccucgaaccgcuuguagauuugccuaucgggauaaacauuacgcgauuucaaacgcuguuggc 
               
               
                 gcuccaccggagcuacuugacuccuggcgauagcagcuccgguuggaccgcuggagcggccgcuuauuacgucggcuau 
               
               
                 cugcaacccaggacguuccugcucaaguauaaugagaacgggacgauuacagaugcaguggauugugcgcuugauccuc 
               
               
                 ucucugaaaccaagugcacucucaagucuuucacgguggagaaaggcauuuaucaaacuaguaacuuucgaguacagccu 
               
               
                 acugagaguaucguuagguucccaaacauuacgaaccucugucccuuuggagaaguauucaaugcuacucgcuuugcaa 
               
               
                 gcguuuaugccuggaaucgcaaacgcaucagcaauugcgucgccgauuauucuguccuuuauaauagcgcaucauuuuc 
               
               
                 aacauuuaaguguuauggggugaguccgacuaagcucaaugauuugugcuucacaaacgucuacgcggacagcuuugug 
               
               
                 auaaggggcgacgaaguucgccaaaucgcucccggccaaacugggaaaaucgcggauuacaacuauaaauugcccgauga 
               
               
                 cuucaccggcugugucauugccuggaacucuaauaaccucgauagcaaggugggcgggaacuauaauuauuuguaccgc 
               
               
                 cuguuucgaaaguccaaucucaaacccuuugagcgggacauuuccacugagaucuaucaggcagggaguacaccuugua 
               
               
                 acggcguggaaggcuuuaacuguuauuuuccccugcaaaguuacgguuuucaaccuaccaacggaguuggcuaucaacc 
               
               
                 uuaucgagucgucgugcugaguuuugaguugcugcaugccccagccaccgucuguggaccuaagaaauccaccaaccuc 
               
               
                 gugaagaacaagugcgucaauuuuaauuuuaacggccugacugggaccgguguccucaccgaaucuaauaagaaguucc 
               
               
                 ugccauuucaacaauucggacgggacaucgcuggaacgacagaugcuguccgugauccucagacacuggagauucugga 
               
               
                 caucacuccuugcagcuuuggcggagucucuguuauuacucccggaacuaacacuucuaaccaaguugcuguccucuau 
               
               
                 caggacgugaacugcacugaagugcccguggcaauccaugcaggccaacugacccccacuuggagagucuacagcacggg 
               
               
                 gagcaaugucuuccaaacaagggccggaugccuuauuggagcggagcacguuaauaacucauacgagugugauauacca 
               
               
                 auuggagcaggaauuugugcuuccuaccagacccaaacuaacagucccaggcgggcuaggagugucgcuagccagagca 
               
               
                 ucaucgcguacacaaugucucucggcgcagaaaacucagucgccuauagcaacaacucaauugccauucccaccaacuuca 
               
               
                 caauuuccguaaccacugaaauucugccuguuagcaugacaaagacaucaguugauuguacaauguacauauguggaga 
               
               
                 cagcaccgaaugcagcaaccuuuugcuucaauauggcuccuuuuguacccaacucaacagggcacucacugggauagcag 
               
               
                 ucgaacaagauaagaacacccaagagguguuugcacaagucaaacaaaucuauaaaacgccgcccauaaaagacuuuggcg 
               
               
                 gauucaauuucagccagaucuugccugacccauccaagccuucaaagaggagcuuuauugaggaucuucucuucaauaaa 
               
               
                 gugacacuggcggacgccgguuuuaucaagcaauauggugauugucucggugacauagcagcuagagaucugauuugc 
               
               
                 gcucagaaauuuaauggccuuacugugcuucccccacugcugaccgaugaaaugauugcacaauauacaagcgcccuuuu 
               
               
                 ggccgggacuauuacuuccggguggaccuucggcgccggcgccgcucugcaaauuccuuucgcaaugcagauggccuac 
               
               
                 cgguucaauggcauaggugucacucagaacguucuuuaugagaaucagaaacucaucgcgaaccaguuuaauucagcga 
               
               
                 ucggcaagauucaggacuccuuguccucaacugcgucagcuuugggaaaacuucaagacgucgugaaccagaaugcuca 
               
               
                 ggcgcucaauacccuggugaaacaacuuagcaguaacuuuggggcuauuucuagcgguccaaacgauauacugucccga 
               
               
                 cucccgaaagucgaggccgaaguccaaauugaucgucuuauuacagggagacuccaaucucuucaaacauaugucacuca 
               
               
                 acagcucauuagggcugcggagauccgggcuuccgcaaaucuugccgcgacaaagaugagugaaugcgucuugggacaa 
               
               
                 ucuaagaggguggacuuuuguggaaaagguuaccaucucauguccuucccucagucagcgccccacggagucguuuucc 
               
               
                 ugcacguaacguaugucccggcucaagagaagaacuucacuacugcaccagcgauuugccaugacgguaaagcccauuuu 
               
               
                 ccccgcgagggcguauuuguguccaacgguacccacugguucguaacccaacggaauuucuaugagccccaaaucauuac 
               
               
                 aacagauaauacagauguuuccgggaauugcgacguuguuauuggcaucguuaacaacaccguuuacgaucccuugcaa 
               
               
                 ccggaacuggacuccuuuaaagaagaacucgacaaguauuuuaagaaccacacaucaccagaugucgaucuuggcgacau 
               
               
                 uuccggcauuaacgcuucaguuguaaauauucagaaagagauagaucgccugaaugagguggcuaagaaccugaacgaa 
               
               
                 ucucucauugaucuccaagagcugggaaaguacgaacaauacaucaaauggccuucugggcgucgccgaagacgacgagg 
               
               
                 guccggcggcucagggagcggcuauaucccugaggcgccucgggacggacaagcuuaugugaggaaagauggagaaugg 
               
               
                 guauugcugucaaccuuccugggauaauga (SEQ ID NO: 93) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KS G IIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIA G TTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHA G QLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT D VSGNCDVVIGIVNNTV 
               
               
                 YDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNE 
               
               
                 SLIDLQELGKYEQYIKWPSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLLS 
               
               
                 TFLG** (SEQ ID NO: 94) 
               
               
                   
               
               
                 WuS_IgE_StrepHis_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaagccaatgcgtgaatctgactacaagga 
               
               
                 ctcagctgccccctgcatacacgaacagtttcacccgcggtgtatattatccggacaaagtattcaggtctagtgtgctgcactcaaccc 
               
               
                 aggatttgtttctgcccttcttctctaacgtgacatggttccacgccatccatgtgtcaggtacgaacggtaccaagagatttgataacccg 
               
               
                 gtactgccatttaatgacggcgtctattttgcttccactgagaagagcaacatcataagaggctggatctttggaactactctggacagca 
               
               
                 aaacccagagcttgctgatcgtgaacaacgcgacaaatgtagtgatcaaagtatgtgagtttcaattctgtaacgatcccttccttggggt 
               
               
                 ttattaccataagaataataagagttggatggagtccgaatttagagtttactcctcagctaataactgtacgttcgagtatgtctcccaacc 
               
               
                 ttttcttatggatctcgaagggaaacagggtaactttaagaatcttcgagaatttgtgttcaagaacatcgacggttattttaagatctacagt 
               
               
                 aagcatactcccataaatctggttagagatctcccgcaaggattttccgcactggagccccttgtagaccttcccattggaataaacataa 
               
               
                 cacgtttccagacactcctcgctctgcataggtcatatctcaccccgggcgattcttccagcggatggaccgctggagctgctgcttact 
               
               
                 acgtaggatacctgcaaccccggacatttctgctcaagtataacgaaaatgggactattacggacgctgtggactgtgctcttgaccca 
               
               
                 cttagcgagacaaaatgcacgctgaaaagttttaccgtggagaaggggatctatcaaacgagcaattttagggttcagcctaccgaatc 
               
               
                 aatcgtcagatttcccaatatcactaacctgtgccctttcggggaagttttcaacgcaacccggtttgcgagcgtatacgcttggaatcgc 
               
               
                 aaaaggataagcaattgcgttgccgattactccgttctttacaattcagcatcattttctacttttaaatgctacggcgtgtctcccacaaaac 
               
               
                 tgaatgacctgtgttttacgaacgtgtatgcagacagctttgtgattaggggtgatgaggttagacaaatcgcaccaggtcagaccggta 
               
               
                 agatcgctgattacaactacaaactgcccgatgacttcacaggatgcgtgattgcctggaattccaacaatctggattctaaggttggcg 
               
               
                 gcaattacaattacctgtataggttgtttcggaagtcaaacctgaaacccttcgaaagagacatttctaccgagatttatcaagcgggttca 
               
               
                 actccttgtaatggagttgaaggcttcaattgttactttccccttcaatcatacggattccaaccaaccaatggggtcggataccagccata 
               
               
                 tagggttgttgtcctgtcattcgaacttctccacgcaccagccaccgtatgtggacccaagaagtctactaatctggtgaagaacaaatg 
               
               
                 cgtcaatttcaactttaatgggttgaccggcactggggtgctgactgaatccaacaagaagtttctgccgttccaacaattcggacgcga 
               
               
                 tatcgctgatacaaccgatgccgttagagatccccaaacattggagattctggatattacgccttgttcattcggtggtgtttccgtgattac 
               
               
                 ccctggcaccaatacgagtaaccaagtggcggtgctgtatcaagatgtgaactgtactgaagtgccggtggctatacatgccgaccaa 
               
               
                 ctcacaccaacatggagagtatatagcacgggttccaatgtgtttcaaactagggctggctgtttgattggcgctgaacatgttaataattc 
               
               
                 ctatgaatgcgatattcccatcggtgccgggatttgcgcaagttatcaaacgcaaactaactcccccgggtcagcatcctctgtcgcttc 
               
               
                 ccaatcaatcatcgcctataccatgagtcttggggcagaaaattccgttgcttattctaacaattccattgcaattcctacgaacttcaccat 
               
               
                 ctcagttactacagaaatacttcccgtgtcaatgacgaagacatccgtagattgcacaatgtatatatgtggggactcaactgaatgctca 
               
               
                 aacctgctcctgcaatacggatcattttgcacccaactgaacagagcattgaccggtatagccgtggagcaagataagaacactcaag 
               
               
                 aagtattcgcccaggtcaaacaaatctataaaactccgcctataaaagattttggcggctttaacttttcccaaatactgcctgacccaagt 
               
               
                 aagccctcaaaacgtagctttatagaggacctcttgtttaataaggtgacactcgctgacgctggattcattaagcaatatggtgactgctt 
               
               
                 gggagatattgccgcccgcgatctcatttgtgcacaaaagttcaacggcctcacagtcctgccccctctgctgacggatgaaatgatcg 
               
               
                 ctcaatacacctcagctctcctggcaggcaccataacaagcgggtggacatttggtgccggggcagcactgcaaatcccattcgcaat 
               
               
                 gcaaatggcttataggttcaatgggatcggcgtaactcaaaatgtcctctacgagaaccagaaactcatagctaaccaattcaattctgc 
               
               
                 aatcgggaaaatccaggactccctgagctcaacggccagcgcactgggcaagctccaagatgtggtcaaccaaaacgcacaagca 
               
               
                 ctgaatactcttgtgaaacaactcagctccaatttcggggcaatatcaagtgtcctcaatgatattcttagcaggcttgatccacccgaag 
               
               
                 ccgaggtgcagatcgacaggctcataacaggcaggctccagtcccttcaaacgtatgtaactcagcaactgattcgggctgccgagat 
               
               
                 tcgagcttcagctaatttggcagctacgaagatgagcgaatgcgtcctgggacagtctaaaagagtagacttttgcggcaaagggtatc 
               
               
                 atctgatgagcttcccacaaagtgctccacatggcgtggttttcctgcatgtcacttatgttcccgcacaagagaagaacttcactaccgc 
               
               
                 accagcgatctgtcacgatggtaaagcacatttcccgcgggaaggcgtattcgtatctaacggcacccactggttcgttactcaacgca 
               
               
                 acttttatgaaccacaaatcattacaaccgataacacttttgtttcaggcaattgcgatgttgtcatcggcattgtgaataacactgtgtacg 
               
               
                 atccacttcaaccagaattggacagctttaaagaggagcttgataagtatttcaagaatcatacctctcccgacgtggacctcggggaca 
               
               
                 tctctggaataaatgctagcgtcgttaatatacagaaagagattgatcgtctgaacgaagtggctaagaatctgaatgaaagccttatcga 
               
               
                 tctgcaagaactggggaagtacgaacagggatacataccggaagccccacgcgacggtcaggcttatgttaggaaggatggagaat 
               
               
                 gggttttgctctccacgtttctcgggcttgaagttttgttccaaggaccctggtcacacccccaatttgagaaacaccatcaccaccatca 
               
               
                 ccaccactgataa (SEQ ID NO: 95) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaagccaaugcgugaaucugac 
               
               
                 uacaaggacucagcugcccccugcauacacgaacaguuucacccgcgguguauauuauccggacaaaguauucaggucua 
               
               
                 gugugcugcacucaacccaggauuuguuucugcccuucuucucuaacgugacaugguuccacgccauccaugugucagg 
               
               
                 uacgaacgguaccaagagauuugauaacccgguacugccauuuaaugacggcgucuauuuugcuuccacugagaagagc 
               
               
                 aacaucauaagaggcuggaucuuuggaacuacucuggacagcaaaacccagagcuugcugaucgugaacaacgcgacaaa 
               
               
                 uguagugaucaaaguaugugaguuucaauucuguaacgaucccuuccuugggguuuauuaccauaagaauaauaagagu 
               
               
                 uggauggaguccgaauuuagaguuuacuccucagcuaauaacuguacguucgaguaugucucccaaccuuuucuuaugg 
               
               
                 aucucgaagggaaacaggguaacuuuaagaaucuucgagaauuuguguucaagaacaucgacgguuauuuuaagaucua 
               
               
                 caguaagcauacucccauaaaucugguuagagaucucccgcaaggauuuuccgcacuggagccccuuguagaccuuccca 
               
               
                 uuggaauaaacauaacacguuuccagacacuccucgcucugcauaggucauaucucaccccgggcgauucuuccagcgga 
               
               
                 uggaccgcuggagcugcugcuuacuacguaggauaccugcaaccccggacauuucugcucaaguauaacgaaaauggga 
               
               
                 cuauuacggacgcuguggacugugcucuugacccacuuagcgagacaaaaugcacgcugaaaaguuuuaccguggagaa 
               
               
                 ggggaucuaucaaacgagcaauuuuaggguucagccuaccgaaucaaucgucagauuucccaauaucacuaaccugugcc 
               
               
                 cuuucggggaaguuuucaacgcaacccgguuugcgagcguauacgcuuggaaucgcaaaaggauaagcaauugcguugc 
               
               
                 cgauuacuccguucuuuacaauucagcaucauuuucuacuuuuaaaugcuacggcgugucucccacaaaacugaaugacc 
               
               
                 uguguuuuacgaacguguaugcagacagcuuugugauuaggggugaugagguuagacaaaucgcaccaggucagaccg 
               
               
                 guaagaucgcugauuacaacuacaaacugcccgaugacuucacaggaugcgugauugccuggaauuccaacaaucuggau 
               
               
                 ucuaagguuggcggcaauuacaauuaccuguauagguuguuucggaagucaaaccugaaacccuucgaaagagacauuu 
               
               
                 cuaccgagauuuaucaagcggguucaacuccuuguaauggaguugaaggcuucaauuguuacuuuccccuucaaucaua 
               
               
                 cggauuccaaccaaccaauggggucggauaccagccauauaggguuguuguccugucauucgaacuucuccacgcaccag 
               
               
                 ccaccguauguggacccaagaagucuacuaaucuggugaagaacaaaugcgucaauuucaacuuuaauggguugaccgg 
               
               
                 cacuggggugcugacugaauccaacaagaaguuucugccguuccaacaauucggacgcgauaucgcugauacaaccgaug 
               
               
                 ccguuagagauccccaaacauuggagauucuggauauuacgccuuguucauucggugguguuuccgugauuaccccugg 
               
               
                 caccaauacgaguaaccaaguggcggugcuguaucaagaugugaacuguacugaagugccgguggcuauacaugccgac 
               
               
                 caacucacaccaacauggagaguauauagcacggguuccaauguguuucaaacuagggcuggcuguuugauuggcgcug 
               
               
                 aacauguuaauaauuccuaugaaugcgauauucccaucggugccgggauuugcgcaaguuaucaaacgcaaacuaacucc 
               
               
                 cccgggucagcauccucugucgcuucccaaucaaucaucgccuauaccaugagucuuggggcagaaaauuccguugcuu 
               
               
                 auucuaacaauuccauugcaauuccuacgaacuucaccaucucaguuacuacagaaauacuucccgugucaaugacgaag 
               
               
                 acauccguagauugcacaauguauauauguggggacucaacugaaugcucaaaccugcuccugcaauacggaucauuuu 
               
               
                 gcacccaacugaacagagcauugaccgguauagccguggagcaagauaagaacacucaagaaguauucgcccaggucaaa 
               
               
                 caaaucuauaaaacuccgccuauaaaagauuuuggcggcuuuaacuuuucccaaauacugccugacccaaguaagcccuc 
               
               
                 aaaacguagcuuuauagaggaccucuuguuuaauaaggugacacucgcugacgcuggauucauuaagcaauauggugac 
               
               
                 ugcuugggagauauugccgcccgcgaucucauuugugcacaaaaguucaacggccucacaguccugcccccucugcuga 
               
               
                 cggaugaaaugaucgcucaauacaccucagcucuccuggcaggcaccauaacaagcggguggacauuuggugccggggc 
               
               
                 agcacugcaaaucccauucgcaaugcaaauggcuuauagguucaaugggaucggcguaacucaaaauguccucuacgaga 
               
               
                 accagaaacucauagcuaaccaauucaauucugcaaucgggaaaauccaggacucccugagcucaacggccagcgcacug 
               
               
                 ggcaagcuccaagauguggucaaccaaaacgcacaagcacugaauacucuugugaaacaacucagcuccaauuucggggc 
               
               
                 aauaucaaguguccucaaugauauucuuagcaggcuugauccacccgaagccgaggugcagaucgacaggcucauaacag 
               
               
                 gcaggcuccagucccuucaaacguauguaacucagcaacugauucgggcugccgagauucgagcuucagcuaauuuggc 
               
               
                 agcuacgaagaugagcgaaugcguccugggacagucuaaaagaguagacuuuugcggcaaaggguaucaucugaugagc 
               
               
                 uucccacaaagugcuccacauggcgugguuuuccugcaugucacuuauguucccgcacaagagaagaacuucacuaccgc 
               
               
                 accagcgaucugucacgaugguaaagcacauuucccgcgggaaggcguauucguaucuaacggcacccacugguucguu 
               
               
                 acucaacgcaacuuuuaugaaccacaaaucauuacaaccgauaacacuuuuguuucaggcaauugcgauguugucaucgg 
               
               
                 cauugugaauaacacuguguacgauccacuucaaccagaauuggacagcuuuaaagaggagcuugauaaguauuucaag 
               
               
                 aaucauaccucucccgacguggaccucggggacaucucuggaauaaaugcuagcgucguuaauauacagaaagagauuga 
               
               
                 ucgucugaacgaaguggcuaagaaucugaaugaaagccuuaucgaucugcaagaacuggggaaguacgaacagggauac 
               
               
                 auaccggaagccccacgcgacggucaggcuuauguuaggaaggauggagaauggguuuugcucuccacguuucucgggc 
               
               
                 uugaaguuuuguuccaaggacccuggucacacccccaauuugagaaacaccaucaccaccaucaccaccacugauaa 
               
               
                 (SEQ ID NO: 96) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHS 
               
               
                 TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGT 
               
               
                 TLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSAN 
               
               
                 NCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSA 
               
               
                 LEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN 
               
               
                 ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGE 
               
               
                 VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY 
               
               
                 ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYL 
               
               
                 YRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV 
               
               
                 VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGR 
               
               
                 DIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIH 
               
               
                 ADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGS 
               
               
                 ASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYIC 
               
               
                 GDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN 
               
               
                 FSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTV 
               
               
                 LPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY 
               
               
                 ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISS 
               
               
                 VLNDILSRLD  EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVL 
               
               
                 GQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP 
               
               
                 REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSF 
               
               
                 KEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY 
               
               
                 EQGYIPEAPRDGQAYVRKDGEWVLLSTFLGLEVLFQGPWSHPQFEKHHHHHHHH** 
               
               
                 (SEQ ID NO: 97) 
               
               
                   
               
               
                 WuS_IgE_DownDS2_2P_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcatcacagtgcgttaatctgaccacccgtac 
               
               
                 acaactcccacccgcatacacaaatagctttacacgcggagtgtattaccccgataaagtctttcggagctcagtgctccattctactcaa 
               
               
                 gatcttttcctgccgttctttagtaacgttacttggtttcatgcaatacatgtgtctggcacaaacggaaccaaacgttttgataatccggtgtt 
               
               
                 gccatttaatgatggtgtatattttgcttccacggaaaagtcaaacatcatccgtgggtggatctttggcaccactcttgatagcaaatgtca 
               
               
                 aagccttctgattgttaataacgctacaaacgtcgtaattaaagtgtgtgaattccagttctgtaatgaccccttcctcggagtatattacca 
               
               
                 caagaataacaaatcttggatggagagcgaatttagagtttacagttcagccaataactgtacatttgaatatgtcagtcagcctttcctcat 
               
               
                 ggacctcgaaggtaaacaaggtaattttaagaacttgagagagttcgtgtttaagaacatcgatggctatttcaaaatttactctaagcaca 
               
               
                 caccaatcaacctggttcgagacctgccccagggtttctcagctttggaaccattggtggacctgccaatcggcattaacattaccagat 
               
               
                 ttcaaactttgttggcactccaccggtcatatcttacccccggagacagttcctcaggctggacggcaggcgccgccgcgtactatgttg 
               
               
                 ggtatctccaaccccgaaccttccttctcaaatacaatgaaaacgggacgattacagatgcagtcgattgcgccctggaccccttgtcc 
               
               
                 gaaactaaatgcactctgaagagtttcacggtagagaagggaatctatcaaacgagcaattttcgagtccaaccaacggaatctattgtg 
               
               
                 cggtttcccaatatcacaaacctctgtccattcggagaagtctttaatgctaccaggtttgcgtctgtatatgcatggaaccgaaagagga 
               
               
                 tttccaattgcgtagcggactacagtgtcctttataacagcgcttcattttccacgtttaagtgttatggtgtttctccaacgaaactcaacga 
               
               
                 cctctgttttactaacgtttacgctgacagctttgttatacgtggggacgaagtcaggcaaattgctcctggacagactggaaagatcgct 
               
               
                 gattataattataaacttcctgacgatttcaccggctgcgttattgcatggaactccaacaatctggattcaaaagtgggtggaaattataat 
               
               
                 tatctgtataggttgtttcggaagagcaatcttaagccctttgagcgggacatatgtaccgaaatttaccaagcaggctccaccccatgca 
               
               
                 atggagtagaagggttcaattgctattttcctctgcaaagttatggctttcaacccaccaacggagttgggtatcaaccttacagggttgtc 
               
               
                 gtgctgagtttcgaattgctccacgcacccgctacagtatgtggccccaagaagtccactaatcttgttaagaataaatgcgtgaacttca 
               
               
                 acttcaatggacttacaggtactggagtactcacggaatcaaacaagaaatttctcccatttcaacagtttggccgagatatagctgacac 
               
               
                 cacagatgctgttcgcgacccccagacgttggaaatacttgatatcactccctgcagcttcggcggcgtgagcgtgatcactccaggta 
               
               
                 ctaatacgagcaatcaagttgccgttctgtaccaagatgtgaactgcaccgaggttccagtggcaattcacgccgaccaacttactccc 
               
               
                 acctggcgggtctattccaccggatcaaacgtcttccaaactcgcgctggttgccttatcggtgcagagcacgttaataattcctatgaat 
               
               
                 gtgacattcccataggagcaggcatctgtgcatcttatcaaacccagactaattcccctggttccgcttcctctgttgcatcccagtccata 
               
               
                 attgcctacactatgagtctcggggctgaaaattccgtggcctattctaataattcaatcgccatcccaaccaattttaccatatccgtaacg 
               
               
                 actgaaatacttcctgtcagtatgaccaagacctcagtggactgcaccatgtacatctgcggcgattctactgaatgttccaatctgctttt 
               
               
                 gcaatatggttcattctgcacccaactcaacagggctcttacagggatcgccgtcgaacaggataagaatacccaggaagtgttcgcc 
               
               
                 caagttaagcaaatttacaagacaccacccatcaaggacttcggcgggttcaacttcagccaaattctgcccgacccgtctaagccttct 
               
               
                 aagcgctctttcattgaggatcttttgttcaataaggttacgcttgccgatgcagggtttatcaaacagtatggcgactgtcttggggatatc 
               
               
                 gcagctagggatcttatttgtgcacagaaatttaatggcctgactgttcttccccctttgctcactgacgagatgattgcccagtacacttca 
               
               
                 gctctcctggccgggactataacttctggttggaccttcggagctggcgccgccctgcaaattccatttgcaatgcagatggcttatcgct 
               
               
                 tcaacggaattggggtgacccaaaatgttctctacgagaaccagaaactcattgcaaaccagttcaattctgcgatcgggaagatccag 
               
               
                 gattccctgtctagtacggctagtgccctcggtaagctccaagacgtcgtcaaccaaaacgcccaggccttgaacacccttgtcaaaca 
               
               
                 actgagctccaattttggggctattagcagtgtgctgaatgatatcctgtcccgccttgacccaccggaagcggaagtccaaattgatcg 
               
               
                 actgatcactgggcgtctccaatcccttcaaacttacgtgacccaacaactcatccgagcagctgagattagggctagcgctaaccttg 
               
               
                 ctgctactaagatgtcagagtgtgtcctcggccagtctaagagagtggacttttgtgggaaagggtaccacttgatgtcattcccacaaa 
               
               
                 gcgccccacacggcgtggtgtttctccacgtcacttacgttccagctcaggaaaagaactttaccaccgcccccgctatatgtcatgatg 
               
               
                 ggaaggcccactttcctcgtgaaggtgtctttgtcagcaatggcacacactggtttgtgacccaacggaatttctatgagcctcagattatt 
               
               
                 accacggataacactttcgtatcagggaattgtgatgtggttatcggcatcgttaataatacagtgtatgacccactgcagccagagcttg 
               
               
                 acagcttcaaagaagagctcgataagtactttaagaatcatacaagtcctgacgttgatcttggggatattagtgggattaacgccagcg 
               
               
                 tcgtcaatattcagaaagagattgacaggttgaacgaagtagctaagaatcttaatgaaagcctgatagatttgcaagaacttggtaagta 
               
               
                 tgagcaggggtacatacccgaggctcctcgggatgggcaggcctatgtacgcaaagacggtgaatgggtattgctcagcacttttctc 
               
               
                 ggctgataa (SEQ ID NO: 98) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaucacagugcguuaaucugac 
               
               
                 cacccguacacaacucccacccgcauacacaaauagcuuuacacgcggaguguauuaccccgauaaagucuuucggagcu 
               
               
                 cagugcuccauucuacucaagaucuuuuccugccguucuuuaguaacguuacuugguuucaugcaauacaugugucugg 
               
               
                 cacaaacggaaccaaacguuuugauaauccgguguugccauuuaaugaugguguauauuuugcuuccacggaaaaguca 
               
               
                 aacaucauccguggguggaucuuuggcaccacucuugauagcaaaugucaaagccuucugauuguuaauaacgcuacaa 
               
               
                 acgucguaauuaaagugugugaauuccaguucuguaaugaccccuuccucggaguauauuaccacaagaauaacaaaucu 
               
               
                 uggauggagagcgaauuuagaguuuacaguucagccaauaacuguacauuugaauaugucagucagccuuuccucaugg 
               
               
                 accucgaagguaaacaagguaauuuuaagaacuugagagaguucguguuuaagaacaucgauggcuauuucaaaauuua 
               
               
                 cucuaagcacacaccaaucaaccugguucgagaccugccccaggguuucucagcuuuggaaccauugguggaccugccaa 
               
               
                 ucggcauuaacauuaccagauuucaaacuuuguuggcacuccaccggucauaucuuacccccggagacaguuccucaggc 
               
               
                 uggacggcaggcgccgccgcguacuauguuggguaucuccaaccccgaaccuuccuucucaaauacaaugaaaacgggac 
               
               
                 gauuacagaugcagucgauugcgcccuggaccccuuguccgaaacuaaaugcacucugaagaguuucacgguagagaag 
               
               
                 ggaaucuaucaaacgagcaauuuucgaguccaaccaacggaaucuauugugcgguuucccaauaucacaaaccucugucc 
               
               
                 auucggagaagucuuuaaugcuaccagguuugcgucuguauaugcauggaaccgaaagaggauuuccaauugcguagcg 
               
               
                 gacuacaguguccuuuauaacagcgcuucauuuuccacguuuaaguguuaugguguuucuccaacgaaacucaacgacc 
               
               
                 ucuguuuuacuaacguuuacgcugacagcuuuguuauacguggggacgaagucaggcaaauugcuccuggacagacugg 
               
               
                 aaagaucgcugauuauaauuauaaacuuccugacgauuucaccggcugcguuauugcauggaacuccaacaaucuggau 
               
               
                 ucaaaaguggguggaaauuauaauuaucuguauagguuguuucggaagagcaaucuuaagcccuuugagcgggacauau 
               
               
                 guaccgaaauuuaccaagcaggcuccaccccaugcaauggaguagaaggguucaauugcuauuuuccucugcaaaguua 
               
               
                 uggcuuucaacccaccaacggaguuggguaucaaccuuacaggguugucgugcugaguuucgaauugcuccacgcaccc 
               
               
                 gcuacaguauguggccccaagaaguccacuaaucuuguuaagaauaaaugcgugaacuucaacuucaauggacuuacagg 
               
               
                 uacuggaguacucacggaaucaaacaagaaauuucucccauuucaacaguuuggccgagauauagcugacaccacagaug 
               
               
                 cuguucgcgacccccagacguuggaaauacuugauaucacucccugcagcuucggcggcgugagcgugaucacuccagg 
               
               
                 uacuaauacgagcaaucaaguugccguucuguaccaagaugugaacugcaccgagguuccaguggcaauucacgccgacc 
               
               
                 aacuuacucccaccuggcgggucuauuccaccggaucaaacgucuuccaaacucgcgcugguugccuuaucggugcaga 
               
               
                 gcacguuaauaauuccuaugaaugugacauucccauaggagcaggcaucugugcaucuuaucaaacccagacuaauuccc 
               
               
                 cugguuccgcuuccucuguugcaucccaguccauaauugccuacacuaugagucucggggcugaaaauuccguggccua 
               
               
                 uucuaauaauucaaucgccaucccaaccaauuuuaccauauccguaacgacugaaauacuuccugucaguaugaccaaga 
               
               
                 ccucaguggacugcaccauguacaucugcggcgauucuacugaauguuccaaucugcuuuugcaauaugguucauucug 
               
               
                 cacccaacucaacagggcucuuacagggaucgccgucgaacaggauaagaauacccaggaaguguucgcccaaguuaagc 
               
               
                 aaauuuacaagacaccacccaucaaggacuucggcggguucaacuucagccaaauucugcccgacccgucuaagccuucu 
               
               
                 aagcgcucuuucauugaggaucuuuuguucaauaagguuacgcuugccgaugcaggguuuaucaaacaguauggcgacu 
               
               
                 gucuuggggauaucgcagcuagggaucuuauuugugcacagaaauuuaauggccugacuguucuucccccuuugcucac 
               
               
                 ugacgagaugauugcccaguacacuucagcucuccuggccgggacuauaacuucugguuggaccuucggagcuggcgcc 
               
               
                 gcccugcaaauuccauuugcaaugcagauggcuuaucgcuucaacggaauuggggugacccaaaauguucucuacgaga 
               
               
                 accagaaacucauugcaaaccaguucaauucugcgaucgggaagauccaggauucccugucuaguacggcuagugcccuc 
               
               
                 gguaagcuccaagacgucgucaaccaaaacgcccaggccuugaacacccuugucaaacaacugagcuccaauuuuggggc 
               
               
                 uauuagcagugugcugaaugauauccugucccgccuugacccaccggaagcggaaguccaaauugaucgacugaucacu 
               
               
                 gggcgucuccaaucccuucaaacuuacgugacccaacaacucauccgagcagcugagauuagggcuagcgcuaaccuugc 
               
               
                 ugcuacuaagaugucagaguguguccucggccagucuaagagaguggacuuuugugggaaaggguaccacuugauguc 
               
               
                 auucccacaaagcgccccacacggcgugguguuucuccacgucacuuacguuccagcucaggaaaagaacuuuaccaccg 
               
               
                 cccccgcuauaugucaugaugggaaggcccacuuuccucgugaaggugucuuugucagcaauggcacacacugguuugu 
               
               
                 gacccaacggaauuucuaugagccucagauuauuaccacggauaacacuuucguaucagggaauugugaugugguuauc 
               
               
                 ggcaucguuaauaauacaguguaugacccacugcagccagagcuugacagcuucaaagaagagcucgauaaguacuuuaa 
               
               
                 gaaucauacaaguccugacguugaucuuggggauauuagugggauuaacgccagcgucgucaauauucagaaagagauu 
               
               
                 gacagguugaacgaaguagcuaagaaucuuaaugaaagccugauagauuugcaagaacuugguaaguaugagcaggggu 
               
               
                 acauacccgaggcuccucgggaugggcaggccuauguacgcaaagacggugaauggguauugcucagcacuuuucucgg 
               
               
                 cugauaa (SEQ ID NO: 99) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHS 
               
               
                 TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGT 
               
               
                 TLDSK  QSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSAN 
               
               
                 NCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSA 
               
               
                 LEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN 
               
               
                 ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGE 
               
               
                 VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY 
               
               
                 ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYL 
               
               
                 YRLFRKSNLKPFERDI  TEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV 
               
               
                 VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGR 
               
               
                 DIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIH 
               
               
                 ADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGS 
               
               
                 ASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYIC 
               
               
                 GDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN 
               
               
                 FSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTV 
               
               
                 LPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY 
               
               
                 ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISS 
               
               
                 VLNDILSRLD  EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVL 
               
               
                 GQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP 
               
               
                 REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSF 
               
               
                 KEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY 
               
               
                 EQGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 100) 
               
               
                   
               
               
                 WuS_IgE_DownDS1 _2P_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcatcccagtgcgtgaacctgaccacccgaa 
               
               
                 ctcaactcccaccagcatacaccaactcatttacaagaggagtttattacccggacaaggtatttcgaagttcagttcttcacagcaccca 
               
               
                 agacctgtttctgccattcttcagtaatgtcacttggtttcacgcgatacatgtcagcggtacaaacgggacaaagcgattcgataaccca 
               
               
                 gtactcccattcaacgacggagtgtattttgcatctacagagaaatccaacattatacgcgggtggatctttggaactactctggactcca 
               
               
                 agacacagagcctgctcattgtgaacaatgcaacgaatgtcgtcataaaagtctgtgaatttcaattttgcaacgatcctttcctcggagtc 
               
               
                 tattaccataagaacaataagagttggatggagagtgagtttcgcgtctattcttccgcgaacaattgtacatttgaatatgtatcacaacc 
               
               
                 ctttcttatggatttggaaggcaaacaaggtaacttcaagaacttgcgcgagttcgtgttcaagaacatagactgttattttaagatctatag 
               
               
                 taagcatacgccaatcaatctggtgcgagatttgcctcagggcttttctgctcttgaacccttggttgatctgcccatcgggatcaacataa 
               
               
                 ccagatttcaaacgttgctcgcactccaccgcagctatctcactcctggcgattcctcatctgggtggaccgccggagctgctgcttatta 
               
               
                 cgtcggctatctccagccgcgtactttcctgctcaagtataatgagaatggcaccattaccgatgctgtggattgtgctcttgatccactct 
               
               
                 ctgaaaccaaatgcactctcaagtcttttaccgtggaaaagggtatttatcagacatctaattttcgggtgcaacctactgagtcaattgtac 
               
               
                 ggtttcctaacataactaacctttgtccatttggggaagtcttcaatgccacgcggttcgcatcagtctatgcatggaacagaaaacgtatc 
               
               
                 tccaactgcgtcgccgattattccgtcctttacaatagcgctagcttttccacattcaaatgttatggcgtatcaccaaccaaacttaacgat 
               
               
                 ctctgctttactaatgtctacgctgactctttcgttattcgaggtgacgaggtgcgccaaattgcgcctggtcaaaccggaaagattgccg 
               
               
                 attataactacaagctccccgacgactttacgggttgtgtgatcgcctggaatagcaataacctcgattctaaagttggcggtaattataac 
               
               
                 tatctgtacagactctttaggaaaagtaatctcaagcccttttgcagggatatctcaaccgaaatctaccaagccggcagcactccttgca 
               
               
                 atggtgtcgaggggtttaattgttatttcccactgcaatcttacggctttcaaccgactaatggagtcggttatcaaccctatagggtggtg 
               
               
                 gtactctcctttgaacttttgcacgctccggcaacagtttgtggaccaaagaaaagtacgaaccttgttaagaataagtgtgttaatttcaat 
               
               
                 tttaacggcctcactggaacaggtgtcctcacagaaagcaacaagaagtttctccctttccaacagtttggacgggatatcgccgacact 
               
               
                 actgacgccgtcagagatcctcaaactctcgaaatcttggatatcacaccatgttctttcggtggtgtctccgtcataacaccaggaacta 
               
               
                 acacctctaatcaagtggccgtgctctatcaggacgtcaattgcacagaagtgcctgtcgcaatccatgctgatcagctcactcccacct 
               
               
                 ggcgtgtgtattccactggctctaatgtctttcagacacgggcaggttgccttattggggcagagcatgtgaacaattcctacgaatgcg 
               
               
                 atatacccattggggcaggcatttgcgccagctaccaaacccaaactaacagccccgggagtgccagcagcgtggcatctcagtcca 
               
               
                 ttattgcctatacgatgagcctgggtgctgaaaatagcgtggcttatagtaataactctatcgccatacccacaaacttcaccatttcagtg 
               
               
                 accaccgaaatccttcctgtttctatgaccaaaacgtccgtcgattgtacaatgtacatttgcggcgatagcactgaatgttcaaacctgct 
               
               
                 cctgcaatacggctctttctgtactcagctcaaccgggcactcaccggcatagccgtcgaacaagacaagaatacccaggaagtctttg 
               
               
                 cgcaggtgaaacaaatctataagaccccaccaataaaagatttcggcggttttaatttcagccaaatcttgcctgatcccagcaagccat 
               
               
                 ctaaacggtctttcattgaagatctcctgttcaacaaggttacgctggctgacgccgggtttattaagcaatatggcgattgccttgggga 
               
               
                 cattgccgcacgagacctcatttgtgcccagaaattcaacgggctcaccgtattgcccccgctcctcacagacgaaatgatcgcccaat 
               
               
                 atacaagcgccctgcttgcgggaaccattacaagcggttggacctttggtgccggcgcagctctgcaaatacccttcgcaatgcaaat 
               
               
                 ggcatatcggtttaatggaattggcgtaacccaaaacgtgctgtatgaaaaccagaaactgatcgcaaatcaattcaatagtgctatagg 
               
               
                 aaagatccaagacagtctgtcttccactgctagcgcgctggggaagctccaagacgttgtgaaccaaaacgcgcaggccctgaatac 
               
               
                 cctggtgaagcaactttcaagcaatttcggtgctatatcttctgtcctcaatgacattctctctcggctcgatcccccggaagccgaagttc 
               
               
                 agatagaccgtttgatcacaggccgcttgcaatccctgcaaacctacgttacacaacaactgattcgcgccgccgaaattcgggcatcc 
               
               
                 gccaatctggccgcaaccaaaatgtccgagtgtgttctcggtcaatccaaacgcgtggatttctgcggaaaaggataccatttgatgtca 
               
               
                 tttccacaatcagctccacacggtgttgtattcctgcacgtgacctacgtgccagcccaggagaagaattttactactgcgcccgccattt 
               
               
                 gtcatgacgggaaggctcattttcctcgggaaggggttttcgtctcaaacggtacccattggttcgtgactcagaggaacttttatgaacc 
               
               
                 tcaaatcataacgaccgataacacgtttgtaagtggcaattgcgacgtggtcatcgggattgtaaacaatactgtctatgaccctctccaa 
               
               
                 ccagagcttgacagctttaaagaagagcttgataaatactttaagaaccatacctcaccagacgtcgatttgggagatatcagtggcatt 
               
               
                 aatgcctctgtcgtcaatatccagaaagagattgaccgcttgaacgaagttgccaagaatcttaatgagtctctgattgacttgcaagaatt 
               
               
                 gggaaaatatgaacaaggatatattccagaagcccctcgcgatgggcaagcatatgttcgaaaggatggggaatgggtgctgctcag 
               
               
                 cacctttctcggttgataa (SEQ ID NO: 101) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaucccagugcgugaaccugac 
               
               
                 cacccgaacucaacucccaccagcauacaccaacucauuuacaagaggaguuuauuacccggacaagguauuucgaaguu 
               
               
                 caguucuucacagcacccaagaccuguuucugccauucuucaguaaugucacuugguuucacgcgauacaugucagcgg 
               
               
                 uacaaacgggacaaagcgauucgauaacccaguacucccauucaacgacggaguguauuuugcaucuacagagaaaucca 
               
               
                 acauuauacgcggguggaucuuuggaacuacucuggacuccaagacacagagccugcucauugugaacaaugcaacgaau 
               
               
                 gucgucauaaaagucugugaauuucaauuuugcaacgauccuuuccucggagucuauuaccauaagaacaauaagaguu 
               
               
                 ggauggagagugaguuucgcgucuauucuuccgcgaacaauuguacauuugaauauguaucacaacccuuucuuaugga 
               
               
                 uuuggaaggcaaacaagguaacuucaagaacuugcgcgaguucguguucaagaacauagacuguuauuuuaagaucuau 
               
               
                 aguaagcauacgccaaucaaucuggugcgagauuugccucagggcuuuucugcucuugaacccuugguugaucugccca 
               
               
                 ucgggaucaacauaaccagauuucaaacguugcucgcacuccaccgcagcuaucucacuccuggcgauuccucaucuggg 
               
               
                 uggaccgccggagcugcugcuuauuacgucggcuaucuccagccgcguacuuuccugcucaaguauaaugagaauggca 
               
               
                 ccauuaccgaugcuguggauugugcucuugauccacucucugaaaccaaaugcacucucaagucuuuuaccguggaaaa 
               
               
                 ggguauuuaucagacaucuaauuuucgggugcaaccuacugagucaauuguacgguuuccuaacauaacuaaccuuugu 
               
               
                 ccauuuggggaagucuucaaugccacgcgguucgcaucagucuaugcauggaacagaaaacguaucuccaacugcgucg 
               
               
                 ccgauuauuccguccuuuacaauagcgcuagcuuuuccacauucaaauguuauggcguaucaccaaccaaacuuaacgau 
               
               
                 cucugcuuuacuaaugucuacgcugacucuuucguuauucgaggugacgaggugcgccaaauugcgccuggucaaaccg 
               
               
                 gaaagauugccgauuauaacuacaagcuccccgacgacuuuacggguugugugaucgccuggaauagcaauaaccucga 
               
               
                 uucuaaaguuggcgguaauuauaacuaucuguacagacucuuuaggaaaaguaaucucaagcccuuuugcagggauauc 
               
               
                 ucaaccgaaaucuaccaagccggcagcacuccuugcaauggugucgagggguuuaauuguuauuucccacugcaaucuu 
               
               
                 acggcuuucaaccgacuaauggagucgguuaucaacccuauaggguggugguacucuccuuugaacuuuugcacgcucc 
               
               
                 ggcaacaguuuguggaccaaagaaaaguacgaaccuuguuaagaauaaguguguuaauuucaauuuuaacggccucacu 
               
               
                 ggaacagguguccucacagaaagcaacaagaaguuucucccuuuccaacaguuuggacgggauaucgccgacacuacuga 
               
               
                 cgccgucagagauccucaaacucucgaaaucuuggauaucacaccauguucuuucgguggugucuccgucauaacaccag 
               
               
                 gaacuaacaccucuaaucaaguggccgugcucuaucaggacgucaauugcacagaagugccugucgcaauccaugcugau 
               
               
                 cagcucacucccaccuggcguguguauuccacuggcucuaaugucuuucagacacgggcagguugccuuauuggggcag 
               
               
                 agcaugugaacaauuccuacgaaugcgauauacccauuggggcaggcauuugcgccagcuaccaaacccaaacuaacagc 
               
               
                 cccgggagugccagcagcguggcaucucaguccauuauugccuauacgaugagccugggugcugaaaauagcguggcuu 
               
               
                 auaguaauaacucuaucgccauacccacaaacuucaccauuucagugaccaccgaaauccuuccuguuucuaugaccaaaa 
               
               
                 cguccgucgauuguacaauguacauuugcggcgauagcacugaauguucaaaccugcuccugcaauacggcucuuucug 
               
               
                 uacucagcucaaccgggcacucaccggcauagccgucgaacaagacaagaauacccaggaagucuuugcgcaggugaaac 
               
               
                 aaaucuauaagaccccaccaauaaaagauuucggcgguuuuaauuucagccaaaucuugccugaucccagcaagccaucu 
               
               
                 aaacggucuuucauugaagaucuccuguucaacaagguuacgcuggcugacgccggguuuauuaagcaauauggcgauu 
               
               
                 gccuuggggacauugccgcacgagaccucauuugugcccagaaauucaacgggcucaccguauugcccccgcuccucaca 
               
               
                 gacgaaaugaucgcccaauauacaagcgcccugcuugcgggaaccauuacaagcgguuggaccuuuggugccggcgcag 
               
               
                 cucugcaaauacccuucgcaaugcaaauggcauaucgguuuaauggaauuggcguaacccaaaacgugcuguaugaaaac 
               
               
                 cagaaacugaucgcaaaucaauucaauagugcuauaggaaagauccaagacagucugucuuccacugcuagcgcgcuggg 
               
               
                 gaagcuccaagacguugugaaccaaaacgcgcaggcccugaauacccuggugaagcaacuuucaagcaauuucggugcua 
               
               
                 uaucuucuguccucaaugacauucucucucggcucgaucccccggaagccgaaguucagauagaccguuugaucacagg 
               
               
                 ccgcuugcaaucccugcaaaccuacguuacacaacaacugauucgcgccgccgaaauucgggcauccgccaaucuggccg 
               
               
                 caaccaaaauguccgaguguguucucggucaauccaaacgcguggauuucugcggaaaaggauaccauuugaugucauu 
               
               
                 uccacaaucagcuccacacgguguuguauuccugcacgugaccuacgugccagcccaggagaagaauuuuacuacugcgc 
               
               
                 ccgccauuugucaugacgggaaggcucauuuuccucgggaagggguuuucgucucaaacgguacccauugguucgugac 
               
               
                 ucagaggaacuuuuaugaaccucaaaucauaacgaccgauaacacguuuguaaguggcaauugcgacguggucaucggg 
               
               
                 auuguaaacaauacugucuaugacccucuccaaccagagcuugacagcuuuaaagaagagcuugauaaauacuuuaagaa 
               
               
                 ccauaccucaccagacgucgauuugggagauaucaguggcauuaaugccucugucgucaauauccagaaagagauugacc 
               
               
                 gcuugaacgaaguugccaagaaucuuaaugagucucugauugacuugcaagaauugggaaaauaugaacaaggauauau 
               
               
                 uccagaagccccucgcgaugggcaagcauauguucgaaaggauggggaaugggugcugcucagcaccuuucucgguuga 
               
               
                 uaa (SEQ ID NO: 102) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHS 
               
               
                 TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGT 
               
               
                 TLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSAN 
               
               
                 NCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNID  YFKIYSKHTPINLVRDLPQGFSA 
               
               
                 LEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN 
               
               
                 ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGE 
               
               
                 VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY 
               
               
                 ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYL 
               
               
                 YRLFRKSNLKPFCRDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV 
               
               
                 VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGR 
               
               
                 DIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIH 
               
               
                 ADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGS 
               
               
                 ASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYIC 
               
               
                 GDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN 
               
               
                 FSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTV 
               
               
                 LPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY 
               
               
                 ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISS 
               
               
                 VLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVL 
               
               
                 GQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP 
               
               
                 REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSF 
               
               
                 KEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY 
               
               
                 EQGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 103) 
               
               
                   
               
               
                 WuS_IgE_2P_UpGly_pVax 
               
               
                 gccaccatggattggacctggatacttttcctcgtggccgcagcaacaagagtccactcctctcagtgcgttaacctgactactagaacc 
               
               
                 caattgcccccggcatacacaaactctttcacccggggtgtctactatcccgacaaagtgtttagaagtagcgtgctgcacagcaccca 
               
               
                 agatctctttctgccattcttctcaaacgtcacctggtttcacgccatccatgtaagcgggaccaacggcacaaagcgttttgataaccct 
               
               
                 gttttgccattcaatgatggcgtgtattttgcttccactgagaaaagcaacatcattagagggtggatatttggcacaacgcttgactccaa 
               
               
                 gacgcagagtcttttgatagtaaacaacgcaactaatgtggtcattaaagtctgtgaatttcaattttgcaatgaccccttccttggagtctat 
               
               
                 taccacaagaacaacaaaagctggatggaaagcgaatttagggtctacagctctgccaataactgcacattcgaatacgtcagccaac 
               
               
                 cattcttgatggacctggaaggcaagcaaggaaactttaagaatctgagggaatttgtgtttaagaatatcgacggatattttaagatctat 
               
               
                 tccaagcatactcccattaatctcgttcgtgaccttcctcagggtttctctgcattggaacccctcgtagatttgcccattgggattaatatca 
               
               
                 ctagattccagacgctgcttgcactccatcgatcttatctgacccctggtgactcctcttccgggtggacggcgggtgctgcagcctact 
               
               
                 acgttggctatttgcaacctaggacctttctgttgaagtataatgagaatgggactattactgatgccgttgattgcgccctcgatccgctgt 
               
               
                 cagaaacaaagtgcaccctgaagagcttcacagtagaaaagggaatctatcaaacctcaaatttccgcgttcaaccaactgaatcaatc 
               
               
                 gtgcgttttcctaacatcacaaatctgtgtccgtttggagaagtatttaatgcgacgcgtttcgcaagcgtctacgcgtggaatcgcaaac 
               
               
                 gtatctctaattgcgtagcagattattctgtgctgtacaatagcgcatctttctcaacgtttaagtgctacggcgttaatgggaccaagctga 
               
               
                 atgatctctgtttcactaatgtgtacgcagacagttttgtaattagaggagacgaggttaggcaaatagcaccgggtcaaactggcaaaa 
               
               
                 tcgccgactataactacaagctccctgatgacttcacgggctgcgtaattgcttggaactctaataacctggactctaaagtcggcggga 
               
               
                 attataattatctctatcggttgtttcgaaaatccaatctcaaaccctttgagcgggacatcaatactacaatttatcaagctggtagtactcct 
               
               
                 tgcaatggggtagaaggcttcaattgttatttcccccttcaatcttacggatttcaacccacgaacggcgtagggtaccagccctatcgag 
               
               
                 tggtggtactgtcattcgaacttaatcacgccccagcaacagtctgcgggcctaagaaaagcacgaatcttgtcaagaataagtgtgta 
               
               
                 aatttcaacttcaatggtcttacaggcacgggagtgctcactgagtctaataagaaatttcttcctttccaacaattcggtcgtgatattgcc 
               
               
                 gatactactgatgcagtccgagatccacaaactctcgaaatcctcgatattactccttgtagttttggcggcgtctccgtgatcaccccag 
               
               
                 ggaccaacactagtaaccaagtggcggtgctctaccaagatgttaactgcacagaagtcccggtagcgatccatgccgaccagctca 
               
               
                 ctcccacatggcgtgtttacagcacagggtcaaacgttttccagacccgtgccggatgtcttataggagccgaacacgtaaataacagt 
               
               
                 tatgaatgcgatatcccaattggtgcaggtatctgtgcgtcatatcaaacccaaactaattctccggggtccgcctcaagcgttgcctcac 
               
               
                 aatcaataatcgcctacacaatgtccctcggtgccgaaaattcagtcgcttactctaacaatagcattgctatccctaccaacttcactattt 
               
               
                 ctgttaccacggaaattttgcctgtatccatgaccaaaacatctgttgattgcacgatgtacatctgcggggattctaccgaatgttctaac 
               
               
                 ctgcttctgcaatacggctccttctgcacccaattgaaccgcgcactgactgggattgctgtggaacaagacaagaatactcaagaagt 
               
               
                 atttgcccaggtcaaacagatttacaaaactcccccaattaaagatttcggcggtttcaattttagtcaaattctgccagatccaagtaagc 
               
               
                 catccaaacgctcatttattgaggacctgctctttaataaagtcacgctggccgacgccggcttcataaaacagtatggcgattgtcttgg 
               
               
                 agacatcgccgcccgcgacctcatttgcgcacaaaagttcaatgggctcaccgtgttgccaccactgctcacagatgagatgatcgca 
               
               
                 cagtacacgagcgcccttcttgccggcactatcacgtctggttggacgttcggtgccggagccgctctgcaaattccctttgcaatgcaa 
               
               
                 atggcctatagatttaatggaattggcgtaacacagaacgtgttgtacgagaaccagaagctcattgccaaccagttcaattccgctattg 
               
               
                 gcaaaatacaagactctctcagctcaactgctagcgcactgggaaaattgcaagacgtagtcaatcaaaatgcccaagccctcaatact 
               
               
                 ctcgtcaaacagttgtcttccaactttggggctatcagtagtgtactcaatgacattctttcaagactggacccgcccgaggcggaagtcc 
               
               
                 aaattgatcgtctgataactggaaggttgcaaagccttcagacctacgttacgcaacaacttattagggctgccgaaataagggcatcc 
               
               
                 gctaatctggcagctacaaagatgtctgaatgtgttttgggacagagcaaacgggttgacttctgcggtaaaggttaccatctcatgtcttt 
               
               
                 tccacaaagcgcaccgcacggagtcgtcttcctgcatgtaacatacgtcccagcccaagaaaagaattttaccacagccccagccatc 
               
               
                 tgccacgacggcaaggcgcatttcccaagggaaggcgtgtttgtatccaacgggacgcattggtttgtcactcaaaggaacttttacga 
               
               
                 accccaaattattaccactgataacaccttcgtttctgggaactgtgatgtcgtgattgggatagtaaacaacacggtatatgatccactgc 
               
               
                 aaccagaactggattccttcaaagaagagctggacaaatacttcaagaatcatactagtcctgacgtcgacctgggcgatatcagtgga 
               
               
                 atcaacgctagcgtcgtaaacattcaaaaggagatcgatagacttaacgaggtcgccaagaatctcaatgaaagcctcatcgatttgca 
               
               
                 agaactcggaaaatatgagcaaagcggatcagggtacattccggaagcccccagggacggacaggcatatgtccgcaaggacgga 
               
               
                 gaatgggttcttcttagcacttttctggggtaatga (SEQ ID NO: 104) 
               
               
                   
               
               
                 gccaccauggauuggaccuggauacuuuuccucguggccgcagcaacaagaguccacuccucucagugcguuaaccugac 
               
               
                 uacuagaacccaauugcccccggcauacacaaacucuuucacccggggugucuacuaucccgacaaaguguuuagaagua 
               
               
                 gcgugcugcacagcacccaagaucucuuucugccauucuucucaaacgucaccugguuucacgccauccauguaagcggg 
               
               
                 accaacggcacaaagcguuuugauaacccuguuuugccauucaaugauggcguguauuuugcuuccacugagaaaagca 
               
               
                 acaucauuagaggguggauauuuggcacaacgcuugacuccaagacgcagagucuuuugauaguaaacaacgcaacuaau 
               
               
                 guggucauuaaagucugugaauuucaauuuugcaaugaccccuuccuuggagucuauuaccacaagaacaacaaaagcu 
               
               
                 ggauggaaagcgaauuuagggucuacagcucugccaauaacugcacauucgaauacgucagccaaccauucuugauggac 
               
               
                 cuggaaggcaagcaaggaaacuuuaagaaucugagggaauuuguguuuaagaauaucgacggauauuuuaagaucuauu 
               
               
                 ccaagcauacucccauuaaucucguucgugaccuuccucaggguuucucugcauuggaaccccucguagauuugcccau 
               
               
                 ugggauuaauaucacuagauuccagacgcugcuugcacuccaucgaucuuaucugaccccuggugacuccucuuccggg 
               
               
                 uggacggcgggugcugcagccuacuacguuggcuauuugcaaccuaggaccuuucuguugaaguauaaugagaauggg 
               
               
                 acuauuacugaugccguugauugcgcccucgauccgcugucagaaacaaagugcacccugaagagcuucacaguagaaaa 
               
               
                 gggaaucuaucaaaccucaaauuuccgcguucaaccaacugaaucaaucgugcguuuuccuaacaucacaaaucuguguc 
               
               
                 cguuuggagaaguauuuaaugcgacgcguuucgcaagcgucuacgcguggaaucgcaaacguaucucuaauugcguagc 
               
               
                 agauuauucugugcuguacaauagcgcaucuuucucaacguuuaagugcuacggcguuaaugggaccaagcugaaugau 
               
               
                 cucuguuucacuaauguguacgcagacaguuuuguaauuagaggagacgagguuaggcaaauagcaccgggucaaacug 
               
               
                 gcaaaaucgccgacuauaacuacaagcucccugaugacuucacgggcugcguaauugcuuggaacucuaauaaccuggac 
               
               
                 ucuaaagucggcgggaauuauaauuaucucuaucgguuguuucgaaaauccaaucucaaacccuuugagcgggacauca 
               
               
                 auacuacaauuuaucaagcugguaguacuccuugcaaugggguagaaggcuucaauuguuauuucccccuucaaucuua 
               
               
                 cggauuucaacccacgaacggcguaggguaccagcccuaucgaguggugguacugucauucgaacuuaaucacgccccag 
               
               
                 caacagucugcgggccuaagaaaagcacgaaucuugucaagaauaaguguguaaauuucaacuucaauggucuuacaggc 
               
               
                 acgggagugcucacugagucuaauaagaaauuucuuccuuuccaacaauucggucgugauauugccgauacuacugaug 
               
               
                 caguccgagauccacaaacucucgaaauccucgauauuacuccuuguaguuuuggcggcgucuccgugaucaccccagg 
               
               
                 gaccaacacuaguaaccaaguggcggugcucuaccaagauguuaacugcacagaagucccgguagcgauccaugccgacc 
               
               
                 agcucacucccacauggcguguuuacagcacagggucaaacguuuuccagacccgugccggaugucuuauaggagccga 
               
               
                 acacguaaauaacaguuaugaaugcgauaucccaauuggugcagguaucugugcgucauaucaaacccaaacuaauucuc 
               
               
                 cgggguccgccucaagcguugccucacaaucaauaaucgccuacacaaugucccucggugccgaaaauucagucgcuuac 
               
               
                 ucuaacaauagcauugcuaucccuaccaacuucacuauuucuguuaccacggaaauuuugccuguauccaugaccaaaac 
               
               
                 aucuguugauugcacgauguacaucugcggggauucuaccgaauguucuaaccugcuucugcaauacggcuccuucugc 
               
               
                 acccaauugaaccgcgcacugacugggauugcuguggaacaagacaagaauacucaagaaguauuugcccaggucaaaca 
               
               
                 gauuuacaaaacucccccaauuaaagauuucggcgguuucaauuuuagucaaauucugccagauccaaguaagccaucca 
               
               
                 aacgcucauuuauugaggaccugcucuuuaauaaagucacgcuggccgacgccggcuucauaaaacaguauggcgauug 
               
               
                 ucuuggagacaucgccgcccgcgaccucauuugcgcacaaaaguucaaugggcucaccguguugccaccacugcucacag 
               
               
                 augagaugaucgcacaguacacgagcgcccuucuugccggcacuaucacgucugguuggacguucggugccggagccgc 
               
               
                 ucugcaaauucccuuugcaaugcaaauggccuauagauuuaauggaauuggcguaacacagaacguguuguacgagaac 
               
               
                 cagaagcucauugccaaccaguucaauuccgcuauuggcaaaauacaagacucucucagcucaacugcuagcgcacuggg 
               
               
                 aaaauugcaagacguagucaaucaaaaugcccaagcccucaauacucucgucaaacaguugucuuccaacuuuggggcua 
               
               
                 ucaguaguguacucaaugacauucuuucaagacuggacccgcccgaggcggaaguccaaauugaucgucugauaacugg 
               
               
                 aagguugcaaagccuucagaccuacguuacgcaacaacuuauuagggcugccgaaauaagggcauccgcuaaucuggcag 
               
               
                 cuacaaagaugucugaauguguuuugggacagagcaaacggguugacuucugcgguaaagguuaccaucucaugucuuu 
               
               
                 uccacaaagcgcaccgcacggagucgucuuccugcauguaacauacgucccagcccaagaaaagaauuuuaccacagcccc 
               
               
                 agccaucugccacgacggcaaggcgcauuucccaagggaaggcguguuuguauccaacgggacgcauugguuugucacu 
               
               
                 caaaggaacuuuuacgaaccccaaauuauuaccacugauaacaccuucguuucugggaacugugaugucgugauuggga 
               
               
                 uaguaaacaacacgguauaugauccacugcaaccagaacuggauuccuucaaagaagagcuggacaaauacuucaagaau 
               
               
                 cauacuaguccugacgucgaccugggcgauaucaguggaaucaacgcuagcgucguaaacauucaaaaggagaucgauag 
               
               
                 acuuaacgaggucgccaagaaucucaaugaaagccucaucgauuugcaagaacucggaaaauaugagcaaagcggaucag 
               
               
                 gguacauuccggaagcccccagggacggacaggcauauguccgcaaggacggagaauggguucuucuuagcacuuuucu 
               
               
                 gggguaauga (SEQ ID NO: 105) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHS 
               
               
                 TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGT 
               
               
                 TLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSAN 
               
               
                 NCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSA 
               
               
                 LEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN 
               
               
                 ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGE 
               
               
                 VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV  TKLNDLCFTNVY 
               
               
                 ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYL 
               
               
                 YRLFRKSNLKPFERDI  T  IYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV 
               
               
                 VVLSFEL  HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGR 
               
               
                 DIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIH 
               
               
                 ADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGS 
               
               
                 ASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYIC 
               
               
                 GDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN 
               
               
                 FSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTV 
               
               
                 LPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLY 
               
               
                 ENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISS 
               
               
                 VLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVL 
               
               
                 GQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP 
               
               
                 REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSF 
               
               
                 KEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKY 
               
               
                 EQSGSGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 106) 
               
               
                   
               
               
                 WuS_DownDS3_D2P_Furin_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgttcgttttcctcgtgctcttgcctttggtt 
               
               
                 tcttctcagtgcgtaaacctcacgactcgaacccaactgcccccagcttatacaaattcctttacgcggggcgtctattacccggataag 
               
               
                 gttttcagatccagcgtgctgcatagtacacaagatctctttcttcctttcttctcaaatgtaacctggtttcacgctattcatgtatccggcac 
               
               
                 caatggaactaaaagatttgataacccggtgttgcccttcaatgatggtgtgtatttcgcttccacggaaaagtcaaacatcatcagaggg 
               
               
                 tggatattcggcacaacattggattccaagtgccagtcactcctcatagtgaacaatgctactaacgtggttataaaggtctgcgaatttca 
               
               
                 attttgtaatgatcctttcctcggtgtttactatcacaagaacaataagtcctggatggaatcagaattccgtgtatacagttctgcgaacaat 
               
               
                 tgcacattcgaatatgtgtcccaaccctttctcatggatctggaagggaagcagggtaactttaagaatctgagagaattcgtgttcaaga 
               
               
                 acattgactgctattttaaaatctatagcaaacacacccctataaacttggtacgggatttgcctcaaggattctcagcactcgaacccttg 
               
               
                 gtcgatttgccaatcggcatcaatatcacccggtttcagacactcctggctcttcaccgctcctacttgacacctggtgattcctcatctggt 
               
               
                 tggaccgccggcgcagcggcatactatgtcggctatcttcaaccaagaaccttcttgctgaaatataatgagaacggaactataactgat 
               
               
                 gccgttgattgtgcccttgatccacttagcgaaacaaagtgcactctgaagtccttcacagttgaaaaggggatctaccaaacatccaac 
               
               
                 ttccgggtacaacctactgagtccatagtgcgatttcctaacattaccaatctgtgcccatttggagaagtattcaacgcaactaggttcgc 
               
               
                 gtccgtttacgcgtggaacaggaaaaggatttccaattgcgtcgccgactatagcgttctctataacagcgcctcatttagcacgtttaag 
               
               
                 tgttacggggttagtccgaccaaactcaatgacttgtgttttaccaatgtctatgcagactcctttgttattagaggcgacgaggtcagaca 
               
               
                 aattgcccccggacagacaggtaagattgcagattataattataaactgccggacgacttcacggggtgtgttattgcatggaactccaa 
               
               
                 taacctggactctaaagtaggcgggaactataactatctgtatcgcctgtttcgcaaatctaacctgaaacccttctgcagggacatatgt 
               
               
                 actgaaatatatcaagctggcagcacaccttgtaatggcgtcgagggattcaattgttacttcccacttcaatcttacggttttcagcctact 
               
               
                 aacggcgtagggtatcaaccctatagagttgtagtgctctctttcgaattgctccatgcccccgcgactgtttgtggacctaagaagtcca 
               
               
                 cgaacctggtaaagaacaagtgtgttaattttaattttaatggactgaccgggactggagtgctgactgaaagtaacaagaaatttctgcc 
               
               
                 tttccaacaatttggccgcgatatcgctgataccaccgacgccgtcagagatccgcagactctcgaaatcctggacatcacgccctgct 
               
               
                 cattcggcggggttagcgttattactccaggcactaacactagcaatcaagttgcagttctgtaccaggatgtgaactgtaccgaagtcc 
               
               
                 ccgtcgccattcatgccgatcagctgaccccgacttggcgggtatattcaaccggcagcaatgtctttcaaacaagggcgggttgtctc 
               
               
                 atcggagcggagcatgtaaataatagttatgaatgcgacatccccattggcgcggggatctgtgcttcatatcaaactcaaaccaattcc 
               
               
                 ccacggcggagacgatcagtagccagtcaatcaataattgcgtatacgatgagtcttggggcagaaaatagcgtggcttattctaataat 
               
               
                 agcatcgctatacctacaaattttacaatcagtgtaactaccgaaatccttcctgtcagcatgaccaaaactagcgtagattgcacgatgt 
               
               
                 atatttgcggagactcaactgagtgcagtaacctgttgttgcaatacggaagtttctgtacccagctgaaccgcgctcttacgggcattgc 
               
               
                 agtagaacaagataagaatacccaagaagtgtttgcccaggtgaaacaaatctacaagactcccccgattaaagactttggcgggttca 
               
               
                 acttcagccagatattgcccgacccgtctcgtcgtagacggtcctttattgaagacctgctcttcaacaaggtcacactggctgatgcag 
               
               
                 gttttattaagcaatacggcgactgtcttggcgacatcgccgctagggaccttatatgtgctcagaaattcaatggtctgacagttctgcca 
               
               
                 cccttgctcactgacgaaatgatcgctcaatatacaagcgccttgctggctgggactattacttccggatggacattcggggcgggtgc 
               
               
                 cgccttgcaaattccttttgcaatgcaaatggcataccgtttcaacggaatcggcgtaacccagaatgtgctctatgaaaaccagaaattg 
               
               
                 atagcaaatcaatttaactcagccataggaaagattcaagactctctcagctcaaccgcgagtgctctcggcaagctccaagacgtagt 
               
               
                 aaatcaaaatgcacaagctttgaacactttggtaaagcaattgtcttccaacttcggggcgatctcatctggccctaacgacatcctgtcc 
               
               
                 cggttgcccaaagtggaagccgaggtgcagatcgaccgcctcatcaccggccgacttcaatcactccaaacctacgtgactcaacaa 
               
               
                 ctgatccgggcagccgagataagggcgagtgcaaacttggcagctacgaaaatgtcagaatgtgttctcggccagagtaaacgggta 
               
               
                 gacttttgtgggaaaggttatcacttgatgtctttccctcaaagcgctcctcacggcgtcgtcttcttgcatgtgacttacgtgccagctcaa 
               
               
                 gaaaagaacttcaccaccgcccctgctatatgccatgacggtaaagctcacttcccccgagagggcgtgttcgttagtaatggaaccc 
               
               
                 attggtttgtgactcaacgaaacttttatgaacctcaaataattaccacggataacacttttgttagtggtaattgtgacgtggtgatcggcat 
               
               
                 tgtgaataacacagtctacgatcctctgcaaccagaactggacagctttaaagaggaacttgacaaatatttcaagaaccatacaagcc 
               
               
                 ccgacgtcgacctgggcgacatcagtggaatcaatgcgtccgtagtcaatatccagaaggagattgatcggcttaatgaagtcgctaa 
               
               
                 gaatttgaatgaaagtcttatagatctgcaagaactcgggaagtacgagcaatatattaaatggccttggtccggacgtagaaggcgca 
               
               
                 ggcggggctcaggcggttcagggtcagggtatattcccgaggcgccacgcgatgggcaagcgtacgtgcgtaaagatggcgaatg 
               
               
                 ggtgttgctttccacattcttggggtgataa (SEQ ID NO: 107) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguucguuuuccucgugc 
               
               
                 ucuugccuuugguuucuucucagugcguaaaccucacgacucgaacccaacugcccccagcuuauacaaauuccuuuacg 
               
               
                 cggggcgucuauuacccggauaagguuuucagauccagcgugcugcauaguacacaagaucucuuucuuccuuucuucu 
               
               
                 caaauguaaccugguuucacgcuauucauguauccggcaccaauggaacuaaaagauuugauaacccgguguugcccuu 
               
               
                 caaugaugguguguauuucgcuuccacggaaaagucaaacaucaucagaggguggauauucggcacaacauuggauucc 
               
               
                 aagugccagucacuccucauagugaacaaugcuacuaacgugguuauaaaggucugcgaauuucaauuuuguaaugauc 
               
               
                 cuuuccucgguguuuacuaucacaagaacaauaaguccuggauggaaucagaauuccguguauacaguucugcgaacaa 
               
               
                 uugcacauucgaauaugugucccaacccuuucucauggaucuggaagggaagcaggguaacuuuaagaaucugagagaa 
               
               
                 uucguguucaagaacauugacugcuauuuuaaaaucuauagcaaacacaccccuauaaacuugguacgggauuugccuca 
               
               
                 aggauucucagcacucgaacccuuggucgauuugccaaucggcaucaauaucacccgguuucagacacuccuggcucuuc 
               
               
                 accgcuccuacuugacaccuggugauuccucaucugguuggaccgccggcgcagcggcauacuaugucggcuaucuuca 
               
               
                 accaagaaccuucuugcugaaauauaaugagaacggaacuauaacugaugccguugauugugcccuugauccacuuagc 
               
               
                 gaaacaaagugcacucugaaguccuucacaguugaaaaggggaucuaccaaacauccaacuuccggguacaaccuacuga 
               
               
                 guccauagugcgauuuccuaacauuaccaaucugugcccauuuggagaaguauucaacgcaacuagguucgcguccguu 
               
               
                 uacgcguggaacaggaaaaggauuuccaauugcgucgccgacuauagcguucucuauaacagcgccucauuuagcacgu 
               
               
                 uuaaguguuacgggguuaguccgaccaaacucaaugacuuguguuuuaccaaugucuaugcagacuccuuuguuauuag 
               
               
                 aggcgacgaggucagacaaauugcccccggacagacagguaagauugcagauuauaauuauaaacugccggacgacuuca 
               
               
                 cgggguguguuauugcauggaacuccaauaaccuggacucuaaaguaggcgggaacuauaacuaucuguaucgccuguu 
               
               
                 ucgcaaaucuaaccugaaacccuucugcagggacauauguacugaaauauaucaagcuggcagcacaccuuguaauggcg 
               
               
                 ucgagggauucaauuguuacuucccacuucaaucuuacgguuuucagccuacuaacggcguaggguaucaacccuauag 
               
               
                 aguuguagugcucucuuucgaauugcuccaugcccccgcgacuguuuguggaccuaagaaguccacgaaccugguaaag 
               
               
                 aacaaguguguuaauuuuaauuuuaauggacugaccgggacuggagugcugacugaaaguaacaagaaauuucugccuu 
               
               
                 uccaacaauuuggccgcgauaucgcugauaccaccgacgccgucagagauccgcagacucucgaaauccuggacaucacg 
               
               
                 cccugcucauucggcgggguuagcguuauuacuccaggcacuaacacuagcaaucaaguugcaguucuguaccaggaug 
               
               
                 ugaacuguaccgaaguccccgucgccauucaugccgaucagcugaccccgacuuggcggguauauucaaccggcagcaau 
               
               
                 gucuuucaaacaagggcggguugucucaucggagcggagcauguaaauaauaguuaugaaugcgacauccccauuggcg 
               
               
                 cggggaucugugcuucauaucaaacucaaaccaauuccccacggcggagacgaucaguagccagucaaucaauaauugcg 
               
               
                 uauacgaugagucuuggggcagaaaauagcguggcuuauucuaauaauagcaucgcuauaccuacaaauuuuacaauca 
               
               
                 guguaacuaccgaaauccuuccugucagcaugaccaaaacuagcguagauugcacgauguauauuugcggagacucaacu 
               
               
                 gagugcaguaaccuguuguugcaauacggaaguuucuguacccagcugaaccgcgcucuuacgggcauugcaguagaac 
               
               
                 aagauaagaauacccaagaaguguuugcccaggugaaacaaaucuacaagacucccccgauuaaagacuuuggcggguuc 
               
               
                 aacuucagccagauauugcccgacccgucucgucguagacgguccuuuauugaagaccugcucuucaacaaggucacacu 
               
               
                 ggcugaugcagguuuuauuaagcaauacggcgacugucuuggcgacaucgccgcuagggaccuuauaugugcucagaaa 
               
               
                 uucaauggucugacaguucugccacccuugcucacugacgaaaugaucgcucaauauacaagcgccuugcuggcuggga 
               
               
                 cuauuacuuccggauggacauucggggcgggugccgccuugcaaauuccuuuugcaaugcaaauggcauaccguuucaa 
               
               
                 cggaaucggcguaacccagaaugugcucuaugaaaaccagaaauugauagcaaaucaauuuaacucagccauaggaaaga 
               
               
                 uucaagacucucucagcucaaccgcgagugcucucggcaagcuccaagacguaguaaaucaaaaugcacaagcuuugaac 
               
               
                 acuuugguaaagcaauugucuuccaacuucggggcgaucucaucuggcccuaacgacauccugucccgguugcccaaag 
               
               
                 uggaagccgaggugcagaucgaccgccucaucaccggccgacuucaaucacuccaaaccuacgugacucaacaacugauc 
               
               
                 cgggcagccgagauaagggcgagugcaaacuuggcagcuacgaaaaugucagaauguguucucggccagaguaaacggg 
               
               
                 uagacuuuugugggaaagguuaucacuugaugucuuucccucaaagcgcuccucacggcgucgucuucuugcaugugac 
               
               
                 uuacgugccagcucaagaaaagaacuucaccaccgccccugcuauaugccaugacgguaaagcucacuucccccgagagg 
               
               
                 gcguguucguuaguaauggaacccauugguuugugacucaacgaaacuuuuaugaaccucaaauaauuaccacggauaa 
               
               
                 cacuuuuguuagugguaauugugacguggugaucggcauugugaauaacacagucuacgauccucugcaaccagaacug 
               
               
                 gacagcuuuaaagaggaacuugacaaauauuucaagaaccauacaagccccgacgucgaccugggcgacaucaguggaau 
               
               
                 caaugcguccguagucaauauccagaaggagauugaucggcuuaaugaagucgcuaagaauuugaaugaaagucuuaua 
               
               
                 gaucugcaagaacucgggaaguacgagcaauauauuaaauggccuugguccggacguagaaggcgcaggcggggcucag 
               
               
                 gcgguucagggucaggguauauucccgaggcgccacgcgaugggcaagcguacgugcguaaagauggcgaaugggugu 
               
               
                 ugcuuuccacauucuuggggugauaa (SEQ ID NO: 108) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKCQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNID  YFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPF  RDI  TEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR  RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS  NDILSRL  KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 109) 
               
               
                   
               
               
                 WuS_DownDS3_D2P_F_NoTriCle_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgttcgtgttcctcgtgctcctgcctctcg 
               
               
                 ttagcagccaatgtgttaatctcaccaccagaacacagctcccacccgcgtatactaactcttttacgaggggagtttattatcccgataa 
               
               
                 ggttttccggtctagcgtactccactccacccaagatctgttcctgcctttctttagcaacgtgacgtggtttcatgcaatccacgtgagtg 
               
               
                 gcaccaatggaaccaagcggttcgataatcctgtgttgccgtttaacgatggcgtgtattttgcctcaactgaaaagtctaacataatacg 
               
               
                 cggctggatcttcgggaccacattggatagtaagtgtcaatctctgcttatcgtgaacaacgctactaacgtcgttataaaggtctgtgag 
               
               
                 ttccaattctgcaacgacccattcctgggtgtgtattaccacaagaataataaatcttggatggagtctgagtttcgcgtatactcttctgcta 
               
               
                 acaactgcacctttgaatatgtaagtcaaccattcctcatggatctggaaggaaaacaaggcaactttaagaacttgcgggaatttgtctt 
               
               
                 caagaacatcgactgttattttaaaatttactcaaaacacaccccgattaatctggtccgcgatttgccccaagggttctctgcattggaac 
               
               
                 cccttgtggacttgcctataggaattaatatcacccgctttcaaactcttctggcgctgcaccgtagctacctgacaccaggagatagctc 
               
               
                 tagtggctggactgctggagccgcggcatattatgtggggtatctgcagccacgtacatttctcctcaaatataatgaaaatggtacaata 
               
               
                 acggatgcagtcgactgcgcattggaccctctgagtgaaacaaaatgcactctcaagagcttcactgttgaaaagggcatataccaaa 
               
               
                 catctaattttagagtccaacccactgaatccattgtccgatttcctaatattacaaacctctgcccatttggagaagtgttcaacgccacta 
               
               
                 ggtttgcatccgtgtacgcatggaacagaaaacgaatttctaattgtgtggcagactatagcgtgctgtataactcagcaagctttagcac 
               
               
                 atttaagtgttatggagttagcccaaccaaattgaatgatctttgtttcacgaacgtgtacgccgatagcttcgttattcgaggggacgagg 
               
               
                 tgaggcaaatcgctccaggtcaaaccggtaaaatcgccgattacaattataaacttcctgatgacttcactggctgtgtcatagcatgga 
               
               
                 actctaataatctcgacagcaaggtcggtgggaactataactatctttatcgactctttagaaagagtaatctcaaaccattttgcagagac 
               
               
                 atttgtacagagatttatcaggcagggagcacaccatgtaatggggtcgagggcttcaactgttacttccccctgcaatcttatgggttcc 
               
               
                 agccgaccaatggagtgggctaccaaccttatcgcgtggtggtcctgtcttttgaactgcttcatgctccagccaccgtatgcggcccta 
               
               
                 agaagtctacaaatttggtcaagaacaagtgcgtcaattttaacttcaatggtctgactggaaccggtgtcctcacagaatctaacaagaa 
               
               
                 atttctgccatttcaacaatttggaagagatatcgcggatactacggatgctgttagggacccccaaacacttgaaattctcgacattaca 
               
               
                 ccctgttcctttggcggggtcagtgtcattaccccgggtacaaatactagtaaccaagtcgcagtactgtatcaagatgttaattgtaccg 
               
               
                 aagtgccggtagcaatacacgctgatcaacttacaccaacatggcgagtgtattctacggggagtaatgtcttccaaacgcgggccgg 
               
               
                 gtgtctgattggcgcggaacacgtaaacaactcctacgaatgtgatattccaataggcgcaggcatatgtgcgagctatcaaacacaaa 
               
               
                 ctaactcccctagacggcgtcggagtgtggctagtcaatcaatcattgcctatacaatgtctctgggagcagaaaacagcgtggcatatt 
               
               
                 ccaataattccatcgctatacctaccaactttaccatcagcgtcactactgagattcttcccgtctccatgacgaaaacttccgttgattgta 
               
               
                 ctatgtacatctgcggagacagcaccgaatgcagtaaccttctcttgcaatatggcagcttttgtactcagctcaacagagctctcacag 
               
               
                 gtattgccgtcgaacaagataagaacacccaagaggtgttcgcccaggtgaaacagatatataagaccccacccatcaaggatttcgg 
               
               
                 cgggtttaattttagtcaaatcctgcccgatccctcacggcgtcgcaggtcctttattgaagatcttctgttcaataaggtcacactcgctga 
               
               
                 cgcaggctttatcaagcagtatggagattgtctgggcgatatagctgcgagggacttgatctgcgcacaaaagttcaacggccttacag 
               
               
                 tgctgcccccgttgctgacagatgagatgattgcgcaatacacttccgcgcttctcgcagggaccatcacgagcggctggacgttcgg 
               
               
                 cgctggcgccgctctgcaaatcccgtttgcaatgcaaatggcctataggtttaatggtatcggtgtaacgcaaaacgtactttatgaaaac 
               
               
                 cagaaactgatcgctaaccaattcaattccgctattggcaaaattcaagacagcctcagcagcacggctagtgcactgggtaaactcca 
               
               
                 agacgtggtgaaccaaaatgcccaagcattgaatacacttgtcaagcaacttagttccaacttcggtgcaatttcaagtggtccaaatga 
               
               
                 catacttagcaggctgcctaaagtagaagccgaagtgcaaatcgatagacttatcaccggccgcctgcaatcccttcaaacatacgtga 
               
               
                 ctcagcagcttatcagggctgctgagattcgagcaagtgcgaacctggccgccaccaaaatgagtgagtgcgtccttgggcaatcca 
               
               
                 agcgcgttgacttttgtggtaaggggtatcatctcatgagcttcccccaatccgcccctcacggagtagtgtttctccatgtgacgtatgtt 
               
               
                 cctgcacaagagaagaacttcacaacggctccggctatatgtcatgacggaaaagcgcactttcctcgcgaaggagtgtttgtgtcaaa 
               
               
                 tggaacgcactggttcgtgacgcaaaggaatttctacgagcctcaaatcatcactacagataatacttttgtctctgggaattgcgacgtg 
               
               
                 gtcattggaatcgtcaacaatacggtttacgatcccctgcaaccagaactggattcattcaaagaagaactcgacaagtacttcaagaat 
               
               
                 cataccagtcctgatgtggatctgggcgatatcagtgggatcaatgcaagcgttgtcaacattcaaaaggaaatagaccgcctcaacga 
               
               
                 agtcgcaaagaatctcaatgaaagccttattgatcttcaagagctcggaaaatatgagcaatatattaagtggccttggtccggcggctc 
               
               
                 aggcggaagtggctcaggatatattcctgaggctccccgagatggacaagcatacgtgagaaaagatggggagtgggtgttgctga 
               
               
                 gtacgttccttggatgataa (SEQ ID NO: 110) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguucguguuccucgugc 
               
               
                 uccugccucucguuagcagccaauguguuaaucucaccaccagaacacagcucccacccgcguauacuaacucuuuuacg 
               
               
                 aggggaguuuauuaucccgauaagguuuuccggucuagcguacuccacuccacccaagaucuguuccugccuuucuuua 
               
               
                 gcaacgugacgugguuucaugcaauccacgugaguggcaccaauggaaccaagcgguucgauaauccuguguugccguu 
               
               
                 uaacgauggcguguauuuugccucaacugaaaagucuaacauaauacgcggcuggaucuucgggaccacauuggauagu 
               
               
                 aagugucaaucucugcuuaucgugaacaacgcuacuaacgucguuauaaaggucugugaguuccaauucugcaacgacc 
               
               
                 cauuccuggguguguauuaccacaagaauaauaaaucuuggauggagucugaguuucgcguauacucuucugcuaacaa 
               
               
                 cugcaccuuugaauauguaagucaaccauuccucauggaucuggaaggaaaacaaggcaacuuuaagaacuugcgggaau 
               
               
                 uugucuucaagaacaucgacuguuauuuuaaaauuuacucaaaacacaccccgauuaaucugguccgcgauuugccccaa 
               
               
                 ggguucucugcauuggaaccccuuguggacuugccuauaggaauuaauaucacccgcuuucaaacucuucuggcgcugc 
               
               
                 accguagcuaccugacaccaggagauagcucuaguggcuggacugcuggagccgcggcauauuaugugggguaucugca 
               
               
                 gccacguacauuucuccucaaauauaaugaaaaugguacaauaacggaugcagucgacugcgcauuggacccucugagug 
               
               
                 aaacaaaaugcacucucaagagcuucacuguugaaaagggcauauaccaaacaucuaauuuuagaguccaacccacugaa 
               
               
                 uccauuguccgauuuccuaauauuacaaaccucugcccauuuggagaaguguucaacgccacuagguuugcauccgugu 
               
               
                 acgcauggaacagaaaacgaauuucuaauuguguggcagacuauagcgugcuguauaacucagcaagcuuuagcacauu 
               
               
                 uaaguguuauggaguuagcccaaccaaauugaaugaucuuuguuucacgaacguguacgccgauagcuucguuauucga 
               
               
                 ggggacgaggugaggcaaaucgcuccaggucaaaccgguaaaaucgccgauuacaauuauaaacuuccugaugacuucac 
               
               
                 uggcugugucauagcauggaacucuaauaaucucgacagcaaggucggugggaacuauaacuaucuuuaucgacucuuu 
               
               
                 agaaagaguaaucucaaaccauuuugcagagacauuuguacagagauuuaucaggcagggagcacaccauguaaugggg 
               
               
                 ucgagggcuucaacuguuacuucccccugcaaucuuauggguuccagccgaccaauggagugggcuaccaaccuuaucg 
               
               
                 cguggugguccugucuuuugaacugcuucaugcuccagccaccguaugcggcccuaagaagucuacaaauuuggucaag 
               
               
                 aacaagugcgucaauuuuaacuucaauggucugacuggaaccgguguccucacagaaucuaacaagaaauuucugccauu 
               
               
                 ucaacaauuuggaagagauaucgcggauacuacggaugcuguuagggacccccaaacacuugaaauucucgacauuacac 
               
               
                 ccuguuccuuuggcggggucagugucauuaccccggguacaaauacuaguaaccaagucgcaguacuguaucaagaugu 
               
               
                 uaauuguaccgaagugccgguagcaauacacgcugaucaacuuacaccaacauggcgaguguauucuacggggaguaau 
               
               
                 gucuuccaaacgcgggccgggugucugauuggcgcggaacacguaaacaacuccuacgaaugugauauuccaauaggcg 
               
               
                 caggcauaugugcgagcuaucaaacacaaacuaacuccccuagacggcgucggaguguggcuagucaaucaaucauugcc 
               
               
                 uauacaaugucucugggagcagaaaacagcguggcauauuccaauaauuccaucgcuauaccuaccaacuuuaccaucag 
               
               
                 cgucacuacugagauucuucccgucuccaugacgaaaacuuccguugauuguacuauguacaucugcggagacagcacc 
               
               
                 gaaugcaguaaccuucucuugcaauauggcagcuuuuguacucagcucaacagagcucucacagguauugccgucgaac 
               
               
                 aagauaagaacacccaagagguguucgcccaggugaaacagauauauaagaccccacccaucaaggauuucggcggguuu 
               
               
                 aauuuuagucaaauccugcccgaucccucacggcgucgcagguccuuuauugaagaucuucuguucaauaaggucacac 
               
               
                 ucgcugacgcaggcuuuaucaagcaguauggagauugucugggcgauauagcugcgagggacuugaucugcgcacaaaa 
               
               
                 guucaacggccuuacagugcugcccccguugcugacagaugagaugauugcgcaauacacuuccgcgcuucucgcaggg 
               
               
                 accaucacgagcggcuggacguucggcgcuggcgccgcucugcaaaucccguuugcaaugcaaauggccuauagguuua 
               
               
                 augguaucgguguaacgcaaaacguacuuuaugaaaaccagaaacugaucgcuaaccaauucaauuccgcuauuggcaaa 
               
               
                 auucaagacagccucagcagcacggcuagugcacuggguaaacuccaagacguggugaaccaaaaugcccaagcauugaa 
               
               
                 uacacuugucaagcaacuuaguuccaacuucggugcaauuucaagugguccaaaugacauacuuagcaggcugccuaaag 
               
               
                 uagaagccgaagugcaaaucgauagacuuaucaccggccgccugcaaucccuucaaacauacgugacucagcagcuuauc 
               
               
                 agggcugcugagauucgagcaagugcgaaccuggccgccaccaaaaugagugagugcguccuugggcaauccaagcgcg 
               
               
                 uugacuuuugugguaagggguaucaucucaugagcuucccccaauccgccccucacggaguaguguuucuccaugugac 
               
               
                 guauguuccugcacaagagaagaacuucacaacggcuccggcuauaugucaugacggaaaagcgcacuuuccucgcgaag 
               
               
                 gaguguuugugucaaauggaacgcacugguucgugacgcaaaggaauuucuacgagccucaaaucaucacuacagauaa 
               
               
                 uacuuuugucucugggaauugcgacguggucauuggaaucgucaacaauacgguuuacgauccccugcaaccagaacug 
               
               
                 gauucauucaaagaagaacucgacaaguacuucaagaaucauaccaguccugauguggaucugggcgauaucaguggga 
               
               
                 ucaaugcaagcguugucaacauucaaaaggaaauagaccgccucaacgaagucgcaaagaaucucaaugaaagccuuauu 
               
               
                 gaucuucaagagcucggaaaauaugagcaauauauuaaguggccuugguccggcggcucaggcggaaguggcucaggau 
               
               
                 auauuccugaggcuccccgagauggacaagcauacgugagaaaagauggggaguggguguugcugaguacguuccuug 
               
               
                 gaugauaa (SEQ ID NO: 111) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSK  QSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNID  YFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPF  RDI  TEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR  RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS  NDILSRL  KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGGSGGSGSGYIPEAPRDGQAYVRKDGEWVLLSTFLG** 
               
               
                 (SEQ ID NO: 112) 
               
               
                   
               
               
                 WuS_DownDS2_2P_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgttcgtgttcttggtgctgctgcctcttgt 
               
               
                 ctcatcacagtgcgttaatctgaccacccgtacacaactcccacccgcatacacaaatagctttacacgcggagtgtattaccccgataa 
               
               
                 agtctttcggagctcagtgctccattctactcaagatcttttcctgccgttctttagtaacgttacttggtttcatgcaatacatgtgtctggca 
               
               
                 caaacggaaccaaacgttttgataatccggtgttgccatttaatgatggtgtatattttgcttccacggaaaagtcaaacatcatccgtggg 
               
               
                 tggatctttggcaccactcttgatagcaaatgtcaaagccttctgattgttaataacgctacaaacgtcgtaattaaagtgtgtgaattccag 
               
               
                 ttctgtaatgaccccttcctcggagtatattaccacaagaataacaaatcttggatggagagcgaatttagagtttacagttcagccaataa 
               
               
                 ctgtacatttgaatatgtcagtcagcctttcctcatggacctcgaaggtaaacaaggtaattttaagaacttgagagagttcgtgtttaagaa 
               
               
                 catcgatggctatttcaaaatttactctaagcacacaccaatcaacctggttcgagacctgccccagggtttctcagctttggaaccattg 
               
               
                 gtggacctgccaatcggcattaacattaccagatttcaaactttgttggcactccaccggtcatatcttacccccggagacagttcctcag 
               
               
                 gctggacggcaggcgccgccgcgtactatgttgggtatctccaaccccgaaccttccttctcaaatacaatgaaaacgggacgattac 
               
               
                 agatgcagtcgattgcgccctggaccccttgtccgaaactaaatgcactctgaagagtttcacggtagagaagggaatctatcaaacga 
               
               
                 gcaattttcgagtccaaccaacggaatctattgtgcggtttcccaatatcacaaacctctgtccattcggagaagtctttaatgctaccagg 
               
               
                 tttgcgtctgtatatgcatggaaccgaaagaggatttccaattgcgtagcggactacagtgtcctttataacagcgcttcattttccacgttt 
               
               
                 aagtgttatggtgtttctccaacgaaactcaacgacctctgttttactaacgtttacgctgacagctttgttatacgtggggacgaagtcag 
               
               
                 gcaaattgctcctggacagactggaaagatcgctgattataattataaacttcctgacgatttcaccggctgcgttattgcatggaactcca 
               
               
                 acaatctggattcaaaagtgggtggaaattataattatctgtataggttgtttcggaagagcaatcttaagccctttgagcgggacatatgt 
               
               
                 accgaaatttaccaagcaggctccaccccatgcaatggagtagaagggttcaattgctattttcctctgcaaagttatggctttcaaccca 
               
               
                 ccaacggagttgggtatcaaccttacagggttgtcgtgctgagtttcgaattgctccacgcacccgctacagtatgtggccccaagaag 
               
               
                 tccactaatcttgttaagaataaatgcgtgaacttcaacttcaatggacttacaggtactggagtactcacggaatcaaacaagaaatttct 
               
               
                 cccatttcaacagtttggccgagatatagctgacaccacagatgctgttcgcgacccccagacgttggaaatacttgatatcactccctg 
               
               
                 cagcttcggcggcgtgagcgtgatcactccaggtactaatacgagcaatcaagttgccgttctgtaccaagatgtgaactgcaccgag 
               
               
                 gttccagtggcaattcacgccgaccaacttactcccacctggcgggtctattccaccggatcaaacgtcttccaaactcgcgctggttgc 
               
               
                 cttatcggtgcagagcacgttaataattcctatgaatgtgacattcccataggagcaggcatctgtgcatcttatcaaacccagactaattc 
               
               
                 ccctggttccgcttcctctgttgcatcccagtccataattgcctacactatgagtctcggggctgaaaattccgtggcctattctaataattc 
               
               
                 aatcgccatcccaaccaattttaccatatccgtaacgactgaaatacttcctgtcagtatgaccaagacctcagtggactgcaccatgtac 
               
               
                 atctgcggcgattctactgaatgttccaatctgcttttgcaatatggttcattctgcacccaactcaacagggctcttacagggatcgccgt 
               
               
                 cgaacaggataagaatacccaggaagtgttcgcccaagttaagcaaatttacaagacaccacccatcaaggacttcggcgggttcaa 
               
               
                 cttcagccaaattctgcccgacccgtctaagccttctaagcgctctttcattgaggatcttttgttcaataaggttacgcttgccgatgcagg 
               
               
                 gtttatcaaacagtatggcgactgtcttggggatatcgcagctagggatcttatttgtgcacagaaatttaatggcctgactgttcttccccc 
               
               
                 tttgctcactgacgagatgattgcccagtacacttcagctctcctggccgggactataacttctggttggaccttcggagctggcgccgc 
               
               
                 cctgcaaattccatttgcaatgcagatggcttatcgcttcaacggaattggggtgacccaaaatgttctctacgagaaccagaaactcatt 
               
               
                 gcaaaccagttcaattctgcgatcgggaagatccaggattccctgtctagtacggctagtgccctcggtaagctccaagacgtcgtcaa 
               
               
                 ccaaaacgcccaggccttgaacacccttgtcaaacaactgagctccaattttggggctattagcagtgtgctgaatgatatcctgtcccg 
               
               
                 ccttgacccaccggaagcggaagtccaaattgatcgactgatcactgggcgtctccaatcccttcaaacttacgtgacccaacaactca 
               
               
                 tccgagcagctgagattagggctagcgctaaccttgctgctactaagatgtcagagtgtgtcctcggccagtctaagagagtggactttt 
               
               
                 gtgggaaagggtaccacttgatgtcattcccacaaagcgccccacacggcgtggtgtttctccacgtcacttacgttccagctcaggaa 
               
               
                 aagaactttaccaccgcccccgctatatgtcatgatgggaaggcccactttcctcgtgaaggtgtctttgtcagcaatggcacacactgg 
               
               
                 tttgtgacccaacggaatttctatgagcctcagattattaccacggataacactttcgtatcagggaattgtgatgtggttatcggcatcgtt 
               
               
                 aataatacagtgtatgacccactgcagccagagcttgacagcttcaaagaagagctcgataagtactttaagaatcatacaagtcctgac 
               
               
                 gttgatcttggggatattagtgggattaacgccagcgtcgtcaatattcagaaagagattgacaggttgaacgaagtagctaagaatctt 
               
               
                 aatgaaagcctgatagatttgcaagaacttggtaagtatgagcaggggtacatacccgaggctcctcgggatgggcaggcctatgtac 
               
               
                 gcaaagacggtgaatgggtattgctcagcacttttctcggctgataa (SEQ ID NO: 113) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguucguguucuuggugc 
               
               
                 ugcugccucuugucucaucacagugcguuaaucugaccacccguacacaacucccacccgcauacacaaauagcuuuaca 
               
               
                 cgcggaguguauuaccccgauaaagucuuucggagcucagugcuccauucuacucaagaucuuuuccugccguucuuua 
               
               
                 guaacguuacuugguuucaugcaauacaugugucuggcacaaacggaaccaaacguuuugauaauccgguguugccauu 
               
               
                 uaaugaugguguauauuuugcuuccacggaaaagucaaacaucauccguggguggaucuuuggcaccacucuugauagc 
               
               
                 aaaugucaaagccuucugauuguuaauaacgcuacaaacgucguaauuaaagugugugaauuccaguucuguaaugacc 
               
               
                 ccuuccucggaguauauuaccacaagaauaacaaaucuuggauggagagcgaauuuagaguuuacaguucagccaauaac 
               
               
                 uguacauuugaauaugucagucagccuuuccucauggaccucgaagguaaacaagguaauuuuaagaacuugagagagu 
               
               
                 ucguguuuaagaacaucgauggcuauuucaaaauuuacucuaagcacacaccaaucaaccugguucgagaccugccccag 
               
               
                 gguuucucagcuuuggaaccauugguggaccugccaaucggcauuaacauuaccagauuucaaacuuuguuggcacucc 
               
               
                 accggucauaucuuacccccggagacaguuccucaggcuggacggcaggcgccgccgcguacuauguuggguaucucca 
               
               
                 accccgaaccuuccuucucaaauacaaugaaaacgggacgauuacagaugcagucgauugcgcccuggaccccuuguccg 
               
               
                 aaacuaaaugcacucugaagaguuucacgguagagaagggaaucuaucaaacgagcaauuuucgaguccaaccaacggaa 
               
               
                 ucuauugugcgguuucccaauaucacaaaccucuguccauucggagaagucuuuaaugcuaccagguuugcgucuguau 
               
               
                 augcauggaaccgaaagaggauuuccaauugcguagcggacuacaguguccuuuauaacagcgcuucauuuuccacguu 
               
               
                 uaaguguuaugguguuucuccaacgaaacucaacgaccucuguuuuacuaacguuuacgcugacagcuuuguuauacgu 
               
               
                 ggggacgaagucaggcaaauugcuccuggacagacuggaaagaucgcugauuauaauuauaaacuuccugacgauuuca 
               
               
                 ccggcugcguuauugcauggaacuccaacaaucuggauucaaaaguggguggaaauuauaauuaucuguauagguuguu 
               
               
                 ucggaagagcaaucuuaagcccuuugagcgggacauauguaccgaaauuuaccaagcaggcuccaccccaugcaauggag 
               
               
                 uagaaggguucaauugcuauuuuccucugcaaaguuauggcuuucaacccaccaacggaguuggguaucaaccuuacag 
               
               
                 gguugucgugcugaguuucgaauugcuccacgcacccgcuacaguauguggccccaagaaguccacuaaucuuguuaag 
               
               
                 aauaaaugcgugaacuucaacuucaauggacuuacagguacuggaguacucacggaaucaaacaagaaauuucucccauu 
               
               
                 ucaacaguuuggccgagauauagcugacaccacagaugcuguucgcgacccccagacguuggaaauacuugauaucacuc 
               
               
                 ccugcagcuucggcggcgugagcgugaucacuccagguacuaauacgagcaaucaaguugccguucuguaccaagaugu 
               
               
                 gaacugcaccgagguuccaguggcaauucacgccgaccaacuuacucccaccuggcgggucuauuccaccggaucaaacg 
               
               
                 ucuuccaaacucgcgcugguugccuuaucggugcagagcacguuaauaauuccuaugaaugugacauucccauaggagc 
               
               
                 aggcaucugugcaucuuaucaaacccagacuaauuccccugguuccgcuuccucuguugcaucccaguccauaauugccu 
               
               
                 acacuaugagucucggggcugaaaauuccguggccuauucuaauaauucaaucgccaucccaaccaauuuuaccauaucc 
               
               
                 guaacgacugaaauacuuccugucaguaugaccaagaccucaguggacugcaccauguacaucugcggcgauucuacuga 
               
               
                 auguuccaaucugcuuuugcaauaugguucauucugcacccaacucaacagggcucuuacagggaucgccgucgaacag 
               
               
                 gauaagaauacccaggaaguguucgcccaaguuaagcaaauuuacaagacaccacccaucaaggacuucggcggguucaa 
               
               
                 cuucagccaaauucugcccgacccgucuaagccuucuaagcgcucuuucauugaggaucuuuuguucaauaagguuacg 
               
               
                 cuugccgaugcaggguuuaucaaacaguauggcgacugucuuggggauaucgcagcuagggaucuuauuugugcacag 
               
               
                 aaauuuaauggccugacuguucuucccccuuugcucacugacgagaugauugcccaguacacuucagcucuccuggccg 
               
               
                 ggacuauaacuucugguuggaccuucggagcuggcgccgcccugcaaauuccauuugcaaugcagauggcuuaucgcuu 
               
               
                 caacggaauuggggugacccaaaauguucucuacgagaaccagaaacucauugcaaaccaguucaauucugcgaucggga 
               
               
                 agauccaggauucccugucuaguacggcuagugcccucgguaagcuccaagacgucgucaaccaaaacgcccaggccuug 
               
               
                 aacacccuugucaaacaacugagcuccaauuuuggggcuauuagcagugugcugaaugauauccugucccgccuugacc 
               
               
                 caccggaagcggaaguccaaauugaucgacugaucacugggcgucuccaaucccuucaaacuuacgugacccaacaacuc 
               
               
                 auccgagcagcugagauuagggcuagcgcuaaccuugcugcuacuaagaugucagaguguguccucggccagucuaaga 
               
               
                 gaguggacuuuugugggaaaggguaccacuugaugucauucccacaaagcgccccacacggcgugguguuucuccacgu 
               
               
                 cacuuacguuccagcucaggaaaagaacuuuaccaccgcccccgcuauaugucaugaugggaaggcccacuuuccucgug 
               
               
                 aaggugucuuugucagcaauggcacacacugguuugugacccaacggaauuucuaugagccucagauuauuaccacgga 
               
               
                 uaacacuuucguaucagggaauugugaugugguuaucggcaucguuaauaauacaguguaugacccacugcagccagag 
               
               
                 cuugacagcuucaaagaagagcucgauaaguacuuuaagaaucauacaaguccugacguugaucuuggggauauuagug 
               
               
                 ggauuaacgccagcgucgucaauauucagaaagagauugacagguugaacgaaguagcuaagaaucuuaaugaaagccu 
               
               
                 gauagauuugcaagaacuugguaaguaugagcagggguacauacccgaggcuccucgggaugggcaggccuauguacgc 
               
               
                 aaagacggugaauggguauugcucagcacuuuucucggcugauaa (SEQ ID NO: 114) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSK  QSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDI  TEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSP  A  SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARD 
               
               
                 LICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYR 
               
               
                 FNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTL 
               
               
                 VKQLSSNFGAISSVLNDILSRLD  EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASA 
               
               
                 NLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT 
               
               
                 APAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNN 
               
               
                 TVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNL 
               
               
                 NESLIDLQELGKYEQGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 115) 
               
               
                   
               
               
                 WuSDownDS1_2P_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgtttgttttccttgttctgctcccgcttgtg 
               
               
                 tcttcccagtgcgtgaacctgaccacccgaactcaactcccaccagcatacaccaactcatttacaagaggagtttattacccggacaa 
               
               
                 ggtatttcgaagttcagttcttcacagcacccaagacctgtttctgccattcttcagtaatgtcacttggtttcacgcgatacatgtcagcgg 
               
               
                 tacaaacgggacaaagcgattcgataacccagtactcccattcaacgacggagtgtattttgcatctacagagaaatccaacattatacg 
               
               
                 cgggtggatctttggaactactctggactccaagacacagagcctgctcattgtgaacaatgcaacgaatgtcgtcataaaagtctgtga 
               
               
                 atttcaattttgcaacgatcctttcctcggagtctattaccataagaacaataagagttggatggagagtgagtttcgcgtctattcttccgc 
               
               
                 gaacaattgtacatttgaatatgtatcacaaccctttcttatggatttggaaggcaaacaaggtaacttcaagaacttgcgcgagttcgtgtt 
               
               
                 caagaacatagactgttattttaagatctatagtaagcatacgccaatcaatctggtgcgagatttgcctcagggcttttctgctcttgaacc 
               
               
                 cttggttgatctgcccatcgggatcaacataaccagatttcaaacgttgctcgcactccaccgcagctatctcactcctggcgattcctcat 
               
               
                 ctgggtggaccgccggagctgctgcttattacgtcggctatctccagccgcgtactttcctgctcaagtataatgagaatggcaccatta 
               
               
                 ccgatgctgtggattgtgctcttgatccactctctgaaaccaaatgcactctcaagtcttttaccgtggaaaagggtatttatcagacatcta 
               
               
                 attttcgggtgcaacctactgagtcaattgtacggtttcctaacataactaacctttgtccatttggggaagtcttcaatgccacgcggttcg 
               
               
                 catcagtctatgcatggaacagaaaacgtatctccaactgcgtcgccgattattccgtcctttacaatagcgctagcttttccacattcaaat 
               
               
                 gttatggcgtatcaccaaccaaacttaacgatctctgctttactaatgtctacgctgactctttcgttattcgaggtgacgaggtgcgccaa 
               
               
                 attgcgcctggtcaaaccggaaagattgccgattataactacaagctccccgacgactttacgggttgtgtgatcgcctggaatagcaat 
               
               
                 aacctcgattctaaagttggcggtaattataactatctgtacagactctttaggaaaagtaatctcaagcccttttgcagggatatctcaacc 
               
               
                 gaaatctaccaagccggcagcactccttgcaatggtgtcgaggggtttaattgttatttcccactgcaatcttacggctttcaaccgactaa 
               
               
                 tggagtcggttatcaaccctatagggtggtggtactctcctttgaacttttgcacgctccggcaacagtttgtggaccaaagaaaagtacg 
               
               
                 aaccttgttaagaataagtgtgttaatttcaattttaacggcctcactggaacaggtgtcctcacagaaagcaacaagaagtttctccctttc 
               
               
                 caacagtttggacgggatatcgccgacactactgacgccgtcagagatcctcaaactctcgaaatcttggatatcacaccatgttctttcg 
               
               
                 gtggtgtctccgtcataacaccaggaactaacacctctaatcaagtggccgtgctctatcaggacgtcaattgcacagaagtgcctgtc 
               
               
                 gcaatccatgctgatcagctcactcccacctggcgtgtgtattccactggctctaatgtctttcagacacgggcaggttgccttattgggg 
               
               
                 cagagcatgtgaacaattcctacgaatgcgatatacccattggggcaggcatttgcgccagctaccaaacccaaactaacagccccg 
               
               
                 ggagtgccagcagcgtggcatctcagtccattattgcctatacgatgagcctgggtgctgaaaatagcgtggcttatagtaataactctat 
               
               
                 cgccatacccacaaacttcaccatttcagtgaccaccgaaatccttcctgtttctatgaccaaaacgtccgtcgattgtacaatgtacattt 
               
               
                 gcggcgatagcactgaatgttcaaacctgctcctgcaatacggctctttctgtactcagctcaaccgggcactcaccggcatagccgtc 
               
               
                 gaacaagacaagaatacccaggaagtctttgcgcaggtgaaacaaatctataagaccccaccaataaaagatttcggcggttttaatttc 
               
               
                 agccaaatcttgcctgatcccagcaagccatctaaacggtctttcattgaagatctcctgttcaacaaggttacgctggctgacgccggg 
               
               
                 tttattaagcaatatggcgattgccttggggacattgccgcacgagacctcatttgtgcccagaaattcaacgggctcaccgtattgcccc 
               
               
                 cgctcctcacagacgaaatgatcgcccaatatacaagcgccctgcttgcgggaaccattacaagcggttggacctttggtgccggcgc 
               
               
                 agctctgcaaatacccttcgcaatgcaaatggcatatcggtttaatggaattggcgtaacccaaaacgtgctgtatgaaaaccagaaact 
               
               
                 gatcgcaaatcaattcaatagtgctataggaaagatccaagacagtctgtcttccactgctagcgcgctggggaagctccaagacgttg 
               
               
                 tgaaccaaaacgcgcaggccctgaataccctggtgaagcaactttcaagcaatttcggtgctatatcttctgtcctcaatgacattctctct 
               
               
                 cggctcgatcccccggaagccgaagttcagatagaccgtttgatcacaggccgcttgcaatccctgcaaacctacgttacacaacaac 
               
               
                 tgattcgcgccgccgaaattcgggcatccgccaatctggccgcaaccaaaatgtccgagtgtgttctcggtcaatccaaacgcgtgga 
               
               
                 tttctgcggaaaaggataccatttgatgtcatttccacaatcagctccacacggtgttgtattcctgcacgtgacctacgtgccagcccag 
               
               
                 gagaagaattttactactgcgcccgccatttgtcatgacgggaaggctcattttcctcgggaaggggttttcgtctcaaacggtacccatt 
               
               
                 ggttcgtgactcagaggaacttttatgaacctcaaatcataacgaccgataacacgtttgtaagtggcaattgcgacgtggtcatcggga 
               
               
                 ttgtaaacaatactgtctatgaccctctccaaccagagcttgacagctttaaagaagagcttgataaatactttaagaaccatacctcacca 
               
               
                 gacgtcgatttgggagatatcagtggcattaatgcctctgtcgtcaatatccagaaagagattgaccgcttgaacgaagttgccaagaat 
               
               
                 cttaatgagtctctgattgacttgcaagaattgggaaaatatgaacaaggatatattccagaagcccctcgcgatgggcaagcatatgttc 
               
               
                 gaaaggatggggaatgggtgctgctcagcacctttctcggttgataa (SEQ ID NO: 116) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguuuguuuuccuuguuc 
               
               
                 ugcucccgcuugugucuucccagugcgugaaccugaccacccgaacucaacucccaccagcauacaccaacucauuuacaa 
               
               
                 gaggaguuuauuacccggacaagguauuucgaaguucaguucuucacagcacccaagaccuguuucugccauucuucag 
               
               
                 uaaugucacuugguuucacgcgauacaugucagcgguacaaacgggacaaagcgauucgauaacccaguacucccauuca 
               
               
                 acgacggaguguauuuugcaucuacagagaaauccaacauuauacgcggguggaucuuuggaacuacucuggacuccaa 
               
               
                 gacacagagccugcucauugugaacaaugcaacgaaugucgucauaaaagucugugaauuucaauuuugcaacgauccu 
               
               
                 uuccucggagucuauuaccauaagaacaauaagaguuggauggagagugaguuucgcgucuauucuuccgcgaacaauu 
               
               
                 guacauuugaauauguaucacaacccuuucuuauggauuuggaaggcaaacaagguaacuucaagaacuugcgcgaguu 
               
               
                 cguguucaagaacauagacuguuauuuuaagaucuauaguaagcauacgccaaucaaucuggugcgagauuugccucag 
               
               
                 ggcuuuucugcucuugaacccuugguugaucugcccaucgggaucaacauaaccagauuucaaacguugcucgcacucc 
               
               
                 accgcagcuaucucacuccuggcgauuccucaucuggguggaccgccggagcugcugcuuauuacgucggcuaucucca 
               
               
                 gccgcguacuuuccugcucaaguauaaugagaauggcaccauuaccgaugcuguggauugugcucuugauccacucucu 
               
               
                 gaaaccaaaugcacucucaagucuuuuaccguggaaaaggguauuuaucagacaucuaauuuucgggugcaaccuacug 
               
               
                 agucaauuguacgguuuccuaacauaacuaaccuuuguccauuuggggaagucuucaaugccacgcgguucgcaucagu 
               
               
                 cuaugcauggaacagaaaacguaucuccaacugcgucgccgauuauuccguccuuuacaauagcgcuagcuuuuccacau 
               
               
                 ucaaauguuauggcguaucaccaaccaaacuuaacgaucucugcuuuacuaaugucuacgcugacucuuucguuauucg 
               
               
                 aggugacgaggugcgccaaauugcgccuggucaaaccggaaagauugccgauuauaacuacaagcuccccgacgacuuua 
               
               
                 cggguugugugaucgccuggaauagcaauaaccucgauucuaaaguuggcgguaauuauaacuaucuguacagacucuu 
               
               
                 uaggaaaaguaaucucaagcccuuuugcagggauaucucaaccgaaaucuaccaagccggcagcacuccuugcaauggug 
               
               
                 ucgagggguuuaauuguuauuucccacugcaaucuuacggcuuucaaccgacuaauggagucgguuaucaacccuauag 
               
               
                 gguggugguacucuccuuugaacuuuugcacgcuccggcaacaguuuguggaccaaagaaaaguacgaaccuuguuaag 
               
               
                 aauaaguguguuaauuucaauuuuaacggccucacuggaacagguguccucacagaaagcaacaagaaguuucucccuu 
               
               
                 uccaacaguuuggacgggauaucgccgacacuacugacgccgucagagauccucaaacucucgaaaucuuggauaucaca 
               
               
                 ccauguucuuucgguggugucuccgucauaacaccaggaacuaacaccucuaaucaaguggccgugcucuaucaggacg 
               
               
                 ucaauugcacagaagugccugucgcaauccaugcugaucagcucacucccaccuggcguguguauuccacuggcucuaa 
               
               
                 ugucuuucagacacgggcagguugccuuauuggggcagagcaugugaacaauuccuacgaaugcgauauacccauuggg 
               
               
                 gcaggcauuugcgccagcuaccaaacccaaacuaacagccccgggagugccagcagcguggcaucucaguccauuauugc 
               
               
                 cuauacgaugagccugggugcugaaaauagcguggcuuauaguaauaacucuaucgccauacccacaaacuucaccauuu 
               
               
                 cagugaccaccgaaauccuuccuguuucuaugaccaaaacguccgucgauuguacaauguacauuugcggcgauagcacu 
               
               
                 gaauguucaaaccugcuccugcaauacggcucuuucuguacucagcucaaccgggcacucaccggcauagccgucgaaca 
               
               
                 agacaagaauacccaggaagucuuugcgcaggugaaacaaaucuauaagaccccaccaauaaaagauuucggcgguuuua 
               
               
                 auuucagccaaaucuugccugaucccagcaagccaucuaaacggucuuucauugaagaucuccuguucaacaagguuacg 
               
               
                 cuggcugacgccggguuuauuaagcaauauggcgauugccuuggggacauugccgcacgagaccucauuugugcccaga 
               
               
                 aauucaacgggcucaccguauugcccccgcuccucacagacgaaaugaucgcccaauauacaagcgcccugcuugcggga 
               
               
                 accauuacaagcgguuggaccuuuggugccggcgcagcucugcaaauacccuucgcaaugcaaauggcauaucgguuua 
               
               
                 auggaauuggcguaacccaaaacgugcuguaugaaaaccagaaacugaucgcaaaucaauucaauagugcuauaggaaag 
               
               
                 auccaagacagucugucuuccacugcuagcgcgcuggggaagcuccaagacguugugaaccaaaacgcgcaggcccugaa 
               
               
                 uacccuggugaagcaacuuucaagcaauuucggugcuauaucuucuguccucaaugacauucucucucggcucgauccc 
               
               
                 ccggaagccgaaguucagauagaccguuugaucacaggccgcuugcaaucccugcaaaccuacguuacacaacaacugau 
               
               
                 ucgcgccgccgaaauucgggcauccgccaaucuggccgcaaccaaaauguccgaguguguucucggucaauccaaacgcg 
               
               
                 uggauuucugcggaaaaggauaccauuugaugucauuuccacaaucagcuccacacgguguuguauuccugcacgugac 
               
               
                 cuacgugccagcccaggagaagaauuuuacuacugcgcccgccauuugucaugacgggaaggcucauuuuccucgggaa 
               
               
                 gggguuuucgucucaaacgguacccauugguucgugacucagaggaacuuuuaugaaccucaaaucauaacgaccgaua 
               
               
                 acacguuuguaaguggcaauugcgacguggucaucgggauuguaaacaauacugucuaugacccucuccaaccagagcu 
               
               
                 ugacagcuuuaaagaagagcuugauaaauacuuuaagaaccauaccucaccagacgucgauuugggagauaucaguggca 
               
               
                 uuaaugccucugucgucaauauccagaaagagauugaccgcuugaacgaaguugccaagaaucuuaaugagucucugau 
               
               
                 ugacuugcaagaauugggaaaauaugaacaaggauauauuccagaagccccucgcgaugggcaagcauauguucgaaag 
               
               
                 gauggggaaugggugcugcucagcaccuuucucgguugauaa(SEQ ID NO: 117) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNID  YFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPF  RDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSP  A  SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISSVLNDILSRLD  EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 118) 
               
               
                   
               
               
                 WuS_2P_pVax 
               
               
                 gccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgtttgtgtttcttgtcctgttgccattggtg 
               
               
                 agctcccaatgtgtcaatctgaccacccggacacaattgccccctgcatatacaaattcattcacgagaggagtatactatcccgacaaa 
               
               
                 gttttccggtcctcagtccttcattccactcaagatcttttccttccattcttttctaacgtaacctggttccatgcaattcatgtcagtgggacc 
               
               
                 aacggcacgaaacggtttgataatccagttcttccattcaatgacggagtatattttgcatcaactgagaaatctaatatcattagagggtg 
               
               
                 gattttcggaacaactcttgactccaagacccaatccttgctcatcgttaacaatgctacaaatgtggttattaaggtctgtgagtttcaattc 
               
               
                 tgtaacgacccctttctcggcgtatactaccataagaataataagtcttggatggagtctgaatttcgtgtctactcatcagcgaacaattgt 
               
               
                 acatttgaatatgtgtcccaaccattcctgatggatctcgaaggaaagcagggcaattttaagaaccttcgggagttcgtctttaagaatat 
               
               
                 cgatggatactttaaaatatatagtaaacacacaccaatcaatctggtccgagatctcccccagggttttagtgctctggagccgctggtg 
               
               
                 gatttgcccatcggtatcaatattacgcgcttccaaacattgctcgccctgcatcggagttaccttacgcctggcgacagtagcagcgga 
               
               
                 tggaccgctggagccgccgcctactatgtcgggtaccttcaaccacgcacttttctcctgaaatacaacgaaaatgggacaattacaga 
               
               
                 cgctgttgattgcgcactcgatcccctgtcagaaacaaaatgtacacttaaatcttttacggtcgagaaagggatttaccagacatctaac 
               
               
                 ttccgagtacaaccaaccgaatctatagtgcggttccccaacattacgaacctgtgcccgttcggcgaagtgttcaacgcaacacgattt 
               
               
                 gcttctgtttacgcttggaaccggaaacgcatctccaattgcgtcgccgattacagcgttctttataattctgcatctttctccaccttcaaat 
               
               
                 gctatggtgtctctcccacaaaactcaatgacctctgttttaccaatgtgtatgcggactccttcgtcatacgcggcgacgaggtgagaca 
               
               
                 aatcgcaccagggcagactggcaagatcgctgattataattacaaactgcctgatgattttaccggatgcgttattgcttggaattctaata 
               
               
                 acctcgattccaaagttggcgggaactacaattacctctaccgattgtttcgcaaatctaaccttaagccgtttgagagagatatcagcac 
               
               
                 agagatttatcaagctggctctaccccttgcaatggagtagaaggctttaactgctattttcctcttcagtcttatggatttcaacctaccaac 
               
               
                 ggggtagggtaccaaccctatagagtcgtcgtgctctcatttgaactccttcacgcccccgctaccgtgtgtgggcctaagaaatccact 
               
               
                 aatctcgttaagaataagtgtgtgaattttaatttcaatggcctgacagggaccggggttctgactgaatctaacaagaaatttctgccgtt 
               
               
                 ccaacaattcgggcgcgatattgcagacacgaccgacgcggtgcgcgatcctcaaacactcgaaatccttgatatcactccttgttcttt 
               
               
                 cggcggtgtaagcgtcattactcctggcaccaatacctctaaccaagtggcagtactctatcaagatgtgaactgcactgaggtcccgg 
               
               
                 ttgcaatacatgcggatcaactcaccccaacatggcgagtgtattccacagggagcaatgtgtttcaaacgagggccggctgtctcatt 
               
               
                 ggggccgaacacgttaataatagttatgagtgcgatattcccattggagcgggcatttgtgccagctatcagacccaaactaactcccc 
               
               
                 cgggtccgcctcatcagtcgctagccaatctattattgcgtacacaatgtccctgggagctgaaaacagcgtggcctactcaaataaca 
               
               
                 gcattgcaatacccacaaattttacgatttcagtaaccactgaaatcctgcccgtctccatgaccaaaacctctgtcgactgcactatgtac 
               
               
                 atatgcggcgactccaccgagtgttccaatctccttctccaatatggaagtttctgcacgcagttgaacagggcacttacagggattgca 
               
               
                 gtcgagcaagacaagaacacccaagaagtattcgcacaagtaaaacagatctacaagacacccccaatcaaagattttggtggcttca 
               
               
                 acttctcccaaatacttccagatccgtcaaagccatccaaacgctcattcatcgaagaccttctgttcaataaggtcacattggcggatgc 
               
               
                 tggatttatcaagcaatatggggattgtttgggagatattgcagcgcgggacctgatatgcgcgcaaaagttcaatgggttgacggtgct 
               
               
                 gccccctctcctcactgacgagatgatagctcagtatacgagcgctctcctcgcgggcactatcacctcaggttggaccttcggggctg 
               
               
                 gcgcggcacttcaaataccatttgctatgcaaatggcctatcgttttaatggcatcggggtgacccaaaacgtgctctatgaaaaccaga 
               
               
                 aactgatagctaatcaattcaatagtgccatcggcaaaatccaggattcattgtccagcaccgcctcagctctcgggaaattgcaagac 
               
               
                 gtcgtcaaccaaaatgctcaagcgctcaacaccctcgttaaacaactctcaagtaatttcggcgcgattagtagcgtgctgaacgatatc 
               
               
                 ttgagtcgtcttgatccacctgaagcagaagtccaaatcgacaggcttattaccggacgtctgcaaagcctgcaaacctacgttacaca 
               
               
                 acaacttataagggcagccgaaataagggcttctgcaaatctggctgccacgaagatgagcgagtgtgtcctcggacaaagcaaaag 
               
               
                 agttgacttttgcggcaaagggtaccaccttatgagtttccctcagtctgcgccccatggagtagtgtttctccacgtgacttatgtaccgg 
               
               
                 cacaagaaaagaactttaccacagccccagcaatatgtcacgatggaaaagcacactttccacgggaaggggttttcgtgtccaacgg 
               
               
                 gacccattggtttgttactcaacgcaacttttatgaaccccaaatcataaccactgataatacatttgtctctgggaactgtgatgtcgtgat 
               
               
                 cggaatagtcaacaacacagtgtatgatccgttgcaaccagagctggattccttcaaagaagaactcgacaagtattttaagaatcacac 
               
               
                 atcaccggacgtggatcttggagacatatcaggcataaacgctagtgtggtgaatatccaaaaggagatcgacaggcttaacgaagtt 
               
               
                 gcaaagaacctcaatgaatctcttatcgatttgcaagaattgggcaaatacgagcaaggctacattcctgaagcaccacgggacgggc 
               
               
                 aagcttacgtgcggaaagatggcgaatgggtgctcttgagtacctttctgggttgataa (SEQ ID NO: 119) 
               
               
                   
               
               
                 gccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguuuguguuucuugucc 
               
               
                 uguugccauuggugagcucccaaugugucaaucugaccacccggacacaauugcccccugcauauacaaauucauucacg 
               
               
                 agaggaguauacuaucccgacaaaguuuuccgguccucaguccuucauuccacucaagaucuuuuccuuccauucuuuu 
               
               
                 cuaacguaaccugguuccaugcaauucaugucagugggaccaacggcacgaaacgguuugauaauccaguucuuccauu 
               
               
                 caaugacggaguauauuuugcaucaacugagaaaucuaauaucauuagaggguggauuuucggaacaacucuugacucc 
               
               
                 aagacccaauccuugcucaucguuaacaaugcuacaaaugugguuauuaaggucugugaguuucaauucuguaacgacc 
               
               
                 ccuuucucggcguauacuaccauaagaauaauaagucuuggauggagucugaauuucgugucuacucaucagcgaacaa 
               
               
                 uuguacauuugaauaugugucccaaccauuccugauggaucucgaaggaaagcagggcaauuuuaagaaccuucgggag 
               
               
                 uucgucuuuaagaauaucgauggauacuuuaaaauauauaguaaacacacaccaaucaaucugguccgagaucuccccca 
               
               
                 ggguuuuagugcucuggagccgcugguggauuugcccaucgguaucaauauuacgcgcuuccaaacauugcucgcccug 
               
               
                 caucggaguuaccuuacgccuggcgacaguagcagcggauggaccgcuggagccgccgccuacuaugucggguaccuuc 
               
               
                 aaccacgcacuuuucuccugaaauacaacgaaaaugggacaauuacagacgcuguugauugcgcacucgauccccuguca 
               
               
                 gaaacaaaauguacacuuaaaucuuuuacggucgagaaagggauuuaccagacaucuaacuuccgaguacaaccaaccga 
               
               
                 aucuauagugcgguuccccaacauuacgaaccugugcccguucggcgaaguguucaacgcaacacgauuugcuucuguu 
               
               
                 uacgcuuggaaccggaaacgcaucuccaauugcgucgccgauuacagcguucuuuauaauucugcaucuuucuccaccu 
               
               
                 ucaaaugcuauggugucucucccacaaaacucaaugaccucuguuuuaccaauguguaugcggacuccuucgucauacg 
               
               
                 cggcgacgaggugagacaaaucgcaccagggcagacuggcaagaucgcugauuauaauuacaaacugccugaugauuuu 
               
               
                 accggaugcguuauugcuuggaauucuaauaaccucgauuccaaaguuggcgggaacuacaauuaccucuaccgauugu 
               
               
                 uucgcaaaucuaaccuuaagccguuugagagagauaucagcacagagauuuaucaagcuggcucuaccccuugcaaugga 
               
               
                 guagaaggcuuuaacugcuauuuuccucuucagucuuauggauuucaaccuaccaacgggguaggguaccaacccuaua 
               
               
                 gagucgucgugcucucauuugaacuccuucacgcccccgcuaccgugugugggccuaagaaauccacuaaucucguuaa 
               
               
                 gaauaagugugugaauuuuaauuucaauggccugacagggaccgggguucugacugaaucuaacaagaaauuucugccg 
               
               
                 uuccaacaauucgggcgcgauauugcagacacgaccgacgcggugcgcgauccucaaacacucgaaauccuugauaucac 
               
               
                 uccuuguucuuucggcgguguaagcgucauuacuccuggcaccaauaccucuaaccaaguggcaguacucuaucaagau 
               
               
                 gugaacugcacugaggucccgguugcaauacaugcggaucaacucaccccaacauggcgaguguauuccacagggagcaa 
               
               
                 uguguuucaaacgagggccggcugucucauuggggccgaacacguuaauaauaguuaugagugcgauauucccauugga 
               
               
                 gcgggcauuugugccagcuaucagacccaaacuaacucccccggguccgccucaucagucgcuagccaaucuauuauugc 
               
               
                 guacacaaugucccugggagcugaaaacagcguggccuacucaaauaacagcauugcaauacccacaaauuuuacgauuu 
               
               
                 caguaaccacugaaauccugcccgucuccaugaccaaaaccucugucgacugcacuauguacauaugcggcgacuccacc 
               
               
                 gaguguuccaaucuccuucuccaauauggaaguuucugcacgcaguugaacagggcacuuacagggauugcagucgagc 
               
               
                 aagacaagaacacccaagaaguauucgcacaaguaaaacagaucuacaagacacccccaaucaaagauuuugguggcuuca 
               
               
                 acuucucccaaauacuuccagauccgucaaagccauccaaacgcucauucaucgaagaccuucuguucaauaaggucaca 
               
               
                 uuggcggaugcuggauuuaucaagcaauauggggauuguuugggagauauugcagcgcgggaccugauaugcgcgcaa 
               
               
                 aaguucaauggguugacggugcugcccccucuccucacugacgagaugauagcucaguauacgagcgcucuccucgcgg 
               
               
                 gcacuaucaccucagguuggaccuucggggcuggcgcggcacuucaaauaccauuugcuaugcaaauggccuaucguuu 
               
               
                 uaauggcaucggggugacccaaaacgugcucuaugaaaaccagaaacugauagcuaaucaauucaauagugccaucggca 
               
               
                 aaauccaggauucauuguccagcaccgccucagcucucgggaaauugcaagacgucgucaaccaaaaugcucaagcgcuc 
               
               
                 aacacccucguuaaacaacucucaaguaauuucggcgcgauuaguagcgugcugaacgauaucuugagucgucuugauc 
               
               
                 caccugaagcagaaguccaaaucgacaggcuuauuaccggacgucugcaaagccugcaaaccuacguuacacaacaacuua 
               
               
                 uaagggcagccgaaauaagggcuucugcaaaucuggcugccacgaagaugagcgaguguguccucggacaaagcaaaaga 
               
               
                 guugacuuuugcggcaaaggguaccaccuuaugaguuucccucagucugcgccccauggaguaguguuucuccacguga 
               
               
                 cuuauguaccggcacaagaaaagaacuuuaccacagccccagcaauaugucacgauggaaaagcacacuuuccacgggaa 
               
               
                 gggguuuucguguccaacgggacccauugguuuguuacucaacgcaacuuuuaugaaccccaaaucauaaccacugaua 
               
               
                 auacauuugucucugggaacugugaugucgugaucggaauagucaacaacacaguguaugauccguugcaaccagagcu 
               
               
                 ggauuccuucaaagaagaacucgacaaguauuuuaagaaucacacaucaccggacguggaucuuggagacauaucaggca 
               
               
                 uaaacgcuaguguggugaauauccaaaaggagaucgacaggcuuaacgaaguugcaaagaaccucaaugaaucucuuauc 
               
               
                 gauuugcaagaauugggcaaauacgagcaaggcuacauuccugaagcaccacgggacgggcaagcuuacgugcggaaaga 
               
               
                 uggcgaaugggugcucuugaguaccuuucuggguugauaa (SEQ ID NO: 120) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSP  A  SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQGYIPEAPRDGQAYVRKDGEWVLLSTFLG** (SEQ ID NO: 121) 
               
               
                   
               
               
                 WuDivS_3F_D2P_Gly_pVax 
               
               
                 ggatccgccaccatggattggacatggatattgttcttggttgcagcagctacccgggtacattccatgttcgtcttcctcgtactgctccc 
               
               
                 acttgtcagtagtcaatgtgtgaacttgactacccggacgcagttgcccccggcctacactaatagcataacgcgtggagtctattaccc 
               
               
                 cgacaaggtgttcaggtcatccgtcctgtatagcactcaagatctcttcttgcccttctttagtaacgtcacttggttccatgcaatccacgt 
               
               
                 aagtggcactaatggcaccaagcgattcgacaatcccgtactcccttttaacgatggggtgtatttcgcgagcacagagaagtccaaca 
               
               
                 tcatccgtggttggatcttcggcaccacactggattctaaaacccaaagcctgcttatagtaaataatgcaacaaacgtggtcattaaagt 
               
               
                 ttgcgaatttcagttttgtaacgaccccttccttggcgtatattaccacaagaacaataaatcctggatggagagcgaatttagggtttaca 
               
               
                 gttcagccaataattgtacattcgaatacgtaagccaacccttcttgatggacctggaaggaaagcaaggaaatttcaagaatctccgtg 
               
               
                 aattcgtgttcaagaacatagacggctattttaaaatatattcaaaacacacaccgattaacctggtacgagatcttccgcaaggattctct 
               
               
                 gcactggaaccgctggtcgatcttcctatcggcattaatatcactcggtttcaaacattgcttgctttgcatcggcgatatcttacacccgg 
               
               
                 ggatagctcaagtggatggactgccggggctgctgcctattacgtaggctatctccaaccacggacattcctgctgaaatataacgaga 
               
               
                 atgggacaatcacagatgctgttgactgcgctttggaccctttgagcgaaacaaagtgcacactcaaatccttcaccgtggaaaaggga 
               
               
                 atctaccaaacgtctaattttcgcgtccaaccaaccgagagcatcgtcagattcccaaacattactaatctttgcccctttggcgaagtctt 
               
               
                 caatgctacgcgatttgcgtccgtctacgcgtggaatcggaagcgcattagcaattgcgtcgcagactattcctttctctataactctgcat 
               
               
                 ccttttctacctttaaatgttatggagtcaacgggacaaagctcaatgacctttgctttacaaatgtctatgcagactcttttgtcatccgtggt 
               
               
                 gatgaggtacgacagatcgcgccaggacaaaccgggaagatcgccgattacaactacaaactgcccgacgatttcaccgggtgcgt 
               
               
                 tattgcttggaactccaataatcttgatagtaaagttggcggcaactacaactacctgtatcgacttttccgtaaaagtaatctcaagccattt 
               
               
                 gaaagagacatcaacacaacaatttatcaggctggatctaccccatgcaacggcgttgaaggatttaactgctacttccctctccaaagt 
               
               
                 tacggtttccaaccaacaaacggcgttggctatcaaccttatagagtcgttgtcctctcttttgagcttaaccatgccccagcgacagtgtg 
               
               
                 tgggccgaagaaaagcactaatttggttaagaataaatgtgttaactttaattttaatggattgacggggacaggggttctgacagagtct 
               
               
                 aacaagaaatttctgccgttccaacagtttgggcgagatattgcagataccacggacgccgttcgagacccccaaacacttgaaattct 
               
               
                 cgatataactccctgcagctttggcggtgtatccgttatcacgcccgggacaaataccagtaaccaagtcgcagtcctgtatcaaggcg 
               
               
                 taaattgtacggaagtgcccgttgctatacacgctgaccaactgactcccacatggagagtctatagtactggttctaatgtgttccaaac 
               
               
                 acgagccggttgcctgatcggagccgaacatgttaacaactcatacgaatgtgacataccgattggcgccggcatttgcgccagctat 
               
               
                 caaacgcagaccaactcaccaagaaggcgtcgcagtgtagcaagtcaatctattatagcgtataccatgtctttgggagcagaaaactc 
               
               
                 cgttgcttactctaataattctattgctatcccaaccaattttacaatctcagttactaccgaaatactgccggtaagcatgactaagacatcc 
               
               
                 gtggattgcactatgtacatctgtggggactcaacagagtgtagtaatttgctgcttcaatatggctccttctgcactcaactgaatcgtgct 
               
               
                 ctcacgggaattgctgttgagcaagataagaatacccaggaagtgtttgcccaagtcaaacaaatttataagacaccaccaattaaagat 
               
               
                 tttggtggatttaatttcagccaaatacttccagatccctcacgcagacgacggtctttcatcgaggaccttctgttcaacaaagttactctg 
               
               
                 gctgatgcaggcttcattaagcagtacggtgattgtcttggagacatcgctgcgcgcgacctcatatgcgcccagaaatttaatgggctg 
               
               
                 accgtacttccccctttgctgactgatgagatgattgcacaatacacttccgcactccttgcgggtactatcacatccgggtggacttttgg 
               
               
                 agctggcgccgctcttcaaattcccttcgccatgcaaatggcgtacaggtttaatggcatcggtgtgacacagaatgtgctctatgagaa 
               
               
                 ccagaaacttatcgcaaaccagttcaattcagccatcgggaaaatccaagatagtctcagtagtactgcctcagctctcggcaagctcc 
               
               
                 aggatgtagtgaatcagaatgcacaagccttgaacactctcgttaaacaactttcttccaactttggtgccatcagcagtgggcctaacg 
               
               
                 atatattgagccgcttgcccaaagtggaagcggaagtccaaatagatagacttattaccggccggctgcaatctctgcaaacctatgtg 
               
               
                 actcaacaattgatccgagctgccgaaatccgtgccagtgcaaatctcgccgcgaccaagatgagcgaatgtgtcttgggacagagc 
               
               
                 aaaagagtcgatttctgcggaaaaggctaccacctgatgtctttccctcaatctgccccgcacggagtggtctttctccatgtgacttatgt 
               
               
                 gccagcccaagaaaagaactttacaaccgcaccggcaatttgccatgacggaaaggcgcatttcccccgtgagggagtctttgtgag 
               
               
                 caacgggacccattggttcgtgacacaacgcaatttctatgagcctcagatcattaccacggacaatactttcgtgtctggcaactgtga 
               
               
                 cgtgctgataggcatcgtgaataataccgtctacgatcccttgcaacttgaactggactcattcaaagaagagctggataagtattttaag 
               
               
                 aaccatacaagccctgatgtcgatcttggggatatatcaggcataaacgcatctgttgtgaatatccaaaaggaaattgatagattgaac 
               
               
                 gaagttgccaagaacctcaatgaaagtcttatcgacctgcaagaactgggaaaatatgagcaatatataaaatggccatggagcgggc 
               
               
                 gccggagacggagaaggggtagcggcggtagtggtagcgggtacatcccagaggcacccagagatggacaagcttacgtaagga 
               
               
                 aggacggggaatgggtgctgctcagtacatttcttggatgataa (SEQ ID NO: 122) 
               
               
                   
               
               
                 ggauccgccaccauggauuggacauggauauuguucuugguugcagcagcuacccggguacauuccauguucgucuucc 
               
               
                 ucguacugcucccacuugucaguagucaaugugugaacuugacuacccggacgcaguugcccccggccuacacuaauagc 
               
               
                 auaacgcguggagucuauuaccccgacaagguguucaggucauccguccuguauagcacucaagaucucuucuugcccu 
               
               
                 ucuuuaguaacgucacuugguuccaugcaauccacguaaguggcacuaauggcaccaagcgauucgacaaucccguacuc 
               
               
                 ccuuuuaacgaugggguguauuucgcgagcacagagaaguccaacaucauccgugguuggaucuucggcaccacacugg 
               
               
                 auucuaaaacccaaagccugcuuauaguaaauaaugcaacaaacguggucauuaaaguuugcgaauuucaguuuuguaac 
               
               
                 gaccccuuccuuggcguauauuaccacaagaacaauaaauccuggauggagagcgaauuuaggguuuacaguucagccaa 
               
               
                 uaauuguacauucgaauacguaagccaacccuucuugauggaccuggaaggaaagcaaggaaauuucaagaaucuccgug 
               
               
                 aauucguguucaagaacauagacggcuauuuuaaaauauauucaaaacacacaccgauuaaccugguacgagaucuuccg 
               
               
                 caaggauucucugcacuggaaccgcuggucgaucuuccuaucggcauuaauaucacucgguuucaaacauugcuugcuu 
               
               
                 ugcaucggcgauaucuuacacccggggauagcucaaguggauggacugccggggcugcugccuauuacguaggcuaucu 
               
               
                 ccaaccacggacauuccugcugaaauauaacgagaaugggacaaucacagaugcuguugacugcgcuuuggacccuuuga 
               
               
                 gcgaaacaaagugcacacucaaauccuucaccguggaaaagggaaucuaccaaacgucuaauuuucgcguccaaccaaccg 
               
               
                 agagcaucgucagauucccaaacauuacuaaucuuugccccuuuggcgaagucuucaaugcuacgcgauuugcguccgu 
               
               
                 cuacgcguggaaucggaagcgcauuagcaauugcgucgcagacuauuccuuucucuauaacucugcauccuuuucuacc 
               
               
                 uuuaaauguuauggagucaacgggacaaagcucaaugaccuuugcuuuacaaaugucuaugcagacucuuuugucaucc 
               
               
                 guggugaugagguacgacagaucgcgccaggacaaaccgggaagaucgccgauuacaacuacaaacugcccgacgauuuc 
               
               
                 accgggugcguuauugcuuggaacuccaauaaucuugauaguaaaguuggcggcaacuacaacuaccuguaucgacuuu 
               
               
                 uccguaaaaguaaucucaagccauuugaaagagacaucaacacaacaauuuaucaggcuggaucuaccccaugcaacggc 
               
               
                 guugaaggauuuaacugcuacuucccucuccaaaguuacgguuuccaaccaacaaacggcguuggcuaucaaccuuauag 
               
               
                 agucguuguccucucuuuugagcuuaaccaugccccagcgacagugugugggccgaagaaaagcacuaauuugguuaag 
               
               
                 aauaaauguguuaacuuuaauuuuaauggauugacggggacagggguucugacagagucuaacaagaaauuucugccgu 
               
               
                 uccaacaguuugggcgagauauugcagauaccacggacgccguucgagacccccaaacacuugaaauucucgauauaacu 
               
               
                 cccugcagcuuuggcgguguauccguuaucacgcccgggacaaauaccaguaaccaagucgcaguccuguaucaaggcg 
               
               
                 uaaauuguacggaagugcccguugcuauacacgcugaccaacugacucccacauggagagucuauaguacugguucuaa 
               
               
                 uguguuccaaacacgagccgguugccugaucggagccgaacauguuaacaacucauacgaaugugacauaccgauuggc 
               
               
                 gccggcauuugcgccagcuaucaaacgcagaccaacucaccaagaaggcgucgcaguguagcaagucaaucuauuauagc 
               
               
                 guauaccaugucuuugggagcagaaaacuccguugcuuacucuaauaauucuauugcuaucccaaccaauuuuacaauc 
               
               
                 ucaguuacuaccgaaauacugccgguaagcaugacuaagacauccguggauugcacuauguacaucuguggggacucaa 
               
               
                 cagaguguaguaauuugcugcuucaauauggcuccuucugcacucaacugaaucgugcucucacgggaauugcuguuga 
               
               
                 gcaagauaagaauacccaggaaguguuugcccaagucaaacaaauuuauaagacaccaccaauuaaagauuuugguggau 
               
               
                 uuaauuucagccaaauacuuccagaucccucacgcagacgacggucuuucaucgaggaccuucuguucaacaaaguuacu 
               
               
                 cuggcugaugcaggcuucauuaagcaguacggugauugucuuggagacaucgcugcgcgcgaccucauaugcgcccaga 
               
               
                 aauuuaaugggcugaccguacuucccccuuugcugacugaugagaugauugcacaauacacuuccgcacuccuugcggg 
               
               
                 uacuaucacauccggguggacuuuuggagcuggcgccgcucuucaaauucccuucgccaugcaaauggcguacagguuu 
               
               
                 aauggcaucggugugacacagaaugugcucuaugagaaccagaaacuuaucgcaaaccaguucaauucagccaucgggaa 
               
               
                 aauccaagauagucucaguaguacugccucagcucucggcaagcuccaggauguagugaaucagaaugcacaagccuuga 
               
               
                 acacucucguuaaacaacuuucuuccaacuuuggugccaucagcagugggccuaacgauauauugagccgcuugcccaaa 
               
               
                 guggaagcggaaguccaaauagauagacuuauuaccggccggcugcaaucucugcaaaccuaugugacucaacaauugau 
               
               
                 ccgagcugccgaaauccgugccagugcaaaucucgccgcgaccaagaugagcgaaugugucuugggacagagcaaaagag 
               
               
                 ucgauuucugcggaaaaggcuaccaccugaugucuuucccucaaucugccccgcacggaguggucuuucuccaugugac 
               
               
                 uuaugugccagcccaagaaaagaacuuuacaaccgcaccggcaauuugccaugacggaaaggcgcauuucccccgugagg 
               
               
                 gagucuuugugagcaacgggacccauugguucgugacacaacgcaauuucuaugagccucagaucauuaccacggacaa 
               
               
                 uacuuucgugucuggcaacugugacgugcugauaggcaucgugaauaauaccgucuacgaucccuugcaacuugaacug 
               
               
                 gacucauucaaagaagagcuggauaaguauuuuaagaaccauacaagcccugaugucgaucuuggggauauaucaggca 
               
               
                 uaaacgcaucuguugugaauauccaaaaggaaauugauagauugaacgaaguugccaagaaccucaaugaaagucuuauc 
               
               
                 gaccugcaagaacugggaaaauaugagcaauauauaaaauggccauggagcgggcgccggagacggagaagggguagcg 
               
               
                 gcgguagugguagcggguacaucccagaggcacccagagauggacaagcuuacguaaggaaggacggggaaugggugcu 
               
               
                 gcucaguacauuucuuggaugauaa (SEQ ID NO: 123) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV  T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI  T  IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL  HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRRRRSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS  NDILSRL  KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 124) 
               
               
                   
               
               
                 WuS_3F_2P_NoTri_pVax 
               
               
                 ggatccgccaccatggactggacgtggattttgtttcttgtcgctgcagctacccgggttcactccatgtttgttttcctggtgctccttccc 
               
               
                 cttgtaagctcacaatgcgtcaatttgaccacgcgtacacaactgcccccagcatatactaattctttcacacgcggggtctactatcccg 
               
               
                 ataaagtctttagaagtagcgtacttcatagtacccaagatttgtttctgcccttcttcagcaatgtcacgtggtttcatgcgatccatgtatc 
               
               
                 cggcacgaacgggacaaaacgatttgataaccccgtgctccccttcaacgacggggtttatttcgccagcaccgagaaatcaaatatta 
               
               
                 tcaggggctggattttcgggacaacacttgattccaagacacaatctcttcttatcgtgaataatgcaactaatgtggtgatcaaggtttgc 
               
               
                 gagttccaattttgtaatgacccttttcttggcgtgtactatcataagaataacaagagttggatggaatcagagttccgggtctacagcag 
               
               
                 tgctaacaattgtacgtttgaatacgtttctcagccttttctgatggaccttgaaggtaagcaaggcaatttcaagaacttgcgggaatttgt 
               
               
                 cttcaagaacatagatggctattttaagatatatagcaaacacactcccataaatctcgtcagagatcttccacagggctttagcgccctg 
               
               
                 gaaccattggttgatttgccaattggaataaacataactcgattccaaaccttgctcgcactccatcggagctacctgacgcctggagatt 
               
               
                 cctcttccggctggactgccggagcagcagcttattatgtaggctacttgcaaccccgcacgttcctgctcaaatataatgaaaatggca 
               
               
                 ctataaccgatgcggtagactgcgctcttgatcccctgagtgaaactaaatgtacgttgaaaagctttactgtagagaaaggcatctatca 
               
               
                 gactagtaactttagggtgcaacccacggagtccattgtacggttcccaaacattaccaacctctgtccattcggagaagtgtttaatgcc 
               
               
                 acaagattcgcttcagtgtatgcctggaaccggaaacgcatctcaaattgcgttgccgattattcagtactttacaactcagccagtttctct 
               
               
                 acttttaagtgctatggcgtttccccgacgaagctcaatgatctgtgctttactaacgtttacgcagactctttcgtcatcagaggcgatgaa 
               
               
                 gtcaggcaaatagctcctggtcaaaccggcaagatcgccgactacaactataaactgcccgatgatttcactgggtgtgtgatcgcgtg 
               
               
                 gaattccaataatttggactctaaggtaggtggcaactataactacctctatcgactcttccgaaaatccaaccttaagccgtttgaacgcg 
               
               
                 atattagtaccgaaatataccaagccgggtctacaccctgtaacggcgttgaaggtttcaattgttactttccactgcagagttatggctttc 
               
               
                 aacccaccaacggggttggctatcagccctatagggttgtggtcctcagttttgagcttctgcatgcaccagcaaccgtgtgcggacct 
               
               
                 aagaagtcaacaaatctcgtgaagaacaagtgtgttaatttcaatttcaatggccttacagggaccggagtgcttacagaaagcaataag 
               
               
                 aagttcttgccctttcaacagttcggcagggacatagcggacacgacagatgcagttcgagacccgcaaactctcgaaattctggatat 
               
               
                 cacaccttgcagttttggtggcgtgtctgttatcacaccaggcaccaacacttccaaccaggtggcagttttgtaccaggatgttaattgta 
               
               
                 cagaggtcccagtggcaatacacgctgaccaactgactccaacttggagagtctactctacaggctcaaacgtcttccaaacacgggc 
               
               
                 ggggtgtctgatcggagcagaacacgttaataacagttacgagtgtgatatcccgataggagctggtatttgcgcttcataccagacgc 
               
               
                 aaacgaactcaccacgaagacgccggtcagttgcatcacaatccattattgcatacaccatgtcactcggagcggagaattctgtagca 
               
               
                 tacagtaacaatagtatcgcaatacctacgaactttaccatttccgtcacaactgaaatcttgcccgtctcaatgacaaagacaagcgtag 
               
               
                 attgtacaatgtatatttgcggagattcaacagagtgctccaacctgctgctccagtacggtagtttctgtacccagctcaatagggccct 
               
               
                 caccggaattgcagttgaacaagacaagaacacccaagaagtgtttgcacaagtcaaacaaatctataaaacacccccaatcaaagat 
               
               
                 ttcggtggcttcaacttttcacaaattctccctgatcctagccgccgccgcagatcattcatcgaagacttgctcttcaataaggttaccctg 
               
               
                 gcagacgccggttttattaaacaatacggagattgcctcggtgacatcgccgctagagaccttatctgtgcccaaaagttcaacggact 
               
               
                 caccgtgctgcccccattgctgaccgatgaaatgattgctcaatatacatctgcgctcctcgcagggaccattacttcagggtggactttt 
               
               
                 ggggctggcgccgcattgcagattcccttcgccatgcagatggcatataggtttaacggcattggagttacccaaaatgtactctacga 
               
               
                 gaaccaaaagctgattgcaaatcagttcaacagtgcaataggcaaaatacaagactctctgtcttcaaccgccagcgctcttggaaagc 
               
               
                 tccaagatgttgttaatcaaaatgcccaagcgttgaataccctcgtgaagcaactctccagcaattttggtgccatctctagcgtgctgaa 
               
               
                 cgacattctgtcacggctcgatcccccggaagccgaggtacaaattgaccgattgataaccgggcgactccaaagccttcagacctac 
               
               
                 gttacacaacagctcattcgcgctgcagaaattagagcctctgcaaatcttgcagctacaaagatgtcagagtgcgttctcggtcaaagc 
               
               
                 aaaagagtggatttctgcggaaaggggtaccacctcatgagtttcccacagagtgcccctcatggcgtagtctttcttcatgttacttatgt 
               
               
                 accagcccaagaaaagaatttcactacagcacccgcgatttgtcatgatggcaaagcgcacttccctcgggaaggcgtgttcgtgtcta 
               
               
                 atggaacacattggttcgtgacgcaacggaatttctacgagccccaaattatcactactgataacaccttcgtctccggaaactgcgatgt 
               
               
                 tgttattggcattgtcaacaataccgtttacgacccgctccaacctgagctggattcatttaaagaggaattggacaaatattttaagaatca 
               
               
                 tacctctccagacgtggatttgggtgacattagcggaataaatgcatctgtggtcaatatccaaaaggaaattgataggctgaacgaggt 
               
               
                 cgccaagaatttgaacgaatctttgattgatcttcaagaacttggcaagtatgaacaatacataaaatggccctggtgatag (SEQ ID 
               
               
                 NO: 125) 
               
               
                   
               
               
                 ggauccgccaccauggacuggacguggauuuuguuucuugucgcugcagcuacccggguucacuccauguuuguuuuc 
               
               
                 cuggugcuccuuccccuuguaagcucacaaugcgucaauuugaccacgcguacacaacugcccccagcauauacuaauuc 
               
               
                 uuucacacgcggggucuacuaucccgauaaagucuuuagaaguagcguacuucauaguacccaagauuuguuucugccc 
               
               
                 uucuucagcaaugucacgugguuucaugcgauccauguauccggcacgaacgggacaaaacgauuugauaaccccgugc 
               
               
                 uccccuucaacgacgggguuuauuucgccagcaccgagaaaucaaauauuaucaggggcuggauuuucgggacaacacu 
               
               
                 ugauuccaagacacaaucucuucuuaucgugaauaaugcaacuaauguggugaucaagguuugcgaguuccaauuuugu 
               
               
                 aaugacccuuuucuuggcguguacuaucauaagaauaacaagaguuggauggaaucagaguuccgggucuacagcagug 
               
               
                 cuaacaauuguacguuugaauacguuucucagccuuuucugauggaccuugaagguaagcaaggcaauuucaagaacuu 
               
               
                 gcgggaauuugucuucaagaacauagauggcuauuuuaagauauauagcaaacacacucccauaaaucucgucagagauc 
               
               
                 uuccacagggcuuuagcgcccuggaaccauugguugauuugccaauuggaauaaacauaacucgauuccaaaccuugcu 
               
               
                 cgcacuccaucggagcuaccugacgccuggagauuccucuuccggcuggacugccggagcagcagcuuauuauguaggc 
               
               
                 uacuugcaaccccgcacguuccugcucaaauauaaugaaaauggcacuauaaccgaugcgguagacugcgcucuugaucc 
               
               
                 ccugagugaaacuaaauguacguugaaaagcuuuacuguagagaaaggcaucuaucagacuaguaacuuuagggugcaa 
               
               
                 cccacggaguccauuguacgguucccaaacauuaccaaccucuguccauucggagaaguguuuaaugccacaagauucgc 
               
               
                 uucaguguaugccuggaaccggaaacgcaucucaaauugcguugccgauuauucaguacuuuacaacucagccaguuuc 
               
               
                 ucuacuuuuaagugcuauggcguuuccccgacgaagcucaaugaucugugcuuuacuaacguuuacgcagacucuuucg 
               
               
                 ucaucagaggcgaugaagucaggcaaauagcuccuggucaaaccggcaagaucgccgacuacaacuauaaacugcccgau 
               
               
                 gauuucacugggugugugaucgcguggaauuccaauaauuuggacucuaagguagguggcaacuauaacuaccucuauc 
               
               
                 gacucuuccgaaaauccaaccuuaagccguuugaacgcgauauuaguaccgaaauauaccaagccgggucuacacccugu 
               
               
                 aacggcguugaagguuucaauuguuacuuuccacugcagaguuauggcuuucaacccaccaacgggguuggcuaucagc 
               
               
                 ccuauaggguugugguccucaguuuugagcuucugcaugcaccagcaaccgugugcggaccuaagaagucaacaaaucu 
               
               
                 cgugaagaacaaguguguuaauuucaauuucaauggccuuacagggaccggagugcuuacagaaagcaauaagaaguuc 
               
               
                 uugcccuuucaacaguucggcagggacauagcggacacgacagaugcaguucgagacccgcaaacucucgaaauucugga 
               
               
                 uaucacaccuugcaguuuugguggcgugucuguuaucacaccaggcaccaacacuuccaaccagguggcaguuuuguac 
               
               
                 caggauguuaauuguacagaggucccaguggcaauacacgcugaccaacugacuccaacuuggagagucuacucuacagg 
               
               
                 cucaaacgucuuccaaacacgggcggggugucugaucggagcagaacacguuaauaacaguuacgagugugauaucccg 
               
               
                 auaggagcugguauuugcgcuucauaccagacgcaaacgaacucaccacgaagacgccggucaguugcaucacaauccau 
               
               
                 uauugcauacaccaugucacucggagcggagaauucuguagcauacaguaacaauaguaucgcaauaccuacgaacuuua 
               
               
                 ccauuuccgucacaacugaaaucuugcccgucucaaugacaaagacaagcguagauuguacaauguauauuugcggagau 
               
               
                 ucaacagagugcuccaaccugcugcuccaguacgguaguuucuguacccagcucaauagggcccucaccggaauugcagu 
               
               
                 ugaacaagacaagaacacccaagaaguguuugcacaagucaaacaaaucuauaaaacacccccaaucaaagauuucggugg 
               
               
                 cuucaacuuuucacaaauucucccugauccuagccgccgccgcagaucauucaucgaagacuugcucuucaauaagguua 
               
               
                 cccuggcagacgccgguuuuauuaaacaauacggagauugccucggugacaucgccgcuagagaccuuaucugugccca 
               
               
                 aaaguucaacggacucaccgugcugcccccauugcugaccgaugaaaugauugcucaauauacaucugcgcuccucgcag 
               
               
                 ggaccauuacuucaggguggacuuuuggggcuggcgccgcauugcagauucccuucgccaugcagauggcauauaggu 
               
               
                 uuaacggcauuggaguuacccaaaauguacucuacgagaaccaaaagcugauugcaaaucaguucaacagugcaauaggc 
               
               
                 aaaauacaagacucucugucuucaaccgccagcgcucuuggaaagcuccaagauguuguuaaucaaaaugcccaagcguu 
               
               
                 gaauacccucgugaagcaacucuccagcaauuuuggugccaucucuagcgugcugaacgacauucugucacggcucgau 
               
               
                 cccccggaagccgagguacaaauugaccgauugauaaccgggcgacuccaaagccuucagaccuacguuacacaacagcu 
               
               
                 cauucgcgcugcagaaauuagagccucugcaaaucuugcagcuacaaagaugucagagugcguucucggucaaagcaaaa 
               
               
                 gaguggauuucugcggaaagggguaccaccucaugaguuucccacagagugccccucauggcguagucuuucuucaugu 
               
               
                 uacuuauguaccagcccaagaaaagaauuucacuacagcacccgcgauuugucaugauggcaaagcgcacuucccucggg 
               
               
                 aaggcguguucgugucuaauggaacacauugguucgugacgcaacggaauuucuacgagccccaaauuaucacuacuga 
               
               
                 uaacaccuucgucuccggaaacugcgauguuguuauuggcauugucaacaauaccguuuacgacccgcuccaaccugagc 
               
               
                 uggauucauuuaaagaggaauuggacaaauauuuuaagaaucauaccucuccagacguggauuugggugacauuagcgg 
               
               
                 aauaaaugcaucuguggucaauauccaaaaggaaauugauaggcugaacgaggucgccaagaauuugaacgaaucuuug 
               
               
                 auugaucuucaagaacuuggcaaguaugaacaauacauaaaauggcccuggugauag (SEQ ID NO: 126) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRR  RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC 
               
               
                 AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG 
               
               
                 IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ 
               
               
                 LSSNFGAISSVLNDILSRLD  EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLA 
               
               
                 ATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 
               
               
                 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPW** (SEQ ID NO: 127) 
               
               
                   
               
               
                 WuS_3F_D2P_Gly_pVax 
               
               
                 ggatccgccaccatggattggacatggatattgttcttggttgcagcagctacccgggtacattccatgttcgtcttcctcgtactgctccc 
               
               
                 acttgtcagtagtcaatgtgtgaacttgactacccggacgcagttgcccccggcctacactaatagctttacgcgtggagtctattacccc 
               
               
                 gacaaggtgttcaggtcatccgtcctgcatagcactcaagatctcttcttgcccttctttagtaacgtcacttggttccatgcaatccacgta 
               
               
                 agtggcactaatggcaccaagcgattcgacaatcccgtactcccttttaacgatggggtgtatttcgcgagcacagagaagtccaacat 
               
               
                 catccgtggttggatcttcggcaccacactggattctaaaacccaaagcctgcttatagtaaataatgcaacaaacgtggtcattaaagtt 
               
               
                 tgcgaatttcagttttgtaacgaccccttccttggcgtatattaccacaagaacaataaatcctggatggagagcgaatttagggtttacag 
               
               
                 ttcagccaataattgtacattcgaatacgtaagccaacccttcttgatggacctggaaggaaagcaaggaaatttcaagaatctccgtga 
               
               
                 attcgtgttcaagaacatagacggctattttaaaatatattcaaaacacacaccgattaacctggtacgagatcttccgcaaggattctctg 
               
               
                 cactggaaccgctggtcgatcttcctatcggcattaatatcactcggtttcaaacattgcttgctttgcatcggagttatcttacacccgggg 
               
               
                 atagctcaagtggatggactgccggggctgctgcctattacgtaggctatctccaaccacggacattcctgctgaaatataacgagaat 
               
               
                 gggacaatcacagatgctgttgactgcgctttggaccctttgagcgaaacaaagtgcacactcaaatccttcaccgtggaaaagggaat 
               
               
                 ctaccaaacgtctaattttcgcgtccaaccaaccgagagcatcgtcagattcccaaacattactaatctttgcccctttggcgaagtcttca 
               
               
                 atgctacgcgatttgcgtccgtctacgcgtggaatcggaagcgcattagcaattgcgtcgcagactattccgtgctctataactctgcatc 
               
               
                 cttttctacctttaaatgttatggagtcaacgggacaaagctcaatgacctttgctttacaaatgtctatgcagactcttttgtcatccgtggtg 
               
               
                 atgaggtacgacagatcgcgccaggacaaaccgggaagatcgccgattacaactacaaactgcccgacgatttcaccgggtgcgtta 
               
               
                 ttgcttggaactccaataatcttgatagtaaagttggcggcaactacaactacctgtatcgacttttccgtaaaagtaatctcaagccatttg 
               
               
                 aaagagacatcaacacaacaatttatcaggctggatctaccccatgcaacggcgttgaaggatttaactgctacttccctctccaaagtta 
               
               
                 cggtttccaaccaacaaacggcgttggctatcaaccttatagagtcgttgtcctctcttttgagcttaaccatgccccagcgacagtgtgt 
               
               
                 gggccgaagaaaagcactaatttggttaagaataaatgtgttaactttaattttaatggattgacggggacaggggttctgacagagtcta 
               
               
                 acaagaaatttctgccgttccaacagtttgggcgagatattgcagataccacggacgccgttcgagacccccaaacacttgaaattctc 
               
               
                 gatataactccctgcagctttggcggtgtatccgttatcacgcccgggacaaataccagtaaccaagtcgcagtcctgtatcaagacgta 
               
               
                 aattgtacggaagtgcccgttgctatacacgctgaccaactgactcccacatggagagtctatagtactggttctaatgtgttccaaacac 
               
               
                 gagccggttgcctgatcggagccgaacatgttaacaactcatacgaatgtgacataccgattggcgccggcatttgcgccagctatca 
               
               
                 aacgcagaccaactcaccaagaaggcgtcgcagtgtagcaagtcaatctattatagcgtataccatgtctttgggagcagaaaactcc 
               
               
                 gttgcttactctaataattctattgctatcccaaccaattttacaatctcagttactaccgaaatactgccggtaagcatgactaagacatccg 
               
               
                 tggattgcactatgtacatctgtggggactcaacagagtgtagtaatttgctgcttcaatatggctccttctgcactcaactgaatcgtgctc 
               
               
                 tcacgggaattgctgttgagcaagataagaatacccaggaagtgtttgcccaagtcaaacaaatttataagacaccaccaattaaagatt 
               
               
                 ttggtggatttaatttcagccaaatacttccagatccctcacgcagacgacggtctttcatcgaggaccttctgttcaacaaagttactctg 
               
               
                 gctgatgcaggcttcattaagcagtacggtgattgtcttggagacatcgctgcgcgcgacctcatatgcgcccagaaatttaatgggctg 
               
               
                 accgtacttccccctttgctgactgatgagatgattgcacaatacacttccgcactccttgcgggtactatcacatccgggtggacttttgg 
               
               
                 agctggcgccgctcttcaaattcccttcgccatgcaaatggcgtacaggtttaatggcatcggtgtgacacagaatgtgctctatgagaa 
               
               
                 ccagaaacttatcgcaaaccagttcaattcagccatcgggaaaatccaagatagtctcagtagtactgcctcagctctcggcaagctcc 
               
               
                 aggatgtagtgaatcagaatgcacaagccttgaacactctcgttaaacaactttcttccaactttggtgccatcagcagtgggcctaacg 
               
               
                 atatattgagccgcttgcccaaagtggaagcggaagtccaaatagatagacttattaccggccggctgcaatctctgcaaacctatgtg 
               
               
                 actcaacaattgatccgagctgccgaaatccgtgccagtgcaaatctcgccgcgaccaagatgagcgaatgtgtcttgggacagagc 
               
               
                 aaaagagtcgatttctgcggaaaaggctaccacctgatgtctttccctcaatctgccccgcacggagtggtctttctccatgtgacttatgt 
               
               
                 gccagcccaagaaaagaactttacaaccgcaccggcaatttgccatgacggaaaggcgcatttcccccgtgagggagtctttgtgag 
               
               
                 caacgggacccattggttcgtgacacaacgcaatttctatgagcctcagatcattaccacggacaatactttcgtgtctggcaactgtga 
               
               
                 cgtggtcataggcatcgtgaataataccgtctacgatcccttgcaacccgaactggactcattcaaagaagagctggataagtattttaa 
               
               
                 gaaccatacaagccctgatgtcgatcttggggatatatcaggcataaacgcatctgttgtgaatatccaaaaggaaattgatagattgaa 
               
               
                 cgaagttgccaagaacctcaatgaaagtcttatcgacctgcaagaactgggaaaatatgagcaatatataaaatggccatggagcggg 
               
               
                 cgccggagacggagaaggggtagcggcggtagtggtagcgggtacatcccagaggcacccagagatggacaagcttacgtaagg 
               
               
                 aaggacggggaatgggtgctgctcagtacatttcttggatgataa (SEQ ID NO: 128) 
               
               
                   
               
               
                 ggauccgccaccauggauuggacauggauauuguucuugguugcagcagcuacccggguacauuccauguucgucuucc 
               
               
                 ucguacugcucccacuugucaguagucaaugugugaacuugacuacccggacgcaguugcccccggccuacacuaauagc 
               
               
                 uuuacgcguggagucuauuaccccgacaagguguucaggucauccguccugcauagcacucaagaucucuucuugcccu 
               
               
                 ucuuuaguaacgucacuugguuccaugcaauccacguaaguggcacuaauggcaccaagcgauucgacaaucccguacuc 
               
               
                 ccuuuuaacgaugggguguauuucgcgagcacagagaaguccaacaucauccgugguuggaucuucggcaccacacugg 
               
               
                 auucuaaaacccaaagccugcuuauaguaaauaaugcaacaaacguggucauuaaaguuugcgaauuucaguuuuguaac 
               
               
                 gaccccuuccuuggcguauauuaccacaagaacaauaaauccuggauggagagcgaauuuaggguuuacaguucagccaa 
               
               
                 uaauuguacauucgaauacguaagccaacccuucuugauggaccuggaaggaaagcaaggaaauuucaagaaucuccgug 
               
               
                 aauucguguucaagaacauagacggcuauuuuaaaauauauucaaaacacacaccgauuaaccugguacgagaucuuccg 
               
               
                 caaggauucucugcacuggaaccgcuggucgaucuuccuaucggcauuaauaucacucgguuucaaacauugcuugcuu 
               
               
                 ugcaucggaguuaucuuacacccggggauagcucaaguggauggacugccggggcugcugccuauuacguaggcuaucu 
               
               
                 ccaaccacggacauuccugcugaaauauaacgagaaugggacaaucacagaugcuguugacugcgcuuuggacccuuuga 
               
               
                 gcgaaacaaagugcacacucaaauccuucaccguggaaaagggaaucuaccaaacgucuaauuuucgcguccaaccaaccg 
               
               
                 agagcaucgucagauucccaaacauuacuaaucuuugccccuuuggcgaagucuucaaugcuacgcgauuugcguccgu 
               
               
                 cuacgcguggaaucggaagcgcauuagcaauugcgucgcagacuauuccgugcucuauaacucugcauccuuuucuacc 
               
               
                 uuuaaauguuauggagucaacgggacaaagcucaaugaccuuugcuuuacaaaugucuaugcagacucuuuugucaucc 
               
               
                 guggugaugagguacgacagaucgcgccaggacaaaccgggaagaucgccgauuacaacuacaaacugcccgacgauuuc 
               
               
                 accgggugcguuauugcuuggaacuccaauaaucuugauaguaaaguuggcggcaacuacaacuaccuguaucgacuuu 
               
               
                 uccguaaaaguaaucucaagccauuugaaagagacaucaacacaacaauuuaucaggcuggaucuaccccaugcaacggc 
               
               
                 guugaaggauuuaacugcuacuucccucuccaaaguuacgguuuccaaccaacaaacggcguuggcuaucaaccuuauag 
               
               
                 agucguuguccucucuuuugagcuuaaccaugccccagcgacagugugugggccgaagaaaagcacuaauuugguuaag 
               
               
                 aauaaauguguuaacuuuaauuuuaauggauugacggggacagggguucugacagagucuaacaagaaauuucugccgu 
               
               
                 uccaacaguuugggcgagauauugcagauaccacggacgccguucgagacccccaaacacuugaaauucucgauauaacu 
               
               
                 cccugcagcuuuggcgguguauccguuaucacgcccgggacaaauaccaguaaccaagucgcaguccuguaucaagacgu 
               
               
                 aaauuguacggaagugcccguugcuauacacgcugaccaacugacucccacauggagagucuauaguacugguucuaau 
               
               
                 guguuccaaacacgagccgguugccugaucggagccgaacauguuaacaacucauacgaaugugacauaccgauuggcgc 
               
               
                 cggcauuugcgccagcuaucaaacgcagaccaacucaccaagaaggcgucgcaguguagcaagucaaucuauuauagcgu 
               
               
                 auaccaugucuuugggagcagaaaacuccguugcuuacucuaauaauucuauugcuaucccaaccaauuuuacaaucuca 
               
               
                 guuacuaccgaaauacugccgguaagcaugacuaagacauccguggauugcacuauguacaucuguggggacucaacag 
               
               
                 aguguaguaauuugcugcuucaauauggcuccuucugcacucaacugaaucgugcucucacgggaauugcuguugagca 
               
               
                 agauaagaauacccaggaaguguuugcccaagucaaacaaauuuauaagacaccaccaauuaaagauuuugguggauuua 
               
               
                 auuucagccaaauacuuccagaucccucacgcagacgacggucuuucaucgaggaccuucuguucaacaaaguuacucug 
               
               
                 gcugaugcaggcuucauuaagcaguacggugauugucuuggagacaucgcugcgcgcgaccucauaugcgcccagaaau 
               
               
                 uuaaugggcugaccguacuucccccuuugcugacugaugagaugauugcacaauacacuuccgcacuccuugcggguac 
               
               
                 uaucacauccggguggacuuuuggagcuggcgccgcucuucaaauucccuucgccaugcaaauggcguacagguuuaau 
               
               
                 ggcaucggugugacacagaaugugcucuaugagaaccagaaacuuaucgcaaaccaguucaauucagccaucgggaaaau 
               
               
                 ccaagauagucucaguaguacugccucagcucucggcaagcuccaggauguagugaaucagaaugcacaagccuugaaca 
               
               
                 cucucguuaaacaacuuucuuccaacuuuggugccaucagcagugggccuaacgauauauugagccgcuugcccaaagu 
               
               
                 ggaagcggaaguccaaauagauagacuuauuaccggccggcugcaaucucugcaaaccuaugugacucaacaauugaucc 
               
               
                 gagcugccgaaauccgugccagugcaaaucucgccgcgaccaagaugagcgaaugugucuugggacagagcaaaagaguc 
               
               
                 gauuucugcggaaaaggcuaccaccugaugucuuucccucaaucugccccgcacggaguggucuuucuccaugugacuu 
               
               
                 augugccagcccaagaaaagaacuuuacaaccgcaccggcaauuugccaugacggaaaggcgcauuucccccgugaggga 
               
               
                 gucuuugugagcaacgggacccauugguucgugacacaacgcaauuucuaugagccucagaucauuaccacggacaauac 
               
               
                 uuucgugucuggcaacugugacguggucauaggcaucgugaauaauaccgucuacgaucccuugcaacccgaacuggac 
               
               
                 ucauucaaagaagagcuggauaaguauuuuaagaaccauacaagcccugaugucgaucuuggggauauaucaggcauaa 
               
               
                 acgcaucuguugugaauauccaaaaggaaauugauagauugaacgaaguugccaagaaccucaaugaaagucuuaucgac 
               
               
                 cugcaagaacugggaaaauaugagcaauauauaaaauggccauggagcgggcgccggagacggagaagggguagcggcg 
               
               
                 guagugguagcggguacaucccagaggcacccagagauggacaagcuuacguaaggaaggacggggaaugggugcugcu 
               
               
                 caguacauuucuuggaugauaa (SEQ ID NO: 129) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV  T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI  T  IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL  HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR  RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS  NDILSRL  KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 130) 
               
               
                   
               
               
                 WuS_3F_D2P_rB_pVax 
               
               
                 ggatccgccaccatggattggacatggattctgtttctcgttgccgccgctacgcgcgtgcacagcatgttcgttttcctcgtactgttgcc 
               
               
                 tctggtatcatctcaatgtgtgaatcttacgacgaggacgcaactgccaccagcttacaccaactcttttactagaggggtctattacccc 
               
               
                 gacaaggttttcagatcctcagtgctgcatagtacacaagatttgtttcttcccttcttctccaatgtcacttggtttcacgctatccacgtgtc 
               
               
                 cggcactaatggaacgaagcggtttgataacccggtacttccatttaatgacggggtatactttgcaagcaccgagaaaagtaatatcat 
               
               
                 tcgtgggtggatctttggcactacactcgactccaagacacaatcccttttgatagtaaataatgctacaaatgtggttataaaggtgtgcg 
               
               
                 agtttcaattctgcaatgaccccttcctcggtgtctattatcacaagaacaataaatcttggatggaaagtgagttcagggtatacagctct 
               
               
                 gcaaacaactgcacatttgagtatgtgagccaaccgtttcttatggatctggaaggtaagcagggtaactttaagaaccttcgggagttc 
               
               
                 gtctttaagaatatagatggctattttaaaatctatagtaaacacactcctattaaccttgtgcgcgatctccctcaagggttctctgcattgg 
               
               
                 aaccgcttgttgatttgcctataggaatcaatattacacgatttcaaacactcctcgctctccataggagctaccttaccccaggcgactca 
               
               
                 agctctggttggacggcaggagctgcagcatactatgtgggttatcttcagccgcggacattcttgcttaagtataatgagaatggaact 
               
               
                 atcactgacgctgttgactgtgccctggaccctctttcagaaacaaaatgtactctcaaatcattcaccgtggagaagggaatatatcaaa 
               
               
                 caagtaactttagggtccaacctaccgagagcatcgtgcgattccctaatattaccaatttgtgtcccttcggtgaagtcttcaacgcgac 
               
               
                 ccgctttgctagcgtctatgcgtggaacaggaagcgaattagcaactgtgttgcagattacagtgtgctgtacaatagtgcgagcttttcc 
               
               
                 acgttcaaatgctatggcgtgaaacctaccaaacttaatgatttgtgcttcactaatgtttatgctgacagcttcgttatccggggtgatgag 
               
               
                 gtgaggcagattgcccccggtcaaactggcaaaattgccgactacaattacaagctccctgatgattttactggatgtgtcatagcgtgg 
               
               
                 aattccaataatctggactctaaggttggtggtaattataactatctctaccgcctgtttcgtaagagcaatctgaaaccctttgaaagagat 
               
               
                 atttggactgagatatatcaagctggctcaactccttgcaacggggtcgaaggtttcaattgttactttccacttcaatcatacgggtttcaa 
               
               
                 ccaactaacggtgtaggttatcaaccctatcgggtggttgtcctgagctttgagctgaaccatgccccggctacagtatgcggcccaaa 
               
               
                 gaaatccactaacttggtcaagaacaaatgcgtcaactttaactttaacggactcacggggacaggagtccttaccgaatccaacaaga 
               
               
                 aattcttgcctttccaacaatttggacgagacattgcggataccacagacgcagtacgcgacccacagactcttgaaatcctcgacataa 
               
               
                 caccctgcagtttcggcggtgtaagtgtcattaccccaggcactaatacgagcaaccaagtggcggtgctctaccaagacgttaattgc 
               
               
                 actgaggtcccagtggctattcacgctgaccaacttacacccacatggagagtgtatagtacaggctcaaacgtcttccagacacggg 
               
               
                 cggggtgccttattggagcagaacatgttaacaattcctatgaatgcgatatcccgattggagccgggatctgtgctagctatcaaaccc 
               
               
                 aaacaaatagccccagacgtcgacgttccgtggctagtcaaagcatcatcgcctacactatgagtcttggggccgaaaattccgttgctt 
               
               
                 acagtaacaacagtatcgctatccccaccaattttactattagtgtaactacagagattctgccggtttccatgacaaagacttccgtggat 
               
               
                 tgtacgatgtatatttgcggcgacagcacagagtgcagcaatctgctgctgcaatacggtagtttctgcacccaattgaaccgtgctctg 
               
               
                 acgggaattgcagttgagcaggacaagaatactcaagaagtatttgcacaagtcaaacagatatacaagacgcccccgattaaagattt 
               
               
                 cggcgggtttaactttagccaaattcttccggaccccagcagacgccgccgaagctttattgaggacctgctgtttaataaagttaccctt 
               
               
                 gctgatgctggttttatcaagcaatacggagattgcctgggagatatcgccgccagggatttgatctgtgcgcaaaagtttaacggcctt 
               
               
                 accgttctcccgccccttctgaccgatgaaatgatagcccaatacacttccgcactcctggcaggcacaattacttccggctggacgttt 
               
               
                 ggggccggggcagccttgcaaattccgtttgctatgcaaatggcatatcgtttcaatggtatcggcgtaacacaaaatgtcctttatgaga 
               
               
                 accagaaactcattgctaatcagtttaattccgctatcggcaagattcaagacagtctcagcagcacggcgagcgcacttggtaaacttc 
               
               
                 aagacgttgtcaaccagaatgctcaagccctgaacactctggtaaaacaacttagctctaatttcggtgcaattagctccggtccgaacg 
               
               
                 atattctgtcacggctcccgaaagtcgaagccgaagtccagatcgataggctgatcacagggcgcttgcagagtctccaaacctacgt 
               
               
                 gacgcaacaactcattcgggcggctgaaattcgtgcaagcgctaatctggccgctaccaaaatgagtgagtgtgttctcggtcaatcaa 
               
               
                 agagggttgacttttgcggcaaaggatatcatttgatgagttttccgcaatctgcccctcatggggtagtatttctgcacgtaacttatgtac 
               
               
                 cagcacaagaaaagaacttcaccacggccccagcaatatgccacgatggcaaagctcatttccctcgcgaaggggtctttgtaagca 
               
               
                 atggaacccactggtttgtcacacaacgcaacttttatgagcctcaaatcattacaaccgataacacttttgtctccgggaactgcgacgt 
               
               
                 ggtgattggaatcgtcaacaacactgtctatgatcccctgcaacctgaactggattcctttaaagaagagcttgataagtatttcaagaac 
               
               
                 cataccagccccgacgtcgatttgggagatattagtgggattaatgctagcgttgttaatatacaaaaggaaatagatcgattgaatgaa 
               
               
                 gtggccaagaatctgaatgagtctctgattgacctgcaggagctcggaaagtatgagcaatatataaaatggccctggtcaggccgca 
               
               
                 ggcgtcggcggcgcggtagcggcggttcaggatctgggtatatacctgaggccccacgagatgggcaggcttatgtacggaaagat 
               
               
                 ggagaatgggtgttgctgagtactttcctcgggtaataa (SEQ ID NO: 131) 
               
               
                   
               
               
                 ggauccgccaccauggauuggacauggauucuguuucucguugccgccgcuacgcgcgugcacagcauguucguuuucc 
               
               
                 ucguacuguugccucugguaucaucucaaugugugaaucuuacgacgaggacgcaacugccaccagcuuacaccaacucu 
               
               
                 uuuacuagaggggucuauuaccccgacaagguuuucagauccucagugcugcauaguacacaagauuuguuucuucccu 
               
               
                 ucuucuccaaugucacuugguuucacgcuauccacguguccggcacuaauggaacgaagcgguuugauaacccgguacu 
               
               
                 uccauuuaaugacgggguauacuuugcaagcaccgagaaaaguaauaucauucguggguggaucuuuggcacuacacuc 
               
               
                 gacuccaagacacaaucccuuuugauaguaaauaaugcuacaaaugugguuauaaaggugugcgaguuucaauucugca 
               
               
                 augaccccuuccucggugucuauuaucacaagaacaauaaaucuuggauggaaagugaguucaggguauacagcucugc 
               
               
                 aaacaacugcacauuugaguaugugagccaaccguuucuuauggaucuggaagguaagcaggguaacuuuaagaaccuu 
               
               
                 cgggaguucgucuuuaagaauauagauggcuauuuuaaaaucuauaguaaacacacuccuauuaaccuugugcgcgauc 
               
               
                 ucccucaaggguucucugcauuggaaccgcuuguugauuugccuauaggaaucaauauuacacgauuucaaacacuccu 
               
               
                 cgcucuccauaggagcuaccuuaccccaggcgacucaagcucugguuggacggcaggagcugcagcauacuaugugggu 
               
               
                 uaucuucagccgcggacauucuugcuuaaguauaaugagaauggaacuaucacugacgcuguugacugugcccuggacc 
               
               
                 cucuuucagaaacaaaauguacucucaaaucauucaccguggagaagggaauauaucaaacaaguaacuuuaggguccaa 
               
               
                 ccuaccgagagcaucgugcgauucccuaauauuaccaauuugugucccuucggugaagucuucaacgcgacccgcuuug 
               
               
                 cuagcgucuaugcguggaacaggaagcgaauuagcaacuguguugcagauuacagugugcuguacaauagugcgagcuu 
               
               
                 uuccacguucaaaugcuauggcgugaaaccuaccaaacuuaaugauuugugcuucacuaauguuuaugcugacagcuuc 
               
               
                 guuauccggggugaugaggugaggcagauugcccccggucaaacuggcaaaauugccgacuacaauuacaagcucccug 
               
               
                 augauuuuacuggaugugucauagcguggaauuccaauaaucuggacucuaagguuggugguaauuauaacuaucucu 
               
               
                 accgccuguuucguaagagcaaucugaaacccuuugaaagagauauuuggacugagauauaucaagcuggcucaacucc 
               
               
                 uugcaacggggucgaagguuucaauuguuacuuuccacuucaaucauacggguuucaaccaacuaacgguguagguuau 
               
               
                 caacccuaucgggugguuguccugagcuuugagcugaaccaugccccggcuacaguaugcggcccaaagaaauccacuaa 
               
               
                 cuuggucaagaacaaaugcgucaacuuuaacuuuaacggacucacggggacaggaguccuuaccgaauccaacaagaaau 
               
               
                 ucuugccuuuccaacaauuuggacgagacauugcggauaccacagacgcaguacgcgacccacagacucuugaaauccuc 
               
               
                 gacauaacacccugcaguuucggcgguguaagugucauuaccccaggcacuaauacgagcaaccaaguggcggugcucua 
               
               
                 ccaagacguuaauugcacugaggucccaguggcuauucacgcugaccaacuuacacccacauggagaguguauaguacag 
               
               
                 gcucaaacgucuuccagacacgggcggggugccuuauuggagcagaacauguuaacaauuccuaugaaugcgauauccc 
               
               
                 gauuggagccgggaucugugcuagcuaucaaacccaaacaaauagccccagacgucgacguuccguggcuagucaaagca 
               
               
                 ucaucgccuacacuaugagucuuggggccgaaaauuccguugcuuacaguaacaacaguaucgcuauccccaccaauuuu 
               
               
                 acuauuaguguaacuacagagauucugccgguuuccaugacaaagacuuccguggauuguacgauguauauuugcggcg 
               
               
                 acagcacagagugcagcaaucugcugcugcaauacgguaguuucugcacccaauugaaccgugcucugacgggaauugc 
               
               
                 aguugagcaggacaagaauacucaagaaguauuugcacaagucaaacagauauacaagacgcccccgauuaaagauuucg 
               
               
                 gcggguuuaacuuuagccaaauucuuccggaccccagcagacgccgccgaagcuuuauugaggaccugcuguuuaauaa 
               
               
                 aguuacccuugcugaugcugguuuuaucaagcaauacggagauugccugggagauaucgccgccagggauuugaucug 
               
               
                 ugcgcaaaaguuuaacggccuuaccguucucccgccccuucugaccgaugaaaugauagcccaauacacuuccgcacucc 
               
               
                 uggcaggcacaauuacuuccggcuggacguuuggggccggggcagccuugcaaauuccguuugcuaugcaaauggcaua 
               
               
                 ucguuucaaugguaucggcguaacacaaaauguccuuuaugagaaccagaaacucauugcuaaucaguuuaauuccgcu 
               
               
                 aucggcaagauucaagacagucucagcagcacggcgagcgcacuugguaaacuucaagacguugucaaccagaaugcuca 
               
               
                 agcccugaacacucugguaaaacaacuuagcucuaauuucggugcaauuagcuccgguccgaacgauauucugucacggc 
               
               
                 ucccgaaagucgaagccgaaguccagaucgauaggcugaucacagggcgcuugcagagucuccaaaccuacgugacgcaa 
               
               
                 caacucauucgggcggcugaaauucgugcaagcgcuaaucuggccgcuaccaaaaugagugaguguguucucggucaau 
               
               
                 caaagaggguugacuuuugcggcaaaggauaucauuugaugaguuuuccgcaaucugccccucaugggguaguauuuc 
               
               
                 ugcacguaacuuauguaccagcacaagaaaagaacuucaccacggccccagcaauaugccacgauggcaaagcucauuucc 
               
               
                 cucgcgaaggggucuuuguaagcaauggaacccacugguuugucacacaacgcaacuuuuaugagccucaaaucauuaca 
               
               
                 accgauaacacuuuugucuccgggaacugcgacguggugauuggaaucgucaacaacacugucuaugauccccugcaacc 
               
               
                 ugaacuggauuccuuuaaagaagagcuugauaaguauuucaagaaccauaccagccccgacgucgauuugggagauauu 
               
               
                 agugggauuaaugcuagcguuguuaauauacaaaaggaaauagaucgauugaaugaaguggccaagaaucugaaugagu 
               
               
                 cucugauugaccugcaggagcucggaaaguaugagcaauauauaaaauggcccuggucaggccgcaggcgucggcggcg 
               
               
                 cgguagcggcgguucaggaucuggguauauaccugaggccccacgagaugggcaggcuuauguacggaaagauggagaa 
               
               
                 uggguguugcugaguacuuuccucggguaauaa (SEQ ID NO: 132) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV  PT 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI  TEIYQAGSTPCNGVEGFNCYFPLQSYGFQP 
               
               
                 TNGVGYQPYRVVVLSFEL  HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTES 
               
               
                 NKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQ 
               
               
                 DVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGIC 
               
               
                 ASYQTQTNSPRR  RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSM 
               
               
                 TKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQI 
               
               
                 YKTPPIKDFGGFNFSQILPDPS  RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARD 
               
               
                 LICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYR 
               
               
                 FNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTL 
               
               
                 VKQLSSNFGAISS  NDILSRL  KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASA 
               
               
                 NLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT 
               
               
                 APAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNN 
               
               
                 TVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNL 
               
               
                 NESLIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEW 
               
               
                 VLLSTFLG** (SEQ ID NO: 133) 
               
               
                   
               
               
                 WuS_3F_D2P_pVax 
               
               
                 ggatccgccaccatggactggacctggatactctttctcgtagcagcagccacacgagtgcattcaatgtttgtcttcttggtcctcttgcc 
               
               
                 actggttagctcccagtgtgtgaatcttactacaaggacacaactgcccccagcttacacaaactcctttactaggggtgtatattaccca 
               
               
                 gacaaagtgtttcgcagttctgtcctgcatagcacccaagaccttttccttccgttcttcagcaacgtcacctggttccatgctatccatgtc 
               
               
                 agtggaacgaatggcacaaagcggttcgataaccctgtcctgccctttaacgacggcgtctatttcgcttcaacagagaagagtaacat 
               
               
                 tatcagaggatggatatttggtacaactcttgatagcaagacacaaagcctgctgattgtaaacaacgcgacaaatgtcgtcatcaaggt 
               
               
                 ttgcgagtttcaattttgcaacgatcccttcttgggcgtgtactatcataagaacaataaaagctggatggagagcgaatttagggtgtata 
               
               
                 gctcagctaataactgtacatttgaatatgtctctcaacccttcctcatggaccttgagggaaagcaaggaaatttcaagaatctcagaga 
               
               
                 atttgtcttcaagaacatcgacgggtatttcaagatctactccaagcatacacccatcaacttggttagggaccttccgcaaggtttctcag 
               
               
                 cactggagcctctggtagatctccctattgggattaatattacaagatttcaaacactcctggccttgcatagatcctatcttacccctggg 
               
               
                 gattccagctcaggttggaccgcgggtgccgcggcgtactatgtcggatatctccaacctcggacattcctgctgaaatacaatgaaaa 
               
               
                 tgggaccatcactgatgccgttgattgtgctctcgatcctctgagtgagaccaaatgcactcttaagagttttacagtggagaaaggtatc 
               
               
                 tatcaaactagtaatttcagagttcaaccaaccgagtcaatagtgcgttttccaaatatcactaatctgtgtccatttggggaagtcttcaat 
               
               
                 gctacccgattcgcaagtgtgtacgcctggaaccggaaacggatttctaactgcgttgccgattatagtgtcctctataattctgcttctttc 
               
               
                 tctacttttaagtgctatggggtgtcccccaccaagctgaacgatctgtgtttcactaacgtctacgccgatagttttgtcattagagggga 
               
               
                 cgaggtacggcaaatcgcgcccggccaaacggggaaaattgccgattacaactacaagcttccagacgacttcacaggttgcgtgat 
               
               
                 tgcatggaattctaataatctggacagtaaagtgggcggcaactataactatctttaccggctgtttcggaagagcaacttgaagcccttc 
               
               
                 gaacgcgacatatccaccgagatctatcaagccggaagtaccccgtgcaacggggtagaaggatttaattgttattttccattgcagtctt 
               
               
                 atggatttcagcccaccaatggtgtgggataccaaccttatagggttgttgttctctccttcgaactcctgcacgctccagctactgtatgt 
               
               
                 gggcctaagaaaagtactaatctcgttaagaataaatgcgtcaatttcaatttcaacggcttgaccgggactggagtgctcaccgaaag 
               
               
                 caacaagaagtttctcccgtttcagcaattcggtagggatattgccgatacgacagatgcagtacgagatccccaaacactcgaaatcc 
               
               
                 tggacattacgccatgtagctttggcggagtaagtgtcatcaccccagggactaacaccagtaaccaagttgcggtactctatcaggat 
               
               
                 gtgaactgcactgaggtacctgtagcaattcacgcagaccaattgacgccgacgtggcgcgtctatagtacaggaagtaacgtctttca 
               
               
                 gacaagagcgggttgtttgattggcgctgaacacgttaacaattcttacgagtgtgatatccccatcggtgcggggatctgcgccagct 
               
               
                 atcagacacaaaccaattccccacgaaggagacgttccgtggccagccagtcaataatcgcgtatactatgtctctgggtgcggagaa 
               
               
                 ttcagtggcctattccaataattctatagccattccaaccaattttactataagcgtcactacagagatcttgccagttagcatgacgaaaac 
               
               
                 cagcgtcgattgtaccatgtatatatgcggcgacagtaccgaatgctcaaatctgctgctccaatatggctcattttgcactcaacttaata 
               
               
                 gagctctgacagggatcgctgtcgaacaagataagaacactcaggaagttttcgcccaagttaagcagatatacaagaccccgcccat 
               
               
                 caaggattttggcggatttaatttctctcagatcctgccggaccctagccgccgacgccggagctttatcgaagacttgctgtttaataag 
               
               
                 gttactctcgcagatgcaggcttcatcaagcaatacggtgactgccttggggatatcgctgctcgggacctgatctgtgctcagaaattc 
               
               
                 aacggtctcacggtgctgcccccactcctgaccgacgaaatgattgcccagtatacgtccgcattgctcgctggcaccatcactagcg 
               
               
                 gctggacctttggggccggagccgcgctccaaataccttttgctatgcaaatggcttatcgcttcaatggtattggggttacgcaaaatgt 
               
               
                 cctctacgaaaatcaaaagctcatagctaaccaattcaatagcgctatagggaaaattcaagacagcctgagttccacagcaagcgcc 
               
               
                 ctcggcaaacttcaagatgtagtgaaccaaaatgctcaagcactcaatacactggtcaaacaactctcaagcaatttcggggcaatctc 
               
               
                 atctggtcctaatgacatattgagcaggctccccaaagtggaagcagaagtacaaatcgacaggctgattaccggacgactccaaagc 
               
               
                 ttgcaaacttatgtaacccaacaacttatcagggctgcagaaatccgtgcaagcgctaacctcgccgctacgaagatgtcagaatgtgt 
               
               
                 acttgggcagtctaagagggttgatttctgtggaaaagggtaccatctgatgagttttccacagagcgctccacatggggtggtgtttctg 
               
               
                 catgtaacctatgttcccgctcaagaaaagaattttactactgcccccgcaatttgccatgacgggaaagcccatttcccccgagaggg 
               
               
                 agttttcgtgagtaacggaacgcactggtttgtcactcagagaaatttctacgagccccaaatcattacgaccgataatacattcgtaagc 
               
               
                 ggtaactgcgatgtcgtcattggcatcgttaacaacactgtttatgatccccttcaacccgagcttgactcatttaaagaggaactggataa 
               
               
                 gtactttaagaatcacacctctcccgatgtcgacctgggcgacatctctggaattaatgcctctgtcgtaaacatccaaaaggaaattgac 
               
               
                 cgactgaatgaggtggcaaagaatcttaatgaatccctgatcgatctgcaggagcttgggaagtatgagcaatacatcaaatggccatg 
               
               
                 gtctggcagacggcgccggagaaggggctctggcggctctggaagcgggtatattccagaggcgcccagggatgggcaagcatat 
               
               
                 gttcggaaggatggggagtgggtgttgttgtccacgttccttggctagtga (SEQ ID NO: 134) 
               
               
                   
               
               
                 ggauccgccaccauggacuggaccuggauacucuuucucguagcagcagccacacgagugcauucaauguuugucuucu 
               
               
                 ugguccucuugccacugguuagcucccagugugugaaucuuacuacaaggacacaacugcccccagcuuacacaaacucc 
               
               
                 uuuacuagggguguauauuacccagacaaaguguuucgcaguucuguccugcauagcacccaagaccuuuuccuuccgu 
               
               
                 ucuucagcaacgucaccugguuccaugcuauccaugucaguggaacgaauggcacaaagcgguucgauaacccuguccu 
               
               
                 gcccuuuaacgacggcgucuauuucgcuucaacagagaagaguaacauuaucagaggauggauauuugguacaacucuu 
               
               
                 gauagcaagacacaaagccugcugauuguaaacaacgcgacaaaugucgucaucaagguuugcgaguuucaauuuugcaa 
               
               
                 cgaucccuucuugggcguguacuaucauaagaacaauaaaagcuggauggagagcgaauuuaggguguauagcucagcu 
               
               
                 aauaacuguacauuugaauaugucucucaacccuuccucauggaccuugagggaaagcaaggaaauuucaagaaucucag 
               
               
                 agaauuugucuucaagaacaucgacggguauuucaagaucuacuccaagcauacacccaucaacuugguuagggaccuuc 
               
               
                 cgcaagguuucucagcacuggagccucugguagaucucccuauugggauuaauauuacaagauuucaaacacuccuggc 
               
               
                 cuugcauagauccuaucuuaccccuggggauuccagcucagguuggaccgcgggugccgcggcguacuaugucggauau 
               
               
                 cuccaaccucggacauuccugcugaaauacaaugaaaaugggaccaucacugaugccguugauugugcucucgauccucu 
               
               
                 gagugagaccaaaugcacucuuaagaguuuuacaguggagaaagguaucuaucaaacuaguaauuucagaguucaaccaa 
               
               
                 ccgagucaauagugcguuuuccaaauaucacuaaucuguguccauuuggggaagucuucaaugcuacccgauucgcaag 
               
               
                 uguguacgccuggaaccggaaacggauuucuaacugcguugccgauuauaguguccucuauaauucugcuucuuucucu 
               
               
                 acuuuuaagugcuauggggugucccccaccaagcugaacgaucuguguuucacuaacgucuacgccgauaguuuuguca 
               
               
                 uuagaggggacgagguacggcaaaucgcgcccggccaaacggggaaaauugccgauuacaacuacaagcuuccagacgac 
               
               
                 uucacagguugcgugauugcauggaauucuaauaaucuggacaguaaagugggcggcaacuauaacuaucuuuaccggc 
               
               
                 uguuucggaagagcaacuugaagcccuucgaacgcgacauauccaccgagaucuaucaagccggaaguaccccgugcaac 
               
               
                 gggguagaaggauuuaauuguuauuuuccauugcagucuuauggauuucagcccaccaauggugugggauaccaaccu 
               
               
                 uauaggguuguuguucucuccuucgaacuccugcacgcuccagcuacuguaugugggccuaagaaaaguacuaaucucg 
               
               
                 uuaagaauaaaugcgucaauuucaauuucaacggcuugaccgggacuggagugcucaccgaaagcaacaagaaguuucuc 
               
               
                 ccguuucagcaauucgguagggauauugccgauacgacagaugcaguacgagauccccaaacacucgaaauccuggacau 
               
               
                 uacgccauguagcuuuggcggaguaagugucaucaccccagggacuaacaccaguaaccaaguugcgguacucuaucag 
               
               
                 gaugugaacugcacugagguaccuguagcaauucacgcagaccaauugacgccgacguggcgcgucuauaguacaggaa 
               
               
                 guaacgucuuucagacaagagcggguuguuugauuggcgcugaacacguuaacaauucuuacgagugugauauccccau 
               
               
                 cggugcggggaucugcgccagcuaucagacacaaaccaauuccccacgaaggagacguuccguggccagccagucaauaa 
               
               
                 ucgcguauacuaugucucugggugcggagaauucaguggccuauuccaauaauucuauagccauuccaaccaauuuuac 
               
               
                 uauaagcgucacuacagagaucuugccaguuagcaugacgaaaaccagcgucgauuguaccauguauauaugcggcgaca 
               
               
                 guaccgaaugcucaaaucugcugcuccaauauggcucauuuugcacucaacuuaauagagcucugacagggaucgcugu 
               
               
                 cgaacaagauaagaacacucaggaaguuuucgcccaaguuaagcagauauacaagaccccgcccaucaaggauuuuggcg 
               
               
                 gauuuaauuucucucagauccugccggacccuagccgccgacgccggagcuuuaucgaagacuugcuguuuaauaaggu 
               
               
                 uacucucgcagaugcaggcuucaucaagcaauacggugacugccuuggggauaucgcugcucgggaccugaucugugcu 
               
               
                 cagaaauucaacggucucacggugcugcccccacuccugaccgacgaaaugauugcccaguauacguccgcauugcucgc 
               
               
                 uggcaccaucacuagcggcuggaccuuuggggccggagccgcgcuccaaauaccuuuugcuaugcaaauggcuuaucgc 
               
               
                 uucaaugguauugggguuacgcaaaauguccucuacgaaaaucaaaagcucauagcuaaccaauucaauagcgcuauagg 
               
               
                 gaaaauucaagacagccugaguuccacagcaagcgcccucggcaaacuucaagauguagugaaccaaaaugcucaagcac 
               
               
                 ucaauacacuggucaaacaacucucaagcaauuucggggcaaucucaucugguccuaaugacauauugagcaggcucccc 
               
               
                 aaaguggaagcagaaguacaaaucgacaggcugauuaccggacgacuccaaagcuugcaaacuuauguaacccaacaacu 
               
               
                 uaucagggcugcagaaauccgugcaagcgcuaaccucgccgcuacgaagaugucagaauguguacuugggcagucuaag 
               
               
                 aggguugauuucuguggaaaaggguaccaucugaugaguuuuccacagagcgcuccacauggggugguguuucugcau 
               
               
                 guaaccuauguucccgcucaagaaaagaauuuuacuacugcccccgcaauuugccaugacgggaaagcccauuucccccg 
               
               
                 agagggaguuuucgugaguaacggaacgcacugguuugucacucagagaaauuucuacgagccccaaaucauuacgacc 
               
               
                 gauaauacauucguaagcgguaacugcgaugucgucauuggcaucguuaacaacacuguuuaugauccccuucaacccg 
               
               
                 agcuugacucauuuaaagaggaacuggauaaguacuuuaagaaucacaccucucccgaugucgaccugggcgacaucucu 
               
               
                 ggaauuaaugccucugucguaaacauccaaaaggaaauugaccgacugaaugagguggcaaagaaucuuaaugaaucccu 
               
               
                 gaucgaucugcaggagcuugggaaguaugagcaauacaucaaauggccauggucuggcagacggcgccggagaaggggc 
               
               
                 ucuggcggcucuggaagcggguauauuccagaggcgcccagggaugggcaagcauauguucggaaggauggggagugg 
               
               
                 guguuguuguccacguuccuuggcuaguga (SEQ ID NO: 135) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRR R RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC 
               
               
                 AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG 
               
               
                 IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ 
               
               
                 LSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLA 
               
               
                 ATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 
               
               
                 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 136) 
               
               
                   
               
               
                 WuS_3F_2P_GlyDSol_pVax 
               
               
                 ggatccgccaccatggactggacatggattttgtttcttgtggcggctgcaacgcgagttcattccatgtttgttttcctggttctcttgccg 
               
               
                 ctcgtctctagtcaatgcgtcaatctgacgacaagaacgcaacttccccctgcctacaccaatagttttacccgtggcgtctattatccag 
               
               
                 ataaagtgtttcgaagttcctgccttcattccacgcaagatctcttccttccattcttctctaatgtcacctggtttcatgcgatccacgtgtct 
               
               
                 ggaaccaacgggactaaacgattcgacaatcccgtcctgccatttaacgatggagtatacttcgcatccaccgagaaatctggcattat 
               
               
                 aagagggtggatattcgggactacactcgacagcaagacacaaagtctcctgattgttaacaacgcgacaaacgtcgtaattaaagttt 
               
               
                 gcgaatttcaattttgtaatgacccgttcttgggcgtgtattatcacaagaataacaaaagttggatggaatccgaattccgggtttattcca 
               
               
                 gcgcgaataattgcacatttgaatacgttagccaacctttcctgatggatctcgaaggcaaacaaggaaactttaagaatcttcgggaatt 
               
               
                 cgttttcaagaacatcgacgggtactttaagatatactcaaaacacaccccaattaatttggtccgagatctgccgcaaggctttagtgcg 
               
               
                 cttgagcccctcgtagatctcccaattggtattaatatcacacgctttcaaaccctgctggcattgcatcggagctatctgactcccggcg 
               
               
                 atagttcttcagggtggacggcgggtgccgctgcttactatgtaggctatctgcagcctcgtacatttctcctcaaatacaatgaaaatgg 
               
               
                 cactattaccgacgccgttgattgcgctctggacccactgagcgagactaaatgcaccctcaaatcattcactgttgagaagggaattta 
               
               
                 ccaaacatcaaacttcagggtccaacctacggaaagcatcgtgcggttccccaacatcactaacctctgcccctttggagaagtatttaa 
               
               
                 cgctacaaggttcgcttccgtctacgcctggaacaggaaaagaatcagtaattgcgtggctgattactccgtgctgtacaattccgcctc 
               
               
                 attttctacatttaagtgttatggcgttaacgggactaagcttaacgacctctgcttcacaaacgtctatgccgacagctttgtcattcgcgg 
               
               
                 ggatgaagtaagacagatagcacccggtcaaactggcaaaattgctgattacaattacaagttgccagatgatttcactggatgcgttat 
               
               
                 agcatggaactctaacaaccttgactcaaaggttggtggcaactataattatttgtatcgcctgtttcgcaaatctaatctcaagcctttcga 
               
               
                 gcgcgacataaatacgaccatataccaagcggggtccaccccttgtaatggagtcgaggggtttaattgctattttccgttgcaatcctac 
               
               
                 gggttccaaccaacaaacggcgtcggctatcaaccctatcgggttgtcgtactctcattcgagctcaaccatgcaccagcaacagtttgt 
               
               
                 ggccccaagaagagcacaaatttggtcaagaataaatgcgttaattttaatttcaatggtctgactggcacaggggttcttaccgaatcaa 
               
               
                 ataagaagtttctgccatttcagcagttcggaagggactgtgcagggaccacagatgccgttagagacccccaaacactcgaaattctg 
               
               
                 gacatcacgccatgcagtttcggtggtgttagcgtgattactccgggtactaatacgtccaaccaagtggctgtgttgtatcaagacgtta 
               
               
                 actgtaccgaagttcctgtagcaatccatgccggtcaactgacccccacgtggcgagtttatagcaccggttccaacgtctttcaaacaa 
               
               
                 gagccggatgtctcataggcgctgaacatgtgaataattcatacgaatgtgacattccaatcggcgcagggatttgcgcctcatatcaga 
               
               
                 cacaaactaactccccgagaagacgtcgctcagtggcgtcacaaagcatcatcgcttatacgatgagcctctgcgccgagaactctgt 
               
               
                 cgcatattctaacaactctattgcaattcctacaaattttacaatttcttgcactactgagatcctgcccgtaagcatgacgaaaacatcctg 
               
               
                 cgactgcacaatgtatatctgtggcgactcaactgagtgctccaatctcctcttgcaatacggatctttctgtactcaactcaacagagcac 
               
               
                 ttacaggaatagccgtcgaacaagacaagaacacacaagaggtcttcgcccaagtaaagcaatgttacaaaaccccacctattaaaga 
               
               
                 ctttggtgggtttaatttctcacagattcttccagatccttcccgtagaaggagaagctttattgaagacctcttgtttaataaagtcactcttg 
               
               
                 cagacgctgggtttattaaacaatatggagactgcttgggagacatagcggcaagagacctgatctgcgctcaaaagtttaatgggtgc 
               
               
                 actgtgttgccaccccttctgaccgacgagatgatcgctcagtataccagtgccttgctggcagggaccataactagcggatggactttc 
               
               
                 ggtgcaggagctgctctgcaaatcccttttgcgatgcaaatggcctacaggtttaatggtataggagttactcagaatgtcctgtacgaaa 
               
               
                 atcaaaagctgatcgccaatcaattcaacagtgctattgggaaaatacaggacagtttgagttcaacagcgagcgctctcggcaaactg 
               
               
                 caggatgttgtgaatcaaaacgcgcaagctttgaacactcttgtgaagcagctttcatccaacttcggagcgatctcatccgtcctgaac 
               
               
                 gacatattgtcaagacttgacccacctgaagcggaagttcagatagaccgactcataacgggccgacttcagtccttgcagacatacgt 
               
               
                 gacccaacaacttatccgcgcagccgaaataagggcttcagctaaccttgcagcaaccaaaatgtcagagtgcgtgctcggtcaaag 
               
               
                 caagcgggtagacttttgtggcaaggggtatcatcttatgtcctttcctcaatccgcccctcacggggtggtcttcttgcactgcacttatgt 
               
               
                 acctgctcaagagaagaattttacgaccgcccctgcgatctgtcacgacgggaaagcacatttcccccgcgagggagtctttgtgtcta 
               
               
                 atggtactcattggtttgttacgcagcggaacttttacgaacctcaaataattacaacggataatacagatgttagtgggaattgcgacgtg 
               
               
                 gtgatcggtatagtcaacaatacggtgtatgatccacttcaaccagaacttgattcctttaaggaagagctggacaaatatttcaagaacc 
               
               
                 atacatcccctgacgtggaccttggcgatataagcggcattaatgcttcagtggtcaatatacaaaaggaaatcgatcgcctgaatgag 
               
               
                 gtcgcaaagaatttgaatgagtccctgatcgacctgcaagagctcgggaaatatgagcagtacatcaagtggccctggtcaggtagac 
               
               
                 gtaggcggcgccggggcagtggcggctcagggagcggttatatacccgaagcccctagagatgggcaagcttatgtccgaaagga 
               
               
                 cggcgaatgggtgctcctttccactttcttgggataatag (SEQ ID NO: 137) 
               
               
                   
               
               
                 ggauccgccaccauggacuggacauggauuuuguuucuuguggcggcugcaacgcgaguucauuccauguuuguuuuc 
               
               
                 cugguucucuugccgcucgucucuagucaaugcgucaaucugacgacaagaacgcaacuucccccugccuacaccaauag 
               
               
                 uuuuacccguggcgucuauuauccagauaaaguguuucgaaguuccugccuucauuccacgcaagaucucuuccuucca 
               
               
                 uucuucucuaaugucaccugguuucaugcgauccacgugucuggaaccaacgggacuaaacgauucgacaaucccgucc 
               
               
                 ugccauuuaacgauggaguauacuucgcauccaccgagaaaucuggcauuauaagaggguggauauucgggacuacacu 
               
               
                 cgacagcaagacacaaagucuccugauuguuaacaacgcgacaaacgucguaauuaaaguuugcgaauuucaauuuugua 
               
               
                 augacccguucuugggcguguauuaucacaagaauaacaaaaguuggauggaauccgaauuccggguuuauuccagcgc 
               
               
                 gaauaauugcacauuugaauacguuagccaaccuuuccugauggaucucgaaggcaaacaaggaaacuuuaagaaucuuc 
               
               
                 gggaauucguuuucaagaacaucgacggguacuuuaagauauacucaaaacacaccccaauuaauuugguccgagaucug 
               
               
                 ccgcaaggcuuuagugcgcuugagccccucguagaucucccaauugguauuaauaucacacgcuuucaaacccugcugg 
               
               
                 cauugcaucggagcuaucugacucccggcgauaguucuucaggguggacggcgggugccgcugcuuacuauguaggcu 
               
               
                 aucugcagccucguacauuucuccucaaauacaaugaaaauggcacuauuaccgacgccguugauugcgcucuggaccca 
               
               
                 cugagcgagacuaaaugcacccucaaaucauucacuguugagaagggaauuuaccaaacaucaaacuucaggguccaacc 
               
               
                 uacggaaagcaucgugcgguuccccaacaucacuaaccucugccccuuuggagaaguauuuaacgcuacaagguucgcuu 
               
               
                 ccgucuacgccuggaacaggaaaagaaucaguaauugcguggcugauuacuccgugcuguacaauuccgccucauuuuc 
               
               
                 uacauuuaaguguuauggcguuaacgggacuaagcuuaacgaccucugcuucacaaacgucuaugccgacagcuuuguc 
               
               
                 auucgcggggaugaaguaagacagauagcacccggucaaacuggcaaaauugcugauuacaauuacaaguugccagauga 
               
               
                 uuucacuggaugcguuauagcauggaacucuaacaaccuugacucaaagguugguggcaacuauaauuauuuguaucgc 
               
               
                 cuguuucgcaaaucuaaucucaagccuuucgagcgcgacauaaauacgaccauauaccaagcgggguccaccccuuguaa 
               
               
                 uggagucgagggguuuaauugcuauuuuccguugcaauccuacggguuccaaccaacaaacggcgucggcuaucaaccc 
               
               
                 uaucggguugucguacucucauucgagcucaaccaugcaccagcaacaguuuguggccccaagaagagcacaaauuugg 
               
               
                 ucaagaauaaaugcguuaauuuuaauuucaauggucugacuggcacagggguucuuaccgaaucaaauaagaaguuucu 
               
               
                 gccauuucagcaguucggaagggacugugcagggaccacagaugccguuagagacccccaaacacucgaaauucuggaca 
               
               
                 ucacgccaugcaguuucggugguguuagcgugauuacuccggguacuaauacguccaaccaaguggcuguguuguauca 
               
               
                 agacguuaacuguaccgaaguuccuguagcaauccaugccggucaacugacccccacguggcgaguuuauagcaccggu 
               
               
                 uccaacgucuuucaaacaagagccggaugucucauaggcgcugaacaugugaauaauucauacgaaugugacauuccaau 
               
               
                 cggcgcagggauuugcgccucauaucagacacaaacuaacuccccgagaagacgucgcucaguggcgucacaaagcauca 
               
               
                 ucgcuuauacgaugagccucugcgccgagaacucugucgcauauucuaacaacucuauugcaauuccuacaaauuuuaca 
               
               
                 auuucuugcacuacugagauccugcccguaagcaugacgaaaacauccugcgacugcacaauguauaucuguggcgacuc 
               
               
                 aacugagugcuccaaucuccucuugcaauacggaucuuucuguacucaacucaacagagcacuuacaggaauagccgucg 
               
               
                 aacaagacaagaacacacaagaggucuucgcccaaguaaagcaauguuacaaaaccccaccuauuaaagacuuugguggg 
               
               
                 uuuaauuucucacagauucuuccagauccuucccguagaaggagaagcuuuauugaagaccucuuguuuaauaaaguca 
               
               
                 cucuugcagacgcuggguuuauuaaacaauauggagacugcuugggagacauagcggcaagagaccugaucugcgcuca 
               
               
                 aaaguuuaaugggugcacuguguugccaccccuucugaccgacgagaugaucgcucaguauaccagugccuugcuggca 
               
               
                 gggaccauaacuagcggauggacuuucggugcaggagcugcucugcaaaucccuuuugcgaugcaaauggccuacaggu 
               
               
                 uuaaugguauaggaguuacucagaauguccuguacgaaaaucaaaagcugaucgccaaucaauucaacagugcuauugg 
               
               
                 gaaaauacaggacaguuugaguucaacagcgagcgcucucggcaaacugcaggauguugugaaucaaaacgcgcaagcuu 
               
               
                 ugaacacucuugugaagcagcuuucauccaacuucggagcgaucucauccguccugaacgacauauugucaagacuugac 
               
               
                 ccaccugaagcggaaguucagauagaccgacucauaacgggccgacuucaguccuugcagacauacgugacccaacaacu 
               
               
                 uauccgcgcagccgaaauaagggcuucagcuaaccuugcagcaaccaaaaugucagagugcgugcucggucaaagcaagc 
               
               
                 ggguagacuuuuguggcaagggguaucaucuuauguccuuuccucaauccgccccucacgggguggucuucuugcacu 
               
               
                 gcacuuauguaccugcucaagagaagaauuuuacgaccgccccugcgaucugucacgacgggaaagcacauuucccccgc 
               
               
                 gagggagucuuugugucuaaugguacucauugguuuguuacgcagcggaacuuuuacgaaccucaaauaauuacaacgg 
               
               
                 auaauacagauguuagugggaauugcgacguggugaucgguauagucaacaauacgguguaugauccacuucaaccaga 
               
               
                 acuugauuccuuuaaggaagagcuggacaaauauuucaagaaccauacauccccugacguggaccuuggcgauauaagcg 
               
               
                 gcauuaaugcuucaguggucaauauacaaaaggaaaucgaucgccugaaugaggucgcaaagaauuugaaugagucccu 
               
               
                 gaucgaccugcaagagcucgggaaauaugagcaguacaucaaguggcccuggucagguagacguaggcggcgccggggc 
               
               
                 aguggcggcucagggagcgguuauauacccgaagccccuagagaugggcaagcuuauguccgaaaggacggcgaauggg 
               
               
                 ugcuccuuuccacuuucuugggauaauag (SEQ ID NO: 138) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSS C LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KS G IIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV NG T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRD C A G TTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHA G QLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR R RSVASQSIIAYTMSLCAENSVAYSNNSIAIPTNFTISCTTEILPVSMT 
               
               
                 KTS C DCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQCY 
               
               
                 KTPPIKDFGGFNFSQILPDPSRRRRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNG C TVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISSVLNDILSRLD PP EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLH C TYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT D VSGNCDVVIGIVNNTV 
               
               
                 YDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNE 
               
               
                 SLIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVL 
               
               
                 LSTFLG** (SEQ ID NO: 139) 
               
               
                   
               
               
                 WuS_3F_2P_Gly_pVax 
               
               
                 ggatccgccaccatggattggacctggatacttttcctcgtggccgcagcaacaagagtccactccatgttcgtcttcttggtacttttgcc 
               
               
                 actcgtcagttctcagtgcgttaacctgactactagaacccaattgcccccggcatacacaaactctttcacccggggtgtctactatccc 
               
               
                 gacaaagtgtttagaagtagcgtgctgcacagcacccaagatctctttctgccattcttctcaaacgtcacctggtttcacgccatccatgt 
               
               
                 aagcgggaccaacggcacaaagcgttttgataaccctgttttgccattcaatgatggcgtgtattttgcttccactgagaaaagcaacatc 
               
               
                 attagagggtggatatttggcacaacgcttgactccaagacgcagagtcttttgatagtaaacaacgcaactaatgtggtcattaaagtct 
               
               
                 gtgaatttcaattttgcaatgaccccttccttggagtctattaccacaagaacaacaaaagctggatggaaagcgaatttagggtctacag 
               
               
                 ctctgccaataactgcacattcgaatacgtcagccaaccattcttgatggacctggaaggcaagcaaggaaactttaagaatctgaggg 
               
               
                 aatttgtgtttaagaatatcgacggatattttaagatctattccaagcatactcccattaatctcgttcgtgaccttcctcagggtttctctgcat 
               
               
                 tggaacccctcgtagatttgcccattgggattaatatcactagattccagacgctgcttgcactccatcgatcttatctgacccctggtgac 
               
               
                 tcctcttccgggtggacggcgggtgctgcagcctactacgttggctatttgcaacctaggacctttctgttgaagtataatgagaatggga 
               
               
                 ctattactgatgccgttgattgcgccctcgatccgctgtcagaaacaaagtgcaccctgaagagcttcacagtagaaaagggaatctatc 
               
               
                 aaacctcaaatttccgcgttcaaccaactgaatcaatcgtgcgttttcctaacatcacaaatctgtgtccgtttggagaagtatttaatgcga 
               
               
                 cgcgtttcgcaagcgtctacgcgtggaatcgcaaacgtatctctaattgcgtagcagattattctgtgctgtacaatagcgcatctttctca 
               
               
                 acgtttaagtgctacggcgttaatgggaccaagctgaatgatctctgtttcactaatgtgtacgcagacagttttgtaattagaggagacg 
               
               
                 aggttaggcaaatagcaccgggtcaaactggcaaaatcgccgactataactacaagctccctgatgacttcacgggctgcgtaattgct 
               
               
                 tggaactctaataacctggactctaaagtcggcgggaattataattatctctatcggttgtttcgaaaatccaatctcaaaccctttgagcg 
               
               
                 ggacatcaatactacaatttatcaagctggtagtactccttgcaatggggtagaaggcttcaattgttatttcccccttcaatcttacggattt 
               
               
                 caacccacgaacggcgtagggtaccagccctatcgagtggtggtactgtcattcgaacttaatcacgccccagcaacagtctgcggg 
               
               
                 cctaagaaaagcacgaatcttgtcaagaataagtgtgtaaatttcaacttcaatggtcttacaggcacgggagtgctcactgagtctaata 
               
               
                 agaaatttcttcctttccaacaattcggtcgtgatattgccgatactactgatgcagtccgagatccacaaactctcgaaatcctcgatatta 
               
               
                 ctccttgtagttttggcggcgtctccgtgatcaccccagggaccaacactagtaaccaagtggcggtgctctaccaagatgttaactgca 
               
               
                 cagaagtcccggtagcgatccatgccgaccagctcactcccacatggcgtgtttacagcacagggtcaaacgttttccagacccgtgc 
               
               
                 cggatgtcttataggagccgaacacgtaaataacagttatgaatgcgatatcccaattggtgcaggtatctgtgcgtcatatcaaaccca 
               
               
                 aactaattctccgagacgacgacggagcgttgcctcacaatcaataatcgcctacacaatgtccctcggtgccgaaaattcagtcgctta 
               
               
                 ctctaacaatagcattgctatccctaccaacttcactatttctgttaccacggaaattttgcctgtatccatgaccaaaacatctgttgattgc 
               
               
                 acgatgtacatctgcggggattctaccgaatgttctaacctgcttctgcaatacggctccttctgcacccaattgaaccgcgcactgactg 
               
               
                 ggattgctgtggaacaagacaagaatactcaagaagtatttgcccaggtcaaacagatttacaaaactcccccaattaaagatttcggc 
               
               
                 ggtttcaattttagtcaaattctgccagatccaagtcgacgccgcaggagctttattgaggacctgctctttaataaagtcacgctggccg 
               
               
                 acgccggcttcataaaacagtatggcgattgtcttggagacatcgccgcccgcgacctcatttgcgcacaaaagttcaatgggctcacc 
               
               
                 gtgttgccaccactgctcacagatgagatgatcgcacagtacacgagcgcccttcttgccggcactatcacgtctggttggacgttcgg 
               
               
                 tgccggagccgctctgcaaattccctttgcaatgcaaatggcctatagatttaatggaattggcgtaacacagaacgtgttgtacgagaa 
               
               
                 ccagaagctcattgccaaccagttcaattccgctattggcaaaatacaagactctctcagctcaactgctagcgcactgggaaaattgca 
               
               
                 agacgtagtcaatcaaaatgcccaagccctcaatactctcgtcaaacagttgtcttccaactttggggctatcagtagtgtactcaatgac 
               
               
                 attctttcaagactggacccgcccgaggcggaagtccaaattgatcgtctgataactggaaggttgcaaagccttcagacctacgttac 
               
               
                 gcaacaacttattagggctgccgaaataagggcatccgctaatctggcagctacaaagatgtctgaatgtgttttgggacagagcaaac 
               
               
                 gggttgacttctgcggtaaaggttaccatctcatgtcttttccacaaagcgcaccgcacggagtcgtcttcctgcatgtaacatacgtccc 
               
               
                 agcccaagaaaagaattttaccacagccccagccatctgccacgacggcaaggcgcatttcccaagggaaggcgtgtttgtatccaa 
               
               
                 cgggacgcattggtttgtcactcaaaggaacttttacgaaccccaaattattaccactgataacaccttcgtttctgggaactgtgatgtcg 
               
               
                 tgattgggatagtaaacaacacggtatatgatccactgcaaccagaactggattccttcaaagaagagctggacaaatacttcaagaat 
               
               
                 catactagtcctgacgtcgacctgggcgatatcagtggaatcaacgctagcgtcgtaaacattcaaaaggagatcgatagacttaacga 
               
               
                 ggtcgccaagaatctcaatgaaagcctcatcgatttgcaagaactcggaaaatatgagcaatacataaaatggccatggtctggcagg 
               
               
                 agaagacgcaggagaggtagcggcggcagcggatcagggtacattccggaagcccccagggacggacaggcatatgtccgcaa 
               
               
                 ggacggagaatgggttcttcttagcacttttctggggtaataa (SEQ ID NO: 140) 
               
               
                   
               
               
                 ggauccgccaccauggauuggaccuggauacuuuuccucguggccgcagcaacaagaguccacuccauguucgucuucu 
               
               
                 ugguacuuuugccacucgucaguucucagugcguuaaccugacuacuagaacccaauugcccccggcauacacaaacucu 
               
               
                 uucacccggggugucuacuaucccgacaaaguguuuagaaguagcgugcugcacagcacccaagaucucuuucugccau 
               
               
                 ucuucucaaacgucaccugguuucacgccauccauguaagcgggaccaacggcacaaagcguuuugauaacccuguuuu 
               
               
                 gccauucaaugauggcguguauuuugcuuccacugagaaaagcaacaucauuagaggguggauauuuggcacaacgcuu 
               
               
                 gacuccaagacgcagagucuuuugauaguaaacaacgcaacuaauguggucauuaaagucugugaauuucaauuuugca 
               
               
                 augaccccuuccuuggagucuauuaccacaagaacaacaaaagcuggauggaaagcgaauuuagggucuacagcucugcc 
               
               
                 aauaacugcacauucgaauacgucagccaaccauucuugauggaccuggaaggcaagcaaggaaacuuuaagaaucugag 
               
               
                 ggaauuuguguuuaagaauaucgacggauauuuuaagaucuauuccaagcauacucccauuaaucucguucgugaccuu 
               
               
                 ccucaggguuucucugcauuggaaccccucguagauuugcccauugggauuaauaucacuagauuccagacgcugcuug 
               
               
                 cacuccaucgaucuuaucugaccccuggugacuccucuuccggguggacggcgggugcugcagccuacuacguuggcua 
               
               
                 uuugcaaccuaggaccuuucuguugaaguauaaugagaaugggacuauuacugaugccguugauugcgcccucgauccg 
               
               
                 cugucagaaacaaagugcacccugaagagcuucacaguagaaaagggaaucuaucaaaccucaaauuuccgcguucaacc 
               
               
                 aacugaaucaaucgugcguuuuccuaacaucacaaaucuguguccguuuggagaaguauuuaaugcgacgcguuucgca 
               
               
                 agcgucuacgcguggaaucgcaaacguaucucuaauugcguagcagauuauucugugcuguacaauagcgcaucuuucu 
               
               
                 caacguuuaagugcuacggcguuaaugggaccaagcugaaugaucucuguuucacuaauguguacgcagacaguuuugu 
               
               
                 aauuagaggagacgagguuaggcaaauagcaccgggucaaacuggcaaaaucgccgacuauaacuacaagcucccugaug 
               
               
                 acuucacgggcugcguaauugcuuggaacucuaauaaccuggacucuaaagucggcgggaauuauaauuaucucuaucg 
               
               
                 guuguuucgaaaauccaaucucaaacccuuugagcgggacaucaauacuacaauuuaucaagcugguaguacuccuugca 
               
               
                 augggguagaaggcuucaauuguuauuucccccuucaaucuuacggauuucaacccacgaacggcguaggguaccagcc 
               
               
                 cuaucgaguggugguacugucauucgaacuuaaucacgccccagcaacagucugcgggccuaagaaaagcacgaaucuug 
               
               
                 ucaagaauaaguguguaaauuucaacuucaauggucuuacaggcacgggagugcucacugagucuaauaagaaauuucu 
               
               
                 uccuuuccaacaauucggucgugauauugccgauacuacugaugcaguccgagauccacaaacucucgaaauccucgaua 
               
               
                 uuacuccuuguaguuuuggcggcgucuccgugaucaccccagggaccaacacuaguaaccaaguggcggugcucuacca 
               
               
                 agauguuaacugcacagaagucccgguagcgauccaugccgaccagcucacucccacauggcguguuuacagcacagggu 
               
               
                 caaacguuuuccagacccgugccggaugucuuauaggagccgaacacguaaauaacaguuaugaaugcgauaucccaauu 
               
               
                 ggugcagguaucugugcgucauaucaaacccaaacuaauucuccgagacgacgacggagcguugccucacaaucaauaau 
               
               
                 cgccuacacaaugucccucggugccgaaaauucagucgcuuacucuaacaauagcauugcuaucccuaccaacuucacua 
               
               
                 uuucuguuaccacggaaauuuugccuguauccaugaccaaaacaucuguugauugcacgauguacaucugcggggauuc 
               
               
                 uaccgaauguucuaaccugcuucugcaauacggcuccuucugcacccaauugaaccgcgcacugacugggauugcugug 
               
               
                 gaacaagacaagaauacucaagaaguauuugcccaggucaaacagauuuacaaaacucccccaauuaaagauuucggcgg 
               
               
                 uuucaauuuuagucaaauucugccagauccaagucgacgccgcaggagcuuuauugaggaccugcucuuuaauaaaguc 
               
               
                 acgcuggccgacgccggcuucauaaaacaguauggcgauugucuuggagacaucgccgcccgcgaccucauuugcgcaca 
               
               
                 aaaguucaaugggcucaccguguugccaccacugcucacagaugagaugaucgcacaguacacgagcgcccuucuugccg 
               
               
                 gcacuaucacgucugguuggacguucggugccggagccgcucugcaaauucccuuugcaaugcaaauggccuauagauu 
               
               
                 uaauggaauuggcguaacacagaacguguuguacgagaaccagaagcucauugccaaccaguucaauuccgcuauuggca 
               
               
                 aaauacaagacucucucagcucaacugcuagcgcacugggaaaauugcaagacguagucaaucaaaaugcccaagcccuca 
               
               
                 auacucucgucaaacaguugucuuccaacuuuggggcuaucaguaguguacucaaugacauucuuucaagacuggaccc 
               
               
                 gcccgaggcggaaguccaaauugaucgucugauaacuggaagguugcaaagccuucagaccuacguuacgcaacaacuua 
               
               
                 uuagggcugccgaaauaagggcauccgcuaaucuggcagcuacaaagaugucugaauguguuuugggacagagcaaacg 
               
               
                 gguugacuucugcgguaaagguuaccaucucaugucuuuuccacaaagcgcaccgcacggagucgucuuccugcaugua 
               
               
                 acauacgucccagcccaagaaaagaauuuuaccacagccccagccaucugccacgacggcaaggcgcauuucccaagggaa 
               
               
                 ggcguguuuguauccaacgggacgcauugguuugucacucaaaggaacuuuuacgaaccccaaauuauuaccacugaua 
               
               
                 acaccuucguuucugggaacugugaugucgugauugggauaguaaacaacacgguauaugauccacugcaaccagaacu 
               
               
                 ggauuccuucaaagaagagcuggacaaauacuucaagaaucauacuaguccugacgucgaccugggcgauaucaguggaa 
               
               
                 ucaacgcuagcgucguaaacauucaaaaggagaucgauagacuuaacgaggucgccaagaaucucaaugaaagccucauc 
               
               
                 gauuugcaagaacucggaaaauaugagcaauacauaaaauggccauggucuggcaggagaagacgcaggagagguagcg 
               
               
                 gcggcagcggaucaggguacauuccggaagcccccagggacggacaggcauauguccgcaaggacggagaauggguucu 
               
               
                 ucuuagcacuuuucugggguaauaa (SEQ ID NO: 141) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV NG T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR R RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISSVLNDILSRLD PP EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 142) 
               
               
                   
               
               
                 WuS_3F_2P_NoClev_pVax 
               
               
                 ggatccgccaccatggattggacgtggattctgtttctggtggccgcagcgacaagggtgcattcaatgtttgtgttcctggtcctgctgc 
               
               
                 cactggtctcatcacagtgtgtaaacctgactacaagaacgcagcttccgcctgcctacacgaacagcttcaccaggggagtgtattat 
               
               
                 cctgacaaagtctttaggagctctgttctccactccactcaagacctgtttctgcccttcttcagtaacgtgacttggtttcacgcaatacat 
               
               
                 gtctccggcacaaatggaaccaaaagattcgataaccctgttctcccattcaatgatggagtatattttgctagcactgaaaagtctaacat 
               
               
                 tattagaggctggatatttggcacgacattggactccaagacgcaaagtctcttgattgtgaacaacgcaacaaacgtggtgataaaagt 
               
               
                 ttgcgaattccaattttgcaatgacccattcctgggagtttactaccacaagaataacaaaagctggatggaatccgagttccgggtttact 
               
               
                 cctctgctaacaactgtacctttgagtatgtgagtcaaccattccttatggatctcgaaggaaaacaaggtaacttcaagaacctgaggg 
               
               
                 agtttgtgtttaagaatatcgatggctattttaagatttatagcaaacacactccgattaatctggtgagagatctcccgcaaggattttctgc 
               
               
                 tttggagccattggttgacttgcctattggaatcaacatcacccgttttcaaactctgcttgcgctgcatagatcctaccttacgcctggcga 
               
               
                 ttcaagcagtggctggaccgcgggagcggccgcctattatgtaggctacttgcagcctcgcacctttctcctcaagtacaatgaaaacg 
               
               
                 gcacaattacagacgcagtggattgtgctctggaccccctcagtgaaactaaatgtaccctgaaaagcttcactgttgagaaaggcatat 
               
               
                 atcaaacctcaaactttagagtgcaacctactgaaagcattgtaagattccctaacattacaaacctgtgcccctttggcgaagtctttaat 
               
               
                 gcaacccggtttgctagcgtgtatgcttggaaccgcaagaggatatccaattgcgtcgcagattattccgtcctgtataactctgccagct 
               
               
                 ttagtaccttcaaatgttatggggtatctcccacaaaactcaatgatctttgtttcacaaatgtctatgctgactcctttgttatcagagggga 
               
               
                 cgaagttcgccaaattgctccaggtcaaacaggaaagattgcagattataactacaagcttcccgacgattttacaggttgtgtgatagct 
               
               
                 tggaactccaataatctggattccaaggtaggcgggaactacaattatctctacaggctcttccggaaatccaatctcaagccgttcgaa 
               
               
                 agggatataagcactgagatctatcaagcaggcagtacaccctgtaacggagtagagggcttcaactgctactttccactgcaatcctat 
               
               
                 gggtttcaaccgactaacggtgtcgggtaccaaccctatcgtgtcgtggtcctgtcctttgagcttctgcacgctcctgctaccgtttgcg 
               
               
                 gccccaagaaaagcacgaatttggtcaagaacaaatgtgtcaactttaacttcaacggattgacagggaccggagtattgaccgaatct 
               
               
                 aataagaaatttctgcccttccaacaattcggacgggacatagcagacacaaccgatgctgtcagggacccacagacacttgaaatac 
               
               
                 tcgatatcaccccatgcagctttggcggagtctcagtcattacgcctggcaccaatacttccaatcaagttgcagtgctctatcaggatgt 
               
               
                 caattgtactgaggtccccgtcgccatccacgcggatcaacttacccccacatggcgagtatatagtaccgggagcaacgtctttcaaa 
               
               
                 cccgagcaggatgtctgataggtgccgaacacgtaaacaacagctacgaatgtgatatcccgatcggcgcagggatttgcgctagct 
               
               
                 accaaacccaaactaattctccgcgccgccgcaggtccgtagcaagtcaatcaataatagcatacaccatgtcattgggagctgaaaa 
               
               
                 cagcgtggcatatagcaacaattccatagctatccctacaaatttcacgatttctgttaccaccgaaattctgccagtgagcatgaccaaa 
               
               
                 acctcagtggattgtacgatgtacatatgcggcgattccacggaatgttccaatctccttttgcaatacggcagcttttgtacccaactgaa 
               
               
                 tagagctctgacgggtatagcagtagagcaggataagaacactcaagaggtgtttgcccaggtcaaacaaatttacaagactccccca 
               
               
                 ataaaagactttggcggcttcaatttcagccaaatcttgccagacccttccaggcggcggcgctcatttatcgaagatttgcttttcaataa 
               
               
                 agtcaccctggccgacgccggatttattaaacaatacggcgattgtctgggcgacatcgccgcaagggacctcatctgtgcgcaaaag 
               
               
                 ttcaatggcctgacggtgcttccaccactcctgactgatgagatgattgcccaatacacatctgccctgctggctggtacaataacgagt 
               
               
                 gggtggacctttggggctggagcagcattgcaaattccattcgccatgcaaatggcatatcgttttaacggcattggagtgactcaaaat 
               
               
                 gtgctgtatgaaaaccaaaagcttattgcaaatcagtttaattccgccattggcaaaatccaggatagcctcagtagtacagcaagcgcc 
               
               
                 ttggggaaactgcaagatgtggttaatcaaaatgcacaagctctcaataccctggtcaagcaacttagtagtaactttggtgccatcagc 
               
               
                 agcgttctcaacgacatcctgagtcgtcttgatcccccagaggcagaggttcaaattgaccggcttatcactggaaggcttcaatccctg 
               
               
                 caaacttacgtgactcagcaactgatacgcgctgcagaaattcgggcctcagcaaaccttgccgcgacaaagatgagcgaatgcgtg 
               
               
                 ctgggacaatccaagcgggtcgacttttgtggtaaaggctatcatctgatgagcttcccacagtccgctccacacggcgtcgttttcctg 
               
               
                 cacgtgacctatgtgccagcacaggagaagaactttacaacagccccggctatctgccacgatggcaaagctcactttcctagagagg 
               
               
                 gagtgtttgtaagcaatggaacccattggttcgttacacaaagaaacttttatgagccgcaaattatcacaacagataatacattcgtctcc 
               
               
                 gggaactgtgacgttgtgatagggattgtcaacaacacagtgtacgaccccctgcaacccgagctggattcatttaaagaagaactcg 
               
               
                 acaagtacttcaagaatcatactagtccagatgtggatctgggcgatatatcaggaatcaatgccagcgtggtcaatattcaaaaggag 
               
               
                 attgatagactgaacgaggttgccaagaatctgaatgaaagcctgatcgatctgcaagaattgggcaagtatgagcagtacattaaatg 
               
               
                 gccctggtctggcgggagcggcggatctgggtctggatatattcccgaagctcctagagatggacaagcttacgtccgtaaagacgg 
               
               
                 cgagtgggttcttctctccacattcctcggctgatga (SEQ ID NO: 143) 
               
               
                   
               
               
                 ggauccgccaccauggauuggacguggauucuguuucugguggccgcagcgacaagggugcauucaauguuuguguuc 
               
               
                 cugguccugcugccacuggucucaucacaguguguaaaccugacuacaagaacgcagcuuccgccugccuacacgaacag 
               
               
                 cuucaccaggggaguguauuauccugacaaagucuuuaggagcucuguucuccacuccacucaagaccuguuucugccc 
               
               
                 uucuucaguaacgugacuugguuucacgcaauacaugucuccggcacaaauggaaccaaaagauucgauaacccuguucu 
               
               
                 cccauucaaugauggaguauauuuugcuagcacugaaaagucuaacauuauuagaggcuggauauuuggcacgacauug 
               
               
                 gacuccaagacgcaaagucucuugauugugaacaacgcaacaaacguggugauaaaaguuugcgaauuccaauuuugcaa 
               
               
                 ugacccauuccugggaguuuacuaccacaagaauaacaaaagcuggauggaauccgaguuccggguuuacuccucugcu 
               
               
                 aacaacuguaccuuugaguaugugagucaaccauuccuuauggaucucgaaggaaaacaagguaacuucaagaaccugag 
               
               
                 ggaguuuguguuuaagaauaucgauggcuauuuuaagauuuauagcaaacacacuccgauuaaucuggugagagaucuc 
               
               
                 ccgcaaggauuuucugcuuuggagccauugguugacuugccuauuggaaucaacaucacccguuuucaaacucugcuug 
               
               
                 cgcugcauagauccuaccuuacgccuggcgauucaagcaguggcuggaccgcgggagcggccgccuauuauguaggcua 
               
               
                 cuugcagccucgcaccuuucuccucaaguacaaugaaaacggcacaauuacagacgcaguggauugugcucuggaccccc 
               
               
                 ucagugaaacuaaauguacccugaaaagcuucacuguugagaaaggcauauaucaaaccucaaacuuuagagugcaaccu 
               
               
                 acugaaagcauuguaagauucccuaacauuacaaaccugugccccuuuggcgaagucuuuaaugcaacccgguuugcua 
               
               
                 gcguguaugcuuggaaccgcaagaggauauccaauugcgucgcagauuauuccguccuguauaacucugccagcuuuag 
               
               
                 uaccuucaaauguuaugggguaucucccacaaaacucaaugaucuuuguuucacaaaugucuaugcugacuccuuuguu 
               
               
                 aucagaggggacgaaguucgccaaauugcuccaggucaaacaggaaagauugcagauuauaacuacaagcuucccgacga 
               
               
                 uuuuacagguugugugauagcuuggaacuccaauaaucuggauuccaagguaggcgggaacuacaauuaucucuacagg 
               
               
                 cucuuccggaaauccaaucucaagccguucgaaagggauauaagcacugagaucuaucaagcaggcaguacacccuguaa 
               
               
                 cggaguagagggcuucaacugcuacuuuccacugcaauccuauggguuucaaccgacuaacggugucggguaccaaccc 
               
               
                 uaucgugucgugguccuguccuuugagcuucugcacgcuccugcuaccguuugcggccccaagaaaagcacgaauuugg 
               
               
                 ucaagaacaaaugugucaacuuuaacuucaacggauugacagggaccggaguauugaccgaaucuaauaagaaauuucug 
               
               
                 cccuuccaacaauucggacgggacauagcagacacaaccgaugcugucagggacccacagacacuugaaauacucgauau 
               
               
                 caccccaugcagcuuuggcggagucucagucauuacgccuggcaccaauacuuccaaucaaguugcagugcucuaucagg 
               
               
                 augucaauuguacugagguccccgucgccauccacgcggaucaacuuacccccacauggcgaguauauaguaccgggagc 
               
               
                 aacgucuuucaaacccgagcaggaugucugauaggugccgaacacguaaacaacagcuacgaaugugauaucccgaucgg 
               
               
                 cgcagggauuugcgcuagcuaccaaacccaaacuaauucuccgcgccgccgcagguccguagcaagucaaucaauaauag 
               
               
                 cauacaccaugucauugggagcugaaaacagcguggcauauagcaacaauuccauagcuaucccuacaaauuucacgauu 
               
               
                 ucuguuaccaccgaaauucugccagugagcaugaccaaaaccucaguggauuguacgauguacauaugcggcgauuccac 
               
               
                 ggaauguuccaaucuccuuuugcaauacggcagcuuuuguacccaacugaauagagcucugacggguauagcaguagag 
               
               
                 caggauaagaacacucaagagguguuugcccaggucaaacaaauuuacaagacucccccaauaaaagacuuuggcggcuu 
               
               
                 caauuucagccaaaucuugccagacccuuccaggcggcggcgcucauuuaucgaagauuugcuuuucaauaaagucaccc 
               
               
                 uggccgacgccggauuuauuaaacaauacggcgauugucugggcgacaucgccgcaagggaccucaucugugcgcaaaa 
               
               
                 guucaauggccugacggugcuuccaccacuccugacugaugagaugauugcccaauacacaucugcccugcuggcuggu 
               
               
                 acaauaacgaguggguggaccuuuggggcuggagcagcauugcaaauuccauucgccaugcaaauggcauaucguuuua 
               
               
                 acggcauuggagugacucaaaaugugcuguaugaaaaccaaaagcuuauugcaaaucaguuuaauuccgccauuggcaaa 
               
               
                 auccaggauagccucaguaguacagcaagcgccuuggggaaacugcaagaugugguuaaucaaaaugcacaagcucucaa 
               
               
                 uacccuggucaagcaacuuaguaguaacuuuggugccaucagcagcguucucaacgacauccugagucgucuugauccc 
               
               
                 ccagaggcagagguucaaauugaccggcuuaucacuggaaggcuucaaucccugcaaacuuacgugacucagcaacugau 
               
               
                 acgcgcugcagaaauucgggccucagcaaaccuugccgcgacaaagaugagcgaaugcgugcugggacaauccaagcggg 
               
               
                 ucgacuuuugugguaaaggcuaucaucugaugagcuucccacaguccgcuccacacggcgucguuuuccugcacgugac 
               
               
                 cuaugugccagcacaggagaagaacuuuacaacagccccggcuaucugccacgauggcaaagcucacuuuccuagagagg 
               
               
                 gaguguuuguaagcaauggaacccauugguucguuacacaaagaaacuuuuaugagccgcaaauuaucacaacagauaau 
               
               
                 acauucgucuccgggaacugugacguugugauagggauugucaacaacacaguguacgacccccugcaacccgagcugg 
               
               
                 auucauuuaaagaagaacucgacaaguacuucaagaaucauacuaguccagauguggaucugggcgauauaucaggaauc 
               
               
                 aaugccagcguggucaauauucaaaaggagauugauagacugaacgagguugccaagaaucugaaugaaagccugaucg 
               
               
                 aucugcaagaauugggcaaguaugagcaguacauuaaauggcccuggucuggcgggagcggcggaucugggucuggau 
               
               
                 auauucccgaagcuccuagagauggacaagcuuacguccguaaagacggcgaguggguucuucucuccacauuccucgg 
               
               
                 cugauga (SEQ ID NO: 144) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRR R RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC 
               
               
                 AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG 
               
               
                 IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ 
               
               
                 LSSNFGAISSVLNDILSRLD PP EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLA 
               
               
                 ATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 
               
               
                 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGGSGGSGSGYIPEAPRDGQAYVRKDGEWVLLSTFLG** 
               
               
                 (SEQ ID NO: 145) 
               
               
                   
               
               
                 WuS_3F_2P_pVax 
               
               
                 ggatccgccaccatggattggacctggattctctttcttgtggcggcggcaacacgcgtccacagcatgttcgtctttctggtattgctgc 
               
               
                 cgcttgtgagtagccagtgtgtgaacttgactaccaggacccagctcccaccggcttataccaattccttcacaagaggtgtctactatc 
               
               
                 cagataaagttttccgcagctcagtgttgcatagcacacaggatctctttctgccattcttcagcaacgtcacgtggtttcatgcgatacac 
               
               
                 gttagtggaacaaacggaacaaaacgcttcgacaaccctgttctgccattcaatgacggagtttactttgcgagtaccgagaaatctaac 
               
               
                 atcattagagggtggatctttgggactacattggattctaaaacccagtcactcctcatagtcaataacgctacaaatgtggtgattaaggt 
               
               
                 atgcgaatttcagttttgcaacgacccatttctcggtgtatattatcacaagaataataaaagttggatggagtccgagttccgcgtctattc 
               
               
                 atcagccaataattgtactttcgaatatgtttctcaaccgtttctcatggatctcgaaggaaagcaagggaattttaagaatctccgggagtt 
               
               
                 tgtcttcaagaacatagatggctattttaaaatttactcaaagcatactcctattaacctcgttcgggatctcccccagggttttagcgccct 
               
               
                 ggagccactggttgatctgccaattgggattaatatcacacgctttcaaactctcctggcccttcacagatcttacttgaccccaggtgatt 
               
               
                 caagtagtggttggacagctggagctgctgcatattatgtaggttatctccaaccccgcacctttctcctcaaatataacgagaacggca 
               
               
                 ccattacagatgcggtggactgtgccttggaccctctttctgagaccaagtgcacactcaaaagcttcactgtcgaaaaggggatttacc 
               
               
                 agacatcaaattttagagttcaacccaccgaaagcattgtgagatttcctaacattacaaacttgtgcccatttggggaagtctttaacgct 
               
               
                 acacgctttgctagcgtctatgcttggaaccgaaaacggattagtaactgcgtagctgattattccgtcttgtacaacagcgcatcttttag 
               
               
                 cactttcaagtgttatggagtaagcccaacaaagctcaacgacctttgttttactaacgtctatgctgattcattcgtgattcgtggggatga 
               
               
                 ggttcgtcagatcgccccaggccaaaccgggaaaatcgctgattataattataaattgcctgacgattttaccggctgtgtaatcgcctg 
               
               
                 gaattccaacaatcttgattccaaggttggcggcaactacaactatctctaccgtctgtttcgcaaatccaatctcaagcccttcgaacgc 
               
               
                 gatatttcaactgaaatctatcaggcagggtccactccgtgtaacggcgtagaaggatttaattgttacttcccattgcaaagttatggcttt 
               
               
                 caacccaccaacggagtcgggtaccaaccatacagagtcgtcgtgctctcatttgagctccttcatgcacctgccacggtgtgcggcc 
               
               
                 caaagaaatcaacgaaccttgtgaagaataaatgtgtcaattttaactttaatggcctgacagggactggcgtcctcacagaatctaataa 
               
               
                 gaagtttctccctttccagcaatttggtcgcgatatagctgataccacagatgcagttagagacccacagacacttgagattctcgatatta 
               
               
                 ccccgtgctcctttggcggcgtgtccgtcattactcccggtaccaatacgtctaaccaggtagcagtgctctaccaagatgtaaattgtac 
               
               
                 tgaggtacccgtggcaatccatgccgaccaactgactccaacgtggcgggtttattcaaccggaagcaacgtgtttcaaacacgggct 
               
               
                 ggctgccttataggcgctgagcacgtgaataatagttacgagtgtgatatcccgatcggagccggcatctgtgcatcttatcaaacacaa 
               
               
                 acaaactccccgcgccggcggagaagcgtggctagccaaagtataatcgcttatacaatgtccttgggcgcggaaaattcagtggctt 
               
               
                 attccaataattcaattgccattcctaccaactttacaattagcgtgaccacagaaatcttgcctgtgtctatgaccaagaccagcgtcgatt 
               
               
                 gcaccatgtatatctgtggagatagcaccgagtgttcaaatttgctcctgcaatacggttccttttgtacacagcttaaccgcgccctcaca 
               
               
                 ggtattgctgttgaacaagacaagaatactcaagaggtatttgctcaggtaaaacaaatttataagaccccaccgataaaagattttggc 
               
               
                 ggtttcaatttctcccaaatattgccagatcctagtaggcgtcgtagatcatttatcgaggatctcctgttcaataaagtaaccctcgccgac 
               
               
                 gctggtttcatcaaacaatatggcgactgcctgggagatattgcagctagggatttgatttgtgcacagaagttcaatggactcaccgttc 
               
               
                 tcccgcctctcctgacagatgagatgattgcacaatacacctctgctcttttggccgggaccattacgagcggttggacttttggcgcgg 
               
               
                 gtgcggctctccaaattcctttcgcgatgcaaatggcgtatagatttaatggaattggcgttactcaaaacgtcttgtacgagaatcagaa 
               
               
                 actgatcgccaaccaatttaacagtgcaattggcaaaatccaagatagccttagttctactgcttcagcattgggtaagttgcaagatgtg 
               
               
                 gtcaaccaaaacgcacaagcactcaataccctcgtgaagcaattgtccagcaattttggagctatctcaagtgtgctcaacgacatccttt 
               
               
                 ctaggcttgatccacccgaggcagaggttcaaatcgacagactgataactggcaggctccaatctctgcaaacgtacgtgacacagca 
               
               
                 actgattagggctgctgagatcagggcgtccgcgaatttggcagcaaccaaaatgagcgaatgcgtgctgggacaatcaaagagagt 
               
               
                 tgatttctgtggaaagggttaccatctcatgtccttccctcaatcagctccccatggagttgtgtttctgcacgttacttacgtgccggcaca 
               
               
                 agaaaagaatttcaccactgcaccggctatatgtcatgatgggaaagcccacttcccgcgggaaggcgttttcgtgtccaacgggact 
               
               
                 cattggttcgtcacacaaaggaacttctatgagccacaaataattacaacagacaacacctttgtctctgggaactgcgatgtcgtgattg 
               
               
                 gaatcgtgaacaacactgtctacgatccgctgcaacccgaactcgactcattcaaagaggaactggataagtatttcaagaaccatacc 
               
               
                 agccccgatgtcgatctgggcgatatctccgggataaatgcttcagtagtaaacattcaaaaggaaatcgaccggctgaacgaggttg 
               
               
                 cgaagaatcttaatgagtcattgatcgacctgcaagaacttggtaagtatgagcagtacatcaagtggccttggtcaggccgcaggcgt 
               
               
                 cggcgtcgtgggagcggcggcagtgggagcggatatattccagaagcgccccgagacggacaagcttacgtacgaaaagacgga 
               
               
                 gaatgggtactgctttccacttttcttggctaatga (SEQ ID NO: 146) 
               
               
                   
               
               
                 ggauccgccaccauggauuggaccuggauucucuuucuuguggcggcggcaacacgcguccacagcauguucgucuuuc 
               
               
                 ugguauugcugccgcuugugaguagccagugugugaacuugacuaccaggacccagcucccaccggcuuauaccaauuc 
               
               
                 cuucacaagaggugucuacuauccagauaaaguuuuccgcagcucaguguugcauagcacacaggaucucuuucugcca 
               
               
                 uucuucagcaacgucacgugguuucaugcgauacacguuaguggaacaaacggaacaaaacgcuucgacaacccuguucu 
               
               
                 gccauucaaugacggaguuuacuuugcgaguaccgagaaaucuaacaucauuagaggguggaucuuugggacuacauug 
               
               
                 gauucuaaaacccagucacuccucauagucaauaacgcuacaaauguggugauuaagguaugcgaauuucaguuuugca 
               
               
                 acgacccauuucucgguguauauuaucacaagaauaauaaaaguuggauggaguccgaguuccgcgucuauucaucagc 
               
               
                 caauaauuguacuuucgaauauguuucucaaccguuucucauggaucucgaaggaaagcaagggaauuuuaagaaucuc 
               
               
                 cgggaguuugucuucaagaacauagauggcuauuuuaaaauuuacucaaagcauacuccuauuaaccucguucgggauc 
               
               
                 ucccccaggguuuuagcgcccuggagccacugguugaucugccaauugggauuaauaucacacgcuuucaaacucuccu 
               
               
                 ggcccuucacagaucuuacuugaccccaggugauucaaguagugguuggacagcuggagcugcugcauauuauguaggu 
               
               
                 uaucuccaaccccgcaccuuucuccucaaauauaacgagaacggcaccauuacagaugcgguggacugugccuuggaccc 
               
               
                 ucuuucugagaccaagugcacacucaaaagcuucacugucgaaaaggggauuuaccagacaucaaauuuuagaguucaac 
               
               
                 ccaccgaaagcauugugagauuuccuaacauuacaaacuugugcccauuuggggaagucuuuaacgcuacacgcuuugc 
               
               
                 uagcgucuaugcuuggaaccgaaaacggauuaguaacugcguagcugauuauuccgucuuguacaacagcgcaucuuuu 
               
               
                 agcacuuucaaguguuauggaguaagcccaacaaagcucaacgaccuuuguuuuacuaacgucuaugcugauucauucg 
               
               
                 ugauucguggggaugagguucgucagaucgccccaggccaaaccgggaaaaucgcugauuauaauuauaaauugccuga 
               
               
                 cgauuuuaccggcuguguaaucgccuggaauuccaacaaucuugauuccaagguuggcggcaacuacaacuaucucuac 
               
               
                 cgucuguuucgcaaauccaaucucaagcccuucgaacgcgauauuucaacugaaaucuaucaggcaggguccacuccgug 
               
               
                 uaacggcguagaaggauuuaauuguuacuucccauugcaaaguuauggcuuucaacccaccaacggagucggguaccaa 
               
               
                 ccauacagagucgucgugcucucauuugagcuccuucaugcaccugccacggugugcggcccaaagaaaucaacgaaccu 
               
               
                 ugugaagaauaaaugugucaauuuuaacuuuaauggccugacagggacuggcguccucacagaaucuaauaagaaguuu 
               
               
                 cucccuuuccagcaauuuggucgcgauauagcugauaccacagaugcaguuagagacccacagacacuugagauucucga 
               
               
                 uauuaccccgugcuccuuuggcggcguguccgucauuacucccgguaccaauacgucuaaccagguagcagugcucuac 
               
               
                 caagauguaaauuguacugagguacccguggcaauccaugccgaccaacugacuccaacguggcggguuuauucaaccg 
               
               
                 gaagcaacguguuucaaacacgggcuggcugccuuauaggcgcugagcacgugaauaauaguuacgagugugauauccc 
               
               
                 gaucggagccggcaucugugcaucuuaucaaacacaaacaaacuccccgcgccggcggagaagcguggcuagccaaagua 
               
               
                 uaaucgcuuauacaauguccuugggcgcggaaaauucaguggcuuauuccaauaauucaauugccauuccuaccaacuu 
               
               
                 uacaauuagcgugaccacagaaaucuugccugugucuaugaccaagaccagcgucgauugcaccauguauaucugugga 
               
               
                 gauagcaccgaguguucaaauuugcuccugcaauacgguuccuuuuguacacagcuuaaccgcgcccucacagguauug 
               
               
                 cuguugaacaagacaagaauacucaagagguauuugcucagguaaaacaaauuuauaagaccccaccgauaaaagauuuu 
               
               
                 ggcgguuucaauuucucccaaauauugccagauccuaguaggcgucguagaucauuuaucgaggaucuccuguucaaua 
               
               
                 aaguaacccucgccgacgcugguuucaucaaacaauauggcgacugccugggagauauugcagcuagggauuugauuug 
               
               
                 ugcacagaaguucaauggacucaccguucucccgccucuccugacagaugagaugauugcacaauacaccucugcucuuu 
               
               
                 uggccgggaccauuacgagcgguuggacuuuuggcgcgggugcggcucuccaaauuccuuucgcgaugcaaauggcgu 
               
               
                 auagauuuaauggaauuggcguuacucaaaacgucuuguacgagaaucagaaacugaucgccaaccaauuuaacagugca 
               
               
                 auuggcaaaauccaagauagccuuaguucuacugcuucagcauuggguaaguugcaagauguggucaaccaaaacgcaca 
               
               
                 agcacucaauacccucgugaagcaauuguccagcaauuuuggagcuaucucaagugugcucaacgacauccuuucuaggc 
               
               
                 uugauccacccgaggcagagguucaaaucgacagacugauaacuggcaggcuccaaucucugcaaacguacgugacacag 
               
               
                 caacugauuagggcugcugagaucagggcguccgcgaauuuggcagcaaccaaaaugagcgaaugcgugcugggacaau 
               
               
                 caaagagaguugauuucuguggaaaggguuaccaucucauguccuucccucaaucagcuccccauggaguuguguuucu 
               
               
                 gcacguuacuuacgugccggcacaagaaaagaauuucaccacugcaccggcuauaugucaugaugggaaagcccacuucc 
               
               
                 cgcgggaaggcguuuucguguccaacgggacucauugguucgucacacaaaggaacuucuaugagccacaaauaauuac 
               
               
                 aacagacaacaccuuugucucugggaacugcgaugucgugauuggaaucgugaacaacacugucuacgauccgcugcaac 
               
               
                 ccgaacucgacucauucaaagaggaacuggauaaguauuucaagaaccauaccagccccgaugucgaucugggcgauauc 
               
               
                 uccgggauaaaugcuucaguaguaaacauucaaaaggaaaucgaccggcugaacgagguugcgaagaaucuuaaugagu 
               
               
                 cauugaucgaccugcaagaacuugguaaguaugagcaguacaucaaguggccuuggucaggccgcaggcgucggcgucg 
               
               
                 ugggagcggcggcagugggagcggauauauuccagaagcgccccgagacggacaagcuuacguacgaaaagacggagaa 
               
               
                 uggguacugcuuuccacuuuucuuggcuaauga (SEQ ID NO: 147) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTK 
               
               
                 LNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDS 
               
               
                 KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDV 
               
               
                 NCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRR R RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK 
               
               
                 TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYK 
               
               
                 TPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC 
               
               
                 AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG 
               
               
                 IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQ 
               
               
                 LSSNFGAISSVLNDILSRLD PP EAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLA 
               
               
                 ATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAI 
               
               
                 CHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 148) 
               
               
                   
               
               
                 WuS_3F_D2P_GlyDSol_pVax 
               
               
                 ggatccgccaccatggattggacctggatcttgtttctcgtcgcagctgccacaagagtccacagtatgtttgtatttctcgttctcctgcct 
               
               
                 cttgtgtcctctcagtgtgtgaatctgacgaccagaactcagctcccacccgcatacactaacagtatcacgaggggcgtttattaccca 
               
               
                 gacaaggttttccgaagcagttgtctgtatagtacacaggatttgttcctgccattctttagtaacgtgacttggtttcatgcgatccacgttt 
               
               
                 ctggcacaaacggtaccaaaagattcgataaccccgtgctgcctttcaatgacggcgtgtatttcgcttctactgaaaagtccggcatca 
               
               
                 tccggggatggatcttcggcactactttggatagcaaaacccaatccctgctgattgtgaataatgcaaccaacgtggtgatcaaagtct 
               
               
                 gtgagtttcaattctgtaatgacccatttctgggcgtttactaccacaagaacaacaaaagttggatggagtccgaatttcgcgtctactca 
               
               
                 tccgcgaacaattgcacatttgagtatgtgagtcaaccattcttgatggatcttgaagggaagcaaggcaatttcaagaacctgcggga 
               
               
                 gtttgtatttaagaacattgacggctatttcaagatatattctaaacatactcccattaacctcgtgcgcgacttgccccagggattcagtgc 
               
               
                 tctggaaccactggtcgatctccccatcggcattaatattacacgctttcaaactctcctcgctttgcatcggtcctatcttactccgggaga 
               
               
                 tagctcaagcggatggacggcaggcgcggcggcatattatgttggatatctccaaccacgcacgttccttctgaaatataatgaaaatg 
               
               
                 gcactattactgatgcagtcgactgcgccctggaccctctgtctgagaccaagtgtaccctgaagtcattcaccgttgagaagggaatct 
               
               
                 accaaacctctaactttagggtacaacctactgagagcattgtccgcttcccgaatatcaccaatctttgtccgtttggtgaggtgtttaac 
               
               
                 gcgacacgatttgcttccgtatacgcctggaatcgcaaacgcatcagcaactgtgtggctgattactcatttctctataattccgcttccttc 
               
               
                 tctactttcaagtgttatggggtgaatgggactaaacttaatgacttgtgctttactaacgtgtatgctgatagcttcgtcattcgtggagatg 
               
               
                 aggtcaggcaaatagctcccggacaaacagggaagatagcggactataactacaaactgcctgatgatttcaccgggtgcgtcatcg 
               
               
                 cgtggaacagcaataacctcgatagcaaggttggcggaaactataattatctctatcgtttgtttaggaaaagcaatctcaagcccttcga 
               
               
                 gcgggatattaatacaacgatatatcaagctggctctaccccgtgcaacggagtagagggcttcaattgctactttcctttgcagtcctac 
               
               
                 ggattccaacccaccaacggagtgggctaccaaccataccgtgtcgtggttttgagtttcgaactgaaccacgcaccagcaacagtct 
               
               
                 gcggaccgaagaagagtacaaaccttgtgaagaataagtgcgtgaactttaatttcaatggcctgactggaaccggagttctgacgga 
               
               
                 atccaataagaaatttctgccgtttcagcaatttggacgggattgtgctggaacgactgatgccgtacgtgatcctcaaacactggaaatc 
               
               
                 ctggacataaccccttgttcctttggtggcgtaagcgttattactccaggcacaaacacatcaaatcaagtcgccgtactgtatcaaggtg 
               
               
                 tcaactgtactgaagtacctgtagccattcatgcaggacaactgacccctacatggcgagtgtattcaacgggaagcaacgtatttcaaa 
               
               
                 ccagggccggctgtctcatcggagcagagcatgtcaataatagttatgaatgcgacatcccaataggtgctgggatctgcgcgagcta 
               
               
                 ccaaacccaaactaatagcccacgaagacggagatctgtcgcgtcccaaagcattattgcgtacacgatgagcctctgtgcagaaaat 
               
               
                 tcagttgcctacagcaacaatagcatcgctattccaaccaatttcactatcagctgtacaacagaaattctcccagtctccatgacgaaga 
               
               
                 catcctgcgattgtacaatgtatatatgcggcgactcaacagaatgttcaaatttgttgctgcaatacgggtccttctgcacccaactcaat 
               
               
                 cgagctcttacaggcatagcggtcgaacaagacaagaacacacaagaagtgtttgcccaagttaaacagtgttacaagacaccaccta 
               
               
                 tcaaagatttcggcggttttaacttttctcagatcttgccagacccatctaggcggcggcgatcctttatcgaggaccttctcttcaataagg 
               
               
                 taactcttgcagacgctggatttattaagcaatacggcgactgtctcggggatatcgccgctagggatctgatctgtgcccagaaatttaa 
               
               
                 cggctgcacggtgctgccccctctgctgactgatgaaatgatagcacaatatacttctgcattgctggccggtaccattacatcaggatg 
               
               
                 gacatttggtgccggggcggcgctccaaattcccttcgccatgcaaatggcctataggtttaacggcatcggggtgacccaaaacgtc 
               
               
                 ctctatgagaatcaaaagctgattgctaaccagtttaactcagcaataggaaagattcaagactctctgtcaagtaccgcatccgcccttg 
               
               
                 gaaagctccaagacgttgttaaccagaatgcacaagctctcaacacgctcgtgaaacaactctcttcaaattttggtgcgatctcttctgg 
               
               
                 cccaaatgacattttgagccggcttcccaaggtagaagctgaagtacaaattgatcgcctgatcaccggacggctccaaagtctgcag 
               
               
                 acgtacgtcacccagcaactgatacgggcagcggagatccgggcttctgccaacctggccgccacgaagatgagcgaatgcgtgct 
               
               
                 cggacagtccaaaagagtagatttctgtggcaagggctatcatctcatgtcctttccccaatccgcccctcacggagttgtcttccttcatt 
               
               
                 gcacttacgtccccgctcaagaaaagaattttactacggcacctgctatctgtcacgacgggaaagcccattttcctagagaaggtgtgt 
               
               
                 ttgtatctaacggcacgcactggttcgtcacgcaacgtaacttttacgagccccagatcatcaccacagacaatacggatgtatcaggta 
               
               
                 attgtgatgtcctgattggtatcgtcaataacactgtatacgatcctttgcaaccggaactggactcctttaaagaggaacttgataagtatt 
               
               
                 tcaagaatcacacttccccagatgtcgatctcggggacatctcaggaattaatgcatcagtggtcaatattcaaaaggaaattgatcgctt 
               
               
                 gaatgaggttgcaaagaatttgaatgaaagccttatcgaccttcaagagctgggcaaatatgagcagtacattaaatggccttggagcg 
               
               
                 gtcgccggcgccgaaggcggggttccggcggtagcggtagcggttatattccagaagctcctcgcgatgggcaggcttatgtgagg 
               
               
                 aaagatggtgaatgggtccttttgtccacgttcctcgggtagtaa (SEQ ID NO: 149) 
               
               
                   
               
               
                 ggauccgccaccauggauuggaccuggaucuuguuucucgucgcagcugccacaagaguccacaguauguuuguauuuc 
               
               
                 ucguucuccugccucuuguguccucucagugugugaaucugacgaccagaacucagcucccacccgcauacacuaacagu 
               
               
                 aucacgaggggcguuuauuacccagacaagguuuuccgaagcaguugucuguauaguacacaggauuuguuccugccau 
               
               
                 ucuuuaguaacgugacuugguuucaugcgauccacguuucuggcacaaacgguaccaaaagauucgauaaccccgugcu 
               
               
                 gccuuucaaugacggcguguauuucgcuucuacugaaaaguccggcaucauccggggauggaucuucggcacuacuuug 
               
               
                 gauagcaaaacccaaucccugcugauugugaauaaugcaaccaacguggugaucaaagucugugaguuucaauucugua 
               
               
                 augacccauuucugggcguuuacuaccacaagaacaacaaaaguuggauggaguccgaauuucgcgucuacucauccgcg 
               
               
                 aacaauugcacauuugaguaugugagucaaccauucuugauggaucuugaagggaagcaaggcaauuucaagaaccugc 
               
               
                 gggaguuuguauuuaagaacauugacggcuauuucaagauauauucuaaacauacucccauuaaccucgugcgcgacuu 
               
               
                 gccccagggauucagugcucuggaaccacuggucgaucuccccaucggcauuaauauuacacgcuuucaaacucuccucg 
               
               
                 cuuugcaucgguccuaucuuacuccgggagauagcucaagcggauggacggcaggcgcggcggcauauuauguuggaua 
               
               
                 ucuccaaccacgcacguuccuucugaaauauaaugaaaauggcacuauuacugaugcagucgacugcgcccuggacccuc 
               
               
                 ugucugagaccaaguguacccugaagucauucaccguugagaagggaaucuaccaaaccucuaacuuuaggguacaaccu 
               
               
                 acugagagcauuguccgcuucccgaauaucaccaaucuuuguccguuuggugagguguuuaacgcgacacgauuugcuu 
               
               
                 ccguauacgccuggaaucgcaaacgcaucagcaacuguguggcugauuacucauuucucuauaauuccgcuuccuucuc 
               
               
                 uacuuucaaguguuauggggugaaugggacuaaacuuaaugacuugugcuuuacuaacguguaugcugauagcuucgu 
               
               
                 cauucguggagaugaggucaggcaaauagcucccggacaaacagggaagauagcggacuauaacuacaaacugccugaug 
               
               
                 auuucaccgggugcgucaucgcguggaacagcaauaaccucgauagcaagguuggcggaaacuauaauuaucucuaucg 
               
               
                 uuuguuuaggaaaagcaaucucaagcccuucgagcgggauauuaauacaacgauauaucaagcuggcucuaccccgugca 
               
               
                 acggaguagagggcuucaauugcuacuuuccuuugcaguccuacggauuccaacccaccaacggagugggcuaccaacca 
               
               
                 uaccgugucgugguuuugaguuucgaacugaaccacgcaccagcaacagucugcggaccgaagaagaguacaaaccuug 
               
               
                 ugaagaauaagugcgugaacuuuaauuucaauggccugacuggaaccggaguucugacggaauccaauaagaaauuucu 
               
               
                 gccguuucagcaauuuggacgggauugugcuggaacgacugaugccguacgugauccucaaacacuggaaauccuggac 
               
               
                 auaaccccuuguuccuuugguggcguaagcguuauuacuccaggcacaaacacaucaaaucaagucgccguacuguauca 
               
               
                 aggugucaacuguacugaaguaccuguagccauucaugcaggacaacugaccccuacauggcgaguguauucaacggga 
               
               
                 agcaacguauuucaaaccagggccggcugucucaucggagcagagcaugucaauaauaguuaugaaugcgacaucccaau 
               
               
                 aggugcugggaucugcgcgagcuaccaaacccaaacuaauagcccacgaagacggagaucugucgcgucccaaagcauua 
               
               
                 uugcguacacgaugagccucugugcagaaaauucaguugccuacagcaacaauagcaucgcuauuccaaccaauuucacu 
               
               
                 aucagcuguacaacagaaauucucccagucuccaugacgaagacauccugcgauuguacaauguauauaugcggcgacuc 
               
               
                 aacagaauguucaaauuuguugcugcaauacggguccuucugcacccaacucaaucgagcucuuacaggcauagcgguc 
               
               
                 gaacaagacaagaacacacaagaaguguuugcccaaguuaaacaguguuacaagacaccaccuaucaaagauuucggcgg 
               
               
                 uuuuaacuuuucucagaucuugccagacccaucuaggcggcggcgauccuuuaucgaggaccuucucuucaauaaggua 
               
               
                 acucuugcagacgcuggauuuauuaagcaauacggcgacugucucggggauaucgccgcuagggaucugaucugugccc 
               
               
                 agaaauuuaacggcugcacggugcugcccccucugcugacugaugaaaugauagcacaauauacuucugcauugcuggc 
               
               
                 cgguaccauuacaucaggauggacauuuggugccggggcggcgcuccaaauucccuucgccaugcaaauggccuauagg 
               
               
                 uuuaacggcaucggggugacccaaaacguccucuaugagaaucaaaagcugauugcuaaccaguuuaacucagcaauagg 
               
               
                 aaagauucaagacucucugucaaguaccgcauccgcccuuggaaagcuccaagacguuguuaaccagaaugcacaagcuc 
               
               
                 ucaacacgcucgugaaacaacucucuucaaauuuuggugcgaucucuucuggcccaaaugacauuuugagccggcuucc 
               
               
                 caagguagaagcugaaguacaaauugaucgccugaucaccggacggcuccaaagucugcagacguacgucacccagcaac 
               
               
                 ugauacgggcagcggagauccgggcuucugccaaccuggccgccacgaagaugagcgaaugcgugcucggacaguccaa 
               
               
                 aagaguagauuucuguggcaagggcuaucaucucauguccuuuccccaauccgccccucacggaguugucuuccuucau 
               
               
                 ugcacuuacguccccgcucaagaaaagaauuuuacuacggcaccugcuaucugucacgacgggaaagcccauuuuccuag 
               
               
                 agaagguguguuuguaucuaacggcacgcacugguucgucacgcaacguaacuuuuacgagccccagaucaucaccacag 
               
               
                 acaauacggauguaucagguaauugugauguccugauugguaucgucaauaacacuguauacgauccuuugcaaccgga 
               
               
                 acuggacuccuuuaaagaggaacuugauaaguauuucaagaaucacacuuccccagaugucgaucucggggacaucucag 
               
               
                 gaauuaaugcaucaguggucaauauucaaaaggaaauugaucgcuugaaugagguugcaaagaauuugaaugaaagccu 
               
               
                 uaucgaccuucaagagcugggcaaauaugagcaguacauuaaauggccuuggagcggucgccggcgccgaaggcggggu 
               
               
                 uccggcgguagcgguagcgguuauauuccagaagcuccucgcgaugggcaggcuuaugugaggaaagauggugaaugg 
               
               
                 guccuuuuguccacguuccucggguaguaa (SEQ ID NO: 150) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSITRGVYYP 
               
               
                 DKVFRSS C L Y STQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEK 
               
               
                 S G IIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMES 
               
               
                 EFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLV 
               
               
                 RDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQ 
               
               
                 PRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFP 
               
               
                 NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSFLYNSASFSTFKCYGV NG TKL 
               
               
                 NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSK 
               
               
                 VGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPTN 
               
               
                 GVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNK 
               
               
                 KFLPFQQFGRD C A G TTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGV 
               
               
                 NCTEVPVAIHA G QLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICAS 
               
               
                 YQTQTNSPRR R RSVASQSIIAYTMSL C AENSVAYSNNSIAIPTNFTIS C TTEILPVSMTK 
               
               
                 TS C DCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQ C YK 
               
               
                 TPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLIC 
               
               
                 AQKFNG C TVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHCTYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNT D VSGNCDV L IGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 151) 
               
               
                   
               
               
                 WuS_3F_D2P_GlyD3_pVax 
               
               
                 ggatccgccaccatggactggacatggatacttttcttggtagcggcggcgacacgcgtgcactccatgtttgttttcctcgtcctgctcc 
               
               
                 cacttgtctcaagtcaatgcgttaacctgactacgaggacgcagctcccgcccgcctacacaaactcttttacccggggtgtgtactacc 
               
               
                 ccgacaaagttttccgcagttcatgtctccactcaacacaggacctctttctgccattcttctcaaatgtcacatggtttcacgccatccacg 
               
               
                 tttccggcactaacggtaccaaacggttcgacaaccctgttctgccattcaatgatggggtgtattttgcgagcacagagaagtccaatat 
               
               
                 aatcagaggttggatcttcggtacaacgctggacagtaaaactcaatctctgctgatagtgaataacgctacgaacgtcgtcattaaggt 
               
               
                 gtgcgagtttcaattttgcaacgatccattcttgggagtgtactatcataagaacaacaaatcatggatggagagcgagtttagggtgtatt 
               
               
                 cctctgcaaacaactgtacatttgaatacgtgagccagccttttcttatggacctcgaaggtaagcaaggtaacttcaagaacttgcggg 
               
               
                 aatttgttttcaagaacattgatggatacttcaaaatttactccaaacatacccctatcaatctggtccgcgaccttccacaaggattttccgc 
               
               
                 acttgaacccttggtcgacctgcctattggaatcaatatcacgcggtttcagacgcttctcgctctccatagatcctacctcacgcccggc 
               
               
                 gacagttcaagtgggtggaccgcaggcgcggcggcctattatgtgggatacttgcaaccccgcacttttctcctgaaatataatgagaa 
               
               
                 tgggaccataaccgatgcagttgattgtgccttggaccccctgtccgagaccaaatgcacgctgaagtctttcacagtagagaaggga 
               
               
                 atttaccaaacttccaacttcagagttcaacccacagaatctatcgttcgctttcccaatattacaaatttgtgtccgtttggagaggtgttca 
               
               
                 atgctacaaggtttgcttccgtatatgcctggaatcgtaaacgcatctctaattgcgtagcggactactcagttttgtataacagtgctagct 
               
               
                 tctccactttcaagtgttacggcgttaatgggaccaagctgaatgacctgtgttttaccaacgtgtatgctgactccttcgtaataagaggg 
               
               
                 gatgaggttaggcaaatcgcccctggccagacagggaaaatcgctgattacaattacaagttgccagatgactttaccgggtgtgtcat 
               
               
                 cgcttggaactccaataatctggattccaaagttggtgggaactataattacctctatcggctgttcagaaaatccaaccttaagcccttcg 
               
               
                 aaagagatatcaacactacaatttatcaggctggttcaactccgtgtaatggggtcgagggtttcaactgctacttcccgttgcagagttat 
               
               
                 gggttccagccgacgaatggggtcgggtaccaaccgtacagagtagtagttctgtcctttgagttgaatcatgccccagcaacagtgtg 
               
               
                 cggcccaaagaaatcaacaaaccttgttaagaataaatgcgtgaacttcaactttaacgggcttactgggactggggtgctcacagaat 
               
               
                 ccaacaagaaattcttgccattccaacaatttggccgcgattgtgcagatacaaccgacgccgtgagagatccccaaacattggagata 
               
               
                 cttgatatcactccctgctcttttggtggcgtcagcgtcatcaccccaggaaccaatacaagcaatcaagtggctgtcctttatcaagatgt 
               
               
                 caattgtaccgaagtcccagtcgcaatacatgcggatcaactgaccccaacatggagagtttactcaacgggatctaacgtgtttcaaa 
               
               
                 ctcgtgctggctgcctgataggagcggagcatgtgaataattcctatgaatgcgacattcccattggggctggaatctgtgcatcctatc 
               
               
                 aaacacaaactaactctccccgccggcggcggagcgtcgccagccaaagcattattgcatatacgatgtccctgtgcgcagaaaattc 
               
               
                 tgttgcatacagcaataactccatcgctatccctacaaactttaccatcagctgtacaaccgaaatcttgcccgtttctatgactaaaacaa 
               
               
                 gttgtgactgcactatgtacatctgtggcgactcaacagagtgttctaaccttctgcttcaatatggatctttctgtacacaacttaatcgcgc 
               
               
                 tctcaccggtatagctgttgagcaagataagaacactcaggaagttttcgcccaagtcaaacaatgttataaaacaccacccataaaag 
               
               
                 acttcggcggatttaatttctctcaaatactgccggacccatccaggagacgaagaagcttcatagaagatcttctcttcaacaaggtgac 
               
               
                 cctggccgatgcggggtttatcaagcaatatggcgactgtctcggcgatattgctgcacgcgatctgatatgtgcacagaaattcaatgg 
               
               
                 gtgtaccgtgctcccacctctgctgacagatgaaatgatcgctcaatataccagtgcgctcttggctggaacaattactagtggttggact 
               
               
                 tttggggctggagccgcactccaaatcccttttgccatgcaaatggcctatcgctttaatgggataggggtcactcagaatgtcttgtatg 
               
               
                 aaaaccagaagttgattgctaaccaatttaattcagctatagggaaaattcaagacagcctcagtagtactgccagtgccctgggcaaa 
               
               
                 ctgcaagatgtcgtgaaccaaaatgctcaagccctgaataccctcgttaagcaacttagctcaaactttggtgcgatttcctcaggcccta 
               
               
                 atgacatcctctcaaggctgcctaaagtggaagctgaggtccaaatcgatcgcctgattacgggtcgcctgcaatcactccaaacatat 
               
               
                 gtcacccagcagttgatcagagcggccgagatacgggcatcagcaaatttggcggccacgaaaatgtcagagtgcgtacttggtcaa 
               
               
                 agtaaaagagttgatttctgcggaaaaggttaccaccttatgtctttcccccagtccgctccacatggagtggtctttctgcattgtacttat 
               
               
                 gtgccagcccaagaaaagaattttactaccgcccccgctatttgtcatgatggtaaggcgcacttccccagagaaggagtgtttgtgtcc 
               
               
                 aacgggactcactggtttgtgactcaaaggaacttttatgaacctcaaattatcaccacagataacacatttgtgtccgggaattgcgatgt 
               
               
                 ggttatcggcattgttaataataccgtttacgatcccttgcaacctgagttggatagtttcaaggaagaacttgacaaatactttaagaatca 
               
               
                 cacttccccggatgtagacctcggggacatttccggaattaatgcgagtgttgtgaatatacagaaagagatagaccgactcaacgag 
               
               
                 gttgctaagaacctcaacgagagccttatcgatcttcaagaactcggcaaatacgagcaatacattaaatggccttggtccggcagaag 
               
               
                 gagacggcgaaggggaagtggcggcagcggctctggatacatcccggaagctccacgggatgggcaagcatatgttcgcaaggat 
               
               
                 ggagaatgggtccttcttagcaccttcttgggataatga (SEQ ID NO: 152) 
               
               
                   
               
               
                 ggauccgccaccauggacuggacauggauacuuuucuugguagcggcggcgacacgcgugcacuccauguuuguuuucc 
               
               
                 ucguccugcucccacuugucucaagucaaugcguuaaccugacuacgaggacgcagcucccgcccgccuacacaaacucu 
               
               
                 uuuacccgggguguguacuaccccgacaaaguuuuccgcaguucaugucuccacucaacacaggaccucuuucugccau 
               
               
                 ucuucucaaaugucacaugguuucacgccauccacguuuccggcacuaacgguaccaaacgguucgacaacccuguucug 
               
               
                 ccauucaaugaugggguguauuuugcgagcacagagaaguccaauauaaucagagguuggaucuucgguacaacgcugg 
               
               
                 acaguaaaacucaaucucugcugauagugaauaacgcuacgaacgucgucauuaaggugugcgaguuucaauuuugcaa 
               
               
                 cgauccauucuugggaguguacuaucauaagaacaacaaaucauggauggagagcgaguuuaggguguauuccucugca 
               
               
                 aacaacuguacauuugaauacgugagccagccuuuucuuauggaccucgaagguaagcaagguaacuucaagaacuugc 
               
               
                 gggaauuuguuuucaagaacauugauggauacuucaaaauuuacuccaaacauaccccuaucaaucugguccgcgaccuu 
               
               
                 ccacaaggauuuuccgcacuugaacccuuggucgaccugccuauuggaaucaauaucacgcgguuucagacgcuucucg 
               
               
                 cucuccauagauccuaccucacgcccggcgacaguucaaguggguggaccgcaggcgcggcggccuauuaugugggaua 
               
               
                 cuugcaaccccgcacuuuucuccugaaauauaaugagaaugggaccauaaccgaugcaguugauugugccuuggaccccc 
               
               
                 uguccgagaccaaaugcacgcugaagucuuucacaguagagaagggaauuuaccaaacuuccaacuucagaguucaaccc 
               
               
                 acagaaucuaucguucgcuuucccaauauuacaaauuuguguccguuuggagagguguucaaugcuacaagguuugcuu 
               
               
                 ccguauaugccuggaaucguaaacgcaucucuaauugcguagcggacuacucaguuuuguauaacagugcuagcuucuc 
               
               
                 cacuuucaaguguuacggcguuaaugggaccaagcugaaugaccuguguuuuaccaacguguaugcugacuccuucgua 
               
               
                 auaagaggggaugagguuaggcaaaucgccccuggccagacagggaaaaucgcugauuacaauuacaaguugccagaug 
               
               
                 acuuuaccgggugugucaucgcuuggaacuccaauaaucuggauuccaaaguuggugggaacuauaauuaccucuaucg 
               
               
                 gcuguucagaaaauccaaccuuaagcccuucgaaagagauaucaacacuacaauuuaucaggcugguucaacuccgugua 
               
               
                 auggggucgaggguuucaacugcuacuucccguugcagaguuauggguuccagccgacgaauggggucggguaccaacc 
               
               
                 guacagaguaguaguucuguccuuugaguugaaucaugccccagcaacagugugcggcccaaagaaaucaacaaaccuug 
               
               
                 uuaagaauaaaugcgugaacuucaacuuuaacgggcuuacugggacuggggugcucacagaauccaacaagaaauucuu 
               
               
                 gccauuccaacaauuuggccgcgauugugcagauacaaccgacgccgugagagauccccaaacauuggagauacuugaua 
               
               
                 ucacucccugcucuuuugguggcgucagcgucaucaccccaggaaccaauacaagcaaucaaguggcuguccuuuaucaa 
               
               
                 gaugucaauuguaccgaagucccagucgcaauacaugcggaucaacugaccccaacauggagaguuuacucaacgggauc 
               
               
                 uaacguguuucaaacucgugcuggcugccugauaggagcggagcaugugaauaauuccuaugaaugcgacauucccauu 
               
               
                 ggggcuggaaucugugcauccuaucaaacacaaacuaacucuccccgccggcggcggagcgucgccagccaaagcauuau 
               
               
                 ugcauauacgaugucccugugcgcagaaaauucuguugcauacagcaauaacuccaucgcuaucccuacaaacuuuacca 
               
               
                 ucagcuguacaaccgaaaucuugcccguuucuaugacuaaaacaaguugugacugcacuauguacaucuguggcgacuc 
               
               
                 aacagaguguucuaaccuucugcuucaauauggaucuuucuguacacaacuuaaucgcgcucucaccgguauagcuguu 
               
               
                 gagcaagauaagaacacucaggaaguuuucgcccaagucaaacaauguuauaaaacaccacccauaaaagacuucggcgga 
               
               
                 uuuaauuucucucaaauacugccggacccauccaggagacgaagaagcuucauagaagaucuucucuucaacaaggugac 
               
               
                 ccuggccgaugcgggguuuaucaagcaauauggcgacugucucggcgauauugcugcacgcgaucugauaugugcacag 
               
               
                 aaauucaauggguguaccgugcucccaccucugcugacagaugaaaugaucgcucaauauaccagugcgcucuuggcug 
               
               
                 gaacaauuacuagugguuggacuuuuggggcuggagccgcacuccaaaucccuuuugccaugcaaauggccuaucgcuu 
               
               
                 uaaugggauaggggucacucagaaugucuuguaugaaaaccagaaguugauugcuaaccaauuuaauucagcuauaggg 
               
               
                 aaaauucaagacagccucaguaguacugccagugcccugggcaaacugcaagaugucgugaaccaaaaugcucaagcccu 
               
               
                 gaauacccucguuaagcaacuuagcucaaacuuuggugcgauuuccucaggcccuaaugacauccucucaaggcugccua 
               
               
                 aaguggaagcugagguccaaaucgaucgccugauuacgggucgccugcaaucacuccaaacauaugucacccagcaguug 
               
               
                 aucagagcggccgagauacgggcaucagcaaauuuggcggccacgaaaaugucagagugcguacuuggucaaaguaaaa 
               
               
                 gaguugauuucugcggaaaagguuaccaccuuaugucuuucccccaguccgcuccacauggaguggucuuucugcauug 
               
               
                 uacuuaugugccagcccaagaaaagaauuuuacuaccgcccccgcuauuugucaugaugguaaggcgcacuuccccagag 
               
               
                 aaggaguguuuguguccaacgggacucacugguuugugacucaaaggaacuuuuaugaaccucaaauuaucaccacaga 
               
               
                 uaacacauuuguguccgggaauugcgaugugguuaucggcauuguuaauaauaccguuuacgaucccuugcaaccugag 
               
               
                 uuggauaguuucaaggaagaacuugacaaauacuuuaagaaucacacuuccccggauguagaccucggggacauuuccg 
               
               
                 gaauuaaugcgaguguugugaauauacagaaagagauagaccgacucaacgagguugcuaagaaccucaacgagagccuu 
               
               
                 aucgaucuucaagaacucggcaaauacgagcaauacauuaaauggccuugguccggcagaaggagacggcgaaggggaag 
               
               
                 uggcggcagcggcucuggauacaucccggaagcuccacgggaugggcaagcauauguucgcaaggauggagaauggguc 
               
               
                 cuucuuagcaccuucuugggauaauga (SEQ ID NO: 153) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSS C LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV NG T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRD C ADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR R RSVASQSIIAYTMSL C AENSVAYSNNSIAIPTNFTIS C TTEILPVSMT 
               
               
                 KTS C DCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQ C Y 
               
               
                 KTPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNG C TVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLH C TYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 154) 
               
               
                   
               
               
                 WuS_3F_D2P_GlyD2_pVax 
               
               
                 ggatccgccaccatggattggacatggatactgtttctggtcgctgctgccacacgtgtccacagcatgtttgtcttcttggtgctcttgcc 
               
               
                 tcttgtgagctcccaatgtgtgaatctgactacacgtacgcaacttccgcctgcctacaccaactctttcaccagaggcgtgtattatccg 
               
               
                 gataaggtgttcaggagctcctgccttcattcaacacaggatttgtttctgcctttcttttcaaacgttacttggttccatgccatccacgtgtc 
               
               
                 aggaacaaatggtaccaagagattcgataacccagttctcccttttaatgatggagtctattttgcaagcactgagaaaagtaatattatac 
               
               
                 gaggttggattttcggaacgacactcgacagtaaaacacaatccctgttgatagtcaacaatgccacgaacgtagttataaaagtttgcg 
               
               
                 aatttcaattttgcaacgatcctttcctgggtgtgtactatcacaagaacaacaaatcttggatggaaagcgagtttcgagtgtattcttcag 
               
               
                 caaacaactgtactttcgaatatgtttctcaaccattcctgatggatctcgaaggtaaacagggcaactttaagaatctgagagagtttgtg 
               
               
                 tttaagaacattgacggctattttaagatttacagcaaacatacgcctataaaccttgtgagagacctgcctcaagggtttagcgccctgg 
               
               
                 aaccactcgtggacctgcctatcggcatcaatattaccagatttcaaacgctccttgccctgcataggagctatttgacacctggggactc 
               
               
                 ttctagcggctggactgcaggcgctgccgcttattacgtgggatatctccagcctagaactttcctcttgaaatacaacgagaatggaac 
               
               
                 cataacagacgcagttgattgtgctctcgaccccttgtccgagaccaaatgcacactgaaaagttttaccgtggagaaagggatctatca 
               
               
                 aactagtaatttccgcgttcaacccactgagagcatagtgaggtttcctaacattacaaatctttgcccgtttggggaagtgtttaatgcca 
               
               
                 ctcgttttgctagtgtatacgcctggaatcgaaagcggatttccaattgcgttgctgactacagtgtactctataatagcgcttcatttagca 
               
               
                 ccttcaagtgctacggggttaacgggaccaaactcaatgacctctgcttcacgaacgtttacgccgactcctttgtcattcgaggtgacg 
               
               
                 aagtaagacaaatcgccccaggccagactggaaagatcgcggactacaactataagctgccagacgacttcactggatgtgtgatcg 
               
               
                 cctggaatagtaacaacctcgactccaaggtgggtggcaattacaattatctctataggctgttcaggaagagtaatttgaaaccattcga 
               
               
                 gcgcgacataaatacaacaatctaccaagcgggttctaccccttgcaacggcgtggaaggttttaattgttacttccctctccaaagctac 
               
               
                 gggtttcaaccaacaaacggcgtgggataccaaccatacagggtggttgtgttgagcttcgaattgaatcatgcacctgcaacagtgtg 
               
               
                 tgggcccaagaagtccaccaatctcgttaagaataaatgcgtgaacttcaactttaacgggttgacagggaccggcgtgcttacggaa 
               
               
                 agtaataagaaattccttcccttccagcaatttggtcgcgactgtgcggatacaacggacgcagtgcgagacccacagacattggagat 
               
               
                 cctggacataacaccttgctcttttggcggggtctccgtaataacacctggaacaaataccagcaatcaagtagcggtcttgtatcaaga 
               
               
                 tgtaaactgtactgaagtcccagttgctatacatgcagaccaacttacaccgacgtggcgcgtgtattctacgggctccaacgtattcca 
               
               
                 aaccagagcagggtgcttgataggggcagagcacgtcaacaatagctatgagtgtgatatcccgataggtgctggaatctgcgcaag 
               
               
                 ttaccagacccaaaccaatagcccccgccggagacgatcagtggcaagccagtctataatagcctacacgatgtcactgtgtgccga 
               
               
                 aaatagcgttgcctatagtaacaatagcatcgccattccaaccaatttcacaatatcagtcactactgagattctgcctgtgtcaatgacta 
               
               
                 aaactagtgtggactgcacaatgtatatttgcggcgattccacagaatgtagcaatcttctgctgcaatatgggagtttctgtacacaattg 
               
               
                 aatcgggcccttactggaatcgccgtagagcaggacaagaacacccaagaagtctttgcgcaagtcaaacaatgttataagactcccc 
               
               
                 caattaaagattttggcggctttaattttagccaaatacttcccgaccccagccgccgacgacgctcctttatcgaagatctgttgtttaata 
               
               
                 aagtcacattggctgatgctggctttatcaaacaatacggtgattgtctgggtgatattgcagcccgagatctgatctgcgcccaaaagtt 
               
               
                 taacggcttgaccgttctcccgccactcctgacagatgagatgatcgcgcaatatacctctgcactcctggcgggaacaatcactagtg 
               
               
                 gttggactttcggcgccggcgctgcactgcaaattcccttcgccatgcaaatggcctatcggtttaacggaattggtgtgactcagaatg 
               
               
                 tgctttacgaaaatcagaaactcatagctaatcagtttaacagcgcaatcgggaaaattcaggattccctcagcagcaccgctagcgcct 
               
               
                 tgggcaagctgcaggacgttgtaaaccagaacgctcaggccctcaacactctcgttaaacaattgagctctaactttggggccataagc 
               
               
                 agtggtcctaacgacatcctgagtcgtctgccaaaggtagaggccgaagtgcaaatcgaccggctcatcactggaagactgcaaagc 
               
               
                 ctgcaaacctatgtcacacagcaacttatacgggccgccgaaatcagggcctcagcaaacctcgcagcaacaaagatgagcgagtgt 
               
               
                 gtgctgggccaatccaagcgcgtggacttctgtggtaagggataccatctgatgtcctttccccaatccgcgcctcatggagtagttttcc 
               
               
                 tgcacgttacgtatgtgcctgcccaagagaagaactttacaacagcaccagccatttgtcatgacggaaaagcccattttcctagagaa 
               
               
                 ggagtctttgtttccaatgggacacattggtttgttacccagcgtaacttttatgagccacaaatcatcaccacggacaatactttcgtgag 
               
               
                 cggtaattgtgatgtggtcattggcatagtgaataacactgtttacgaccccctgcaaccggaattggacagcttcaaagaagaactgga 
               
               
                 caagtacttcaagaaccacacatccccagacgtagacctcggagatatttccggaattaacgcatcagtagttaacatccagaaagaaa 
               
               
                 tagatcgactgaatgaggtcgctaagaacttgaacgaatcacttatagatctccaggaactcggcaaatatgagcaatatattaaatggc 
               
               
                 cctggtcaggtcgcagaagacgccgccggggttccggcggatctggatctggatatattcccgaagctccacgggatgggcaagcc 
               
               
                 tacgtaagaaaggatggagaatgggtacttttgtccacgttcttgggctagtag (SEQ ID NO: 155) 
               
               
                   
               
               
                 ggauccgccaccauggauuggacauggauacuguuucuggucgcugcugccacacguguccacagcauguuugucuucu 
               
               
                 uggugcucuugccucuugugagcucccaaugugugaaucugacuacacguacgcaacuuccgccugccuacaccaacuc 
               
               
                 uuucaccagaggcguguauuauccggauaagguguucaggagcuccugccuucauucaacacaggauuuguuucugccu 
               
               
                 uucuuuucaaacguuacuugguuccaugccauccacgugucaggaacaaaugguaccaagagauucgauaacccaguuc 
               
               
                 ucccuuuuaaugauggagucuauuuugcaagcacugagaaaaguaauauuauacgagguuggauuuucggaacgacacu 
               
               
                 cgacaguaaaacacaaucccuguugauagucaacaaugccacgaacguaguuauaaaaguuugcgaauuucaauuuugca 
               
               
                 acgauccuuuccuggguguguacuaucacaagaacaacaaaucuuggauggaaagcgaguuucgaguguauucuucagc 
               
               
                 aaacaacuguacuuucgaauauguuucucaaccauuccugauggaucucgaagguaaacagggcaacuuuaagaaucuga 
               
               
                 gagaguuuguguuuaagaacauugacggcuauuuuaagauuuacagcaaacauacgccuauaaaccuugugagagaccu 
               
               
                 gccucaaggguuuagcgcccuggaaccacucguggaccugccuaucggcaucaauauuaccagauuucaaacgcuccuug 
               
               
                 cccugcauaggagcuauuugacaccuggggacucuucuagcggcuggacugcaggcgcugccgcuuauuacgugggaua 
               
               
                 ucuccagccuagaacuuuccucuugaaauacaacgagaauggaaccauaacagacgcaguugauugugcucucgaccccu 
               
               
                 uguccgagaccaaaugcacacugaaaaguuuuaccguggagaaagggaucuaucaaacuaguaauuuccgcguucaaccc 
               
               
                 acugagagcauagugagguuuccuaacauuacaaaucuuugcccguuuggggaaguguuuaaugccacucguuuugcua 
               
               
                 guguauacgccuggaaucgaaagcggauuuccaauugcguugcugacuacaguguacucuauaauagcgcuucauuuag 
               
               
                 caccuucaagugcuacgggguuaacgggaccaaacucaaugaccucugcuucacgaacguuuacgccgacuccuuuguca 
               
               
                 uucgaggugacgaaguaagacaaaucgccccaggccagacuggaaagaucgcggacuacaacuauaagcugccagacgac 
               
               
                 uucacuggaugugugaucgccuggaauaguaacaaccucgacuccaagguggguggcaauuacaauuaucucuauaggc 
               
               
                 uguucaggaagaguaauuugaaaccauucgagcgcgacauaaauacaacaaucuaccaagcggguucuaccccuugcaac 
               
               
                 ggcguggaagguuuuaauuguuacuucccucuccaaagcuacggguuucaaccaacaaacggcgugggauaccaaccau 
               
               
                 acagggugguuguguugagcuucgaauugaaucaugcaccugcaacagugugugggcccaagaaguccaccaaucucgu 
               
               
                 uaagaauaaaugcgugaacuucaacuuuaacggguugacagggaccggcgugcuuacggaaaguaauaagaaauuccuu 
               
               
                 cccuuccagcaauuuggucgcgacugugcggauacaacggacgcagugcgagacccacagacauuggagauccuggacau 
               
               
                 aacaccuugcucuuuuggcggggucuccguaauaacaccuggaacaaauaccagcaaucaaguagcggucuuguaucaag 
               
               
                 auguaaacuguacugaagucccaguugcuauacaugcagaccaacuuacaccgacguggcgcguguauucuacgggcuc 
               
               
                 caacguauuccaaaccagagcagggugcuugauaggggcagagcacgucaacaauagcuaugagugugauaucccgaua 
               
               
                 ggugcuggaaucugcgcaaguuaccagacccaaaccaauagcccccgccggagacgaucaguggcaagccagucuauaau 
               
               
                 agccuacacgaugucacugugugccgaaaauagcguugccuauaguaacaauagcaucgccauuccaaccaauuucacaa 
               
               
                 uaucagucacuacugagauucugccugugucaaugacuaaaacuaguguggacugcacaauguauauuugcggcgauuc 
               
               
                 cacagaauguagcaaucuucugcugcaauaugggaguuucuguacacaauugaaucgggcccuuacuggaaucgccgua 
               
               
                 gagcaggacaagaacacccaagaagucuuugcgcaagucaaacaauguuauaagacucccccaauuaaagauuuuggcgg 
               
               
                 cuuuaauuuuagccaaauacuucccgaccccagccgccgacgacgcuccuuuaucgaagaucuguuguuuaauaaaguca 
               
               
                 cauuggcugaugcuggcuuuaucaaacaauacggugauugucugggugauauugcagcccgagaucugaucugcgccca 
               
               
                 aaaguuuaacggcuugaccguucucccgccacuccugacagaugagaugaucgcgcaauauaccucugcacuccuggcgg 
               
               
                 gaacaaucacuagugguuggacuuucggcgccggcgcugcacugcaaauucccuucgccaugcaaauggccuaucgguu 
               
               
                 uaacggaauuggugugacucagaaugugcuuuacgaaaaucagaaacucauagcuaaucaguuuaacagcgcaaucggg 
               
               
                 aaaauucaggauucccucagcagcaccgcuagcgccuugggcaagcugcaggacguuguaaaccagaacgcucaggcccu 
               
               
                 caacacucucguuaaacaauugagcucuaacuuuggggccauaagcagugguccuaacgacauccugagucgucugccaa 
               
               
                 agguagaggccgaagugcaaaucgaccggcucaucacuggaagacugcaaagccugcaaaccuaugucacacagcaacuu 
               
               
                 auacgggccgccgaaaucagggccucagcaaaccucgcagcaacaaagaugagcgagugugugcugggccaauccaagcg 
               
               
                 cguggacuucugugguaagggauaccaucugauguccuuuccccaauccgcgccucauggaguaguuuuccugcacguu 
               
               
                 acguaugugccugcccaagagaagaacuuuacaacagcaccagccauuugucaugacggaaaagcccauuuuccuagaga 
               
               
                 aggagucuuuguuuccaaugggacacauugguuuguuacccagcguaacuuuuaugagccacaaaucaucaccacggac 
               
               
                 aauacuuucgugagcgguaauugugauguggucauuggcauagugaauaacacuguuuacgacccccugcaaccggaau 
               
               
                 uggacagcuucaaagaagaacuggacaaguacuucaagaaccacacauccccagacguagaccucggagauauuuccgga 
               
               
                 auuaacgcaucaguaguuaacauccagaaagaaauagaucgacugaaugaggucgcuaagaacuugaacgaaucacuuau 
               
               
                 agaucuccaggaacucggcaaauaugagcaauauauuaaauggcccuggucaggucgcagaagacgccgccgggguucc 
               
               
                 ggcggaucuggaucuggauauauucccgaagcuccacgggaugggcaagccuacguaagaaaggauggagaauggguac 
               
               
                 uuuuguccacguucuugggcuaguag (SEQ ID NO: 156) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSS C LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV NG T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRD C ADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR R RSVASQSIIAYTMSL C AENSVAYSNNSIAIPTNFTISVTTEILPVSMT 
               
               
                 KTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQ C   
               
               
                 YKTPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARD 
               
               
                 LICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYR 
               
               
                 FNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTL 
               
               
                 VKQLSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASA 
               
               
                 NLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTT 
               
               
                 APAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNN 
               
               
                 TVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNL 
               
               
                 NESLIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEW 
               
               
                 VLLSTFLG** (SEQ ID NO: 157) 
               
               
                   
               
               
                 WuS_3F_D2P_GlyD1_pVax 
               
               
                 ggatccgccaccatggactggacatggatacttttcttggtggcagctgctacacgcgtccactcaatgttcgtctttctggtgctcttgcc 
               
               
                 actggtgagcagccaatgcgttaacctcaccacacgcacgcagcttccacccgcatacactaactcctttacgcgcggcgtgtactatc 
               
               
                 cagataaagtgttccgaagtagcgtcttgcatagcacccaggatctgtttctcccattctttagcaatgtcacatggttccacgctatccac 
               
               
                 gtgtctgggacgaatggaactaaacgttttgacaatcctgttcttccttttaacgacggcgtatactttgctagtactgagaagtctaacatt 
               
               
                 atccgcggctggattttcgggacaaccctggactccaaaacccagtctctgctgatagtaaacaatgccaccaacgtcgtcattaaagt 
               
               
                 gtgcgagtttcaattctgcaacgacccctttctgggtgtctattaccacaagaacaataagtcttggatggagtcagaatttcgtgtctattc 
               
               
                 ttctgccaataattgtacatttgagtatgtttctcaaccctttctcatggacctcgaaggcaagcaggggaattttaagaacctgcgggaatt 
               
               
                 cgtctttaagaatatcgacggctatttcaaaatttacagcaaacacacgcctataaacctcgtgcgagatctcccccaaggcttctcagca 
               
               
                 ttggagccattggtcgacttgccaatcggaattaatatcacaaggtttcagactctgctggccctgcatcgctcctatcttacccctggcg 
               
               
                 attcctcaagtggctggacggccggcgcagcagcctattacgtcggctatctccagccaaggacgtttcttttgaagtataatgaaaatg 
               
               
                 ggactattactgacgccgtcgactgcgctttggaccccctgagcgagacaaagtgcacattgaaaagcttcacggtggagaagggtat 
               
               
                 ttatcaaacttccaactttagggtgcaaccaacagagagcatcgtgaggttccctaatatcactaatctctgtccatttggcgaggtgttta 
               
               
                 acgcgaccagatttgcaagcgtatatgcctggaataggaagagaataagcaattgtgttgccgattactctgtcttgtataacagcgcat 
               
               
                 ctttcagcacttttaagtgctatggtgtcaacgggacaaaacttaacgatctttgcttcaccaacgtttacgcagactcttttgtcatacgcg 
               
               
                 gagatgaggtccgacaaatagctcccggccagactgggaaaatcgctgattataactataagcttccagatgacttcacaggatgcgta 
               
               
                 attgcatggaactctaacaacctggactcaaaagttggtggcaactataactatctctatcgtttgttccgaaaatcaaaccttaaacccttt 
               
               
                 gaacgggatattaatacgacaatttaccaagcagggagcactccttgtaacggtgtagaaggtttcaattgttattttcctctgcaatcata 
               
               
                 cggattccaaccaacaaacggtgtgggttatcaaccttatcgggttgtagttttgagcttcgagcttaaccatgcacccgccacagtatgc 
               
               
                 ggaccgaagaagagtacaaacctggttaagaataaatgtgtaaacttcaactttaatggactgacggggacgggagtactcactgaaa 
               
               
                 gcaataagaaattcttgccttttcagcaattcgggcgggacatagcggacactacagacgccgtgcgcgacccccagactctcgaaat 
               
               
                 cctggacataaccccgtgctcatttggcggagtttcagtcatcactccagggaccaatacctcaaaccaagtagctgtgctgtatcaaga 
               
               
                 tgtgaattgcaccgaagtaccagtggccattcacgccgatcagctgaccccgacatggcgggtgtactcaaccggttcaaatgtgtttc 
               
               
                 aaacaagagcaggttgtcttattggcgctgaacacgtgaataactcctatgaatgcgacatcccaattggtgccggaatctgtgcctctta 
               
               
                 tcaaacacaaactaattcaccaaggcgtaggcgcagcgtcgcctctcaatcaattatagcctacaccatgtcactgggtgccgaaaact 
               
               
                 ccgtcgcgtacagcaacaatagcattgccatccctaccaacttcaccatcagctgtacaactgagatcctgcctgtatccatgacaaaga 
               
               
                 catcctgcgattgcactatgtacatctgtggagactctactgagtgtagcaacctcttgctccaatacgggagtttctgtacgcaactcaac 
               
               
                 cgtgccctcaccggcatagccgtagagcaagataagaatacccaggaagtatttgcccaagtaaagcaaatttataagacgccaccca 
               
               
                 ttaaagactttggcggtttcaacttcagtcaaatactgccagacccgtctcgcaggagaaggagttttattgaagacctgctctttaacaa 
               
               
                 ggtgactcttgccgatgctggatttattaaacaatatggggattgtctcggagatatcgctgctcgggatcttatctgcgcgcagaaattca 
               
               
                 acgggtgtaccgtgctcccacccttgctcactgacgaaatgatcgcgcaatatacctcagcacttctggcgggaactattacatctggtt 
               
               
                 ggacattcggcgcaggggcagctctccaaattcccttcgcaatgcaaatggcttacaggttcaatggcataggtgtcacacaaaacgt 
               
               
                 gctgtacgagaatcaaaagcttatagccaatcagtttaatagcgccataggcaagatccaagattccctgagctccacggcaagcgctc 
               
               
                 tgggaaaattgcaagacgtagtcaatcaaaacgctcaagcgctgaatacccttgtgaaacaactttcttcaaactttggagctatctcatct 
               
               
                 gggcccaacgatattctgagtcgactgccaaaggttgaagctgaagtccaaattgatcggttgatcacaggaaggctgcaatccctgc 
               
               
                 agacttacgtgacccagcaactgatcagggcagccgaaataagggcttccgccaatctggcagccacaaagatgtctgaatgtgtctt 
               
               
                 gggtcaaagcaaacgcgtcgatttctgtggcaaggggtaccatctgatgtcattccctcaatctgcccctcacggtgtggtatttctccatt 
               
               
                 gcacttatgttcccgcacaggagaagaacttcacaacagctcccgccatttgccacgacggaaaggcgcattttccccgcgaaggtgt 
               
               
                 cttcgtgtccaatgggactcattggtttgtgactcagaggaatttctatgagccgcagattatcaccaccgacaacactttcgtctccggta 
               
               
                 actgcgacgtcgttatcggaatcgtcaataacacagtgtatgatcctctgcagccggagctggactcattcaaagaggagttggataaat 
               
               
                 attttaagaatcatacaagccccgacgtcgatctgggcgatattagtggtatcaatgcgtccgtggttaacattcagaaagagattgaca 
               
               
                 gactcaatgaggtcgccaagaacttgaacgaatccttgattgatctccaggagttgggcaagtatgagcaatatatcaagtggccatgg 
               
               
                 tctgggcgaaggcgccgtcgcagagggtccggcggtagtggttccgggtacataccagaagctccacgagatggtcaagcttatgta 
               
               
                 aggaaagacggagagtgggtcctgcttagcacattcttgggttgataa (SEQ ID NO: 158) 
               
               
                   
               
               
                 ggauccgccaccauggacuggacauggauacuuuucuugguggcagcugcuacacgcguccacucaauguucgucuuuc 
               
               
                 uggugcucuugccacuggugagcagccaaugcguuaaccucaccacacgcacgcagcuuccacccgcauacacuaacucc 
               
               
                 uuuacgcgcggcguguacuauccagauaaaguguuccgaaguagcgucuugcauagcacccaggaucuguuucucccau 
               
               
                 ucuuuagcaaugucacaugguuccacgcuauccacgugucugggacgaauggaacuaaacguuuugacaauccuguucu 
               
               
                 uccuuuuaacgacggcguauacuuugcuaguacugagaagucuaacauuauccgcggcuggauuuucgggacaacccug 
               
               
                 gacuccaaaacccagucucugcugauaguaaacaaugccaccaacgucgucauuaaagugugcgaguuucaauucugcaa 
               
               
                 cgaccccuuucugggugucuauuaccacaagaacaauaagucuuggauggagucagaauuucgugucuauucuucugcc 
               
               
                 aauaauuguacauuugaguauguuucucaacccuuucucauggaccucgaaggcaagcaggggaauuuuaagaaccugc 
               
               
                 gggaauucgucuuuaagaauaucgacggcuauuucaaaauuuacagcaaacacacgccuauaaaccucgugcgagaucuc 
               
               
                 ccccaaggcuucucagcauuggagccauuggucgacuugccaaucggaauuaauaucacaagguuucagacucugcugg 
               
               
                 cccugcaucgcuccuaucuuaccccuggcgauuccucaaguggcuggacggccggcgcagcagccuauuacgucggcua 
               
               
                 ucuccagccaaggacguuucuuuugaaguauaaugaaaaugggacuauuacugacgccgucgacugcgcuuuggacccc 
               
               
                 cugagcgagacaaagugcacauugaaaagcuucacgguggagaaggguauuuaucaaacuuccaacuuuagggugcaac 
               
               
                 caacagagagcaucgugagguucccuaauaucacuaaucucuguccauuuggcgagguguuuaacgcgaccagauuugc 
               
               
                 aagcguauaugccuggaauaggaagagaauaagcaauuguguugccgauuacucugucuuguauaacagcgcaucuuuc 
               
               
                 agcacuuuuaagugcuauggugucaacgggacaaaacuuaacgaucuuugcuucaccaacguuuacgcagacucuuuug 
               
               
                 ucauacgcggagaugagguccgacaaauagcucccggccagacugggaaaaucgcugauuauaacuauaagcuuccagau 
               
               
                 gacuucacaggaugcguaauugcauggaacucuaacaaccuggacucaaaaguugguggcaacuauaacuaucucuaucg 
               
               
                 uuuguuccgaaaaucaaaccuuaaacccuuugaacgggauauuaauacgacaauuuaccaagcagggagcacuccuugua 
               
               
                 acgguguagaagguuucaauuguuauuuuccucugcaaucauacggauuccaaccaacaaacgguguggguuaucaacc 
               
               
                 uuaucggguuguaguuuugagcuucgagcuuaaccaugcacccgccacaguaugcggaccgaagaagaguacaaaccug 
               
               
                 guuaagaauaaauguguaaacuucaacuuuaauggacugacggggacgggaguacucacugaaagcaauaagaaauucu 
               
               
                 ugccuuuucagcaauucgggcgggacauagcggacacuacagacgccgugcgcgacccccagacucucgaaauccuggac 
               
               
                 auaaccccgugcucauuuggcggaguuucagucaucacuccagggaccaauaccucaaaccaaguagcugugcuguauca 
               
               
                 agaugugaauugcaccgaaguaccaguggccauucacgccgaucagcugaccccgacauggcggguguacucaaccggu 
               
               
                 ucaaauguguuucaaacaagagcagguugucuuauuggcgcugaacacgugaauaacuccuaugaaugcgacaucccaa 
               
               
                 uuggugccggaaucugugccucuuaucaaacacaaacuaauucaccaaggcguaggcgcagcgucgccucucaaucaauu 
               
               
                 auagccuacaccaugucacugggugccgaaaacuccgucgcguacagcaacaauagcauugccaucccuaccaacuucacc 
               
               
                 aucagcuguacaacugagauccugccuguauccaugacaaagacauccugcgauugcacuauguacaucuguggagacuc 
               
               
                 uacugaguguagcaaccucuugcuccaauacgggaguuucuguacgcaacucaaccgugcccucaccggcauagccguag 
               
               
                 agcaagauaagaauacccaggaaguauuugcccaaguaaagcaaauuuauaagacgccacccauuaaagacuuuggcggu 
               
               
                 uucaacuucagucaaauacugccagacccgucucgcaggagaaggaguuuuauugaagaccugcucuuuaacaagguga 
               
               
                 cucuugccgaugcuggauuuauuaaacaauauggggauugucucggagauaucgcugcucgggaucuuaucugcgcgc 
               
               
                 agaaauucaacggguguaccgugcucccacccuugcucacugacgaaaugaucgcgcaauauaccucagcacuucuggcg 
               
               
                 ggaacuauuacaucugguuggacauucggcgcaggggcagcucuccaaauucccuucgcaaugcaaauggcuuacaggu 
               
               
                 ucaauggcauaggugucacacaaaacgugcuguacgagaaucaaaagcuuauagccaaucaguuuaauagcgccauaggc 
               
               
                 aagauccaagauucccugagcuccacggcaagcgcucugggaaaauugcaagacguagucaaucaaaacgcucaagcgcu 
               
               
                 gaauacccuugugaaacaacuuucuucaaacuuuggagcuaucucaucugggcccaacgauauucugagucgacugccaa 
               
               
                 agguugaagcugaaguccaaauugaucgguugaucacaggaaggcugcaaucccugcagacuuacgugacccagcaacu 
               
               
                 gaucagggcagccgaaauaagggcuuccgccaaucuggcagccacaaagaugucugaaugugucuugggucaaagcaaac 
               
               
                 gcgucgauuucuguggcaagggguaccaucugaugucauucccucaaucugccccucacggugugguauuucuccauug 
               
               
                 cacuuauguucccgcacaggagaagaacuucacaacagcucccgccauuugccacgacggaaaggcgcauuuuccccgcg 
               
               
                 aaggugucuucguguccaaugggacucauugguuugugacucagaggaauuucuaugagccgcagauuaucaccaccga 
               
               
                 caacacuuucgucuccgguaacugcgacgucguuaucggaaucgucaauaacacaguguaugauccucugcagccggag 
               
               
                 cuggacucauucaaagaggaguuggauaaauauuuuaagaaucauacaagccccgacgucgaucugggcgauauuagug 
               
               
                 guaucaaugcguccgugguuaacauucagaaagagauugacagacucaaugaggucgccaagaacuugaacgaauccuu 
               
               
                 gauugaucuccaggaguugggcaaguaugagcaauauaucaaguggccauggucugggcgaaggcgccgucgcagaggg 
               
               
                 uccggcgguagugguuccggguacauaccagaagcuccacgagauggucaagcuuauguaaggaaagacggagaguggg 
               
               
                 uccugcuuagcacauucuuggguugauaa (SEQ ID NO: 159) 
               
               
                   
               
               
                 MDWTWILFLVAAATRVHSMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYY 
               
               
                 PDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE 
               
               
                 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWM 
               
               
                 ESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIN 
               
               
                 LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGY 
               
               
                 LQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVR 
               
               
                 FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV NG T 
               
               
                 KLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD 
               
               
                 SKVGGNYNYLYRLFRKSNLKPFERDI N T T IYQAGSTPCNGVEGFNCYFPLQSYGFQPT 
               
               
                 NGVGYQPYRVVVLSFEL N HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESN 
               
               
                 KKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQD 
               
               
                 VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICA 
               
               
                 SYQTQTNSPRR R RSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTIS C TTEILPVSMT 
               
               
                 KTSCDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIY 
               
               
                 KTPPIKDFGGFNFSQILPDPS RRR RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI 
               
               
                 CAQKFNG C TVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFN 
               
               
                 GIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVK 
               
               
                 QLSSNFGAISS GP NDILSRL P KVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL 
               
               
                 AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLH C TYVPAQEKNFTTAPA 
               
               
                 ICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVY 
               
               
                 DPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES 
               
               
                 LIDLQELGKYEQYIKWPWSGRRRRRRGSGGSGSGYIPEAPRDGQAYVRKDGEWVLL 
               
               
                 STFLG** (SEQ ID NO: 160) 
               
               
                   
               
            
           
         
       
     
     In some embodiments therefore, the expressible nucleic acid sequence comprised in the composition of the disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence comprised in the composition of the disclosure encodes a polypeptide comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. In some embodiments, the expressible nucleic acid sequence encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. 
     B. Nucleic Acid Molecule 
     In one aspect, the present disclosure also relates to a nucleic acid molecule that comprises any of the disclosed expressible nucleic acid sequences. In some embodiments, the nucleic acid molecule comprising one or a plurality of the disclosed expressible nucleic acid sequences is in form of a messanger RNA. In some embodiments, the nucleic acid molecule comprising one or a plurality of the disclosed expressible nucleic acid sequences is in form of a DNA. In some embodiments, the expressible nucleic acid sequence disclosed herein can be part of a plasmid and thus the nucleic acid molecule is a plasmid comprising such an expressible nucleic acid sequence. In some embodiments, provided herein is a vector or plasmid that is capable of expressing at least a monomer of a self-assembling nanoparticle and a viral antigen construct or constructs in the cell of a mammal in a quantity effective to elicit an immune response in the mammal. The vector or plasmid may comprise heterologous nucleic acid encoding the one or more viral antigens (such as SARS-CoV-2 antigens). In some embodiments, provided herein is a vector or plasmid that is capable of expressing at least one soluble trimer of a coronavirus or SARS-CoV-2 envelope polypeptide or constructs in the cell of a mammal in a quantity effective to elicit an immune response in the mammal. In some embodiments, the nucleic acid expresses a trimer of the spike protein of SARS-CoV-2 or a functional fragment or variant thereof. The vector may be a plasmid. The plasmid may be useful for transfecting cells with nucleic acid encoding a viral antigen, which the transformed host cell is cultured and maintained under conditions wherein expression of the viral antigen takes place and wherein the structure of the nanoparticle with the antigen or trimer elicits an immune response of a magnitude greater than and/or more therapeutically effective than the immune repsonse elicited by the antigen alone. The plasmid may further comprise an initiation codon, which may be upstream of the expressible sequence, and a stop codon, which may be downstream of the coding sequence. The initiation and termination codon may be in frame with the expressible sequence. 
     The plasmid may also comprise a promoter that is operably linked to the coding sequence. The promoter operably linked to the coding sequence may be a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter may also be a promoter from a human gene such as human actin, human myosin, human hemoglobin, human muscle creatine, or human metalothionein. The promoter may also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic. Examples of such promoters are described in US patent application publication No. US20040175727, the contents of which are incorporated herein in its entirety. The plasmid may also comprise a polyadenylation signal, which may be downstream of the coding sequence. The polyadenylation signal may be a SV40 polyadenylation signal, LTR polyadenylation signal, bovine growth hormone (bGH) polyadenylation signal, human growth hormone (hGH) polyadenylation signal, or human β-globin polyadenylation signal. The SV40 polyadenylation signal may be a polyadenylation signal from a pCEP4 plasmid (Invitrogen, San Diego, Calif.). 
     The plasmid may also comprise an enhancer upstream of the coding sequence. The enhancer may be human actin, human myosin, human hemoglobin, human muscle creatine or a viral enhancer such as one from CMV, FMDV, RSV or EBV. Polynucleotide function enhancers are described in U.S. Pat. Nos. 5,593,972, 5,962,428, and WO94/016737, the contents of each are fully incorporated by reference. The plasmid may also comprise a mammalian origin of replication in order to maintain the plasmid extrachromosomally and produce multiple copies of the plasmid in a cell. The plasmid may be pVAX1, pCEP4 or pREP4 from ThermoFisher Scientific (San Diego, Calif.), which may comprise the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region, which may produce high copy episomal replication without integration. 
     In some embodiments, the vector can be pVAX1 or a pVax1 variant with changes such as the variant plasmid described herein. The variant pVax1 plasmid is a 2998 basepair variant of the backbone vector plasmid pVAX1 (Invitrogen, Carlsbad Calif.). The CMV promoter is located at bases 137-724. The T7 promoter/priming site is at bases 664-683. Multiple cloning sites are at bases 696-811. Bovine GH polyadenylation signal is at bases 829-1053. The Kanamycin resistance gene is at bases 1226-2020. The pUC origin is at bases 2320-2993. The vaccine may comprise the consensus antigens and plasmids at quantities of from about 1 nanogram to 100 milligrams; about 1 microgram to about 10 milligrams; or preferably about 0.1 microgram to about 10 milligrams; or more preferably about 1 milligram to about 2 milligram. In some embodiments, pharmaceutical compositions according to the present disclosure comprise from about 1 nanogram to about 1000 micrograms of DNA. The nucleic acid sequence for the pVAX1 backbone sequence is as follows: 
     
       
         
           
               
               
            
               
                   
                 (SEQ ID NO: 161)  
               
               
                   
                 gactcttcgcgatgtacgggccagatatacgcgttgacat 
               
               
                   
                   
               
               
                   
                 tgattattgactagttattaatagtaatcaattacggggt 
               
               
                   
                   
               
               
                   
                 cattagttcatagcccatatatggagttccgcgttacata 
               
               
                   
                   
               
               
                   
                 acttacggtaaatggcccgcctggctgaccgcccaacgac 
               
               
                   
                   
               
               
                   
                 ccccgcccattgacgtcaataatgacgtatgttcccatag 
               
               
                   
                   
               
               
                   
                 taacgccaatagggactttccattgacgtcaatgggtgga 
               
               
                   
                   
               
               
                   
                 ctatttacggtaaactgcccacttggcagtacatcaagtg 
               
               
                   
                   
               
               
                   
                 tatcatatgccaagtacgccccctattgacgtcaatgacg 
               
               
                   
                   
               
               
                   
                 gtaaatggcccgcctggcattatgcccagtacatgacctt 
               
               
                   
                   
               
               
                   
                 atgggactttcctacttggcagtacatctacgtattagtc 
               
               
                   
                   
               
               
                   
                 atcgctattaccatggtgatgcggttttggcagtacatca 
               
               
                   
                   
               
               
                   
                 atgggcgtggatagcggtttgactcacggggatttccaag 
               
               
                   
                   
               
               
                   
                 tctccaccccattgacgtcaatgggagtttgttttggcac 
               
               
                   
                   
               
               
                   
                 caaaatcaacgggactttccaaaatgtcgtaacaactccg 
               
               
                   
                   
               
               
                   
                 ccccattgacgcaaatgggcggtaggcgtgtacggtggga 
               
               
                   
                   
               
               
                   
                 ggtctatataagcagagctctctggctaactagagaaccc 
               
               
                   
                   
               
               
                   
                 actgcttactggcttatcgaaattaatacgactcactata 
               
               
                   
                   
               
               
                   
                 gggagacccaagctggctagcgtttaaacttaagcttggt 
               
               
                   
                   
               
               
                   
                 accgagctcggatccactagtccagtgtggtggaattctg 
               
               
                   
                   
               
               
                   
                 cagatatccagcacagtggcggccgctcgagtctagaggg 
               
               
                   
                   
               
               
                   
                 cccgtttaaacccgctgatcagcctcgactgtgccttcta 
               
               
                   
                   
               
               
                   
                 gttgccagccatctgttgtttgcccctcccccgtgccttc 
               
               
                   
                   
               
               
                   
                 cttgaccctggaaggtgccactcccactgtcctttcctaa 
               
               
                   
                   
               
               
                   
                 taaaatgaggaaattgcatcgcattgtctgagtaggtgtc 
               
               
                   
                   
               
               
                   
                 attctattctggggggtggggtggggcaggacagcaaggg 
               
               
                   
                   
               
               
                   
                 ggaggattgggaagacaatagcaggcatgctggggatgcg 
               
               
                   
                   
               
               
                   
                 gtgggctctatggcttctactgggcggttttatggacagc 
               
               
                   
                   
               
               
                   
                 aagcgaaccggaattgccagctggggcgccctctggtaag 
               
               
                   
                   
               
               
                   
                 gttgggaagccctgcaaagtaaactggatggctttctcgc 
               
               
                   
                   
               
               
                   
                 cgccaaggatctgatggcgcaggggatcaagctctgatca 
               
               
                   
                   
               
               
                   
                 agagacaggatgaggatcgtttcgcatgattgaacaagat 
               
               
                   
                   
               
               
                   
                 ggattgcacgcaggttctccggccgcttgggtggagaggc 
               
               
                   
                   
               
               
                   
                 tattcggctatgactgggcacaacagacaatcggctgctc 
               
               
                   
                   
               
               
                   
                 tgatgccgccgtgttccggctgtcagcgcaggggcgcccg 
               
               
                   
                   
               
               
                   
                 gttctttttgtcaagaccgacctgtccggtgccctgaatg 
               
               
                   
                   
               
               
                   
                 aactgcaagacgaggcagcgcggctatcgtggctggccac 
               
               
                   
                   
               
               
                   
                 gacgggcgttccttgcgcagctgtgctcgacgttgtcact 
               
               
                   
                   
               
               
                   
                 gaagcgggaagggactggctgctattgggcgaagtgccgg 
               
               
                   
                   
               
               
                   
                 ggcaggatctcctgtcatctcaccttgctcctgccgagaa 
               
               
                   
                   
               
               
                   
                 agtatccatcatggctgatgcaatgcggcggctgcatacg 
               
               
                   
                   
               
               
                   
                 cttgatccggctacctgcccattcgaccaccaagcgaaac 
               
               
                   
                   
               
               
                   
                 atcgcatcgagcgagcacgtactcggatggaagccggtct 
               
               
                   
                   
               
               
                   
                 tgtcgatcaggatgatctggacgaagagcatcaggggctc 
               
               
                   
                   
               
               
                   
                 gcgccagccgaactgttcgccaggctcaaggcgagcatgc 
               
               
                   
                   
               
               
                   
                 ccgacggcgaggatctcgtcgtgacccatggcgatgcctg 
               
               
                   
                   
               
               
                   
                 cttgccgaatatcatggtggaaaatggccgcttttctgga 
               
               
                   
                   
               
               
                   
                 ttcatcgactgtggccggctgggtgtggcggaccgctatc 
               
               
                   
                   
               
               
                   
                 aggacatagcgttggctacccgtgatattgctgaagagct 
               
               
                   
                   
               
               
                   
                 tggcggcgaatgggctgaccgcttcctcgtgctttacggt 
               
               
                   
                   
               
               
                   
                 atcgccgctcccgattcgcagcgcatcgccttctatcgcc 
               
               
                   
                   
               
               
                   
                 ttcttgacgagttcttctgaattattaacgcttacaattt 
               
               
                   
                   
               
               
                   
                 cctgatgcggtattttctccttacgcatctgtgcggtatt 
               
               
                   
                   
               
               
                   
                 tcacaccgcatacaggtggcacttttcggggaaatgtgcg 
               
               
                   
                   
               
               
                   
                 cggaacccctatttgtttatttttctaaatacattcaaat 
               
               
                   
                   
               
               
                   
                 atgtatccgctcatgagacaataaccctgataaatgcttc 
               
               
                   
                   
               
               
                   
                 aataatagcacgtgctaaaacttcatttttaatttaaaag 
               
               
                   
                   
               
               
                   
                 gatctaggtgaagatcctttttgataatctcatgaccaaa 
               
               
                   
                   
               
               
                   
                 atcccttaacgtgagttttcgttccactgagcgtcagacc 
               
               
                   
                   
               
               
                   
                 ccgtagaaaagatcaaaggatcttcttgagatcctttttt 
               
               
                   
                   
               
               
                   
                 tctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccg 
               
               
                   
                   
               
               
                   
                 ctaccagcggtggtttgtttgccggatcaagagctaccaa 
               
               
                   
                   
               
               
                   
                 ctctttttccgaaggtaactggcttcagcagagcgcagat 
               
               
                   
                   
               
               
                   
                 accaaatactgtccttctagtgtagccgtagttaggccac 
               
               
                   
                   
               
               
                   
                 cacttcaagaactctgtagcaccgcctacatacctcgctc 
               
               
                   
                   
               
               
                   
                 tgctaatcctgttaccagtggctgctgccagtggcgataa 
               
               
                   
                   
               
               
                   
                 gtcgtgtcttaccgggttggactcaagacgatagttaccg 
               
               
                   
                   
               
               
                   
                 gataaggcgcagcggtcgggctgaacggggggttcgtgca 
               
               
                   
                   
               
               
                   
                 cacagcccagcttggagcgaacgacctacaccgaactgag 
               
               
                   
                   
               
               
                   
                 atacctacagcgtgagctatgagaaagcgccacgcttccc 
               
               
                   
                   
               
               
                   
                 gaagggagaaaggcggacaggtatccggtaagcggcaggg 
               
               
                   
                   
               
               
                   
                 tcggaacaggagagcgcacgagggagcttccagggggaaa 
               
               
                   
                   
               
               
                   
                 cgcctggtatctttatagtcctgtcgggtttcgccacctc 
               
               
                   
                   
               
               
                   
                 tgacttgagcgtcgatttttgtgatgctcgtcaggggggc 
               
               
                   
                   
               
               
                   
                 ggagcctatggaaaaacgccagcaacgcggcctttttacg 
               
               
                   
                   
               
               
                   
                 gttcctgggcttttgctggccttttgctcacatgttctt 
               
            
           
         
       
     
     Other vectors or plasmids that can be used herein to produce the vaccine of the present disclosure include, but not limited to, pcDNA3.1(+), pCI mammalian expression vector, pSI vector, pZeoSV2(+), phCMV1, pTCP and pIRES with their respective backbone sequence as follows. 
     The pcDNA3.1(+) backbone sequence (SEQ ID NO: 162): 
     
       
         
           
               
               
            
               
                   
                 gacggatcgggagatctcccgatcccctatggtgcactct 
               
               
                   
                   
               
               
                   
                 cagtacaatctgctctgatgccgcatagttaagccagtat 
               
               
                   
                   
               
               
                   
                 ctgctccctgcttgtgtgttggaggtcgctgagtagtgcg 
               
               
                   
                   
               
               
                   
                 cgagcaaaatttaagctacaacaaggcaaggcttgaccga 
               
               
                   
                   
               
               
                   
                 caattgcatgaagaatctgcttagggttaggcgttttgcg 
               
               
                   
                   
               
               
                   
                 ctgcttcgcgatgtacgggccagatatacgcgttgacatt 
               
               
                   
                   
               
               
                   
                 gattattgactagttattaatagtaatcaattacggggtc 
               
               
                   
                   
               
               
                   
                 attagttcatagcccatatatggagttccgcgttacataa 
               
               
                   
                   
               
               
                   
                 cttacggtaaatggcccgcctggctgaccgcccaacgacc 
               
               
                   
                   
               
               
                   
                 cccgcccattgacgtcaataatgacgtatgttcccatagt 
               
               
                   
                   
               
               
                   
                 aacgccaatagggactttccattgacgtcaatgggtggag 
               
               
                   
                   
               
               
                   
                 tatttacggtaaactgcccacttggcagtacatcaagtgt 
               
               
                   
                   
               
               
                   
                 atcatatgccaagtacgccccctattgacgtcaatgacgg 
               
               
                   
                   
               
               
                   
                 taaatggcccgcctggcattatgcccagtacatgacctta 
               
               
                   
                   
               
               
                   
                 tgggactttcctacttggcagtacatctacgtattagtca 
               
               
                   
                   
               
               
                   
                 tcgctattaccatggtgatgcggttttggcagtacatcaa 
               
               
                   
                   
               
               
                   
                 tgggcgtggatagcggtttgactcacggggatttccaagt 
               
               
                   
                   
               
               
                   
                 ctccaccccattgacgtcaatgggagtttgttttggcacc 
               
               
                   
                   
               
               
                   
                 aaaatcaacgggactttccaaaatgtcgtaacaactccgc 
               
               
                   
                   
               
               
                   
                 cccattgacgcaaatgggcggtaggcgtgtacggtgggag 
               
               
                   
                   
               
               
                   
                 gtctatataagcagagctctctggctaactagagaaccca 
               
               
                   
                   
               
               
                   
                 ctgcttactggcttatcgaaattaatacgactcactatag 
               
               
                   
                   
               
               
                   
                 ggagacccaagctggctagcgtttaaacttaagcttggta 
               
               
                   
                   
               
               
                   
                 ccgagctcggatccactagtccagtgtggtggaattctgc 
               
               
                   
                   
               
               
                   
                 agatatccagcacagtggcggccgctcgagtctagagggc 
               
               
                   
                   
               
               
                   
                 ccgtttaaacccgctgatcagcctcgactgtgccttctag 
               
               
                   
                   
               
               
                   
                 ttgccagccatctgttgtttgcccctcccccgtgccttcc 
               
               
                   
                   
               
               
                   
                 ttgaccctggaaggtgccactcccactgtcctttcctaat 
               
               
                   
                   
               
               
                   
                 aaaatgaggaaattgcatcgcattgtctgagtaggtgtca 
               
               
                   
                   
               
               
                   
                 ttctattctggggggtggggtggggcaggacagcaagggg 
               
               
                   
                   
               
               
                   
                 gaggattgggaagacaatagcaggcatgctggggatgcgg 
               
               
                   
                   
               
               
                   
                 tgggctctatggcttctgaggcggaaagaaccagctgggg 
               
               
                   
                   
               
               
                   
                 ctctagggggtatccccacgcgccctgtagcggcgcatta 
               
               
                   
                   
               
               
                   
                 agcgcggcgggtgtggtggttacgcgcagcgtgaccgcta 
               
               
                   
                   
               
               
                   
                 cacttgccagcgccctagcgcccgctcctttcgctttctt 
               
               
                   
                   
               
               
                   
                 cccttcctttctcgccacgttcgccggctttccccgtcaa 
               
               
                   
                   
               
               
                   
                 gctctaaatcgggggctccctttagggttccgatttagtg 
               
               
                   
                   
               
               
                   
                 ctttacggcacctcgaccccaaaaaacttgattagggtga 
               
               
                   
                   
               
               
                   
                 tggttcacgtagtgggccatcgccctgatagacggttttt 
               
               
                   
                   
               
               
                   
                 cgccctttgacgttggagtccacgttctttaatagtggac 
               
               
                   
                   
               
               
                   
                 tcttgttccaaactggaacaacactcaaccctatctcggt 
               
               
                   
                   
               
               
                   
                 ctattcttttgatttataagggattttgccgatttcggcc 
               
               
                   
                   
               
               
                   
                 tattggttaaaaaatgagctgatttaacaaaaatttaacg 
               
               
                   
                   
               
               
                   
                 cgaattaattctgtggaatgtgtgtcagttagggtgtgga 
               
               
                   
                   
               
               
                   
                 aagtccccaggctccccagcaggcagaagtatgcaaagca 
               
               
                   
                   
               
               
                   
                 tgcatctcaattagtcagcaaccaggtgtggaaagtcccc 
               
               
                   
                   
               
               
                   
                 aggctccccagcaggcagaagtatgcaaagcatgcatctc 
               
               
                   
                   
               
               
                   
                 aattagtcagcaaccatagtcccgcccctaactccgccca 
               
               
                   
                   
               
               
                   
                 tcccgcccctaactccgcccagttccgcccattctccgcc 
               
               
                   
                   
               
               
                   
                 ccatggctgactaattttttttatttatgcagaggccgag 
               
               
                   
                   
               
               
                   
                 gccgcctctgcctctgagctattccagaagtagtgaggag 
               
               
                   
                   
               
               
                   
                 gcttttttggaggcctaggcttttgcaaaaagctcccggg 
               
               
                   
                   
               
               
                   
                 agcttgtatatccattttcggatctgatcaagagacagga 
               
               
                   
                   
               
               
                   
                 tgaggatcgtttcgcatgattgaacaagatggattgcacg 
               
               
                   
                   
               
               
                   
                 caggttctccggccgcttgggtggagaggctattcggcta 
               
               
                   
                   
               
               
                   
                 tgactgggcacaacagacaatcggctgctctgatgccgcc 
               
               
                   
                   
               
               
                   
                 gtgttccggctgtcagcgcaggggcgcccggttctttttg 
               
               
                   
                   
               
               
                   
                 tcaagaccgacctgtccggtgccctgaatgaactgcagga 
               
               
                   
                   
               
               
                   
                 cgaggcagcgcggctatcgtggctggccacgacgggcgtt 
               
               
                   
                   
               
               
                   
                 ccttgcgcagctgtgctcgacgttgtcactgaagcgggaa 
               
               
                   
                   
               
               
                   
                 gggactggctgctattgggcgaagtgccggggcaggatct 
               
               
                   
                   
               
               
                   
                 cctgtcatctcaccttgctcctgccgagaaagtatccatc 
               
               
                   
                   
               
               
                   
                 atggctgatgcaatgcggcggctgcatacgcttgatccgg 
               
               
                   
                   
               
               
                   
                 ctacctgcccattcgaccaccaagcgaaacatcgcatcga 
               
               
                   
                   
               
               
                   
                 gcgagcacgtactcggatggaagccggtcttgtcgatcag 
               
               
                   
                   
               
               
                   
                 gatgatctggacgaagagcatcaggggctcgcgccagccg 
               
               
                   
                   
               
               
                   
                 aactgttcgccaggctcaaggcgcgcatgcccgacggcga 
               
               
                   
                   
               
               
                   
                 ggatctcgtcgtgacccatggcgatgcctgcttgccgaat 
               
               
                   
                   
               
               
                   
                 atcatggtggaaaatggccgcttttctggattcatcgact 
               
               
                   
                   
               
               
                   
                 gtggccggctgggtgtggcggaccgctatcaggacatagc 
               
               
                   
                   
               
               
                   
                 gttggctacccgtgatattgctgaagagcttggcggcgaa 
               
               
                   
                   
               
               
                   
                 tgggctgaccgcttcctcgtgctttacggtatcgccgctc 
               
               
                   
                   
               
               
                   
                 ccgattcgcagcgcatcgccttctatcgccttcttgacga 
               
               
                   
                   
               
               
                   
                 gttcttctgagcgggactctggggttcgaaatgaccgacc 
               
               
                   
                   
               
               
                   
                 aagcgacgcccaacctgccatcacgagatttcgattccac 
               
               
                   
                   
               
               
                   
                 cgccgccttctatgaaaggttgggcttcggaatcgttttc 
               
               
                   
                   
               
               
                   
                 cgggacgccggctggatgatcctccagcgcggggatctca 
               
               
                   
                   
               
               
                   
                 tgctggagttcttcgcccaccccaacttgtttattgcagc 
               
               
                   
                   
               
               
                   
                 ttataatggttacaaataaagcaatagcatcacaaatttc 
               
               
                   
                   
               
               
                   
                 acaaataaagcatttttttcactgcattctagttgtggtt 
               
               
                   
                   
               
               
                   
                 tgtccaaactcatcaatgtatcttatcatgtctgtatacc 
               
               
                   
                   
               
               
                   
                 gtcgacctctagctagagcttggcgtaatcatggtcatag 
               
               
                   
                   
               
               
                   
                 ctgtttcctgtgtgaaattgttatccgctcacaattccac 
               
               
                   
                   
               
               
                   
                 acaacatacgagccggaagcataaagtgtaaagcctgggg 
               
               
                   
                   
               
               
                   
                 tgcctaatgagtgagctaactcacattaattgcgttgcgc 
               
               
                   
                   
               
               
                   
                 tcactgcccgctttccagtcgggaaacctgtcgtgccagc 
               
               
                   
                   
               
               
                   
                 tgcattaatgaatcggccaacgcgcggggagaggcggttt 
               
               
                   
                   
               
               
                   
                 gcgtattgggcgctcttccgcttcctcgctcactgactcg 
               
               
                   
                   
               
               
                   
                 ctgcgctcggtcgttcggctgcggcgagcggtatcagctc 
               
               
                   
                   
               
               
                   
                 actcaaaggcggtaatacggttatccacagaatcagggga 
               
               
                   
                   
               
               
                   
                 taacgcaggaaagaacatgtgagcaaaaggccagcaaaag 
               
               
                   
                   
               
               
                   
                 gccaggaaccgtaaaaaggccgcgttgctggcgtttttcc 
               
               
                   
                   
               
               
                   
                 ataggctccgcccccctgacgagcatcacaaaaatcgacg 
               
               
                   
                   
               
               
                   
                 ctcaagtcagaggtggcgaaacccgacaggactataaaga 
               
               
                   
                   
               
               
                   
                 taccaggcgtttccccctggaagctccctcgtgcgctctc 
               
               
                   
                   
               
               
                   
                 ctgttccgaccctgccgcttaccggatacctgtccgcctt 
               
               
                   
                   
               
               
                   
                 tctcccttcgggaagcgtggcgctttctcatagctcacgc 
               
               
                   
                   
               
               
                   
                 tgtaggtatctcagttcggtgtaggtcgttcgctccaagc 
               
               
                   
                   
               
               
                   
                 tgggctgtgtgcacgaaccccccgttcagcccgaccgctg 
               
               
                   
                   
               
               
                   
                 cgccttatccggtaactatcgtcttgagtccaacccggta 
               
               
                   
                   
               
               
                   
                 agacacgacttatcgccactggcagcagccactggtaaca 
               
               
                   
                   
               
               
                   
                 ggattagcagagcgaggtatgtaggcggtgctacagagtt 
               
               
                   
                   
               
               
                   
                 cttgaagtggtggcctaactacggctacactagaagaaca 
               
               
                   
                   
               
               
                   
                 gtatttggtatctgcgctctgctgaagccagttaccttcg 
               
               
                   
                   
               
               
                   
                 gaaaaagagttggtagctcttgatccggcaaacaaaccac 
               
               
                   
                   
               
               
                   
                 cgctggtagcggtttttttgtttgcaagcagcagattacg 
               
               
                   
                   
               
               
                   
                 cgcagaaaaaaaggatctcaagaagatcctttgatctttt 
               
               
                   
                   
               
               
                   
                 ctacggggtctgacgctcagtggaacgaaaactcacgtta 
               
               
                   
                   
               
               
                   
                 agggattttggtcatgagattatcaaaaaggatcttcacc 
               
               
                   
                   
               
               
                   
                 tagatccttttaaattaaaaatgaagttttaaatcaatct 
               
               
                   
                   
               
               
                   
                 aaagtatatatgagtaaacttggtctgacagttaccaatg 
               
               
                   
                   
               
               
                   
                 cttaatcagtgaggcacctatctcagcgatctgtctattt 
               
               
                   
                   
               
               
                   
                 cgttcatccatagttgcctgactccccgtcgtgtagataa 
               
               
                   
                   
               
               
                   
                 ctacgatacgggagggcttaccatctggccccagtgctgc 
               
               
                   
                   
               
               
                   
                 aatgataccgcgagacccacgctcaccggctccagattta 
               
               
                   
                   
               
               
                   
                 tcagcaataaaccagccagccggaagggccgagcgcagaa 
               
               
                   
                   
               
               
                   
                 gtggtcctgcaactttatccgcctccatccagtctattaa 
               
               
                   
                   
               
               
                   
                 ttgttgccgggaagctagagtaagtagttcgccagttaat 
               
               
                   
                   
               
               
                   
                 agtttgcgcaacgttgttgccattgctacaggcatcgtgg 
               
               
                   
                   
               
               
                   
                 tgtcacgctcgtcgtttggtatggcttcattcagctccgg 
               
               
                   
                   
               
               
                   
                 ttcccaacgatcaaggcgagttacatgatcccccatgttg 
               
               
                   
                   
               
               
                   
                 tgcaaaaaagcggttagctccttcggtcctccgatcgttg 
               
               
                   
                   
               
               
                   
                 tcagaagtaagttggccgcagtgttatcactcatggttat 
               
               
                   
                   
               
               
                   
                 ggcagcactgcataattctcttactgtcatgccatccgta 
               
               
                   
                   
               
               
                   
                 agatgcttttctgtgactggtgagtactcaaccaagtcat 
               
               
                   
                   
               
               
                   
                 tctgagaatagtgtatgcggcgaccgagttgctcttgccc 
               
               
                   
                   
               
               
                   
                 ggcgtcaatacgggataataccgcgccacatagcagaact 
               
               
                   
                   
               
               
                   
                 ttaaaagtgctcatcattggaaaacgttcttcggggcgaa 
               
               
                   
                   
               
               
                   
                 aactctcaaggatcttaccgctgttgagatccagttcgat 
               
               
                   
                   
               
               
                   
                 gtaacccactcgtgcacccaactgatcttcagcatctttt 
               
               
                   
                   
               
               
                   
                 actttcaccagcgtttctgggtgagcaaaaacaggaaggc 
               
               
                   
                   
               
               
                   
                 aaaatgccgcaaaaaagggaataagggcgacacggaaatg 
               
               
                   
                   
               
               
                   
                 ttgaatactcatactcttcctttttcaatattattgaagc 
               
               
                   
                   
               
               
                   
                 atttatcagggttattgtctcatgagcggatacatatttg 
               
               
                   
                   
               
               
                   
                 aatgtatttagaaaaataaacaaataggggttccgcgcac 
               
               
                   
                   
               
               
                   
                 atttccccgaaaagtgccacctgacgtc  
               
            
           
         
       
     
     The pCI mammalian expression vector backbone sequence (SEQ ID NO: 163): 
     
       
         
           
               
               
            
               
                   
                 tcaatattggccattagccatattattcattggttatata 
               
               
                   
                   
               
               
                   
                 gcataaatcaatattggctattggccattgcatacgttgt 
               
               
                   
                   
               
               
                   
                 atctatatcataatatgtacatttatattggctcatgtcc 
               
               
                   
                   
               
               
                   
                 aatatgaccgccatgttggcattgattattgactagttat 
               
               
                   
                   
               
               
                   
                 taatagtaatcaattacggggtcattagttcatagcccat 
               
               
                   
                   
               
               
                   
                 atatggagttccgcgttacataacttacggtaaatggccc 
               
               
                   
                   
               
               
                   
                 gcctggctgaccgcccaacgacccccgcccattgacgtca 
               
               
                   
                   
               
               
                   
                 ataatgacgtatgttcccatagtaacgccaatagggactt 
               
               
                   
                   
               
               
                   
                 tccattgacgtcaatgggtggagtatttacggtaaactgc 
               
               
                   
                   
               
               
                   
                 ccacttggcagtacatcaagtgtatcatatgccaagtccg 
               
               
                   
                   
               
               
                   
                 ccccctattgacgtcaatgacggtaaatggcccgcctggc 
               
               
                   
                   
               
               
                   
                 attatgcccagtacatgaccttacgggactttcctacttg 
               
               
                   
                   
               
               
                   
                 gcagtacatctacgtattagtcatcgctattaccatggtg 
               
               
                   
                   
               
               
                   
                 atgcggttttggcagtacaccaatgggcgtggatagcggt 
               
               
                   
                   
               
               
                   
                 ttgactcacggggatttccaagtctccaccccattgacgt 
               
               
                   
                   
               
               
                   
                 caatgggagtttgttttggcaccaaaatcaacgggacttt 
               
               
                   
                   
               
               
                   
                 ccaaaatgtcgtaataaccccgccccgttgacgcaaatgg 
               
               
                   
                   
               
               
                   
                 gcggtaggcgtgtacggtgggaggtctatataagcagagc 
               
               
                   
                   
               
               
                   
                 tcgtttagtgaaccgtcagatcactagaagctttattgcg 
               
               
                   
                   
               
               
                   
                 gtagtttatcacagttaaattgctaacgcagtcagtgctt 
               
               
                   
                   
               
               
                   
                 ctgacacaacagtctcgaacttaagctgcagaagttggtc 
               
               
                   
                   
               
               
                   
                 gtgaggcactgggcaggtaagtatcaaggttacaagacag 
               
               
                   
                   
               
               
                   
                 gtttaaggagaccaatagaaactgggcttgtcgagacaga 
               
               
                   
                   
               
               
                   
                 gaagactcttgcgtttctgataggcacctattggtcttac 
               
               
                   
                   
               
               
                   
                 tgacatccactttgcctttctctccacaggtgtccactcc 
               
               
                   
                   
               
               
                   
                 cagttcaattacagctcttaaggctagagtacttaatacg 
               
               
                   
                   
               
               
                   
                 actcactataggctagcctcgagaattcacgcgtggtacc 
               
               
                   
                   
               
               
                   
                 tctagagtcgacccgggcggccgcttcgagcagacatgat 
               
               
                   
                   
               
               
                   
                 aagatacattgatgagtttggacaaaccacaactagaatg 
               
               
                   
                   
               
               
                   
                 cagtgaaaaaaatgctttatttgtgaaatttgtgatgcta 
               
               
                   
                   
               
               
                   
                 ttgctttatttgtaaccattataagctgcaataaacaagt 
               
               
                   
                   
               
               
                   
                 taacaacaacaattgcattcattttatgtttcaggttcag 
               
               
                   
                   
               
               
                   
                 ggggagatgtgggaggttttttaaagcaagtaaaacctct 
               
               
                   
                   
               
               
                   
                 acaaatgtggtaaaatcgataaggatccgggctggcgtaa 
               
               
                   
                   
               
               
                   
                 tagcgaagaggcccgcaccgatcgcccttcccaacagttg 
               
               
                   
                   
               
               
                   
                 cgcagcctgaatggcgaatggacgcgccctgtagcggcgc 
               
               
                   
                   
               
               
                   
                 attaagcgcggcgggtgtggtggttacgcgcagcgtgacc 
               
               
                   
                   
               
               
                   
                 gctacacttgccagcgccctagcgcccgctcctttcgctt 
               
               
                   
                   
               
               
                   
                 tcttcccttcctttctcgccacgttcgccggctttccccg 
               
               
                   
                   
               
               
                   
                 tcaagctctaaatcgggggctccctttagggttccgattt 
               
               
                   
                   
               
               
                   
                 agtgctttacggcacctcgaccccaaaaaacttgattagg 
               
               
                   
                   
               
               
                   
                 gtgatggttcacgtagtgggccatcgccctgatagacggt 
               
               
                   
                   
               
               
                   
                 ttttcgccctttgacgttggagtccacgttctttaatagt 
               
               
                   
                   
               
               
                   
                 ggactcttgttccaaactggaacaacactcaaccctatct 
               
               
                   
                   
               
               
                   
                 cggtctattcttttgatttataagggattttgccgatttc 
               
               
                   
                   
               
               
                   
                 ggcctattggttaaaaaatgagctgatttaacaaaaattt 
               
               
                   
                   
               
               
                   
                 aacgcgaattttaacaaaatattaacgcttacaatttcct 
               
               
                   
                   
               
               
                   
                 gatgcggtattttctccttacgcatctgtgcggtatttca 
               
               
                   
                   
               
               
                   
                 caccgcatatggtgcactctcagtacaatctgctctgatg 
               
               
                   
                   
               
               
                   
                 ccgcatagttaagccagccccgacacccgccaacacccgc 
               
               
                   
                   
               
               
                   
                 tgacgcgccctgacgggcttgtctgctcccggcatccgct 
               
               
                   
                   
               
               
                   
                 tacagacaagctgtgaccgtctccgggagctgcatgtgtc 
               
               
                   
                   
               
               
                   
                 agaggttttcaccgtcatcaccgaaacgcgcgagacgaaa 
               
               
                   
                   
               
               
                   
                 gggcctcgtgatacgcctatttttataggttaatgtcatg 
               
               
                   
                   
               
               
                   
                 ataataatggtttcttagacgtcaggtggcacttttcggg 
               
               
                   
                   
               
               
                   
                 gaaatgtgcgcggaacccctatttgtttatttttctaaat 
               
               
                   
                   
               
               
                   
                 acattcaaatatgtatccgctcatgagacaataaccctga 
               
               
                   
                   
               
               
                   
                 taaatgcttcaataatattgaaaaaggaagagtatgagta 
               
               
                   
                   
               
               
                   
                 ttcaacatttccgtgtcgcccttattcccttttttgcggc 
               
               
                   
                   
               
               
                   
                 attttgccttcctgtttttgctcacccagaaacgctggtg 
               
               
                   
                   
               
               
                   
                 aaagtaaaagatgctgaagatcagttgggtgcacgagtgg 
               
               
                   
                   
               
               
                   
                 gttacatcgaactggatctcaacagcggtaagatccttga 
               
               
                   
                   
               
               
                   
                 gagttttcgccccgaagaacgttttccaatgatgagcact 
               
               
                   
                   
               
               
                   
                 tttaaagttctgctatgtggcgcggtattatcccgtattg 
               
               
                   
                   
               
               
                   
                 acgccgggcaagagcaactcggtcgccgcatacactattc 
               
               
                   
                   
               
               
                   
                 tcagaatgacttggttgagtactcaccagtcacagaaaag 
               
               
                   
                   
               
               
                   
                 catcttacggatggcatgacagtaagagaattatgcagtg 
               
               
                   
                   
               
               
                   
                 ctgccataaccatgagtgataacactgcggccaacttact 
               
               
                   
                   
               
               
                   
                 tctgacaacgatcggaggaccgaaggagctaaccgctttt 
               
               
                   
                   
               
               
                   
                 ttgcacaacatgggggatcatgtaactcgccttgatcgtt 
               
               
                   
                   
               
               
                   
                 gggaaccggagctgaatgaagccataccaaacgacgagcg 
               
               
                   
                   
               
               
                   
                 tgacaccacgatgcctgtagcaatggcaacaacgttgcgc 
               
               
                   
                   
               
               
                   
                 aaactattaactggcgaactacttactctagcttcccggc 
               
               
                   
                   
               
               
                   
                 aacaattaatagactggatggaggcggataaagttgcagg 
               
               
                   
                   
               
               
                   
                 accacttctgcgctcggcccttccggctggctggtttatt 
               
               
                   
                   
               
               
                   
                 gctgataaatctggagccggtgagcgtgggtctcgcggta 
               
               
                   
                   
               
               
                   
                 tcattgcagcactggggccagatggtaagccctcccgtat 
               
               
                   
                   
               
               
                   
                 cgtagttatctacacgacggggagtcaggcaactatggat 
               
               
                   
                   
               
               
                   
                 gaacgaaatagacagatcgctgagataggtgcctcactga 
               
               
                   
                   
               
               
                   
                 ttaagcattggtaactgtcagaccaagtttactcatatat 
               
               
                   
                   
               
               
                   
                 actttagattgatttaaaacttcatttttaatttaaaagg 
               
               
                   
                   
               
               
                   
                 atctaggtgaagatcctttttgataatctcatgaccaaaa 
               
               
                   
                   
               
               
                   
                 tcccttaacgtgagttttcgttccactgagcgtcagaccc 
               
               
                   
                   
               
               
                   
                 cgtagaaaagatcaaaggatcttcttgagatccttttttt 
               
               
                   
                   
               
               
                   
                 ctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgc 
               
               
                   
                   
               
               
                   
                 taccagcggtggtttgtttgccggatcaagagctaccaac 
               
               
                   
                   
               
               
                   
                 tctttttccgaaggtaactggcttcagcagagcgcagata 
               
               
                   
                   
               
               
                   
                 ccaaatactgttcttctagtgtagccgtagttaggccacc 
               
               
                   
                   
               
               
                   
                 acttcaagaactctgtagcaccgcctacatacctcgctct 
               
               
                   
                   
               
               
                   
                 gctaatcctgttaccagtggctgctgccagtggcgataag 
               
               
                   
                   
               
               
                   
                 tcgtgtcttaccgggttggactcaagacgatagttaccgg 
               
               
                   
                   
               
               
                   
                 ataaggcgcagcggtcgggctgaacggggggttcgtgcac 
               
               
                   
                   
               
               
                   
                 acagcccagcttggagcgaacgacctacaccgaactgaga 
               
               
                   
                   
               
               
                   
                 tacctacagcgtgagctatgagaaagcgccacgcttcccg 
               
               
                   
                   
               
               
                   
                 aagggagaaaggcggacaggtatccggtaagcggcagggt 
               
               
                   
                   
               
               
                   
                 cggaacaggagagcgcacgagggagcttccagggggaaac 
               
               
                   
                   
               
               
                   
                 gcctggtatctttatagtcctgtcgggtttcgccacctct 
               
               
                   
                   
               
               
                   
                 gacttgagcgtcgatttttgtgatgctcgtcaggggggcg 
               
               
                   
                   
               
               
                   
                 gagcctatggaaaaacgccagcaacgcggcctttttacgg 
               
               
                   
                   
               
               
                   
                 ttcctggccttttgctggccttttgctcacatggctcgac 
               
               
                   
                   
               
               
                   
                 agatct 
               
            
           
         
       
     
     The pSI vector backbone sequence (SEQ ID NO: 164): 
     
       
         
           
               
               
            
               
                   
                 gcgcagcaccatggcctgaaataacctctgaaagaggaac 
               
               
                   
                   
               
               
                   
                 ttggttaggtaccttctgaggcggaaagaaccagctgtgg 
               
               
                   
                   
               
               
                   
                 aatgtgtgtcagttagggtgtggaaagtccccaggctccc 
               
               
                   
                   
               
               
                   
                 cagcaggcagaagtatgcaaagcatgcatctcaattagtc 
               
               
                   
                   
               
               
                   
                 agcaaccaggtgtggaaagtccccaggctccccagcaggc 
               
               
                   
                   
               
               
                   
                 agaagtatgcaaagcatgcatctcaattagtcagcaacca 
               
               
                   
                   
               
               
                   
                 tagtcccgcccctaactccgcccatcccgcccctaactcc 
               
               
                   
                   
               
               
                   
                 gcccagttccgcccattctccgccccatggctgactaatt 
               
               
                   
                   
               
               
                   
                 ttttttatttatgcagaggccgaggccgcctcggcctctg 
               
               
                   
                   
               
               
                   
                 agctattccagaagtagtgaggaggcttttttggaggcct 
               
               
                   
                   
               
               
                   
                 aggcttttgcaaaaagcttgattcttctgacacaacagtc 
               
               
                   
                   
               
               
                   
                 tcgaacttaagctgcagaagttggtcgtgaggcactgggc 
               
               
                   
                   
               
               
                   
                 aggtaagtatcaaggttacaagacaggtttaaggagacca 
               
               
                   
                   
               
               
                   
                 atagaaactgggcttgtcgagacagagaagactcttgcgt 
               
               
                   
                   
               
               
                   
                 ttctgataggcacctattggtcttactgacatccactttg 
               
               
                   
                   
               
               
                   
                 cctttctctccacaggtgtccactcccagttcaattacag 
               
               
                   
                   
               
               
                   
                 ctcttaaggctagagtacttaatacgactcactataggct 
               
               
                   
                   
               
               
                   
                 agcctcgagaattcacgcgtggtacctctagagtcgaccc 
               
               
                   
                   
               
               
                   
                 gggcggccgcttcgagcagacatgataagatacattgatg 
               
               
                   
                   
               
               
                   
                 agtttggacaaaccacaactagaatgcagtgaaaaaaatg 
               
               
                   
                   
               
               
                   
                 ctttatttgtgaaatttgtgatgctattgctttatttgta 
               
               
                   
                   
               
               
                   
                 accattataagctgcaataaacaagttaacaacaacaatt 
               
               
                   
                   
               
               
                   
                 gcattcattttatgtttcaggttcagggggaggtgtggga 
               
               
                   
                   
               
               
                   
                 ggttttttaaagcaagtaaaacctctacaaatgtggtaaa 
               
               
                   
                   
               
               
                   
                 atcgataaggatccgggctggcgtaatagcgaagaggccc 
               
               
                   
                   
               
               
                   
                 gcaccgatcgcccttcccaacagttgcgcagcctgaatgg 
               
               
                   
                   
               
               
                   
                 cgaatggacgcgccctgtagcggcgcattaagcgcggcgg 
               
               
                   
                   
               
               
                   
                 gtgtggtggttacgcgcagcgtgaccgctacacttgccag 
               
               
                   
                   
               
               
                   
                 cgccctagcgcccgctcctttcgctttcttcccttccttt 
               
               
                   
                   
               
               
                   
                 ctcgccacgttcgccggctttccccgtcaagctctaaatc 
               
               
                   
                   
               
               
                   
                 gggggctccctttagggttccgatttagtgctttacggca 
               
               
                   
                   
               
               
                   
                 cctcgaccccaaaaaacttgattagggtgatggttcacgt 
               
               
                   
                   
               
               
                   
                 agtgggccatcgccctgatagacggtttttcgccctttga 
               
               
                   
                   
               
               
                   
                 cgttggagtccacgttctttaatagtggactcttgttcca 
               
               
                   
                   
               
               
                   
                 aactggaacaacactcaaccctatctcggtctattctttt 
               
               
                   
                   
               
               
                   
                 gatttataagggattttgccgatttcggcctattggttaa 
               
               
                   
                   
               
               
                   
                 aaaatgagctgatttaacaaaaatttaacgcgaattttaa 
               
               
                   
                   
               
               
                   
                 caaaatattaacgcttacaatttcctgatgcggtattttc 
               
               
                   
                   
               
               
                   
                 tccttacgcatctgtgcggtatttcacaccgcatatggtg 
               
               
                   
                   
               
               
                   
                 cactctcagtacaatctgctctgatgccgcatagttaagc 
               
               
                   
                   
               
               
                   
                 cagccccgacacccgccaacacccgctgacgcgccctgac 
               
               
                   
                   
               
               
                   
                 gggcttgtctgctcccggcatccgcttacagacaagctgt 
               
               
                   
                   
               
               
                   
                 gaccgtctccgggagctgcatgtgtcagaggttttcaccg 
               
               
                   
                   
               
               
                   
                 tcatcaccgaaacgcgcgagacgaaagggcctcgtgatac 
               
               
                   
                   
               
               
                   
                 gcctatttttataggttaatgtcatgataataatggtttc 
               
               
                   
                   
               
               
                   
                 ttagacgtcaggtggcacttttcggggaaatgtgcgcgga 
               
               
                   
                   
               
               
                   
                 acccctatttgtttatttttctaaatacattcaaatatgt 
               
               
                   
                   
               
               
                   
                 atccgctcatgagacaataaccctgataaatgcttcaata 
               
               
                   
                   
               
               
                   
                 atattgaaaaaggaagagtatgagtattcaacatttccgt 
               
               
                   
                   
               
               
                   
                 gtcgcccttattcccttttttgcggcattttgccttcctg 
               
               
                   
                   
               
               
                   
                 tttttgctcacccagaaacgctggtgaaagtaaaagatgc 
               
               
                   
                   
               
               
                   
                 tgaagatcagttgggtgcacgagtgggttacatcgaactg 
               
               
                   
                   
               
               
                   
                 gatctcaacagcggtaagatccttgagagttttcgccccg 
               
               
                   
                   
               
               
                   
                 aagaacgttttccaatgatgagcacttttaaagttctgct 
               
               
                   
                   
               
               
                   
                 atgtggcgcggtattatcccgtattgacgccgggcaagag 
               
               
                   
                   
               
               
                   
                 caactcggtcgccgcatacactattctcagaatgacttgg 
               
               
                   
                   
               
               
                   
                 ttgagtactcaccagtcacagaaaagcatcttacggatgg 
               
               
                   
                   
               
               
                   
                 catgacagtaagagaattatgcagtgctgccataaccatg 
               
               
                   
                   
               
               
                   
                 agtgataacactgcggccaacttacttctgacaacgatcg 
               
               
                   
                   
               
               
                   
                 gaggaccgaaggagctaaccgcttttttgcacaacatggg 
               
               
                   
                   
               
               
                   
                 ggatcatgtaactcgccttgatcgttgggaaccggagctg 
               
               
                   
                   
               
               
                   
                 aatgaagccataccaaacgacgagcgtgacaccacgatgc 
               
               
                   
                   
               
               
                   
                 ctgtagcaatggcaacaacgttgcgcaaactattaactgg 
               
               
                   
                   
               
               
                   
                 cgaactacttactctagcttcccggcaacaattaatagac 
               
               
                   
                   
               
               
                   
                 tggatggaggcggataaagttgcaggaccacttctgcgct 
               
               
                   
                   
               
               
                   
                 cggcccttccggctggctggtttattgctgataaatctgg 
               
               
                   
                   
               
               
                   
                 agccggtgagcgtgggtctcgcggtatcattgcagcactg 
               
               
                   
                   
               
               
                   
                 gggccagatggtaagccctcccgtatcgtagttatctaca 
               
               
                   
                   
               
               
                   
                 cgacggggagtcaggcaactatggatgaacgaaatagaca 
               
               
                   
                   
               
               
                   
                 gatcgctgagataggtgcctcactgattaagcattggtaa 
               
               
                   
                   
               
               
                   
                 ctgtcagaccaagtttactcatatatactttagattgatt 
               
               
                   
                   
               
               
                   
                 taaaacttcatttttaatttaaaaggatctaggtgaagat 
               
               
                   
                   
               
               
                   
                 cctttttgataatctcatgaccaaaatcccttaacgtgag 
               
               
                   
                   
               
               
                   
                 ttttcgttccactgagcgtcagaccccgtagaaaagatca 
               
               
                   
                   
               
               
                   
                 aaggatcttcttgagatcctttttttctgcgcgtaatctg 
               
               
                   
                   
               
               
                   
                 ctgcttgcaaacaaaaaaaccaccgctaccagcggtggtt 
               
               
                   
                   
               
               
                   
                 tgtttgccggatcaagagctaccaactctttttccgaagg 
               
               
                   
                   
               
               
                   
                 taactggcttcagcagagcgcagataccaaatactgttct 
               
               
                   
                   
               
               
                   
                 tctagtgtagccgtagttaggccaccacttcaagaactct 
               
               
                   
                   
               
               
                   
                 gtagcaccgcctacatacctcgctctgctaatcctgttac 
               
               
                   
                   
               
               
                   
                 cagtggctgctgccagtggcgataagtcgtgtcttaccgg 
               
               
                   
                   
               
               
                   
                 gttggactcaagacgatagttaccggataaggcgcagcgg 
               
               
                   
                   
               
               
                   
                 tcgggctgaacggggggttcgtgcacacagcccagcttgg 
               
               
                   
                   
               
               
                   
                 agcgaacgacctacaccgaactgagatacctacagcgtga 
               
               
                   
                   
               
               
                   
                 gctatgagaaagcgccacgcttcccgaagggagaaaggcg 
               
               
                   
                   
               
               
                   
                 gacaggtatccggtaagcggcagggtcggaacaggagagc 
               
               
                   
                   
               
               
                   
                 gcacgagggagcttccagggggaaacgcctggtatcttta 
               
               
                   
                   
               
               
                   
                 tagtcctgtcgggtttcgccacctctgacttgagcgtcga 
               
               
                   
                   
               
               
                   
                 tttttgtgatgctcgtcaggggggcggagcctatggaaaa 
               
               
                   
                   
               
               
                   
                 acgccagcaacgcggcctttttacggttcctggccttttg 
               
               
                   
                   
               
               
                   
                 ctggccttttgctcacatggctcgacagatct 
               
            
           
         
       
     
     The pZeoSV2(+) backbone sequence (SEQ ID NO: 165): 
     
       
         
           
               
               
            
               
                   
                 ggatcgatccggctgtggaatgtgtgtcagttagggtgtg 
               
               
                   
                   
               
               
                   
                 gaaagtccccaggctccccagcaggcagaagtatgcaaag 
               
               
                   
                   
               
               
                   
                 catgcatctcaattagtcagcaaccaggtgtggaaagtcc 
               
               
                   
                   
               
               
                   
                 ccaggctccccagcaggcagaagtatgcaaagcatgcatc 
               
               
                   
                   
               
               
                   
                 tcaattagtcagcaaccatagtcccgcccctaactccgcc 
               
               
                   
                   
               
               
                   
                 catcccgcccctaactccgcccagttccgcccattctccg 
               
               
                   
                   
               
               
                   
                 ccccatggctgactaattttttttatttatgcagaggccg 
               
               
                   
                   
               
               
                   
                 aggccgcctcggcctctgagctattccagaagtagtgagg 
               
               
                   
                   
               
               
                   
                 aggcttttttggaggcctaggcttttgcaaaaagctctct 
               
               
                   
                   
               
               
                   
                 ggctaactagagaacccactgcttactggcttatcgaaat 
               
               
                   
                   
               
               
                   
                 taatacgactcactatagggagacccaagctggctagcgt 
               
               
                   
                   
               
               
                   
                 ttaaacttaagcttggtaccgagctcggatccactagtcc 
               
               
                   
                   
               
               
                   
                 agtgtggtggaattctgcagatatccagcacagtggcggc 
               
               
                   
                   
               
               
                   
                 cgctcgagtctagagggcccgtttaaacccgctgatcagc 
               
               
                   
                   
               
               
                   
                 ctcgactgtgccttctagttgccagccatctgttgtttgc 
               
               
                   
                   
               
               
                   
                 ccctcccccgtgccttccttgaccctggaaggtgccactc 
               
               
                   
                   
               
               
                   
                 ccactgtcctttcctaataaaatgaggaaattgcatcgca 
               
               
                   
                   
               
               
                   
                 ttgtctgagtaggtgtcattctattctggggggtggggtg 
               
               
                   
                   
               
               
                   
                 gggcaggacagcaagggggaggattgggaagacaatagca 
               
               
                   
                   
               
               
                   
                 ggcatgctggggatgcggtgggctctatggcttctgaggc 
               
               
                   
                   
               
               
                   
                 ggaaagaaccagcatgtgagcaaaaggccagcaaaaggcc 
               
               
                   
                   
               
               
                   
                 aggaaccgtaaaaaggccgcgttgctggcgtttttccata 
               
               
                   
                   
               
               
                   
                 ggctccgcccccctgacgagcatcacaaaaatcgacgctc 
               
               
                   
                   
               
               
                   
                 aagtcagaggtggcgaaacccgacaggactataaagatac 
               
               
                   
                   
               
               
                   
                 caggcgtttccccctggaagctccctcgtgcgctctcctg 
               
               
                   
                   
               
               
                   
                 ttccgaccctgccgcttaccggatacctgtccgcctttct 
               
               
                   
                   
               
               
                   
                 cccttcgggaagcgtggcgctttctcatagctcacgctgt 
               
               
                   
                   
               
               
                   
                 aggtatctcagttcggtgtaggtcgttcgctccaagctgg 
               
               
                   
                   
               
               
                   
                 gctgtgtgcacgaaccccccgttcagcccgaccgctgcgc 
               
               
                   
                   
               
               
                   
                 cttatccggtaactatcgtcttgagtccaacccggtaaga 
               
               
                   
                   
               
               
                   
                 cacgacttatcgccactggcagcagccactggtaacagga 
               
               
                   
                   
               
               
                   
                 ttagcagagcgaggtatgtaggcggtgctacagagttctt 
               
               
                   
                   
               
               
                   
                 gaagtggtggcctaactacggctacactagaagaacagta 
               
               
                   
                   
               
               
                   
                 tttggtatctgcgctctgctgaagccagttaccttcggaa 
               
               
                   
                   
               
               
                   
                 aaagagttggtagctcttgatccggcaaacaaaccaccgc 
               
               
                   
                   
               
               
                   
                 tggtagcggtggtttttttgtttgcaagcagcagattacg 
               
               
                   
                   
               
               
                   
                 cgcagaaaaaaaggatctcaagaagatcctttgatctttt 
               
               
                   
                   
               
               
                   
                 ctacggggtctgacgctcagtggaacgaaaactcacgtta 
               
               
                   
                   
               
               
                   
                 agggattttggtcatgacattaacctataaaaataggcgt 
               
               
                   
                   
               
               
                   
                 atcacgaggccctttcgtctcgcgcgtttcggtgatgacg 
               
               
                   
                   
               
               
                   
                 gtgaaaacctctgacacatgcagctcccggagacggtcac 
               
               
                   
                   
               
               
                   
                 agcttgtctgtaagcggatgccgggagcagacaagcccgt 
               
               
                   
                   
               
               
                   
                 cagggcgcgtcagcgggtgttggcgggtgtcggggctggc 
               
               
                   
                   
               
               
                   
                 ttaactatgcggcatcagagcagattgtactgagagtgca 
               
               
                   
                   
               
               
                   
                 ccatatgcggtgtgaaataccgcacagatgcgtaaggaga 
               
               
                   
                   
               
               
                   
                 aaataccgcatcaggacgcgccctgtagcggcgcattaag 
               
               
                   
                   
               
               
                   
                 cgcggcgggtgtggtggttacgcgcagcgtgaccgctaca 
               
               
                   
                   
               
               
                   
                 cttgccagcgccctagcgcccgctcctttcgctttcttcc 
               
               
                   
                   
               
               
                   
                 cttcctttctcgccacgttcgccggctttccccgtcaagc 
               
               
                   
                   
               
               
                   
                 tctaaatcgggggctccctttagggttccgatttagtgct 
               
               
                   
                   
               
               
                   
                 ttacggcacctcgaccccaaaaaacttgattagggtgatg 
               
               
                   
                   
               
               
                   
                 gttcacgtagtgggccatcgccctgatagacggtttttcg 
               
               
                   
                   
               
               
                   
                 ccctttgacgttggagtccacgttctttaatagtggactc 
               
               
                   
                   
               
               
                   
                 ttgttccaaactggaacaacactcaaccctatctcggtct 
               
               
                   
                   
               
               
                   
                 attcttttgatttataagggattttgccgatttcggccta 
               
               
                   
                   
               
               
                   
                 ttggttaaaaaatgagctgatttaacaaaaatttaacgcg 
               
               
                   
                   
               
               
                   
                 aattttaacaaaatattaacgcttacaatttccattcgcc 
               
               
                   
                   
               
               
                   
                 attcaggctgaactagatctagagtccgttacataactta 
               
               
                   
                   
               
               
                   
                 cggtaaatggcccgcctggctgaccgcccaacgacccccg 
               
               
                   
                   
               
               
                   
                 cccattgacgtcaataatgacgtatgttcccatagtaacg 
               
               
                   
                   
               
               
                   
                 ccaatagggactttccattgacgtcaatgggtggagtatt 
               
               
                   
                   
               
               
                   
                 tacggtaaactgcccacttggcagtacatcaagtgtatca 
               
               
                   
                   
               
               
                   
                 tatgccaagtacgccccctattgacgtcaatgacggtaaa 
               
               
                   
                   
               
               
                   
                 tggcccgcctggcattatgcccagtacatgaccttatggg 
               
               
                   
                   
               
               
                   
                 actttcctacttggcagtacatctacgtattagtcatcgc 
               
               
                   
                   
               
               
                   
                 tattaccatggtgatgcggttttggcagtacatcaatggg 
               
               
                   
                   
               
               
                   
                 cgtggatagcggtttgactcacggggatttccaagtctcc 
               
               
                   
                   
               
               
                   
                 accccattgacgtcaatgggagtttgttttggcaccaaaa 
               
               
                   
                   
               
               
                   
                 tcaacgggactttccaaaatgtcgtaacaactccgcccca 
               
               
                   
                   
               
               
                   
                 ttgacgcaaatgggcggtaggcgtgtacggtgggaggtct 
               
               
                   
                   
               
               
                   
                 atataagcagagctcgtttagtgaaccgtcagatcgcctg 
               
               
                   
                   
               
               
                   
                 gagacgccatccacgctgttttgacctccatagaagacac 
               
               
                   
                   
               
               
                   
                 cgggaccgatccagcctccgcggccgggaacggtgcattg 
               
               
                   
                   
               
               
                   
                 gaacggaccgtgttgacaattaatcatcggcatagtatat 
               
               
                   
                   
               
               
                   
                 cggcatagtataatacgacaaggtgaggaactaaaccatg 
               
               
                   
                   
               
               
                   
                 gccaagttgaccagtgccgttccggtgctcaccgcgcgcg 
               
               
                   
                   
               
               
                   
                 acgtcgccggagcggtcgagttctggaccgaccggctcgg 
               
               
                   
                   
               
               
                   
                 gttctcccgggacttcgtggaggacgacttcgccggtgtg 
               
               
                   
                   
               
               
                   
                 gtccgggacgacgtgaccctgttcatcagcgcggtccagg 
               
               
                   
                   
               
               
                   
                 accaggtggtgccggacaacaccctggcctgggtgtgggt 
               
               
                   
                   
               
               
                   
                 gcgcggcctggacgagctgtacgccgagtggtcggaggtc 
               
               
                   
                   
               
               
                   
                 gtgtccacgaacttccgggacgcctccgggccggccatga 
               
               
                   
                   
               
               
                   
                 ccgagatcggcgagcagccgtgggggcgggagttcgccct 
               
               
                   
                   
               
               
                   
                 gcgcgacccggccggcaactgcgtgcacttcgtggccgag 
               
               
                   
                   
               
               
                   
                 gagcaggactgacactcgacctcgaaacttgtttattgca 
               
               
                   
                   
               
               
                   
                 gcttataatggttacaaataaagcaatagcatcacaaatt 
               
               
                   
                   
               
               
                   
                 tcacaaataaagcatttttttcactgcattctagttgtgg 
               
               
                   
                   
               
               
                   
                 tttgtccaaactcatcaatgtatcttatcatgtct 
               
            
           
         
       
     
     The phCMV1 backbone sequence (SEQ ID NO: 166): 
     
       
         
           
               
               
            
               
                   
                 tagttattaatagtaatcaattacggggtcattagttcat 
               
               
                   
                   
               
               
                   
                 agcccatatatggagttccgcgttacataacttacggtaa 
               
               
                   
                   
               
               
                   
                 atggcccgcctggctgaccgcccaacgacccccgcccatt 
               
               
                   
                   
               
               
                   
                 gacgtcaataatgacgtatgttcccatagtaacgccaata 
               
               
                   
                   
               
               
                   
                 gggactttccattgacgtcaatgggtggagtatttacggt 
               
               
                   
                   
               
               
                   
                 aaactgcccacttggcagtacatcaagtgtatcatatgcc 
               
               
                   
                   
               
               
                   
                 aagtacgccccctattgacgtcaatgacggtaaatggccc 
               
               
                   
                   
               
               
                   
                 gcctggcattatgcccagtacatgaccttatgggactttc 
               
               
                   
                   
               
               
                   
                 ctacttggcagtacatctacgtattagtcatcgctattac 
               
               
                   
                   
               
               
                   
                 catggtgatgcggttttggcagtacatcaatgggcgtgga 
               
               
                   
                   
               
               
                   
                 tagcggtttgactcacggggatttccaagtctccacccca 
               
               
                   
                   
               
               
                   
                 ttgacgtcaatgggagtttgttttggcaccaaaatcaacg 
               
               
                   
                   
               
               
                   
                 ggactttccaaaatgtcgtaacaactccgccccattgacg 
               
               
                   
                   
               
               
                   
                 caaatgggcggtaggcgtgtacggtgggaggtctatataa 
               
               
                   
                   
               
               
                   
                 gcagagctcgtttagtgaaccgtcagatcgcctggagacg 
               
               
                   
                   
               
               
                   
                 ccatccacgctgttttgacctccatagaagacaccgggac 
               
               
                   
                   
               
               
                   
                 cgatccagcctccgcggccgggaacggtgcattggaacgc 
               
               
                   
                   
               
               
                   
                 ggattccccgtgccaagagtgacgtaagtaccgcctatag 
               
               
                   
                   
               
               
                   
                 actctataggcacacccctttggctcttatgcatgaatta 
               
               
                   
                   
               
               
                   
                 atacgactcactatagggagacagactgttcctttcctgg 
               
               
                   
                   
               
               
                   
                 gtcttttctgcaggcaccgtcgtcgacttaacagatctcg 
               
               
                   
                   
               
               
                   
                 agctcaagcttcgaattctgcagtcgacggtaccgcgggc 
               
               
                   
                   
               
               
                   
                 ccgggatccaccgggtacaagtaaagcggccgcgactcta 
               
               
                   
                   
               
               
                   
                 gatcataatcagccataccacatttgtagaggttttactt 
               
               
                   
                   
               
               
                   
                 gctttaaaaaacctcccacacctccccctgaacctgaaac 
               
               
                   
                   
               
               
                   
                 ataaaatgaatgcaattgttgttgttaacttgtttattgc 
               
               
                   
                   
               
               
                   
                 agcttataatggttacaaataaagcaatagcatcacaaat 
               
               
                   
                   
               
               
                   
                 ttcacaaataaagcatttttttcactgcattctagttgtg 
               
               
                   
                   
               
               
                   
                 gtttgtccaaactcatcaatgtatcttaaggcgtaaattg 
               
               
                   
                   
               
               
                   
                 taagcgttaatattttgttaaaattcgcgttaaatttttg 
               
               
                   
                   
               
               
                   
                 ttaaatcagctcattttttaaccaataggccgaaatcggc 
               
               
                   
                   
               
               
                   
                 aaaatcccttataaatcaaaagaatagaccgagatagggt 
               
               
                   
                   
               
               
                   
                 tgagtgttgttccagtttggaacaagagtccactattaaa 
               
               
                   
                   
               
               
                   
                 gaacgtggactccaacgtcaaagggcgaaaaaccgtctat 
               
               
                   
                   
               
               
                   
                 cagggcgatggcccactacgtgaaccatcaccctaatcaa 
               
               
                   
                   
               
               
                   
                 gttttttggggtcgaggtgccgtaaagcactaaatcggaa 
               
               
                   
                   
               
               
                   
                 ccctaaagggagcccccgatttagagcttgacggggaaag 
               
               
                   
                   
               
               
                   
                 ccggcgaacgtggcgagaaaggaagggaagaaagcgaaag 
               
               
                   
                   
               
               
                   
                 gagcgggcgctagggcgctggcaagtgtagcggtcacgct 
               
               
                   
                   
               
               
                   
                 gcgcgtaaccaccacacccgccgcgcttaatgcgccgcta 
               
               
                   
                   
               
               
                   
                 cagggcgcgtcaggtggcacttttcggggaaatgtgcgcg 
               
               
                   
                   
               
               
                   
                 gaacccctatttgtttatttttctaaatacattcaaatat 
               
               
                   
                   
               
               
                   
                 gtatccgctcatgagacaataaccctgataaatgcttcaa 
               
               
                   
                   
               
               
                   
                 taatattgaaaaaggaagagtcctgaggcggaaagaacca 
               
               
                   
                   
               
               
                   
                 gctgtggaatgtgtgtcagttagggtgtggaaagtcccca 
               
               
                   
                   
               
               
                   
                 ggctccccagcaggcagaagtatgcaaagcatgcatctca 
               
               
                   
                   
               
               
                   
                 attagtcagcaaccaggtgtggaaagtccccaggctcccc 
               
               
                   
                   
               
               
                   
                 agcaggcagaagtatgcaaagcatgcatctcaattagtca 
               
               
                   
                   
               
               
                   
                 gcaaccatagtcccgcccctaactccgcccatcccgcccc 
               
               
                   
                   
               
               
                   
                 taactccgcccagttccgcccattctccgccccatggctg 
               
               
                   
                   
               
               
                   
                 actaattttttttatttatgcagaggccgaggccgcctcg 
               
               
                   
                   
               
               
                   
                 gcctctgagctattccagaagtagtgaggaggcttttttg 
               
               
                   
                   
               
               
                   
                 gaggcctaggcttttgcaaagatcgatcaagagacaggat 
               
               
                   
                   
               
               
                   
                 gaggatcgtttcgcatgattgaacaagatggattgcacgc 
               
               
                   
                   
               
               
                   
                 aggttctccggccgcttgggtggagaggctattcggctat 
               
               
                   
                   
               
               
                   
                 gactgggcacaacagacaatcggctgctctgatgccgccg 
               
               
                   
                   
               
               
                   
                 tgttccggctgtcagcgcaggggcgcccggttctttttgt 
               
               
                   
                   
               
               
                   
                 caagaccgacctgtccggtgccctgaatgaactgcaagac 
               
               
                   
                   
               
               
                   
                 gaggcagcgcggctatcgtggctggccacgacgggcgttc 
               
               
                   
                   
               
               
                   
                 cttgcgcagctgtgctcgacgttgtcactgaagcgggaag 
               
               
                   
                   
               
               
                   
                 ggactggctgctattgggcgaagtgccggggcaggatctc 
               
               
                   
                   
               
               
                   
                 ctgtcatctcaccttgctcctgccgagaaagtatccatca 
               
               
                   
                   
               
               
                   
                 tggctgatgcaatgcggcggctgcatacgcttgatccggc 
               
               
                   
                   
               
               
                   
                 tacctgcccattcgaccaccaagcgaaacatcgcatcgag 
               
               
                   
                   
               
               
                   
                 cgagcacgtactcggatggaagccggtcttgtcgatcagg 
               
               
                   
                   
               
               
                   
                 atgatctggacgaagagcatcaggggctcgcgccagccga 
               
               
                   
                   
               
               
                   
                 actgttcgccaggctcaaggcgagcatgcccgacggcgag 
               
               
                   
                   
               
               
                   
                 gatctcgtcgtgacccatggcgatgcctgcttgccgaata 
               
               
                   
                   
               
               
                   
                 tcatggtggaaaatggccgcttttctggattcatcgactg 
               
               
                   
                   
               
               
                   
                 tggccggctgggtgtggcggaccgctatcaggacatagcg 
               
               
                   
                   
               
               
                   
                 ttggctacccgtgatattgctgaagagcttggcggcgaat 
               
               
                   
                   
               
               
                   
                 gggctgaccgcttcctcgtgctttacggtatcgccgctcc 
               
               
                   
                   
               
               
                   
                 cgattcgcagcgcatcgccttctatcgccttcttgacgag 
               
               
                   
                   
               
               
                   
                 ttcttctgagcgggactctggggttcgaaatgaccgacca 
               
               
                   
                   
               
               
                   
                 agcgacgcccaacctgccatcacgagatttcgattccacc 
               
               
                   
                   
               
               
                   
                 gccgccttctatgaaaggttgggcttcggaatcgttttcc 
               
               
                   
                   
               
               
                   
                 gggacgccggctggatgatcctccagcgcggggatctcat 
               
               
                   
                   
               
               
                   
                 gctggagttcttcgcccaccctagggggaggctaactgaa 
               
               
                   
                   
               
               
                   
                 acacggaaggagacaataccggaaggaacccgcgctatga 
               
               
                   
                   
               
               
                   
                 cggcaataaaaagacagaataaaacgcacggtgttgggtc 
               
               
                   
                   
               
               
                   
                 gtttgttcataaacgcggggttcggtcccagggctggcac 
               
               
                   
                   
               
               
                   
                 tctgtcgataccccaccgagaccccattggggccaatacg 
               
               
                   
                   
               
               
                   
                 cccgcgtttcttccttttccccaccccaccccccaagttc 
               
               
                   
                   
               
               
                   
                 gggtgaaggcccagggctcgcagccaacgtcggggcggca 
               
               
                   
                   
               
               
                   
                 ggccctgccatagcctcaggttactcatatatactttaga 
               
               
                   
                   
               
               
                   
                 ttgatttaaaacttcatttttaatttaaaaggatctaggt 
               
               
                   
                   
               
               
                   
                 gaagatcctttttgataatctcatgaccaaaatcccttaa 
               
               
                   
                   
               
               
                   
                 cgtgagttttcgttccactgagcgtcagaccccgtagaaa 
               
               
                   
                   
               
               
                   
                 agatcaaaggatcttcttgagatcctttttttctgcgcgt 
               
               
                   
                   
               
               
                   
                 aatctgctgcttgcaaacaaaaaaaccaccgctaccagcg 
               
               
                   
                   
               
               
                   
                 gtggtttgtttgccggatcaagagctaccaactctttttc 
               
               
                   
                   
               
               
                   
                 cgaaggtaactggcttcagcagagcgcagataccaaatac 
               
               
                   
                   
               
               
                   
                 tgtccttctagtgtagccgtagttaggccaccacttcaag 
               
               
                   
                   
               
               
                   
                 aactctgtagcaccgcctacatacctcgctctgctaatcc 
               
               
                   
                   
               
               
                   
                 tgttaccagtggctgctgccagtggcgataagtcgtgtct 
               
               
                   
                   
               
               
                   
                 taccgggttggactcaagacgatagttaccggataaggcg 
               
               
                   
                   
               
               
                   
                 cagcggtcgggctgaacggggggttcgtgcacacagccca 
               
               
                   
                   
               
               
                   
                 gcttggagcgaacgacctacaccgaactgagatacctaca 
               
               
                   
                   
               
               
                   
                 gcgtgagctatgagaaagcgccacgcttcccgaagggaga 
               
               
                   
                   
               
               
                   
                 aaggcggacaggtatccggtaagcggcagggtcggaacag 
               
               
                   
                   
               
               
                   
                 gagagcgcacgagggagcttccagggggaaacgcctggta 
               
               
                   
                   
               
               
                   
                 tctttatagtcctgtcgggtttcgccacctctgacttgag 
               
               
                   
                   
               
               
                   
                 cgtcgatttttgtgatgctcgtcaggggggcggagcctat 
               
               
                   
                   
               
               
                   
                 ggaaaaacgccagcaacgcggcctttttacggttcctggc 
               
               
                   
                   
               
               
                   
                 cttttgctggccttttgctcacatgttctttcctgcgtta 
               
               
                   
                   
               
               
                   
                 tcccctgattctgtggataaccgtattaccgccatgcat 
               
            
           
         
       
     
     The pTCP backbone sequence (SEQ ID NO: 167): 
     
       
         
           
               
               
            
               
                   
                 tagttattaatagtaatcaattacggggtcattagttcat 
               
               
                   
                   
               
               
                   
                 agcccatatatggagttccgcgttacataacttacggtaa 
               
               
                   
                   
               
               
                   
                 atggcccgcctggctgaccgcccaacgacccccgcccatt 
               
               
                   
                   
               
               
                   
                 gacgtcaataatgacgtatgttcccatagtaacgccaata 
               
               
                   
                   
               
               
                   
                 gggactttccattgacgtcaatgggtggagtatttacggt 
               
               
                   
                   
               
               
                   
                 aaactgcccacttggcagtacatcaagtgtatcatatgcc 
               
               
                   
                   
               
               
                   
                 aagtacgccccctattgacgtcaatgacggtaaatggccc 
               
               
                   
                   
               
               
                   
                 gcctggcattatgcccagtacatgaccttatgggactttc 
               
               
                   
                   
               
               
                   
                 ctacttggcagtacatctacgtattagtcatcgctattac 
               
               
                   
                   
               
               
                   
                 catggtgatgcggttttggcagtacatcaatgggcgtgga 
               
               
                   
                   
               
               
                   
                 tagcggtttgactcacggggatttccaagtctccacccca 
               
               
                   
                   
               
               
                   
                 ttgacgtcaatgggagtttgttttggcaccaaaatcaacg 
               
               
                   
                   
               
               
                   
                 ggactttccaaaatgtcgtaacaactccgccccattgacg 
               
               
                   
                   
               
               
                   
                 caaatgggcggtaggcgtgtacggtgggaggtctatataa 
               
               
                   
                   
               
               
                   
                 gcagagctggtttagtgaaccgtggatcccgtcgcttacc 
               
               
                   
                   
               
               
                   
                 gattcagaatggttgatatccgccattctgaatcggtaag 
               
               
                   
                   
               
               
                   
                 cgacgaagcttaataaaggatcttttattttcattggatc 
               
               
                   
                   
               
               
                   
                 tgtgtgttggttttttgtgtgcggccgccctcgactgtgc 
               
               
                   
                   
               
               
                   
                 cttctagaagacaatagcaggcatgctggggatgcggtgg 
               
               
                   
                   
               
               
                   
                 gctctatggcttctgaggcggaaagaaccagctggggctc 
               
               
                   
                   
               
               
                   
                 tagggggtatccccacgcgccctgtagcggcgcattaagc 
               
               
                   
                   
               
               
                   
                 gcggcgggtgtggtggttacgcgcagcgtgaccgctacac 
               
               
                   
                   
               
               
                   
                 ttgccagcgccctagcgcccgctcctttcgctttcttccc 
               
               
                   
                   
               
               
                   
                 ttcctttctcgccacgttcgccggctttccccgtcaagct 
               
               
                   
                   
               
               
                   
                 ctaaatcgggggctccctttagggttccgatttagtgctt 
               
               
                   
                   
               
               
                   
                 tacggcacctcgaccccaaaaaacttgattagggtgatgg 
               
               
                   
                   
               
               
                   
                 ttcacgtagtgggccatcgccctgatagacggtttttcgc 
               
               
                   
                   
               
               
                   
                 cctttgacgttggagtccacgttctttaatagtggactct 
               
               
                   
                   
               
               
                   
                 tgttccaaactggaacaacactcaaccctatctcggtcta 
               
               
                   
                   
               
               
                   
                 ttcttttgatttataagggattttgccgatttcggcctat 
               
               
                   
                   
               
               
                   
                 tggttaaaaaatgagctgatttaacaaaaatttaacgcga 
               
               
                   
                   
               
               
                   
                 attaattctgtggaatgtgtgtcagttagggtgtggaaag 
               
               
                   
                   
               
               
                   
                 tccccaggctccccagcaggcagaagtatgcaaagcatgc 
               
               
                   
                   
               
               
                   
                 atctcaattagtcagcaaccaggtgtggaaagtccccagg 
               
               
                   
                   
               
               
                   
                 ctccccagcaggcagaagtatgcaaagcatgcatctcaat 
               
               
                   
                   
               
               
                   
                 tagtcagcaaccatagtcccgcccctaactccgcccatcc 
               
               
                   
                   
               
               
                   
                 cgcccctaactccgcccagttccgcccattctccgcccca 
               
               
                   
                   
               
               
                   
                 tggctgactaattttttttatttatgcagaggccgaggcc 
               
               
                   
                   
               
               
                   
                 gcctctgcctctgagctattccagaagtagtgaggaggct 
               
               
                   
                   
               
               
                   
                 tttttggaggcctaggcttttgcaaaaagctcccgggatg 
               
               
                   
                   
               
               
                   
                 accgagtacaagcccacggtgcgcctcgccacccgcgacg 
               
               
                   
                   
               
               
                   
                 acgtcccgcgggccgtacgcaccctcgccgccgcgttcgc 
               
               
                   
                   
               
               
                   
                 cgactaccccgccacgcgccacaccgtcgacccggaccgc 
               
               
                   
                   
               
               
                   
                 cacatcgagcgggtcaccgagctgcaagaactcttcctca 
               
               
                   
                   
               
               
                   
                 cgcgcgtcgggctcgacatcggcaaggtgtgggtcgcgga 
               
               
                   
                   
               
               
                   
                 cgacggcgccgcggtggcggtctggaccacgccggagagc 
               
               
                   
                   
               
               
                   
                 gtcgaagcgggggcggtgttcgccgagatcggcccgcgca 
               
               
                   
                   
               
               
                   
                 tggccgagttgagcggttcccggctggccgcgcagcaaca 
               
               
                   
                   
               
               
                   
                 gatggaaggcctcctggcgccgcaccggcccaaggagccc 
               
               
                   
                   
               
               
                   
                 gcgtggttcctggccaccgtcggcgtctcgcccgaccacc 
               
               
                   
                   
               
               
                   
                 agggcaagggtctgggcagcgccgtcgtgctccccggagt 
               
               
                   
                   
               
               
                   
                 ggaggcggccgagcgcgccggggtgcccgccttcctggag 
               
               
                   
                   
               
               
                   
                 acctccgcgccccgcaacctccccttctacgagcggctcg 
               
               
                   
                   
               
               
                   
                 gcttcaccgtcaccgccgacgtcgaggtgcccgaaggacc 
               
               
                   
                   
               
               
                   
                 gcgcacctggtgcatgacccgcaagcccggtgcctgattc 
               
               
                   
                   
               
               
                   
                 gaatgaccgaccaagcgacgcccaacctgccatcacgaga 
               
               
                   
                   
               
               
                   
                 tttcgattccaccgccgccttctatgaaaggttgggcttc 
               
               
                   
                   
               
               
                   
                 ggaatcgttttccgggacgccggctggatgatcctccagc 
               
               
                   
                   
               
               
                   
                 gcggggatctcatgctggagttcttcgcccaccccaactt 
               
               
                   
                   
               
               
                   
                 gtttattgcagcttataatggttacaaataaagcaatagc 
               
               
                   
                   
               
               
                   
                 atcacaaatttcacaaataaagcatttttttcactgcatt 
               
               
                   
                   
               
               
                   
                 ctagttgtggtttgtccaaactcatcaatgtatcttatca 
               
               
                   
                   
               
               
                   
                 tgtctgtataccgtcgacctctagctagagcttggcgtaa 
               
               
                   
                   
               
               
                   
                 tcatggtcatagctgtttcctgtgtgaaattgttatccgc 
               
               
                   
                   
               
               
                   
                 tcacaattccacacaacatacgagccggaagcataaagtg 
               
               
                   
                   
               
               
                   
                 taaagcctggggtgcctaatgagtgagctaactcacatta 
               
               
                   
                   
               
               
                   
                 attgcgttgcgctcactgcccgctttccagtcgggaaacc 
               
               
                   
                   
               
               
                   
                 tgtcgtgccagctgcattaatgaatcggccaacgcgcggg 
               
               
                   
                   
               
               
                   
                 gagaggcggtttgcgtattgggcgctcttccgcttcctcg 
               
               
                   
                   
               
               
                   
                 ctcactgactcgctgcgctcggtcgttcggctgcggcgag 
               
               
                   
                   
               
               
                   
                 cggtatcagctcactcaaaggcggtaatacggttatccac 
               
               
                   
                   
               
               
                   
                 agaatcaggggataacgcaggaaagaacatgtgagcaaaa 
               
               
                   
                   
               
               
                   
                 ggccagcaaaaggccaggaaccgtaaaaaggccgcgttgc 
               
               
                   
                   
               
               
                   
                 tggcgtttttccataggctccgcccccctgacgagcatca 
               
               
                   
                   
               
               
                   
                 caaaaatcgacgctcaagtcagaggtggcgaaacccgaca 
               
               
                   
                   
               
               
                   
                 ggactataaagataccaggcgtttccccctggaagctccc 
               
               
                   
                   
               
               
                   
                 tcgtgcgctctcctgttccgaccctgccgcttaccggata 
               
               
                   
                   
               
               
                   
                 cctgtccgcctttctcccttcgggaagcgtggcgctttct 
               
               
                   
                   
               
               
                   
                 catagctcacgctgtaggtatctcagttcggtgtaggtcg 
               
               
                   
                   
               
               
                   
                 ttcgctccaagctgggctgtgtgcacgaaccccccgttca 
               
               
                   
                   
               
               
                   
                 gcccgaccgctgcgccttatccggtaactatcgtcttgag 
               
               
                   
                   
               
               
                   
                 tccaacccggtaagacacgacttatcgccactggcagcag 
               
               
                   
                   
               
               
                   
                 ccactggtaacaggattagcagagcgaggtatgtaggcgg 
               
               
                   
                   
               
               
                   
                 tgctacagagttcttgaagtggtggcctaactacggctac 
               
               
                   
                   
               
               
                   
                 actagaagaacagtatttggtatctgcgctctgctgaagc 
               
               
                   
                   
               
               
                   
                 cagttaccttcggaaaaagagttggtagctcttgatccgg 
               
               
                   
                   
               
               
                   
                 caaacaaaccaccgctggtagcggtttttttgtttgcaag 
               
               
                   
                   
               
               
                   
                 cagcagattacgcgcagaaaaaaaggatctcaagaagatc 
               
               
                   
                   
               
               
                   
                 ctttgatcttttctacggggtctgacgctcagtggaacga 
               
               
                   
                   
               
               
                   
                 aaactcacgttaagggattttggtcatgagattatcaaaa 
               
               
                   
                   
               
               
                   
                 aggatcttcacctagatccttttaaattaaaaatgaagtt 
               
               
                   
                   
               
               
                   
                 ttaaatcaatctaaagtatatatgagtaaacttggtctga 
               
               
                   
                   
               
               
                   
                 cagttaccaatgcttaatcagtgaggcacctatctcagcg 
               
               
                   
                   
               
               
                   
                 atctgtctatttcgttcatccatagttgcctgactccccg 
               
               
                   
                   
               
               
                   
                 tcgtgtagataactacgatacgggagggcttaccatctgg 
               
               
                   
                   
               
               
                   
                 ccccagtgctgcaatgataccgcgagacccacgctcaccg 
               
               
                   
                   
               
               
                   
                 gctccagatttatcagcaataaaccagccagccggaaggg 
               
               
                   
                   
               
               
                   
                 ccgagcgcagaagtggtcctgcaactttatccgcctccat 
               
               
                   
                   
               
               
                   
                 ccagtctattaattgttgccgggaagctagagtaagtagt 
               
               
                   
                   
               
               
                   
                 tcgccagttaatagtttgcgcaacgttgttgccattgcta 
               
               
                   
                   
               
               
                   
                 caggcatcgtggtgtcacgctcgtcgtttggtatggcttc 
               
               
                   
                   
               
               
                   
                 attcagctccggttcccaacgatcaaggcgagttacatga 
               
               
                   
                   
               
               
                   
                 tcccccatgttgtgcaaaaaagcggttagctccttcggtc 
               
               
                   
                   
               
               
                   
                 ctccgatcgttgtcagaagtaagttggccgcagtgttatc 
               
               
                   
                   
               
               
                   
                 actcatggttatggcagcactgcataattctcttactgtc 
               
               
                   
                   
               
               
                   
                 atgccatccgtaagatgcttttctgtgactggtgagtact 
               
               
                   
                   
               
               
                   
                 caaccaagtcattctgagaatagtgtatgcggcgaccgag 
               
               
                   
                   
               
               
                   
                 ttgctcttgcccggcgtcaatacgggataataccgcgcca 
               
               
                   
                   
               
               
                   
                 catagcagaactttaaaagtgctcatcattggaaaacgtt 
               
               
                   
                   
               
               
                   
                 cttcggggcgaaaactctcaaggatcttaccgctgttgag 
               
               
                   
                   
               
               
                   
                 atccagttcgatgtaacccactcgtgcacccaactgatct 
               
               
                   
                   
               
               
                   
                 tcagcatcttttactttcaccagcgtttctgggtgagcaa 
               
               
                   
                   
               
               
                   
                 aaacaggaaggcaaaatgccgcaaaaaagggaataagggc 
               
               
                   
                   
               
               
                   
                 gacacggaaatgttgaatactcatactcttcctttttcaa 
               
               
                   
                   
               
               
                   
                 tattattgaagcatttatcagggttattgtctcatgagcg 
               
               
                   
                   
               
               
                   
                 gatacatatttgaatgtatttagaaaaataaacaaatagg 
               
               
                   
                   
               
               
                   
                 ggttccgcgcacatttccccgaaaagtgccacctgacgtc 
               
               
                   
                   
               
               
                   
                 gacggatcgggagatctcccgatcccctatggtgcactct 
               
               
                   
                   
               
               
                   
                 cagtacaatctgctctgatgccgcatagttaagccagtat 
               
               
                   
                   
               
               
                   
                 ctgctccctgcttgtgtgttggaggtcgctgagtagtgcg 
               
               
                   
                   
               
               
                   
                 cgagcaaaatttaagctacaacaaggcaaggcttgaccga 
               
               
                   
                   
               
               
                   
                 caattgcatgaagaatctgcttagggttaggcgttttgcg 
               
               
                   
                   
               
               
                   
                 ctgcttcgcgatgtacgggccagatatacgcgttgacatt 
               
               
                   
                   
               
               
                   
                 gattattgac 
               
            
           
         
       
     
     The pIRES backbone sequence (SEQ ID NO: 168): 
     
       
         
           
               
               
            
               
                   
                 tcaatattggccattagccatattattcattggttatata 
               
               
                   
                   
               
               
                   
                 gcataaatcaatattggctattggccattgcatacgttgt 
               
               
                   
                   
               
               
                   
                 atctatatcataatatgtacatttatattggctcatgtcc 
               
               
                   
                   
               
               
                   
                 aatatgaccgccatgttggcattgattattgactagttat 
               
               
                   
                   
               
               
                   
                 taatagtaatcaattacggggtcattagttcatagcccat 
               
               
                   
                   
               
               
                   
                 atatggagttccgcgttacataacttacggtaaatggccc 
               
               
                   
                   
               
               
                   
                 gcctggctgaccgcccaacgacccccgcccattgacgtca 
               
               
                   
                   
               
               
                   
                 ataatgacgtatgttcccatagtaacgccaatagggactt 
               
               
                   
                   
               
               
                   
                 tccattgacgtcaatgggtggagtatttacggtaaactgc 
               
               
                   
                   
               
               
                   
                 ccacttggcagtacatcaagtgtatcatatgccaagtccg 
               
               
                   
                   
               
               
                   
                 ccccctattgacgtcaatgacggtaaatggcccgcctggc 
               
               
                   
                   
               
               
                   
                 attatgcccagtacatgaccttacgggactttcctacttg 
               
               
                   
                   
               
               
                   
                 gcagtacatctacgtattagtcatcgctattaccatggtg 
               
               
                   
                   
               
               
                   
                 atgcggttttggcagtacaccaatgggcgtggatagcggt 
               
               
                   
                   
               
               
                   
                 ttgactcacggggatttccaagtctccaccccattgacgt 
               
               
                   
                   
               
               
                   
                 caatgggagtttgttttggcaccaaaatcaacgggacttt 
               
               
                   
                   
               
               
                   
                 ccaaaatgtcgtaacaactgcgatcgcccgccccgttgac 
               
               
                   
                   
               
               
                   
                 gcaaatgggcggtaggcgtgtacggtgggaggtctatata 
               
               
                   
                   
               
               
                   
                 agcagagctcgtttagtgaaccgtcagatcactagaagct 
               
               
                   
                   
               
               
                   
                 ttattgcggtagtttatcacagttaaattgctaacgcagt 
               
               
                   
                   
               
               
                   
                 cagtgcttctgacacaacagtctcgaacttaagctgcagt 
               
               
                   
                   
               
               
                   
                 gactctcttaaggtagccttgcagaagttggtcgtgaggc 
               
               
                   
                   
               
               
                   
                 actgggcaggtaagtatcaaggttacaagacaggtttaag 
               
               
                   
                   
               
               
                   
                 gagaccaatagaaactgggcttgtcgagacagagaagact 
               
               
                   
                   
               
               
                   
                 cttgcgtttctgataggcacctattggtcttactgacatc 
               
               
                   
                   
               
               
                   
                 cactttgcctttctctccacaggtgtccactcccagttca 
               
               
                   
                   
               
               
                   
                 attacagctcttaaggctagagtacttaatacgactcact 
               
               
                   
                   
               
               
                   
                 ataggctagcctcgagaattcacgcgtcgagcatgcatct 
               
               
                   
                   
               
               
                   
                 agggcggccaattccgcccctctcccccccccccctctcc 
               
               
                   
                   
               
               
                   
                 ctcccccccccctaacgttactggccgaagccgcttggaa 
               
               
                   
                   
               
               
                   
                 taaggccggtgtgcgtttgtctatatgttattttccacca 
               
               
                   
                   
               
               
                   
                 tattgccgtcttttggcaatgtgagggcccggaaacctgg 
               
               
                   
                   
               
               
                   
                 ccctgtcttcttgacgagcattcctaggggtctttcccct 
               
               
                   
                   
               
               
                   
                 ctcgccaaaggaatgcaaggtctgttgaatgtcgtgaagg 
               
               
                   
                   
               
               
                   
                 aagcagttcctctggaagcttcttgaagacaaacaacgtc 
               
               
                   
                   
               
               
                   
                 tgtagcgaccctttgcaggcagcggaaccccccacctggc 
               
               
                   
                   
               
               
                   
                 gacaggtgcctctgcggccaaaagccacgtgtataagata 
               
               
                   
                   
               
               
                   
                 cacctgcaaaggcggcacaaccccagtgccacgttgtgag 
               
               
                   
                   
               
               
                   
                 ttggatagttgtggaaagagtcaaatggctctcctcaagc 
               
               
                   
                   
               
               
                   
                 gtattcaacaaggggctgaaggatgcccagaaggtacccc 
               
               
                   
                   
               
               
                   
                 attgtatgggatctgatctggggcctcggtgcacatgctt 
               
               
                   
                   
               
               
                   
                 tacatgtgtttagtcgaggttaaaaaaacgtctaggcccc 
               
               
                   
                   
               
               
                   
                 ccgaaccacggggacgtggttttcctttgaaaaacacgat 
               
               
                   
                   
               
               
                   
                 gataagcttgccacaacccgggatcctctagagtcgaccc 
               
               
                   
                   
               
               
                   
                 gggcggccgcttccctttagtgagggttaatgcttcgagc 
               
               
                   
                   
               
               
                   
                 agacatgataagatacattgatgagtttggacaaaccaca 
               
               
                   
                   
               
               
                   
                 actagaatgcagtgaaaaaaatgctttatttgtgaaattt 
               
               
                   
                   
               
               
                   
                 gtgatgctattgctttatttgtaaccattataagctgcaa 
               
               
                   
                   
               
               
                   
                 taaacaagttaacaacaacaattgcattcattttatgttt 
               
               
                   
                   
               
               
                   
                 caggttcagggggagatgtgggaggttttttaaagcaagt 
               
               
                   
                   
               
               
                   
                 aaaacctctacaaatgtggtaaaatccgataaggatcgat 
               
               
                   
                   
               
               
                   
                 ccgggctggcgtaatagcgaagaggcccgcaccgatcgcc 
               
               
                   
                   
               
               
                   
                 cttcccaacagttgcgcagcctgaatggcgaatggacgcg 
               
               
                   
                   
               
               
                   
                 ccctgtagcggcgcattaagcgcggcgggtgtggtggtta 
               
               
                   
                   
               
               
                   
                 cgcgcagcgtgaccgctacacttgccagcgccctagcgcc 
               
               
                   
                   
               
               
                   
                 cgctcctttcgctttcttcccttcctttctcgccacgttc 
               
               
                   
                   
               
               
                   
                 gccggctttccccgtcaagctctaaatcgggggctccctt 
               
               
                   
                   
               
               
                   
                 tagggttccgatttagtgctttacggcacctcgaccccaa 
               
               
                   
                   
               
               
                   
                 aaaacttgattagggtgatggttcacgtagtgggccatcg 
               
               
                   
                   
               
               
                   
                 ccctgatagacggtttttcgccctttgacgttggagtcca 
               
               
                   
                   
               
               
                   
                 cgttctttaatagtggactcttgttccaaactggaacaac 
               
               
                   
                   
               
               
                   
                 actcaaccctatctcggtctattcttttgatttataaggg 
               
               
                   
                   
               
               
                   
                 attttgccgatttcggcctattggttaaaaaatgagctga 
               
               
                   
                   
               
               
                   
                 tttaacaaaaatttaacgcgaattttaacaaaatattaac 
               
               
                   
                   
               
               
                   
                 gcttacaatttcctgatgcggtattttctccttacgcatc 
               
               
                   
                   
               
               
                   
                 tgtgcggtatttcacaccgcatacgcggatctgcgcagca 
               
               
                   
                   
               
               
                   
                 ccatggcctgaaataacctctgaaagaggaacttggttag 
               
               
                   
                   
               
               
                   
                 gtaccttctgaggcggaaagaaccagctgtggaatgtgtg 
               
               
                   
                   
               
               
                   
                 tcagttagggtgtggaaagtccccaggctccccagcaggc 
               
               
                   
                   
               
               
                   
                 agaagtatgcaaagcatgcatctcaattagtcagcaacca 
               
               
                   
                   
               
               
                   
                 ggtgtggaaagtccccaggctccccagcaggcagaagtat 
               
               
                   
                   
               
               
                   
                 gcaaagcatgcatctcaattagtcagcaaccatagtcccg 
               
               
                   
                   
               
               
                   
                 cccctaactccgcccatcccgcccctaactccgcccagtt 
               
               
                   
                   
               
               
                   
                 ccgcccattctccgccccatggctgactaattttttttat 
               
               
                   
                   
               
               
                   
                 ttatgcagaggccgaggccgcctcggcctctgagctattc 
               
               
                   
                   
               
               
                   
                 cagaagtagtgaggaggcttttttggaggcctaggctttt 
               
               
                   
                   
               
               
                   
                 gcaaaaagcttgattcttctgacacaacagtctcgaactt 
               
               
                   
                   
               
               
                   
                 aaggctagagccaccatgattgaacaagatggattgcacg 
               
               
                   
                   
               
               
                   
                 caggttctccggccgcttgggtggagaggctattcggcta 
               
               
                   
                   
               
               
                   
                 tgactgggcacaacagacaatcggctgctctgatgccgcc 
               
               
                   
                   
               
               
                   
                 gtgttccggctgtcagcgcaggggcgcccggttctttttg 
               
               
                   
                   
               
               
                   
                 tcaagaccgacctgtccggtgccctgaatgaactgcagga 
               
               
                   
                   
               
               
                   
                 cgaggcagcgcggctatcgtggctggccacgacgggcgtt 
               
               
                   
                   
               
               
                   
                 ccttgcgcagctgtgctcgacgttgtcactgaagcgggaa 
               
               
                   
                   
               
               
                   
                 gggactggctgctattgggcgaagtgccggggcaggatct 
               
               
                   
                   
               
               
                   
                 cctgtcatctcaccttgctcctgccgagaaagtatccatc 
               
               
                   
                   
               
               
                   
                 atggctgatgcaatgcggcggctgcatacgcttgatccgg 
               
               
                   
                   
               
               
                   
                 ctacctgcccattcgaccaccaagcgaaacatcgcatcga 
               
               
                   
                   
               
               
                   
                 gcgagcacgtactcggatggaagccggtcttgtcgatcag 
               
               
                   
                   
               
               
                   
                 gatgatctggacgaagagcatcaggggctcgcgccagccg 
               
               
                   
                   
               
               
                   
                 aactgttcgccaggctcaaggcgcgcatgcccgacggcga 
               
               
                   
                   
               
               
                   
                 ggatctcgtcgtgacccatggcgatgcctgcttgccgaat 
               
               
                   
                   
               
               
                   
                 atcatggtggaaaatggccgcttttctggattcatcgact 
               
               
                   
                   
               
               
                   
                 gtggccggctgggtgtggcggaccgctatcaggacatagc 
               
               
                   
                   
               
               
                   
                 gttggctacccgtgatattgctgaagagcttggcggcgaa 
               
               
                   
                   
               
               
                   
                 tgggctgaccgcttcctcgtgctttacggtatcgccgctc 
               
               
                   
                   
               
               
                   
                 ccgattcgcagcgcatcgccttctatcgccttcttgacga 
               
               
                   
                   
               
               
                   
                 gttcttctgagcgggactctggggttcgaaatgaccgacc 
               
               
                   
                   
               
               
                   
                 aagcgacgcccaacctgccatcacgatggccgcaataaaa 
               
               
                   
                   
               
               
                   
                 tatctttattttcattacatctgtgtgttggttttttgtg 
               
               
                   
                   
               
               
                   
                 tgaatcgatagcgataaggatccgcgtatggtgcactctc 
               
               
                   
                   
               
               
                   
                 agtacaatctgctctgatgccgcatagttaagccagcccc 
               
               
                   
                   
               
               
                   
                 gacacccgccaacacccgctgacgcgccctgacgggcttg 
               
               
                   
                   
               
               
                   
                 tctgctcccggcatccgcttacagacaagctgtgaccgtc 
               
               
                   
                   
               
               
                   
                 tccgggagctgcatgtgtcagaggttttcaccgtcatcac 
               
               
                   
                   
               
               
                   
                 cgaaacgcgcgagacgaaagggcctcgtgatacgcctatt 
               
               
                   
                   
               
               
                   
                 tttataggttaatgtcatgataataatggtttcttagacg 
               
               
                   
                   
               
               
                   
                 tcaggtggcacttttcggggaaatgtgcgcggaaccccta 
               
               
                   
                   
               
               
                   
                 tttgtttatttttctaaatacattcaaatatgtatccgct 
               
               
                   
                   
               
               
                   
                 catgagacaataaccctgataaatgcttcaataatattga 
               
               
                   
                   
               
               
                   
                 aaaaggaagagtatgagtattcaacatttccgtgtcgccc 
               
               
                   
                   
               
               
                   
                 ttattcccttttttgcggcattttgccttcctgtttttgc 
               
               
                   
                   
               
               
                   
                 tcacccagaaacgctggtgaaagtaaaagatgctgaagat 
               
               
                   
                   
               
               
                   
                 cagttgggtgcacgagtgggttacatcgaactggatctca 
               
               
                   
                   
               
               
                   
                 acagcggtaagatccttgagagttttcgccccgaagaacg 
               
               
                   
                   
               
               
                   
                 ttttccaatgatgagcacttttaaagttctgctatgtggc 
               
               
                   
                   
               
               
                   
                 gcggtattatcccgtattgacgccgggcaagagcaactcg 
               
               
                   
                   
               
               
                   
                 gtcgccgcatacactattctcagaatgacttggttgagta 
               
               
                   
                   
               
               
                   
                 ctcaccagtcacagaaaagcatcttacggatggcatgaca 
               
               
                   
                   
               
               
                   
                 gtaagagaattatgcagtgctgccataaccatgagtgata 
               
               
                   
                   
               
               
                   
                 acactgcggccaacttacttctgacaacgatcggaggacc 
               
               
                   
                   
               
               
                   
                 gaaggagctaaccgcttttttgcacaacatgggggatcat 
               
               
                   
                   
               
               
                   
                 gtaactcgccttgatcgttgggaaccggagctgaatgaag 
               
               
                   
                   
               
               
                   
                 ccataccaaacgacgagcgtgacaccacgatgcctgtagc 
               
               
                   
                   
               
               
                   
                 aatggcaacaacgttgcgcaaactattaactggcgaacta 
               
               
                   
                   
               
               
                   
                 cttactctagcttcccggcaacaattaatagactggatgg 
               
               
                   
                   
               
               
                   
                 aggcggataaagttgcaggaccacttctgcgctcggccct 
               
               
                   
                   
               
               
                   
                 tccggctggctggtttattgctgataaatctggagccggt 
               
               
                   
                   
               
               
                   
                 gagcgtgggtctcgcggtatcattgcagcactggggccag 
               
               
                   
                   
               
               
                   
                 atggtaagccctcccgtatcgtagttatctacacgacggg 
               
               
                   
                   
               
               
                   
                 gagtcaggcaactatggatgaacgaaatagacagatcgct 
               
               
                   
                   
               
               
                   
                 gagataggtgcctcactgattaagcattggtaactgtcag 
               
               
                   
                   
               
               
                   
                 accaagtttactcatatatactttagattgatttaaaact 
               
               
                   
                   
               
               
                   
                 tcatttttaatttaaaaggatctaggtgaagatccttttt 
               
               
                   
                   
               
               
                   
                 gataatctcatgaccaaaatcccttaacgtgagttttcgt 
               
               
                   
                   
               
               
                   
                 tccactgagcgtcagaccccgtagaaaagatcaaaggatc 
               
               
                   
                   
               
               
                   
                 ttcttgagatcctttttttctgcgcgtaatctgctgcttg 
               
               
                   
                   
               
               
                   
                 caaacaaaaaaaccaccgctaccagcggtggtttgtttgc 
               
               
                   
                   
               
               
                   
                 cggatcaagagctaccaactctttttccgaaggtaactgg 
               
               
                   
                   
               
               
                   
                 cttcagcagagcgcagataccaaatactgttcttctagtg 
               
               
                   
                   
               
               
                   
                 tagccgtagttaggccaccacttcaagaactctgtagcac 
               
               
                   
                   
               
               
                   
                 cgcctacatacctcgctctgctaatcctgttaccagtggc 
               
               
                   
                   
               
               
                   
                 tgctgccagtggcgataagtcgtgtcttaccgggttggac 
               
               
                   
                   
               
               
                   
                 tcaagacgatagttaccggataaggcgcagcggtcgggct 
               
               
                   
                   
               
               
                   
                 gaacggggggttcgtgcacacagcccagcttggagcgaac 
               
               
                   
                   
               
               
                   
                 gacctacaccgaactgagatacctacagcgtgagctatga 
               
               
                   
                   
               
               
                   
                 gaaagcgccacgcttcccgaagggagaaaggcggacaggt 
               
               
                   
                   
               
               
                   
                 atccggtaagcggcagggtcggaacaggagagcgcacgag 
               
               
                   
                   
               
               
                   
                 ggagcttccagggggaaacgcctggtatctttatagtcct 
               
               
                   
                   
               
               
                   
                 gtcgggtttcgccacctctgacttgagcgtcgatttttgt 
               
               
                   
                   
               
               
                   
                 gatgctcgtcaggggggcggagcctatggaaaaacgccag 
               
               
                   
                   
               
               
                   
                 caacgcggcctttttacggttcctggccttttgctggcct 
               
               
                   
                   
               
               
                   
                 tttgctcacatggctcgacagatct 
               
            
           
         
       
     
     In some embodiments therefore, the composition of the disclosure comprises a nucleic acid molecule comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule that is a pVax variant. 
     In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%. 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a scaffold domain comprising any of the self-assembling polypeptides disclosed herein, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding an antigen domain comprising any of the viral antigens disclosed herein, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a scaffold domain comprising a self-assembling polypeptide comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding an antigen domain comprising a viral antigen comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment or variant thereof, and a second nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof. In some embodiments, such nucleic acid molecules or plasmids may further comprise a third nucleic acid sequence encoding a leader sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof. In such embodiments, the third nucleic acid sequence encoding a leader sequence may comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof. 
     In some embodiments, the nucleic acid molecules or plasmids of the disclosure may additionally comprise another nucleic acid sequence encoding a linker comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. In some embodiments, the nucleic acid sequence encoding a linker may comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. 
     In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a leader sequence comprising any of the leader sequences disclosed herein, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding a viral trimer (or three viral monomers) comprising any of the viral antigens disclosed herein, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a leader sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding three viral monomers, each viral monomer independently comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof, and a second nucleic acid sequence encoding three viral monomers, each viral monomer independently being encoded by a nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof. In some embodiments, each of the viral monomers is linked by one or more linker peptides comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. In some embodiments, each of the viral monomers is linked by one or more linker peptides encoded by a nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. 
     In some embodiments, any of the nucleic acid molecules or plasmids of the disclosure additionally comprises a nucleic acid sequence encoding a furin cleavage site comprising at least about 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 67, or a functional fragment or variant thereof. 
     In some embodiments, the nucleic acid molecule or plasmid may further comprises a nucleic acid encoding a transmembrane domain and a foldon domain. A non-limiting example of the transmembrane domain is the transmembrane domain of a platelet derived growth factor receptor comprising the sequence of AVGQDTQEVIVVPHSL PFKVVVISAILALVVLTIISLIILIMLWQKKPR (SEQ ID NO: 169). A non-limiting example of the foldon domain may comprise the sequence of YIPEAPRDGQAYVRKD GEWVLLSTFL (SEQ ID NO: 170). Thus, in some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising a nucleic acid sequence encoding a transmembrane domain comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 169, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising a nucleic acid sequence encoding a foldon domain comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 170, or a functional fragment or variant thereof. 
     In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising the nucleotide sequence of SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence encoding a polypeptide comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. In some embodiments, the composition of the disclosure comprises a nucleic acid molecule or a plasmid comprising the nucleotide sequence of SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 1676 or SEQ ID NO: 168, or a functional fragment or variant thereof, and an expressible nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. 
     In some embodiments, the disclosure relates to a vector or a plasmid comprising one or a plurality of regulatory sequences operably linked to one or more of any of the disclosed expressible nucleic acid sequences. In some embodiments, the disclosure relates to a composition comprising a nucleic acid molecule comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 161, or a functional fragment or variant thereof, and positioned within the multiple cloning site thereof is one or more expressible nucleic acid sequences according to the present disclosure. In some embodiments, the disclosure relates to a composition comprising one or a plurality of RNA molecules, each individually comprising the RNA sequences disclosed herein, including but not limited to SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 84, SEQ ID NO: 87, SEQ ID NO: 90, SEQ ID NO: 93, SEQ ID NO: 96, SEQ ID NO: 99, SEQ ID NO: 102, SEQ ID NO: 105, SEQ ID NO: 108, SEQ ID NO: 111, SEQ ID NO: 114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO: 123, SEQ ID NO: 126, SEQ ID NO: 129, SEQ ID NO: 132, SEQ ID NO: 135, SEQ ID NO: 138, SEQ ID NO: 141, SEQ ID NO: 144, SEQ ID NO: 147, SEQ ID NO: 150, SEQ ID NO: 153, SEQ ID NO: 156 or SEQ ID NO: 159, or a functional fragment or variant thereof. 
     C. Polypeptide Sequences 
     Disclosed are the polypeptide sequences encoded by the disclosed nucleic acid sequences. In some embodiments, the disclosure relates to compositions comprising polypeptide sequences encoded by the expressible nucleic acid molecules of the present disclosure comprising a scaffold domain comprising a self-assembling polypeptide and an antigen domain comprising a viral antigen, and optionally comprising a leader domain comprising a leader sequence and/or a linker domain comprising a linker peptide. In some embodiments, the disclosure relates to compositions comprising polypeptide sequences encoded by the expressible nucleic acid molecules of the present disclosure comprising a leader domain comprising a leader sequence and an antigen domain comprising three viral monomers (trimer), and optionally comprising one or plurality of linker domains each comprising a linker peptide. The disclosure also relates to cells expressing one or more such polypeptides disclosed herein. 
     In some embodiments, the antigen domain comprised in the polypeptides of the disclosure comprises a soluble viral trimer or a soluble monomer thereof, wherein the soluble viral trimer or the soluble monomer thereof is from a virus of the family Coronaviridae. A “viral trimer” refers to a protein complex formed by three covalently or non-convalently bound viral proteins. Each of these viral proteins, when present by itself, is called as a “monomer” of the viral trimer. 
     Solubility of the disclosed viral trimer or monomer thereof can be determined using any methods known in the art. Protein solubility is a thermodynamic parameter defined as the concentration of protein in a saturated solution that is in equilibrium with a solid phase, either crystalline or amorphous, under a given set of conditions. Solubility can be influenced by a number of extrinsic and intrinsic factors. Extrinsic factors that influence protein solubility include pH, ionic strength, temperature, and the presence of various solvent additives. Varying these extrinsic factors can lead to increased solubility; however, altering the solution conditions is not always appropriate or sufficient to increase protein solubility to the extent required. The intrinsic factors that influence protein solubility are defined primarily by the amino acids on the protein surface, but a detailed understanding of how one can alter the intrinsic properties of a protein to increase its solubility is lacking. 
     There are generally two methods used to measure protein solubility in aqueous solution: (1) adding lyophilized protein to solvent; and (2) concentrating a protein solution by ultrafiltration. Both of these methods require that the concentration of protein in solution be increased until saturation is reached; however, this is often difficult to do, especially with very soluble proteins, because gel-like or supersaturated solutions may form, making it difficult to determine the solubility values accurately. When lyophilized protein is added to solvent, the variable water and salt content of the lyophilized powder is difficult to control and can have a significant effect on solubility measurements. 
     One way to avoid the difficulties of measuring protein solubility is to make use of an extraneous agent that lowers the solubility of a protein called a precipitant. Protein precipitants can be divided into three classes: salts, organic solvents, and long-chain polymers. These precipitants are used by crystallographers to achieve slow precipitation and crystal formation; however, they can also be used to induce amorphous precipitation by direct mixing with protein solutions. Common examples from each of these three classes of precipitants, respectively, are ammonium sulfate, isopropanol, and polyethylene glycol (PEG). The relationship between precipitant concentration to protein solubility is described by the following general expression: 
       Log  S =constant−β[Precipitant],  Equation (1)
 
     where S is the measured solubility at a given concentration of precipitant, and 13 is the dependence of solubility on precipitant concentration for a given protein. The constant is the y-intercept of the solubility plot, and for PEG precipitations is equal to the logarithm of the protein activity. For dilute protein solutions, as the activity constant approaches one, Equation (1) becomes 
       Log  S =Log  S   o −β[Precipitant],  Equation (2)
 
     where S 0  is the solubility in the absence of precipitant. It is showed that for PEG precipitations, the linearity of Equation (1) extends to zero precipitant for proteins whose solubility can be accurately measured in buffer alone. In this case, the constant portion of Equation (2), Log S 0 , can be used as an estimate of solubility in the absence of precipitant. For salts, Equation (1) only describes the salting-out region of the solubility plot. At low salt concentrations, salting-in is observed and the solubility is higher than in the absence of salt. Therefore, the constant obtained from salt precipitations represents a projection of the salting-out region onto the y axis. In some embodiments, the nucleic acid sequences of certain compositions encode viral monomers that, upon expression, preferentially form into viral trimers. In some embodiments, the viral antigens form into viral trimer proteins displayed upon a scaffold polypeptide, such as a self-assembling polypeptide polyhedron. In some embodiments, the viral anigens are at a concentration within the disclosed compositions that does not exceed a concentration that causes precipitation out of solution. In some embodiments, the scaffold peptide and the displayed viral antigens are soluble in aqueous solution, such as PBS, sterile water or buffered Ringer&#39;s solution. 
     In some embodiments, the polypeptide encoded by the expressible nucleic acid molecule of the present disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. In some embodiments, the polypeptide is encoded by a nucleic acid sequence comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 158 or SEQ ID NO: 159, or a functional fragment or variant thereof. 
     In some embodiments, the leader sequence encoded by the expressible nucleic acid sequence of the disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 5, or a functional fragment or variant thereof. In some embodiments, the leader sequence is encoded by a nucleic acid sequence comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 6, or a functional fragment or variant thereof. 
     In some embodiments, the self-assembling polypeptide encoded by the expressible nucleic acid sequence of the disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 or SEQ ID NO: 20, or a functional fragment or variant thereof. In some embodiments, the self-assembling polypeptide is encoded by a nucleic acid sequence comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17 or SEQ ID NO: 19, or a functional fragment or variant thereof. 
     In some embodiments, the linker peptide encoded by the expressible nucleic acid sequence of the disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 or SEQ ID NO: 58, or a functional fragment or variant thereof. In some embodiments, the linker peptide is encoded by a nucleic acid sequence comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55 or SEQ ID NO: 57 or a functional fragment or variant thereof. 
     In some embodiments, the viral antigen or monomer encoded by the expressible nucleic acid sequence of the disclosure comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176 or SEQ ID NO: 177, or a functional fragment or variant thereof. In some embodiments, the viral antigen or monomer is encoded by a nucleic acid sequence comprises at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63 or SEQ ID NO: 65, or a functional fragment or variant thereof. 
     In some embodiments, the polypeptides encoded by the expressible nucleic acid molecule of the present disclosure comprises a furin cleavage site comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 67. In some embodiments, the polypeptides encoded by the expressible nucleic acid molecule of the present disclosure comprises a transmembrane domain comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 169. In some embodiments, the polypeptides encoded by the expressible nucleic acid molecule of the present disclosure comprises a foldon domain comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 170. 
     D. Pharmaceutical Compositions 
     Disclosed are pharmaceutical compositions comprising any one or more of the disclosed compositions and a pharmaceutically acceptable carrier. Disclosed are pharmaceutical compositions comprising therapeutically effective amounts of any one or more of the disclosed compositions and a pharmaceutically acceptable carrier. 
     In some embodiments, any of the disclosed compositions is from about 1 to about 30 micrograms of the disclosed DNA and/or RNA vaccine. For example, any of the disclosed compositions can be from about 1 to about 5 micrograms the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain from about 5 nanograms to about 800 micrograms of the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain about 25 to about 250 micrograms, from about 100 to about 200 micrograms, from about 1 nanogram to 100 milligrams; from about 1 microgram to about 10 milligrams; from about 0.1 microgram to about 10 milligrams; from about 1 milligram to about 2 milligrams, from about 5 nanograms to about 1000 micrograms, from about 10 nanograms to about 800 micrograms, from about 0.1 to about 500 micrograms, from about 1 to about 350 micrograms, from about 25 to about 250 micrograms, from about 100 to about 200 micrograms of the DNA and/or RNA vaccine or plasmid thereof. The pharmaceutical compositions can comprise from about 5 nanograms to about 10 mg of the disclosed DNA and/or RNA vaccine. In some embodiments, pharmaceutical compositions according to the present disclosure comprise from about 25 nanograms to about 5 mg of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain from about 50 nanograms to about 1 mg of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about from about 0.1 to about 500 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain from about 1 to about 350 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain from about 5 to about 250 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain from about 10 to about 200 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain from about 15 to about 150 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about 20 to about 100 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about 25 to about 75 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about 30 to about 50 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about 35 to about 40 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions contain about 100 to about 200 micrograms the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions comprise about 10 micrograms to about 100 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions comprise about 20 micrograms to about 80 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions comprise about 25 micrograms to about 60 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions comprise about 30 nanograms to about 50 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions comprise about 35 nanograms to about 45 micrograms of the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain about 0.1 to about 500 micrograms of the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain about 1 to about 350 micrograms of the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain about 1 to about 250 micrograms of the disclosed DNA and/or RNA vaccine. In some preferred embodiments, the pharmaceutical compositions contain about 2 to about 200 micrograms the disclosed DNA and/or RNA vaccine. 
     In some embodiments, pharmaceutical compositions according to the present disclosure comprise at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 nanograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical compositions can comprise at least about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995 or 1000 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical composition can comprise at least 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg or more of the disclosed DNA and/or RNA vaccine. 
     In other embodiments, the pharmaceutical composition can comprise up to and including about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 nanograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical composition can comprise up to and including about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, or 1000 micrograms of the disclosed DNA and/or RNA vaccine. In some embodiments, the pharmaceutical composition can comprise up to and including about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or about 10 mg of the disclosed DNA and/or RNA vaccine. The pharmaceutical composition can further comprise other agents for formulation purposes according to the mode of administration to be used. In cases where pharmaceutical compositions are injectable pharmaceutical compositions, they are sterile, pyrogen free and particulate free. An isotonic formulation is preferably used. Generally, additives for isotonicity can include sodium chloride, dextrose, mannitol, sorbitol and lactose. In some cases, isotonic solutions such as phosphate buffered saline are preferred. Stabilizers include gelatin and albumin. In some embodiments, a vasoconstriction agent is added to the formulation. 
     The vaccine can further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient can be functional molecules as vehicles, adjuvants, carriers, or diluents. The pharmaceutically acceptable excipient can be a transfection facilitating agent, which can include surface active agents, such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or other known transfection facilitating agents. In some embodiments, the vaccine is a composition comprising a plasmid DNA molecule, RNA molecule or DNA/RNA hybrid molecule encoding an expressible nucleic acid sequence, the expressible nucleic acid sequence comprising a first nucleic acid encoding a self-assembling nanoparticle comprising a viral antigen, optionally encoding a leader sequence disclosed herein. 
     The transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. The transfection facilitating agent is poly-L-glutamate, and more preferably, the poly-L-glutamate is present in the vaccine at a concentration less than 6 mg/ml. The transfection facilitating agent can also include surface active agents such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs and vesicles such as squalene and squalene, and hyaluronic acid can also be used administered in conjunction with the genetic construct. In some embodiments, the DNA vector vaccines can also include a transfection facilitating agent such as lipids, liposomes, including lecithin liposomes or other liposomes known in the art, as a DNA-liposome mixture (see for example WO9324640), calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. In some embodiments, the transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. Concentration of the transfection agent in the vaccine is less than about 4 mg/ml, less than about 2 mg/ml, less than about 1 mg/ml, less than about 0.750 mg/ml, less than about 0.500 mg/ml, less than about 0.250 mg/ml, less than about 0.100 mg/ml, less than about 0.050 mg/ml, or less than about 0.010 mg/ml. 
     The pharmaceutically acceptable excipient can be an adjuvant. The adjuvant can be other genes that are expressed in alternative plasmid or are deneurological systemed as proteins in combination with the plasmid above in the vaccine. The adjuvant can be selected from: α-interferon(IFN-α), β-interferon (IFN-β), γ-interferon, platelet derived growth factor (PDGF), TNFα, TNFβ, GM-CSF, epidermal growth factor (EGF), cutaneous T cell-attracting chemokine (CTACK), epithelial thymus-expressed chemokine (TECK), mucosae-associated epithelial chemokine (MEC), IL-12, IL-15, MHC, CD80, CD86 including IL-15 having the signal sequence deleted and optionally including the signal peptide from IgE. The adjuvant can be IL-12, IL-15, IL-28, CTACK, TECK, platelet derived growth factor (PDGF), TNFα, TNFβ, GM-CSF, epidermal growth factor (EGF), IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-18, or a combination thereof. In an exemplary embodiment, the adjuvant is IL-12. 
     Other genes which can be useful adjuvants include those encoding: MCP-1, MIP-1a, MIP-1p, IL-8, RANTES, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, IL-4, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Fit, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGRF, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRCS, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof or a combination thereof. 
     In some embodiments adjuvant may be one or more proteins and/or nucleic acid molecules that encode proteins selected from the group consisting of: CCL-20, IL-12, IL-15, IL-28, CTACK, TECK, MEC or RANTES. Examples of IL-12 constructs and sequences are disclosed in PCT application No. PCT/US1997/019502 (published as WO98/017799) and corresponding U.S. application Ser. No. 08/956,865, and U.S. Provisional Application No. 61/569,600 filed Dec. 12, 2011, which are each incorporated herein by reference in their entireties. Examples of IL-15 constructs and sequences are disclosed in PCT application No. PCT/US04/18962 (published as WO2005/000235) and corresponding U.S. application Ser. No. 10/560,650, and in PCT application No. PCT/US07/00886 (published as WO2007/087178) and corresponding U.S. application Ser. No. 12/160,766, and in PCT Application Serial No. PCT/US10/048827 (published as WO2011/032179), which are each incorporated herein by reference in their entireties. Examples of IL-28 constructs and sequences are disclosed in PCT application no. PCT/US09/039648 (published as WO2009/124309) and corresponding U.S. application Ser. No. 12/936,192, which are each incorporated herein by reference in their entireties. Examples of RANTES and other constructs and sequences are disclosed in PCT application No. PCT/US 1999/004332 (published as WO99/043839) and corresponding U.S. application Ser. No. 09/622,452, which are each incorporated herein by reference in their entieties. Other examples of RANTES constructs and sequences are disclosed in PCT Application No. PCT/US Ser. No. 11/024,098 (published as WO2011/097640), which is incorporated herein by reference. Examples of RANTES and other constructs and sequences are disclosed in PCT Application No. PCT/US 1999/004332 and corresponding U.S. application Ser. No. 09/622,452, which are each incorporated herein by reference. Other examples of RANTES constructs and sequences are disclosed in PCT application No. PCT/US11/024098 (published as WO2011/097640), which is incorporated herein by reference in its entirety. Examples of chemokines CTACK, TECK and MEC constructs and sequences are disclosed in PCT Application No. PCT/US2005/042231 (published as WO2007/050095) and corresponding U.S. application Ser. No. 11/719,646, which are each incorporated herein by reference in their entireties. Examples of OX40 and other immunomodulators are disclosed in U.S. application Ser. No. 10/560,653, which is incorporated herein by reference in its entirety. Examples of DR5 and other immunomodulators are disclosed in U.S. application Ser. No. 09/622,452, which is incorporated herein by reference in its entirety. 
     The pharmaceutial compoistion may be formulated according to the mode of administration to be used. An injectable vaccine pharmaceutical composition may be sterile, pyrogen free and particulate free. An isotonic formulation or solution may be used. Additives for isotonicity may include sodium chloride, dextrose, mannitol, sorbitol, and lactose. The vaccine may comprise a vasoconstriction agent. The isotonic solutions may include phosphate buffered saline. Vaccine may further comprise stabilizers including gelatin and albumin. The stabilizing may allow the formulation to be stable at room or ambient temperature for extended periods of time such as LGS or polycations or polyanions to the vaccine formulation. 
     The vaccine can be a DNA or RNA vaccine. In some embodiments, the vaccine is a DNA vaccine. DNA vaccines are disclosed in U.S. Pat. Nos. 5,593,972, 5,739,118, 5,817,637, 5,830,876, 5,962,428, 5,981,505, 5,580,859, 5,703,055, and 5,676,594, which are incorporated herein fully by reference. The DNA vaccine can further comprise elements or reagents that inhibit it from integrating into the chromosome. Examples of attenuated live vaccines, those using recombinant vectors to foreign antigens, subunit vaccines and glycoprotein vaccines are described in U.S. Pat. Nos. 4,510,245; 4,797,368; 4,722,848; 4,790,987; 4,920,209; 5,017,487; 5,077,044; 5,110,587; 5,112,749; 5,174,993; 5,223,424; 5,225,336; 5,240,703; 5,242,829; 5,294,441; 5,294,548; 5,310,668; 5,387,744; 5,389,368; 5,424,065; 5,451,499; 5,453,364; 5,462,734; 5,470,734; 5,474,935; 5,482,713; 5,591,439; 5,643,579; 5,650,309; 5,698,202; 5,955,088; 6,034,298; 6,042,836; 6,156,319 and 6,589,529, which are each incorporated herein by reference in their entireties. In other embodiments, the vaccine is a RNA vaccine. RNA vaccines are disclosed in, for example, U.S. Pat. Nos. 10,064,934; 10,064,935; 10,124,055; 10,238,731; 10,272,150; 10,383,937; 10,449,244; 10,517,940; 10,543,269; 10,675,342; 10,702,597; 10,702,599; and 10,716,846; and U.S. Application Publication Nos. 2011/0033416; 2014/0134129; 2017/0136121; 2018/0344838; 2020/0016274; 2020/0030432; 2020/0405844; and 2021/0046173, which are each incorporated herein by reference in their entireties. 
     In some embodiments, the vaccine is a lipid nanoparticles (LNP) comprising one or a modified RNA molecule. In some embodiments, the vaccine comprises a modified mRNA. Modified polynucleotides (such as, but not limited to, primary constructs), formulations and compositions comprising modified polynucleotides, and methods of making, using and administering modified polynucleotides are described in U.S. Provisional Patent Application Nos. 61/618,862; 61/681,645; 61/737,130; 61/618,866; 61/681,647; 61/737,134; 61/618,868; 61/681,648; 61/737,135; 61/618,873; 61/681,650; 61/737,147; 61/618,878; 61/681,654; 61/737,152; 61/618,885; 61/681,658; 61/737,155; 61/618,896; 61/668,157; 61/681,661; 61/737,160; 61/618,911; 61/681,667; 61/737,168; 61/618,922; 61/681,675; 61/737,174; 61/618,935; U61/681,687; 61/737,184; 61/618,945; 61/681,696; 61/737,191; 61/618,953; 61/681,704; 61/737,203; 61/681,720; 61/737,213; 61/681,742; 61/618,870; 61/681,649; and 61/737,139; and International Application Nos. PCT/US2013/030062; PCT/US2013/030064; PCT/US2013/030059; PCT/US2013/030066; PCT/US2013/030067; PCT/US2013/030060; PCT/US2013/030061; PCT/US2013/030070; PCT/US2013/030068; PCT/US2013/030063; and PCT/US2013/031821, the contents of each of which are herein incorporated by reference in their entireties. Any of the recited polypeptides of the modified polynucleotides of the foregoing are considered useful as a polypeptide of interest or antigen of the LNPs of the present disclosure. 
     The genetic construct can also be part of a genome of a recombinant viral vector, including recombinant adenovirus, recombinant adenovirus associated virus and recombinant vaccinia. The genetic construct can be part of the genetic material in attenuated live microorganisms or recombinant microbial vectors which live in cells. 
     In some embodiments, the disclosure relates to a DNA vector pVAX1 comprising any one or more of the expressible nucliec acid sequences disclosed herein or an RNA transcript thereof. In some embodiments, the disclosure relates to a pharmaceuical composition comprising a nucleic acid sequencethat includes one or a plurality of the expressible nucleic acid sequences discloed herein or an RNA transcript thereof, and a pharmaceutically acceptable carrier. 
     E. Methods 
     Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention and/or treatment of an infection of a virus from the family of Coronaviridae, particularly a coronavirus infection, in humans and other mammals. Virus vaccines can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat infectious disease. In exemplary aspects, the vaccines of the present disclosure are used to provide prophylactic protection from coronavirus. Prophylactic protection from coronavirus can be achieved following administration of a prophylactically effective dose of a coronavirus DNA or RNA vaccine of the present disclosure. A prophylactically effective dose is a therapeutically effective dose that prevents infection with the virus at a clinically acceptable level. In some embodiments, the therapeutically effective dose is a dose listed in a package insert for the vaccine. Vaccines can be administered once, twice, three times, four times or more. It is possible, although less desirable, to administer the vaccine to an infected individual to achieve a therapeutic response. Dosing may need to be adjusted accordingly. 
     In some embodiments, disclosed are methods of vaccinating a subject comprising administering a therapeutically effective amount of any of the disclosed nucleic acid molecules, compositions, pharmaceutical compositions, cells or vaccines to the subject. In some embodiments, the vaccination is against viral infection. In some embodiments, the viral infection is an infection of a virus from the family of Coronaviridae. In some embodiments, the viral infection is an infection of a coronavirus. In some embodiments, the viral infection is an infection of SARS-CoV. In some embodiments, the viral infection is an infection of HCoV NL63. In some embodiments, the viral infection is an infection of HKU1. In some embodiments, the viral infection is an infection of MERS-CoV. In some embodiments, the viral infection is an infection of SARS-CoV-2. 
     In some embodiments, disclosed are methods of inducing an immune response in a subject comprising administering to the subject any of the disclosed pharmaceutical compositions. In some embodiments, the methods are for inducing an immune response against a viral antigen in the subject. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from a virus from the family of Coronaviridae. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from a coronavirus. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from SARS-CoV. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from HCoV NL63. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from HKU1. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from MERS-CoV. In some embodiments, the immune response induced by the disclosed methods is against a viral antigen from SARS-CoV-2. 
     In some embodiments, disclosed are methods of neutralizing one or a plurality of viruses in a subject comprising administering to the subject any of the disclosed pharmaceutical compositions. In some embodiments, the virus being neutralized by the disclosed method is a virus from the family of Coronaviridae. In some embodiments, the virus being neutralized by the disclosed method is a coronavirus. In some embodiments, the virus being neutralized by the disclosed method is SARS-CoV. In some embodiments, the virus being neutralized by the disclosed method is HCoV NL63. In some embodiments, the virus being neutralized by the disclosed method is HKU1. In some embodiments, the virus being neutralized by the disclosed method is MERS-CoV. In some embodiments, the virus being neutralized by the disclosed method is SARS-CoV-2. 
     In some embodiments, disclosed are methods of neutralizing infection of one or a plurality of viruses in a subject comprising administering to the subject any of the disclosed pharmaceutical compositions. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of a virus from the family of Coronaviridae. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of coronavirus. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of SARS-CoV. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of HCoV NL63. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of HKU1. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of MERS-CoV. In some embodiments, the viral infection being neutralized by the disclosed method is an infection of SARS-CoV-2. 
     In some embodiments, disclosed are methods of stimulating a therapeutically effective antigen-specific immune response against a virus in a mammal infected with the virus comprising administering any of the disclosed pharmaceutical compositions. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against a virus from the family of Coronaviridae. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against a coronavirus. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against SARS-CoV. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against HCoV NL63. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against HKU1. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against MERS-CoV. In some embodiments, the disclosed method is a method of stimulating a therapeutically effective antigen-specific immune response against SARS-CoV-2. 
     In some embodiments, disclosed are methods of inducing expression of a self-assembling vaccine in a subject comprising administering any of the disclosed pharmaceutical compositions. Also disclosed are methods of treating a subject having a viral infection or susceptible to becoming infected with a virus comprising administering to the subject a therapeutically effective amount of any of the disclosed pharmaceutical compositions. In some embodiments, the viral infection is an infection of a virus from the family of Coronaviridae. In some embodiments, the viral infection is an infection of coronavirus. In some embodiments, the viral infection is an infection of SARS-CoV. In some embodiments, the viral infection is an infection of HCoV NL63. In some embodiments, the viral infection is an infection of HKU1. In some embodiments, the viral infection is an infection of MERS-CoV. In some embodiments, the viral infection is an infection of SARS-CoV-2. 
     The disclosed pharmaceutical compositions may be administered by any route of administration. Accordingly, in some embodiments, the administration is accomplished by oral administration. In some embodiments, the administration is accomplished by parenteral administration. In some embodiments, the administration is accomplished by sublingual administration. In some embodiments, the administration is accomplished by transdermal administration. In some embodiments, the administration is accomplished by rectal administration. In some embodiments, the administration is accomplished by transmucosal administration. In some embodiments, the administration is accomplished by topical administration. In some embodiments, the administration is accomplished by inhalation. In some embodiments, the administration is accomplished by buccal administration. In some embodiments, the administration is accomplished by intrapleural administration. In some embodiments, the administration is accomplished by intravenous administration. In some embodiments, the administration is accomplished by intraarterial administration. In some embodiments, the administration is accomplished by intraperitoneal administration. In some embodiments, the administration is accomplished by subcutaneous administration. In some embodiments, the administration is accomplished by intramuscular administration. In some embodiments, the administration is accomplished by intranasal administration. In some embodiments, the administration is accomplished by intrathecal administration. In some embodiments, the administration is accomplished by intraarticular administration. In some embodiments, the administration is accomplished by intradermal administration. In some embodiments, the above modes of action are accomplished by injection of the pharmaceutical compositions disclosed herein. 
     In some embodiments, the therapeutically effective dose can be from about 1 to about 30 micrograms of expressible nucleic acid sequence. In some embodiments, the therapeutically effective dose can be from about 0.001 micrograms of the composition per kilogram of subject to about 0.050 micrograms per kilogram of subject. 
     In some embodiments, any of the disclosed methods can be free of activating any mannose-binding lectin or complement process. In some embodiments, any of the disclosed methods is performed without inducing the MBL-complement pathway. 
     In some embodiments, the subject can be a human. In some embodiments, the subject is diagnosed with or suspected of having a viral infection. In some embodiments, the subject is diagnosed with or suspected of having an infection of a virus from the family of Coronaviridae. In some embodiments, the subject is diagnosed with or suspected of having an infection of coronavirus. In some embodiments, the subject is diagnosed with or suspected of having an infection of SARS-CoV. In some embodiments, the subject is diagnosed with or suspected of having an infection of HCoV NL63. In some embodiments, the subject is diagnosed with or suspected of having an infection of HKU1. In some embodiments, the subject is diagnosed with or suspected of having an infection of MERS-CoV. In some embodiments, the subject is diagnosed with or suspected of having an infection of SARS-CoV-2. 
     In some embodiments of the methods of inducing an immune response, the immune response can be an antigen-specific imune response. In some embodiments, the antigen-specific immune response can be an antigen-specific to SARS-CoV-2 antigen immune response. In some embodiments, the antigen-specific immune response can be a therapeutically effective CD-4+ antigen-specific SARS-CoV-2 immune response. In some embodiments, the antigen-specific immune response can be a therapeutically effective CD-8+ antigen-specific SARS-CoV-2 immune response. In some embodiments, the antigen-specific immune response can be a therapeutically effective CD-4+ and CD-8+ antigen-specific SARS-CoV-2 immune response. 
     In some embodiments, the methods are free of administering any polypeptide directly to the subject. 
     In some embodiments, any of the disclosed methods can further comprise administering to the subject a pharmaceutical composition comprising one or more pharmaceutically active agents, such as antiviral drugs, among many others. In some embodiments, the one or more pharmaceutically active agents include other anticoronarival medications used to inhibit coronavirus, for example nucleoside analog reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. Among the available drugs that may be used as a pharmaceutically active agent are zidovudine or AZT (or Retrovir®), didanosine or DDI (or Videx®), stavudine or D4T (or Zerit®), lamivudine or 3TC (or Epivir®), zalcitabine or DDC (or Hivid®), abacavir succinate (or Ziagen″), tenofovir disoproxil fumarate salt (or Viread®), emtricitabine (or Emtriva®), Combivir® (contains 3TC and AZT), Trizivir® (contains abacavir, 3TC and AZT); three non-nucleoside reverse transcriptase inhibitors: nevirapine (or Viramune®), delavirdine (or Rescriptor®) and efavirenz (or Sustiva®), eight peptidomimetic protease inhibitors or approved formulations: saquinavir (or Invirase® or Fortovase″), indinavir (or Crixivan®), ritonavir (or Norvir®), nelfinavir (or Viracept″), amprenavir (or Agenerase®), atazanavir (Reyataz), fosamprenavir (or Lexiva), Kaletra®(contains lopinavir and ritonavir), and one fusion inhibitor enfuvirtide (or T-20 or Fuzeon®). 
     In some embodiments, the methods of inducing an immune response can include inducing a humoral or cellular immune response. A humoral immune response mainly refers to antibody production. A cellular immune response can include activation of CD4+ T-cells and activation CD8+ cells and associated cytotoxic activity. In one aspect, the present disclosure features a method of inducing an immune response in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of any of the nucleic acid molecules comprising any one or a plurality of the disclosed expressible nucleic acid sequences or embodiments herein, or any one of the pharmaceutical compositions disclosed herein. In one aspect, the present disclosure features a method of inducing a CD8+ T cell immune response in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of any of the nucleic acid molecules comprising any one or a plurality of the disclosed expressible nucleic acid sequences or embodiments herein, or any one of the pharmaceutical compositions disclosed herein. 
     In one aspect, the present disclosure features a method of enhancing an immune response in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of any of the nucleic acid molecules comprising any one or a plurality of the disclosed expressible nucleic acid sequences or embodiments herein, or any one of the pharmaceutical compositions disclosed herein. 
     In one aspect, the present disclosure features a method of enhancing a CD8+ T cell immune response in a subject, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of any of the nucleic acid molecules comprising any one or a plurality of the disclosed expressible nucleic acid sequences or embodiments herein, or any one of the pharmaceutical compositions disclosed herein. 
     In some embodiments, the subject has a viral infection and is in need of therapy for the viral infection. In some embodiments, the viral infection is an infection of a virus from the family of Coronaviridae. In some embodiments, the viral infection is an infection of coronavirus. In some embodiments, the viral infection is an infection of SARS-CoV. In some embodiments, the viral infection is an infection of HCoV NL63. In some embodiments, the viral infection is an infection of HKU1. In some embodiments, the viral infection is an infection of MERS-CoV. In some embodiments, the viral infection is an infection of SARS-CoV-2. 
     In some embodiments, the subject has previously been treated, and not responded to anti-viral therapy. In some embodiments, the nucleic acid molecule and/or the expressible nucleic acid sequence of the disclosure is administered to the subject by electroporation. 
     The vaccine may be administered by different routes including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrapleurally, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal intrathecal, and intraarticular or combinations thereof. For veterinary use, the composition may be administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal. The vaccine may be administered by traditional syringes, needleless injection devices, “microprojectile bombardment gone guns,” or other physical methods such as electroporation (“EP”), “hydrodynamic method,” or ultrasound. 
     The plasmid of the vaccine may be delivered to the mammal by several well-known technologies including DNA injection (also referred to as DNA vaccination) with and without in vivo electroporation, liposome mediated, nanoparticle facilitated, recombinant vectors such as recombinant adenovirus, recombinant adenovirus associated virus and recombinant vaccinia. The antigen may be delivered via DNA injection and along with in vivo electroporation. 
     The vaccine or pharmaceutical composition can be administered by electroporation. Administration of the vaccine via electroporation of the plasmids of the vaccine may be accomplished using electroporation devices that can be configured to deliver to a desired tissue of a mammal a pulse of energy effective to cause reversible pores to form in cell membranes, and preferable the pulse of energy is a constant current similar to a preset current input by a user. The electroporation device may comprise an electroporation component and an electrode assembly or handle assembly. The electroporation component may include and incorporate one or more of the various elements of the electroporation devices, including controller, current waveform generator, impedance tester, waveform logger, input element, status reporting element, communication port, memory component, power source, and power switch. The electroporation can be accomplished using an in vivo electroporation device, for example CELLECTRA® EP system (Inovio Pharmaceuticals, Inc., Blue Bell, Pa.) or Elgen electroporator (Inovio Pharmaceuticals, Inc.) to facilitate transfection of cells by the plasmid. 
     The electroporation component may function as one element of the electroporation devices, and the other elements are separate elements (or components) in communication with the electroporation component. The electroporation component may function as more than one element of the electroporation devices, which may be in communication with still other elements of the electroporation devices separate from the electroporation component. The elements of the electroporation devices existing as parts of one electromechanical or mechanical device may not limited as the elements can function as one device or as separate elements in communication with one another. The electroporation component may be capable of delivering the pulse of energy that produces the constant current in the desired tissue, and includes a feedback mechanism. The electrode assembly may include an electrode array having a plurality of electrodes in a spatial arrangement, wherein the electrode assembly receives the pulse of energy from the electroporation component and delivers the same to the desired tissue through the electrodes. At least one of the plurality of electrodes is neutral during delivery of the pulse of energy and measures impedance in the desired tissue and communicates the impedance to the electroporation component. The feedback mechanism may receive the measured impedance and can adjust the pulse of energy delivered by the electroporation component to maintain the constant current. 
     A plurality of electrodes may deliver the pulse of energy in a decentralized pattern. The plurality of electrodes may deliver the pulse of energy in the decentralized pattern through the control of the electrodes under a programmed sequence, and the programmed sequence is input by a user to the electroporation component. The programmed sequence may comprise a plurality of pulses delivered in sequence, wherein each pulse of the plurality of pulses is delivered by at least two active electrodes with one neutral electrode that measures impedance, and wherein a subsequent pulse of the plurality of pulses is delivered by a different one of at least two active electrodes with one neutral electrode that measures impedance. 
     The feedback mechanism may be performed by either hardware or software. The feedback mechanism may be performed by an analog closed-loop circuit. The feedback occurs every 50 μs, 20 μs, 10 μs or 1 μs, but is preferably a real-time feedback or instantaneous (i.e., substantially instantaneous as determined by available techniques for determining response time). The neutral electrode may measure the impedance in the desired tissue and communicates the impedance to the feedback mechanism, and the feedback mechanism responds to the impedance and adjusts the pulse of energy to maintain the constant current at a value similar to the preset current. The feedback mechanism may maintain the constant current continuously and instantaneously during the delivery of the pulse of energy. 
     Examples of electroporation devices and electroporation methods that may facilitate delivery of the DNA vaccines of the present disclosure, include those described in U.S. Pat. No. 7,245,963 by Draghia-Akli, et al., U.S. Patent Pub. 2005/0052630 submitted by Smith, et al., the contents of which are hereby incorporated by reference in their entirety. Other electroporation devices and electroporation methods that may be used for facilitating delivery of the DNA vaccines include those provided in co-pending and co-owned U.S. patent application Ser. No. 11/874,072, filed Oct. 17, 2007, which claims the benefit under 35 USC 119(e) to U.S. Provisional Applications Ser. No. 60/852,149, filed Oct. 17, 2006, and 60/978,982, filed Oct. 10, 2007, all of which are hereby incorporated in their entirety. 
     U.S. Pat. No. 7,245,963 by Draghia-Akli, et al. describes modular electrode systems and their use for facilitating the introduction of a biomolecule into cells of a selected tissue in a body or plant. The modular electrode systems may comprise a plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. An operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert them into the selected tissue in a body or plant. The biomolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes. The applied constant-current electrical pulse facilitates the introduction of the biomolecule into the cell between the plurality of electrodes. The entire content of U.S. Pat. No. 7,245,963 is hereby incorporated by reference in its entirety. 
     U.S. Patent Pub. 2005/0052630 submitted by Smith, et al. describes an electroporation device which may be used to effectively facilitate the introduction of a biomolecule into cells of a selected tissue in a body or plant. The electroporation device comprises an electro-kinetic device (“EKD device”) whose operation is specified by software or firmware. The EKD device produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters, and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk. The entire content of U.S. Patent Pub. 2005/0052630 is hereby incorporated by reference in its entirety. The electrode arrays and methods described in U.S. Pat. No. 7,245,963 and U.S. Patent Pub. 2005/0052630 may be adapted for deep penetration into not only tissues such as muscle, but also other tissues or organs. Because of the configuration of the electrode array, the injection needle (to deliver the biomolecule of choice) is also inserted completely into the target organ, and the injection is administered perpendicular to the target issue, in the area that is pre-delineated by the electrodes. The electrodes described in U.S. Pat. No. 7,245,963 and U.S. Patent Pub. 2005/005263 are preferably 20 mm long and 21 gauge. 
     Additionally, contemplated in some embodiments that incorporate electroporation devices and uses thereof, there are electroporation devices that are those described in U.S. Pat. Nos. 5,273,525; 6,110,161; 6,261,281; 6,958,060; and 6,939,862. Furthermore, patents covering subject matter provided in U.S. Pat. No. 6,697,669, which concerns delivery of DNA using any of a variety of devices, and U.S. Pat. No. 7,328,064, drawn to a method of injecting DNA, are contemplated herein. The above patents are incorporated by reference in their entireties. 
     Methods of preparing the nucleic acid molecules are disclosed. In some embodiments, plasmids with one or more multiple cloning sites may be purchased from commercially available vendors and the expressible nucleic acids disclosed herein may be ligated into the plasmids after a digestion with a known restriction enzyme needed to cut the plasmid DNA. In another alternative embodiment, membrane-based purification methods disclosed herein offer reduced cost, high binding capacity, and high flow rates, resulting in a superior purification process. The purification process is further demonstrated to produce plasmid products substantially free of genomic DNA, RNA, protein, and endotoxin. 
     In some embodiments, all of the described aspects of the present disclosure are advantageously combined to provide an integrated process for preparing substantially purified cellular components of interest from cells in bioreactors. Again, the cells are most preferably plasmid-containing cells, and the cellular components of interest are most preferably plasmids. The substantially purified plasmids are suitable for various uses, including, but not limited to, gene therapy, plasmid-mediated therapy, as DNA vaccines for human, veterinary, or agricultural use, or for any other application that requires large quantities of purified plasmid. In this aspect, all of the advantages described for individual aspects of the present disclosure accrue to the complete, integrated process, providing a highly advantageous method that is rapid, scalable, and inexpensive. Enzymes and other animal-derived or biologically sourced products are avoided, as are carcinogenic, mutagenic, or otherwise toxic substances. Potentially flammable, explosive, or toxic organic solvents are similarly avoided. 
     One aspect of the present disclosure is an apparatus for isolating plasmid DNA from a suspension of cells having both plasmid DNA and genomic DNA. An embodiment of the apparatus comprises a first tank and second tank in fluid communication with a mixer. The first tank is used for holding the suspension cells and the second tank is used for holding a lysis solution. The suspension of cells from the first tank and the lysis solution from the second tank are both allowed to flow into the mixer forming a lysate mixture or lysate fluid. The mixer comprises a high shear, low residence-time mixing device with a residence time of equal to or less than about 1 second. In a preferred embodiment, the mixing device comprises a flow through, rotor/stator mixer or emulsifier having linear flow rates from about 0.1 L/min to about 20 L/min. The lysate-mixture flows from the mixer into a holding coil for a period of time sufficient to lyse the cells and forming a cell lysate suspension, wherein the lysate-mixture has resident time in the holding coil in a range of about 2-8 minutes with a continuous linear flow rate. 
     The cell lysate suspension is then allowed to flow into a bubble-mixer chamber for precipitation of cellular components from the plasmid DNA. In the bubble mixer chamber, the cell lysate suspension and a precipitation solution or a neutralization solution from a third tank are mixed together using gas bubbles, which forms a mixed gas suspension comprising a precipitate and an unclarified lysate or plasmid containing fluid. The precipitate of the mixed gas suspension is less dense than the plasmid containing fluid, which facilitates the separation of the precipitate from the plasmid containing fluid. The precipitate is removed from the mixed gas suspension to give a clarified lysate having the plasmid DNA, and the precipitate having cellular debris and genomic DNA. 
     In some embodiments, the bubble mixer-chamber comprises a closed vertical column with a top, a bottom, a first, and a second side with a vent proximal to the top of the column. A first inlet port of the bubble mixer-chamber is on the first side proximal to the bottom of the column and in fluid communication with the holding coil. A second inlet port of the bubble mixer-chamber is proximal to the bottom on a second side opposite of the first inlet port and in fluid communication with a third tank, wherein the third tank is used for holding a precipitation or a neutralization solution. A third inlet port of the bubble mixer-chamber is proximal to the bottom of the column and about in the middle of the first and second inlets and is in fluid communication with a gas source the third inlet entering the bubble-mixer-chamber. A preferred embodiment utilizes a sintered sparger inside the closed vertical column of the third inlet port. The outlet port exiting the bubble mixing chamber is proximal to the top of the closed vertical column. The outlet port is in fluid communication with a fourth tank, wherein the mixed gas suspension containing the plasmid DNA is allowed to flow from the bubble-mixer-chamber into the fourth tank. The fourth tank is used for separating the precipitate of the mixed gas suspension having a plasmid containing fluid, and can also include an impeller mixer sufficient to provide uniform mixing of fluid without disturbing the precipitate. A fifth tank is used for a holding the clarified lysate or clarified plasmid containing fluid. The clarified lysate is then filtered at least once. A first filter has a particle size limit of about 5-10 μm and the second filter has a cut of about 0.2 μm. Although gravity, pressure, vacuum, or a mixture thereof can be used for transporting: suspension of cells; lysis solutions; precipitation solutions; neutralization solutions; or mixed gas suspensions from any of the tanks to mixers, holding coils or different tanks, pumps are utilized in a preferred embodiments. In a more preferred embodiment, at least one pump having a linear flow rate from about 0.1 to about 1 ft/second is used. 
     In another specific embodiment, a Y-connector having a having a first bifurcated branch, a second bifurcated branch and an exit branch is used to contact the cell suspension and the lysis solutions before they enter the high shear, low residence-time mixing device. The first tank holding the cell suspension is in fluid communication with the first bifurcated branch of the Y-connector through the first pump and the second tank holding the lysis solution is in fluid communication with the second bifurcated branch of the Y-connector through the second pump. The high shear, low residence-time mixing device is in fluid communication with an exit branch of the Y-connector, wherein the first and second pumps provide a linear flow rate of about 0.1 to about 2 ft/second for a contacted fluid exiting the Y-connector. 
     Another specific aspect of the present disclosure is a method of substantially separating plasmid DNA and genomic DNA from a bacterial cell lysate. The method comprises: delivering a cell lysate into a chamber; delivering a precipitation fluid or a neutralization fluid into the chamber; mixing the cell lysate and the precipitation fluid or a neutralization fluid in the chamber with gas bubbles forming a gas mixed suspension, wherein the gas mixed suspension comprises the plasmid DNA in a fluid portion (i.e. an unclarified lysate) and the genomic DNA is in a precipitate that is less dense than the fluid portion; floating the precipitate on top of the fluid portion; removing the fluid portion from the precipitate forming a clarified lysate, whereby the plasmid DNA in the clarified lysate is substantially separated from genomic DNA in the precipitate. In some embodiments, the chamber is the bubble mixing chamber as described above; the lysing solution comprises an alkali, an acid, a detergent, an organic solvent, an enzyme, a chaotrope, or a denaturant; the precipitation fluid or the neutralization fluid comprises potassium acetate, ammonium acetate, or a mixture thereof; and the gas bubbles comprise compressed air or an inert gas. Additionally, the decanted-fluid portion containing the plasmid DNA is preferably further purified with one or more purification steps selected from a group consisting of: ion exchange, hydrophobic interaction, size exclusion, reverse phase purification, endotoxin depletion, affinity purification, adsorption to silica, glass, or polymeric materials, expanded bed chromatography, mixed mode chromatography, displacement chromatography, hydroxyapatite purification, selective precipitation, aqueous two-phase purification, DNA condensation, thiophilic purification, ion-pair purification, metal chelate purification, filtration through nitrocellulose, or ultrafiltration. 
     In some embodiments, a method for isolating a plasmid DNA from cells comprising: mixing a suspension of cells having the plasmid DNA and genomic DNA with a lysis solution in a high-shear-low-residence-time-mixing-device for a first period of time forming a cell lysate fluid; incubating the cell lysate fluid for a second period of time in a holding coil forming a cell lysate suspension; delivering the cell lysate suspension into a chamber; delivering a precipitation/neutralization fluid into the chamber; mixing the cell lysate suspension and the a precipitation/neutralization fluid in the chamber with gas bubbles forming a gas mixed suspension, wherein the gas mixed suspension comprises an unclarified lysate containing the plasmid DNA and a precipitate containing the genomic DNA, wherein the precipitate is less dense than the unclarified lysate; floating the precipitate on top of the unclarified lysate; removing the precipitate from the unclarified lysate forming a clarified lysate, whereby the plasmid DNA is substantially separated from genomic DNA; precipitating the plasmid DNA from the clarified lysate forming a precipitated plasmid DNA; and resuspending the precipitated plasmid DNA in an aqueous solution. 
     The disclosure also relates to a method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with a composition comprising one or a plurality of the RNA molecules disclosed herein. In some embodiments, the therapeutic and/or prophylactic agent is an mRNA, and wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest (e.g., nanoparticle or trimer of the disclosure). Compositions comprising RNA nucleic acid sequences of the disclosure can be delivered via lipid-containing nanoparticles and/or modification of the RNA nucleic acid sequence encoding the one or more viral polypeptides. 
     In some embodiments, the composition includes at least one RNA polynucleotide having an open reading frame encoding at least one SARS-CoV-2 antigenic polypeptide having at least one modification, at least one 5′ terminal cap, and is formulated within a lipid nanoparticle. 
     In some embodiments, a 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp. In some embodiments, at least one chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2′-O-methyl uridine. 
     In some embodiments, a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid. In some embodiments, a cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, a cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino) butanoyl)oxy)heptadecanedioate (L319), (12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (L608), and N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine (L530). 
     In some embodiments, SARS-CoV-2 RNA (e.g., mRNA) vaccines are formulated in a lipid nanoparticle. In some embodiments, SARS-CoV-2 RNA (e.g., mRNA) vaccines are formulated in a lipid-polycation complex, referred to as a cationic lipid nanoparticle. The formation of the lipid nanoparticle may be accomplished by methods known in the art and/or as described in U.S. Publication No. 20120178702, herein incorporated by reference in its entirety. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine and the cationic peptides described in International Publication No. WO2012013326 or U.S. Publication No. US20130142818; each of which is herein incorporated by reference in its entirety. In some embodiments, SARS-CoV-2 RNA (e.g., mRNA) vaccines are formulated in a lipid nanoparticle that includes a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE). 
     A lipid nanoparticle formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of the PEGylation, ratio of all components, and biophysical parameters such as size. In one example by Semple et al. (Nature Biotech. 2010 28:172-176; herein incorporated by reference in its entirety), the lipid nanoparticle formulation is composed of 57.1% cationic lipid, 7.1% dipalmitoylphosphatidylcholine, 34.3% cholesterol, and 1.4% PEG-c-DMA. As another example, changing the composition of the cationic lipid was shown to more effectively deliver siRNA to various antigen presenting cells (Basha et al. Mol Ther. 2011 19:2186-2200; herein incorporated by reference in its entirety). 
     In some embodiments, lipid nanoparticle formulations may comprise about 35% to about 45% cationic lipid, about 40% to about 50% cationic lipid, about 50% to about 60% cationic lipid and/or about 55% to about 65% cationic lipid. In some embodiments, the ratio of lipid to RNA (e.g., mRNA) in lipid nanoparticles may be about 5:1 to about 20:1, about 10:1 to about 25:1, about 15:1 to about 30:1, and/or at least about 30:1. 
     In some embodiments, the ratio of PEG in the lipid nanoparticle formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the lipid nanoparticle formulations. As a non-limiting example, lipid nanoparticle formulations may contain about 0.5% to about 3.0%, about 1.0% to about 3.5%, about 1.5% to about 4.0%, about 2.0% to about 4.5%, about 2.5% to about 5.0%, and/or about 3.0% to about 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(co-methoxy-poly(ethyleneglycol)2000) carb-amoyl)]-1,2-dimyristyloxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC, and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200, and DLin-KC2-DMA. 
     In some embodiments, a SARS-CoV-2 RNA (e.g., mRNA) vaccine formulation is a nanoparticle that comprises at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, (12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (L608), N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine (L530), PEGylated lipids, and amino alcohol lipids. 
     In some embodiments, a lipid nanoparticle formulation includes about 25% to about 75% on a molar basis of a cationic lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., about 35% to about 65%, about 45% to about 65%, about 60%, 57.5%, 50% or 40% on a molar basis. 
     In some embodiments, a lipid nanoparticle formulation includes about 0.5% to about 15% on a molar basis of the neutral lipid, e.g., about 3% to about 12%, about 5% to about 10% or about 15%, 10%, or 7.5% on a molar basis. Examples of neutral lipids include, without limitation, DSPC, POPC, DPPC, DOPE, and SM. In some embodiments, the formulation includes about 5% to about 50% on a molar basis of the sterol (e.g., about 15% to about 45%, about 20% to about 40%, about 40%, 38.5%, 35%, or 31% on a molar basis. A non-limiting example of a sterol is cholesterol. In some embodiments, a lipid nanoparticle formulation includes about 0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid (e.g., about 0.5% to about 10%, about 0.5% to about 5%, about 1.5%, 0.5%, 1.5%, 3.5%, or 5% on a molar basis. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of about 2,000 Da. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than about 2,000, for example about 1,500 Da, about 1,000 Da, or about 500 Da. Non-limiting examples of PEG-modified lipids include PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), and PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the content of which is herein incorporated by reference in its entirety). 
     In some embodiments, lipid nanoparticle formulations include about 25-75% of a cationic lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 0.5-15% of the neutral lipid, about 5-50% of the sterol, and about 0.5-20% of the PEG or PEG-modified lipid on a molar basis. 
     In some embodiments, lipid nanoparticle formulations include about 35-65% of a cationic lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 3-12% of the neutral lipid, about 15-45% of the sterol, and about 0.5-10% of the PEG or PEG-modified lipid on a molar basis. 
     In some embodiments, lipid nanoparticle formulations include about 45-65% of a cationic lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 5-10% of the neutral lipid, about 25-40% of the sterol, and about 0.5-10% of the PEG or PEG-modified lipid on a molar basis. 
     In some embodiments, lipid nanoparticle formulations include about 60% of a cationic lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.5% of the neutral lipid, about 31% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis. 
     Some embodiments of the present disclosure provide a SARS-CoV-2 vaccine that includes at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one SARS-CoV-2 antigenic polypeptide, wherein at least about 80% of the uracil in the open reading frame have a chemical modification, optionally wherein the SARS-CoV-2 vaccine is formulated in a lipid nanoparticle. In some embodiments, the RNA vaccine pharmaceutical compositions may be formulated in liposomes such as, but not limited to, DiLa2 liposomes (Marina Biotech, Bothell, Wash.), SMARTICLES® (Marina Biotech, Bothell, Wash.), neutral DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) based liposomes (e.g., siRNA delivery for ovarian cancer (Landen et al. Cancer Biology &amp; Therapy 2006 5(12)1708-1713); herein incorporated by reference in its entirety) and hyaluronan-coated liposomes (Quiet Therapeutics, Israel). In some embodiments, the RNA vaccines may be formulated in a lyophilized gel-phase liposomal composition as described in U.S. Publication No. US2012060293, herein incorporated by reference in its entirety. 
     The nanoparticle formulations may comprise a phosphate conjugate. The phosphate conjugate may increase in vivo circulation times and/or increase the targeted delivery of the nanoparticle. Phosphate conjugates for use with the present disclosure may be made by the methods described in International Publication No. WO2013033438 or U.S. Publication No. US20130196948, the content of each of which is herein incorporated by reference in its entirety. As a non-limiting example, the phosphate conjugates may include a compound of any one of the formulas described in International Publication No. WO2013033438, herein incorporated by reference in its entirety. In particular, the present disclosure relates to a pharmaceutical composition comprising nanoparticles which comprise RNA encoding at least one antigen, wherein: (i) the number of positive charges in the nanoparticles does not exceed the number of negative charges in the nanoparticles and/or (ii) the nanoparticles have a neutral or net negative charge and/or (iii) the charge ratio of positive charges to negative charges in the nanoparticles is about 1.4:1 or less and/or (iv) the zeta potential of the nanoparticles is about 0 or less. 
     In some embodiments, the nanoparticles described herein are colloidally stable for at least about 2 hours in the sense that no aggregation, precipitation or increase of size and polydispersity index by more than about 30% as measured by dynamic light scattering takes place. In some embodiments, the charge ratio of positive charges to negative charges in the nanoparticles is between about 1.4:1 and about 1:8, preferably between about 1.2:1 and about 1:4, e.g. between about 1:1 and about 1:3 such as between about 1:1.2 and about 1:2, about 1:1.2 and about 1:1.8, about 1:1.3 and about 1:1.7, in particular between about 1:1.4 and about 1:1.6, such as about 1:1.5. In some embodiments, the zeta potential of the nanoparticles is about −5 or less, about −10 or less, about −15 or less, about −20 or less or about −25 or less. In various embodiments, the zeta potential of the nanoparticles is about −35 or higher, about −30 or higher or about −25 or higher. In some embodiments, the nanoparticles have a zeta potential from about 0 mV to about −50 mV, preferably about 0 mV to about −40 mV or about −10 mV to about −30 mV. 
     In some embodiments pharamceutical compositions of the disclosure comprise a nanoparticle or a liposome that encapsulates a DNA, RNA or DNA/RNA hydbrid comprising at least one expressible nucleic acid sequence. Liposomes are microscopic lipidic vesicles often having one or more bilayers of a vesicle-forming lipid, such as a phospholipid, and are capable of encapsulating a drug. Different types of liposomes may be employed in the context of the present disclosure, including, without being limited thereto, multilamellar vesicles (MLV), small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), sterically stabilized liposomes (SSL), multivesicular vesicles (MV), and large multivesicular vesicles (LMV) as well as other bilayered forms known in the art. The size and lamellarity of the liposome will depend on the manner of preparation and the selection of the type of vesicles to be used will depend on the preferred mode of administration. There are several other forms of supramolecular organization in which lipids may be present in an aqueous medium, comprising lamellar phases, hexagonal and inverse hexagonal phases, cubic phases, micelles, reverse micelles composed of monolayers. These phases may also be obtained in the combination with DNA or RNA, and the interaction with RNA and DNA may substantially affect the phase state. The described phases may be present in the nanoparticulate RNA formulations of the present disclosure. 
     For formation of RNA lipoplexes from RNA and liposomes, any suitable method of forming liposomes can be used so long as it provides the envisaged RNA lipoplexes. Liposomes may be formed using standard methods such as the reverse evaporation method (REV), the ethanol injection method, the dehydration-rehydration method (DRV), sonication or other suitable methods. 
     After liposome formation, the liposomes can be sized to obtain a population of liposomes having a substantially homogeneous size range. 
     Bilayer-forming lipids have typically two hydrocarbon chains, particularly acyl chains, and a head group, either polar or nonpolar. Bilayer-forming lipids are either composed of naturally-occurring lipids or of synthetic origin, including the phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatide acid, phosphatidylinositol, and sphingomyelin, where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation. Other suitable lipids for use in the composition of the present disclosure include glycolipids and sterols such as cholesterol and its various analogs which can also be used in the liposomes. 
     Cationic lipids typically have a lipophilic moiety, such as a sterol, an acyl or diacyl chain, and have an overall net positive charge. The head group of the lipid typically carries the positive charge. The cationic lipid preferably has a positive charge of about 1 to about 10 valences, more preferably a positive charge of about 1 to about 3 valences, and more preferably a positive charge of about 1 valence. Examples of cationic lipids include, but are not limited to 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA); dimethyl-dioctadecylammonium (DDAB); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propanes; 1,2-dialkyloxy-3-dimethylammonium propanes; dioctadecyldimethyl ammonium chloride (DODAC), 1,2-dimyristoyloxypropyl-1,3-dimethylhydroxyethyl ammonium (DMRIE), and 2,3-dioleoyloxy-N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-1-propanamium trifluoroacetate (DOSPA). Preferred are DOTMA, DOTAP, DODAC, and DOSPA. Most preferred is DOTMA. 
     In addition, the nanoparticles described herein preferably further include a neutral lipid in view of structural stability and the like. The neutral lipid can be appropriately selected in view of the delivery efficiency of the RNA-lipid complex. Examples of neutral lipids include, but are not limited to, 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), diacylphosphatidyl choline, diacylphosphatidyl ethanol amine, ceramide, sphingoemyelin, cephalin, sterol, and cerebroside. Preferred is DOPE and/or DOPC. Most preferred is DOPE. In the case where a cationic liposome includes both a cationic lipid and a neutral lipid, the molar ratio of the cationic lipid to the neutral lipid can be appropriately determined in view of stability of the liposome and the like. 
     According to one embodiment, the nanoparticles described herein may comprise phospholipids. The phospholipids may be a glycerophospholipid. Examples of glycerophospholipid include, without being limited thereto, three types of lipids: (i) zwitterionic phospholipids, which include, for example, phosphatidylcholine (PC), egg yolk phosphatidylcholine, soybean-derived PC in natural, partially hydrogenated or fully hydrogenated form, dimyristoyl phosphatidylcholine (DMPC) sphingomyelin (SM); (ii) negatively charged phospholipids: which include, for example, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), phosphatidylglycerol (PG) dipalmipoyl PG, dimyristoyl phosphatidylglycerol (DMPG); synthetic derivatives in which the conjugate renders a zwitterionic phospholipid negatively charged such is the case of methoxypolyethylene, glycol-distearoyl phosphatidylethanolamine (mPEG-DSPE); and (iii) cationic phospholipids, which include, for example, phosphatidylcholine or sphingomyelin of which the phosphomonoester was O-methylated to form the cationic lipids. 
     Association of RNA to the lipid carrier can occur, for example, by the RNA filling interstitial spaces of the carrier, such that the carrier physically entraps the RNA, or by covalent, ionic, or hydrogen bonding, or by means of adsorption by non-specific bonds. Whatever the mode of association, the RNA must retain its therapeutic, i.e. antigen-encoding, properties. 
     In some embodiments, the nanoparticles comprise at least one lipid. In some embodiments, the nanoparticles comprise at least one cationic lipid. The cationic lipid can be monocationic or polycationic. Any cationic amphiphilic molecule, eg, a molecule which comprises at least one hydrophilic and lipophilic moiety is a cationic lipid within the meaning of the present disclosure. In some embodiments, the positive charges are contributed by the at least one cationic lipid and the negative charges are contributed by the RNA. In some embodiments, the nanoparticles comprises at least one helper lipid. The helper lipid may be a neutral or an anionic lipid. The helper lipid may be a natural lipid, such as a phospholipid or an analogue of a natural lipid, or a fully synthetic lipid, or lipid-like molecule, with no similarities with natural lipids. In some embodiments, the cationic lipid and/or the helper lipid is a bilayer forming lipid. 
     In some embodiments, the at least one cationic lipid comprises 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) or analogs or derivatives thereof and/or 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or analogs or derivatives thereof. In some embodiments, the at least one helper lipid comprises 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or analogs or derivatives thereof, cholesterol (Chol) or analogs or derivatives thereof and/or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or analogs or derivatives thereof. In some embodiments, the molar ratio of the at least one cationic lipid to the at least one helper lipid is from about 10:0 to about 3:7, preferably about 9:1 to about 3:7, about 4:1 to about 1:2, about 4:1 to about 2:3, about 7:3 to about 1:1, or about 2:1 to about 1:1, preferably about 1:1. In some embodiments, in this ratio, the molar amount of the cationic lipid results from the molar amount of the cationic lipid multiplied by the number of positive charges in the cationic lipid. In various embodiments, the lipids are not functionalized such as functionalized by mannose, histidine and/or imidazole, the nanoparticles do not comprise a targeting ligand such as mannose functionalized lipids and/or the nanoparticles do not comprise one or more of the following: pH dependent compounds, cationic polymers such as polymers containing histidine and/or polylysine, wherein the polymers may optionally be PEGylated and/or histidylated, or divalent ions such as Ca 2+. 
     In various embodiments, the RNA nanoparticles may comprise peptides, preferentially with a molecular weight of up to about 2500 Da. 
     In the nanoparticles described herein the lipid may form a complex with and/or may encapsulate the RNA. In some embodiments, the nanoparticles comprise a lipoplex or liposome. In some embodiments, the lipid is comprised in a vesicle encapsulating said RNA. The vesicle may be a multilamellar vesicle, an unilamellar vesicle, or a mixture thereof. The vesicle may be a liposome. In some embodiments, the nanoparticles are lipoplexes comprising DOTMA and DOPE in a molar ratio of about 10:0 to about 1:9, preferably about 8:2 to about 3:7, and more preferably of about 7:3 to about 5:5 and wherein the charge ratio of positive charges in DOTMA to negative charges in the RNA is about 1.8:2 to about 0.8:2, more preferably about 1.6:2 to about 1:2, even more preferably about 1.4:2 to about 1.1:2 and even more preferably about 1.2:2. 
     In some embodiments, the nanoparticles are lipoplexes comprising DOTMA and Cholesterol in a molar ratio of about 10:0 to about 1:9, preferably about 8:2 to about 3:7, and more preferably of about 7:3 to about 5:5 and wherein the charge ratio of positive charges in DOTMA to negative charges in the RNA is about 1.8:2 to about 0.8:2, more preferably about 1.6:2 to about 1:2, even more preferably about 1.4:2 to about 1.1:2 and even more preferably about 1.2:2. In some embodiments, the nanoparticles are lipoplexes comprising DOTAP and DOPE in a molar ratio of about 10:0 to about 1:9, preferably about 8:2 to about 3:7, and more preferably of about 7:3 to about 5:5 and wherein the charge ratio of positive charges in DOTMA to negative charges in the RNA is about 1.8:2 to about 0.8:2, more preferably about 1.6:2 to about 1:2, even more preferably about 1.4:2 to about 1.1:2 and even more preferably about 1.2:2. In some embodiments, the nanoparticles are lipoplexes comprising DOTMA and DOPE in a molar ratio of about 2:1 to about 1:2, preferably about 2:1 to about 1:1, and wherein the charge ratio of positive charges in DOTMA to negative charges in the RNA is about 1.4:1 or less. In some embodiments, the nanoparticles are lipoplexes comprising DOTMA and cholesterol in a molar ratio of about 2:1 to about 1:2, preferably about 2:1 to about 1:1, and wherein the charge ratio of positive charges in DOTMA to negative charges in the RNA is about 1.4:1 or less. In some embodiments, the nanoparticles are lipoplexes comprising DOTAP and DOPE in a molar ratio of about 2:1 to about 1:2, preferably about 2:1 to about 1:1, and wherein the charge ratio of positive charges in DOTAP to negative charges in the RNA is about 1.4:1 or less. In some embodiments, the nanoparticles have an avarage diameter in the range of from about 50 nm to about 1000 nm, preferably from about 50 nm to about 400 nm, preferably about 100 nm to about 300 nm such as about 150 nm to about 200 nm. In some embodiments, the nanoparticles have a diameter in the range of about 200 to about 700 nm, about 200 to about 600 nm, preferably about 250 to about 550 nm, in particular about 300 to about 500 nm or about 200 to about 400 nm. 
     In some embodiments, the polydispersity index of the nanoparticles described herein as measured by dynamic light scattering is about 0.5 or less, preferably about 0.4 or less or even more preferably about 0.3 or less. In some embodiments, the nanoparticles described herein are obtainable by one or more of the following: (i) incubation of liposomes in an aqueous phase with the RNA in an aqueous phase, (ii) incubation of the lipid dissolved in an organic, water miscible solvent, such as ethanol, with the RNA in aqueous solution, (iii) reverse phase evaporation technique, (iv) freezing and thawing of the product, (v) dehydration and rehydration of the product, (vi) lyophilization and rehydration of the of the product, or (vii) spray drying and rehydration of the product. 
     The nanoparticle formulation may comprise a polymer conjugate. The polymer conjugate may be a water-soluble conjugate. The polymer conjugate may have a structure as described in U.S. Publication No. 20130059360, the content of which is herein incorporated by reference in its entirety. In some aspects, polymer conjugates with the polynucleotides of the present disclosure may be made using the methods and/or segmented polymeric reagents described in U.S. Publication No. 20130072709, herein incorporated by reference in its entirety. In other aspects, the polymer conjugate may have pendant side groups comprising ring moieties such as, but not limited to, the polymer conjugates described in U.S. Publication No. US20130196948, the contents of which is herein incorporated by reference in its entirety. 
     The nanoparticle formulations may comprise a conjugate to enhance the delivery of nanoparticles of the present disclosure in a subject. Further, the conjugate may inhibit phagocytic clearance of the nanoparticles in a subject. In some aspects, the conjugate may be a “self” peptide designed from the human membrane protein CD47 (e.g., the “self” particles described by Rodriguez et al. (Science 2013, 339, 971-975), herein incorporated by reference in its entirety). As shown by Rodriguez et al., the self peptides delayed macrophage-mediated clearance of nanoparticles which enhanced delivery of the nanoparticles. In other aspects, the conjugate may be the membrane protein CD47 (e.g., see Rodriguez et al. Science 2013, 339, 971-975, herein incorporated by reference in its entirety). Rodriguez et al. showed that, similarly to “self” peptides, CD47 can increase the circulating particle ratio in a subject as compared to scrambled peptides and PEG coated nanoparticles. 
     In some embodiments, about 100% of the uracil in the open reading frame have a chemical modification. In some embodiments, a chemical modification is in the 5-position of the uracil. In some embodiments, a chemical modification is a N 1 -methyl pseudouridine. In some embodiments, about 100% of the uracil in the open reading frame have a N 1 -methyl pseudouridine in the 5-position of the uracil. 
     In some embodiments, efficacy of RNA vaccines RNA (e.g., mRNA) can be significantly enhanced when combined with a flagellin adjuvant, in particular, when one or more antigen-encoding mRNAs is combined with an mRNA encoding flagellin. 
     RNA (e.g., mRNA) vaccines combined with the flagellin adjuvant (e.g., mRNA-encoded flagellin adjuvant) have superior properties in that they may produce much larger antibody titers and produce responses earlier than commercially available vaccine formulations. While not wishing to be bound by theory, it is believed that the RNA vaccines, for example, as mRNA polynucleotides, are better designed to produce the appropriate protein conformation upon translation, for both the antigen and the adjuvant, as the RNA (e.g., mRNA) vaccines co-opt natural cellular machinery. Unlike traditional vaccines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion. 
     Some embodiments of the present disclosure provide RNA (e.g., mRNA) vaccines that include at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to the antigenic polypeptide) and at least one RNA (e.g., mRNA polynucleotide) having an open reading frame encoding a flagellin adjuvant. 
     In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is a flagellin protein. In some embodiments, at least one flagellin polypeptide (e.g., encoded flagellin polypeptide) is an immunogenic flagellin fragment. In some embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are encoded by a single RNA (e.g., mRNA) polynucleotide. In other embodiments, at least one flagellin polypeptide and at least one antigenic polypeptide are each encoded by a different RNA polynucleotide. 
     Some embodiments of the present disclosure provide methods of inducing an antigen specific immune response in a subject, comprising administering to the subject a SARS-CoV-2 vaccine in an amount effective to produce an antigen specific immune response. 
     In some aspects, vaccines of the disclosure (e.g., LNP-encapsulated mRNA vaccines) produce prophylactically- and/or therapeutically-efficacious levels, concentrations and/or titers of antigen-specific antibodies in the blood or serum of a vaccinated subject. As defined herein, the term antibody titer refers to the amount of antigen-specific antibody produces in s subject, e.g., a human subject. In exemplary embodiments, antibody titer is expressed as the inverse of the greatest dilution (in a serial dilution) that still gives a positive result. In exemplary embodiments, antibody titer is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody titer is determined or measured by neutralization assay, e.g., by microneutralization assay. In certain aspects, antibody titer measurement is expressed as a ratio, such as about 1:40, 1:100, etc. 
     In exemplary embodiments of the disclosure, an efficacious vaccine produces an antibody titer of greater than about 1:40, greater that about 1:100, greater than about 1:400, greater than about 1:1000, greater than about 1:2000, greater than about 1:3000, greater than about 1:4000, greater than about 1:500, greater than about 1:6000, greater than about 1:7500, greater than about 1:10000. In exemplary embodiments, the antibody titer is produced or reached by about 10 days following vaccination, by about 20 days following vaccination, by about 30 days following vaccination, by about 40 days following vaccination, or by about 50 or more days following vaccination. In exemplary embodiments, the titer is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the titer is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.) 
     In exemplary aspects of the disclosure, antigen-specific antibodies are measured in units of g/ml or are measured in units of IU/L (International Units per liter) or mIU/ml (milli International Units per ml). In exemplary embodiments of the disclosure, an efficacious vaccine produces more than about 0.5 μg/ml, 0.1 μg/ml, 0.2 μg/ml, 0.35 μg/ml, 0.5 μg/ml, 1 μg/ml, 2 μg/ml, 5 μg/ml or 10 μg/ml of antigen-specific antibodies. In exemplary embodiments of the disclosure, an efficacious vaccine produces more than about 10 mIU/ml, 20 mIU/ml, 50 mIU/ml, 100 mIU/ml, 200 mIU/ml, 500 mIU/ml or 1000 mIU/ml of antigen-specific antibodies. In exemplary embodiments, the antibody level or concentration is produced or reached by about 10 days following vaccination, by about 20 days following vaccination, by about 30 days following vaccination, by about 40 days following vaccination, or by about 50 or more days following vaccination. In exemplary embodiments, the level or concentration is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the level or concentration is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose). In exemplary embodiments, antibody level or concentration is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody level or concentration is determined or measured by neutralization assay, e.g., by microneutralization assay. 
     In some embodiments, the SARS-CoV-2 vaccine includes at least one RNA polynucleotide having an open reading frame encoding at least one SARS-CoV-2 antigenic polypeptide having at least one modification, at least one 5′ terminal cap, and is formulated within a lipid nanoparticle. 5′-capping of polynucleotides may be completed concomitantly during the in vitro-transcription reaction using the following chemical RNA cap analogs to generate the 5′-guanosine cap structure according to manufacturer protocols: 3′-O-Me-m7G(5′)ppp(5′) G [the ARCA cap]; G(5′)ppp(5′)A; G(5′)ppp(5′)G; m7G(5′)ppp(5′)A; m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). 5′-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the “Cap 0” structure: m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2′-O methyl-transferase to generate m7G(5′)ppp(5′)G-2′-O-methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2′-O-methylation of the 5′-antepenultimate nucleotide using a 2′-O methyl-transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2′-O-methylation of the 5′-preantepenultimate nucleotide using a 2′-O methyl-transferase. Enzymes are preferably derived from a recombinant source. 
     When transfected into mammalian cells, the modified mRNAs have a stability of from about 12 to about 18 hours or more than about 18 hours, e.g., about 24, 36, 48, 60, 72, or greater than about 72 hours. 
     In some embodiments, a codon optimized RNA may, for instance, be one in which the levels of G/C are enhanced. The G/C-content of nucleic acid molecules may influence the stability of the RNA. RNA having an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. WO02/098443 discloses a pharmaceutical composition containing an mRNA stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by substituting existing codons for those that promote greater RNA stability without changing the resulting amino acid. The approach is limited to coding regions of the RNA. 
     In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases. 
     In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of pseudouridine (ψ), 2-thiouridine (s2U), 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methoxyuridine, 2′-O-methyl uridine, 1-methyl-pseudouridine (m1ψ), 1-ethyl-pseudouridine (e1ψ), 5-methoxyuridine (mo5U), 5-methyl-cytidine (m5C), α-thio-guanosine, α-thio-adenosine, 5-cyano uridine, 4′-thio uridine 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenosine (m6A), and 2,6-Diaminopurine, (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 2,8-dimethyladenosine, 2-geranylthiouridine, 2-lysidine, 2-selenouridine, 3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine, 3-(3-amino-3-carboxypropyl)pseudouridine, 3-methylpseudouridine, 5-(carboxyhydroxymethyl)-2′-O-methyluridine methyl ester, 5-aminomethyl-2-geranylthiouridine, 5-aminomethyl-2-selenouridine, 5-aminomethyluridine, 5-carbamoylhydroxymethyluridine, 5-carbamoylmethyl-2-thiouridine, 5-carboxymethyl-2-thiouridine, 5-carboxymethyl aminomethyl-2-geranylthiouridine, 5-carboxymethylaminomethyl-2-selenouridine, 5-cyanomethyluridine, 5-hydroxycytidine, 5-methylaminomethyl-2-geranylthiouridine, 7-aminocarboxypropyl-demethylwyosine, 7-aminocarboxypropylwyosine, 7-aminocarboxypropylwyosine methyl ester, 8-methyladenosine, N4,N4-dimethylcytidine, N6-formyladenosine, N6-hydroxymethyladenosine, agmatidine, cyclic N6-threonylcarbamoyladenosine, glutamyl-queuosine, methylated undermodified hydroxywybutosine, N4,N4,2′-O-trimethylcytidine, geranylated 5-methylaminomethyl-2-thiouridine, geranylated 5-carboxymethylaminomethyl-2-thiouridine, Qbase, preQ0base, preQ1base, and combinations of two or more thereof. In some embodiments, the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, 1-methyl-pseudouridine, 1-ethyl-pseudouridine, 5-methylcytosine, 5-methoxyuridine, and a combination thereof. In some embodiments, the polyribonucleotide (e.g., RNA polyribonucleotide, such as mRNA polyribonucleotide) includes a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases. In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases. 
     The expressible nucleic acid sequence of the present disclosure may be partially or fully modified along the entire length of the molecule. For example, one or more or all or a given type of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may be uniformly modified in a polynucleotide of the disclosure, or in a given predetermined sequence region thereof (e.g., in the mRNA including or excluding the polyA tail). In some embodiments, all nucleotides X in a polynucleotide of the present disclosure (or in a given sequence region thereof) are modified nucleotides, wherein X may be any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C, or A+G+C. 
     The polynucleotide may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from about 1% to about 20%, from about 1% to about 25%, from about 1% to about 50%, from about 1% to about 60%, from about 1% to about 70%, from about 1% to about 80%, from about 1% to about 90%, from about 1% to about 95%, from about 10% to about 20%, from about 10% to about 25%, from about 10% to about 50%, from about 10% to about 60%, from about 10% to about 70%, from about 10% to about 80%, from about 10% to about 90%, from about 10% to about 95%, from about 10% to about 100%, from about 20% to about 25%, from about 20% to about 50%, from about 20% to about 60%, from about 20% to about 70%, from about 20% to about 80%, from about 20% to about 90%, from about 20% to about 95%, from about 20% to about 100%, from about 50% to about 60%, from about 50% to about 70%, from about 50% to about 80%, from about 50% to about 90%, from about 50% to about 95%, from about 50% to about 100%, from about 70% to about 80%, from about 70% to about 90%, from about 70% to about 95%, from about 70% to about 100%, from about 80% to about 90%, from about 80% to about 95%, from about 80% to about 100%, from about 90% to about 95%, from about 90% to about 100%, and from about 95% to about 100%). It will be understood that any remaining percentage is accounted for by the presence of unmodified A, G, U, or C. 
     The nucleic acid sequences may contain at a minimum about 1% and at maximum about 100% modified nucleotides, or any intervening percentage, such as at least about 5% modified nucleotides, at least about 10% modified nucleotides, at least about 25% modified nucleotides, at least about 50% modified nucleotides, at least about 80% modified nucleotides, or at least about 90% modified nucleotides. For example, the polynucleotides may contain a modified pyrimidine such as a modified uracil or cytosine. In some embodiments, at least about 5%, at least about 10%, at least about 25%, at least about 50%, at least about 80%, at least about 90% or about 100% of the uracil in the polynucleotide is replaced with a modified uracil (e.g., a 5-substituted uracil). The modified uracil can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., about 2, 3, 4, or more unique structures). In some embodiments, at least about 5%, at least about 10%, at least about 25%, at least about 50%, at least about 80%, at least about 90%, or about 100% of the cytosine in the polynucleotide is replaced with a modified cytosine (e.g., a 5-substituted cytosine). The modified cytosine can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., about 2, 3, 4, or more unique structures). 
     Thus, in some embodiments, the RNA vaccines and/or RNA nucleic acid seqeunces comprise a 5′UTR element, an optionally codon optimized open reading frame, and a 3′UTR element, a poly(A) sequence and/or a polyadenylation signal wherein the RNA is not chemically modified. 
     Viral vaccines of the present disclosure comprise at least one RNA polynucleotide, such as a mRNA (e.g., modified mRNA). mRNA, for example, is transcribed in vitro from template DNA, referred to as an “in vitro transcription template.” In some embodiments, the at least one RNA polynucleotide has at least one chemical modification. The at least one chemical modification may include, but is expressly not limited to, any modification described herein. 
     In vitro transcription of RNA is known in the art and is described in WO/2014/152027, which is incorporated by reference herein in its entirety. For example, in some embodiments, the RNA transcript is generated using a non-amplified, linearized DNA template in an in vitro transcription reaction to generate the RNA transcript. In some embodiments, the RNA transcript is capped via enzymatic capping. In some embodiments, the RNA transcript is purified via chromatographic methods, e.g., use of an oligo dT substrate. Some embodiments exclude the use of DNase. In some embodiments, the RNA transcript is synthesized from a non-amplified, linear DNA template coding for the gene of interest via an enzymatic in vitro transcription reaction utilizing a T7 phage RNA polymerase and nucleotide triphosphates of the desired chemistry. Any number of RNA polymerases or variants may be used in the method of the present disclosure. The polymerase may be selected from, but is not limited to, a phage RNA polymerase, e.g., a T7 RNA polymerase, a T3 RNA polymerase, a SP6 RNa polymerase, and/or mutant polymerases such as, but not limited to, polymerases able to incorporate modified nucleic acids and/or modified nucleotides, including chemically modified nucleic acids and/or nucleotides. 
     In some embodiments, a non-amplified, linearized plasmid DNA is utilized as the template DNA for in vitro transcription. In some embodiments, the template DNA is isolated DNA. In some embodiments, the template DNA is cDNA. In some embodiments, the cDNA is formed by reverse transcription of a RNA polynucleotide, for example, but not limited to SARS-CoV-2 RNA, e.g. SARS-CoV-2 mRNA. In some embodiments, cells, e.g., bacterial cells, e.g.,  E. coli , e.g., DH-1 cells are transfected with the plasmid DNA template. In some embodiments, the transfected cells are cultured to replicate the plasmid DNA which is then isolated and purified. In some embodiments, the DNA template includes a RNA polymerase promoter, e.g., a T7 promoter located 5′ to and operably linked to the gene of interest. 
     F. Vaccines 
     Disclosed are DNA vaccines comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83, SEQ ID NO: 86, SEQ ID NO: 89, SEQ ID NO: 92, SEQ ID NO: 95, SEQ ID NO: 98, SEQ ID NO: 101, SEQ ID NO: 104, SEQ ID NO: 107, SEQ ID NO: 110, SEQ ID NO: 113, SEQ ID NO: 116, SEQ ID NO: 119, SEQ ID NO: 122, SEQ ID NO: 125, SEQ ID NO: 128, SEQ ID NO: 131, SEQ ID NO: 134, SEQ ID NO: 137, SEQ ID NO: 140, SEQ ID NO: 143, SEQ ID NO: 146, SEQ ID NO: 149, SEQ ID NO: 152, SEQ ID NO: 155 or SEQ ID NO: 158, or a functional fragment or variant thereof. Also disclosed are RNA vaccines comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 84, SEQ ID NO: 87, SEQ ID NO: 90, SEQ ID NO: 93, SEQ ID NO: 96, SEQ ID NO: 99, SEQ ID NO: 102, SEQ ID NO: 105, SEQ ID NO: 108, SEQ ID NO: 111, SEQ ID NO: 114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO: 123, SEQ ID NO: 126, SEQ ID NO: 129, SEQ ID NO: 132, SEQ ID NO: 135, SEQ ID NO: 138, SEQ ID NO: 141, SEQ ID NO: 144, SEQ ID NO: 147, SEQ ID NO: 150, SEQ ID NO: 153, SEQ ID NO: 156 or SEQ ID NO: 159, or a functional fragment or variant thereof. In some embodiment, the DNA or RNA vaccine disclosed herein encodes a polypeptide comprising at least about 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 76, SEQ ID NO: 79, SEQ ID NO: 82, SEQ ID NO: 85, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 97, SEQ ID NO: 100, SEQ ID NO: 103, SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, SEQ ID NO: 115, SEQ ID NO: 118, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 127, SEQ ID NO: 130, SEQ ID NO: 133, SEQ ID NO: 136, SEQ ID NO: 139, SEQ ID NO: 142, SEQ ID NO: 145, SEQ ID NO: 148, SEQ ID NO: 151, SEQ ID NO: 154, SEQ ID NO: 157 or SEQ ID NO: 160, or a functional fragment or variant thereof. 
     The vaccines of the disclosure can be formulated using one or more excipients to: increase stability; increase cell transfection; permit the sustained or delayed release (e.g., from a depot formulation); alter the biodistribution (e.g., target to specific tissues or cell types); increase the translation of encoded protein in vivo; and/or alter the release profile of encoded protein (antigen) in vivo. In some embodiments therefore, the disclosed vaccine further comprises a pharmaceutically acceptable excipient. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, hyaluronidase, nanoparticle mimics and combinations thereof. In some embodiments, the pharmaceutically acceptable excipient is an adjuvant. In some embodiments, the vaccines of the disclosure do not include an adjuvant (they are adjuvant free). 
     In some embodiments, the vaccines of the disclosure are formulated in a nanoparticle as described herein elsewhere. In some embodiments, the vaccines of the disclosure are formulated in a lipid nanoparticle as described herein elsewhere. In some embodiments, the vaccines of the disclosure are formulated in a lipid-polycation complex, referred to as a cationic lipid nanoparticle, as described herein elsewhere. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, the vaccines of the disclosure are formulated in a lipid nanoparticle that includes a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE) as described herein elsewhere. 
     In some embodiments, the vaccines of the disclosure are administered prophylactically as part of an active immunization scheme to healthy individuals. In some embodiments, the vaccines of the disclosure are administered therapeutically early in infection during the incubation phase. In some embodiments, the vaccines of the disclosure are administered therapeutically during active infection after onset of symptoms. In some embodiments, the amount of DNA or RNA (e.g., mRNA) vaccine of the present disclosure provided to a cell, a tissue or a subject may be an amount effective for immune prophylaxis. In some embodiments, the vaccines of the disclosure are administrated with other prophylactic or therapeutic compounds. In some embodiments, the prophylactic or therapeutic compound is an adjuvant. In some embodiments, the prophylactic or therapeutic compound is a booster. As used herein, when referring to a prophylactic composition, such as a vaccine, the term “booster” refers to an extra administration of the prophylactic (vaccine) composition. A booster (or booster vaccine) may be given after an earlier administration of the prophylactic composition. The time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50 or 55 minutes, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 hours, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or 30 days, or about 1, 2, 3, 4, 5, or 6 weeks, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 years. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 1 week. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 2 weeks. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 3 weeks. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 1 month. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 2 months. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 3 months. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 6 months. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster is about 1 year. 
     G. Kits 
     The materials described above as well as other materials can be packaged together in any suitable combination as a kit useful for performing, or aiding in the performance of, the disclosed method. It is useful if the kit components in a given kit are designed and adapted for use together in the disclosed method. For example disclosed are kits comprising any of the elements of the disclosed nucleic acid compositions. For example, disclosed are kits comprising nucleic acid sequences comprising a leader sequence, a linker sequence, a nucleic acid sequence encoding a self-assembling polypeptide, and/or a nucleic acid sequence encoding a viral antigen. In some embodiments, the kits can further comprise a plasmid backbone. 
     Other embodiments are described in the following non-limiting Examples. Various publications, including patents, published applications, technical articles and scholarly articles are cited throughout the specification. Each of these cited publications is incorporated by reference herein in its entirety. 
     EXAMPLES 
     Example 1. Experimental Validation of Prefusion CoV2 Trimers 
     The SARS-CoV-2 prefusion trimers would be tested by size-exclusion chromatography, multi-angle light scattering, ELISA binding to various receptors and anti-CoV2 antibodies, negative-stain EM to determine relative populations of prefusion states, SPR binding to various receptors and anti-CoV2 antibodies, native page western blots and thermal stability in buffer and serum using DSF. Collectively, these measurements will enable us to determine if the SARS-CoV-2 trimers have the relevant design characteristics. The trimers must demonstrate a homogenous, trimeric oligomerization state as determined by SEC-MALS, western blot and negative stain EM. The trimers must also have alterations in frequencies of relevant prefusion conformations as determined by negative stain EM. The trimers must bind to receptors (such as ACE2) or selected anti-CoV2 antibodies as determined by ELISA and SPR. The trimers must have an increase in thermal stability in PBS and serum as determined by DSF. Other equivalent biophysical methods to determine these parameters may be alternatively employed. 
     Size-Exclusion Chromatography and Multi-Angle Light Scattering 
     Expi293F cells will be transfected with a plasmid vector carrying the trimer transgene with PEI/OPTI-MEM and harvested 6 days post-transfection. Transfection supernatant will be first purified with either affinity chromatography using the AKTA pure 25 system and an IMAC Nickel column OR gravity flow columns filled with GNL Lectin beads. The eluate fractions from the affinity purification will be pooled, concentrated and dialyzed into 1×PBS buffer before being loaded onto the SEC column and then purified with size exclusion chromatography, for which the Superdex 200 Increase 10/300 GL column or Superose 6 Increase 10/300 GL column or equivalent will be run at 0.5 mL/min. Identified eluate fractions will then collected and concentrated to 1 mg/mL in PBS. The oligomeric state of the trimers will then be confirmed by size exclusion chromatography-multi-angle light scattering (SECMALS) using the DAWN HELEOS II multi-angle light scattering system with Optilab T-rEX refractometer (Wyatt Technology). 
     ELISA 
     The trimers will be assessed by ELISAs to determine binding against human ACE2 with a detectable tag. Nunc ELISA plates will be coated with 1 μg/ml rabbit anti-His6X in 1× PBS for 4-6 hours at room temperature and washed 4 times with washing buffer (1× PBS and 0.05% Tween 20). Plates will be blocked overnight at 4° C. with blocking buffer (1× PBS, 0.05% Tween 20, 5% evaporated milk and 1% FBS). Plates will be washed four times with washing buffer then incubated with full length (S1+S2) spike protein containing a C-terminal His tag (Sino Biologics, cat. 40589-V08B1) at 10 ug/ml for 1 hour at room temperature. Plates will be washed and then serial dilutions of recombinant human ACE2 with a human Fc tag (ACE2-IgHu) and incubated for 1-2 hours at room temperature. Plates will be again washed and then incubated with 1:10,000 dilution of horseradish peroxidase (HRP) conjugated anti-human IgG secondary antibody (Bethyl, cat. A80-304P) and incubated for 1 hour at room temperature. After final wash plates will be developed using 1-Step Ultra TMB-ELISA Substrate (ThermoFisher, cat. 34029) and the reaction stopped with 1 M Sulfuric Acid. Plates will be read at 450 nm wavelength within 30 minutes using a SpectraMax Plus 384 Microplate Reader (Molecular Devices, Sunnyvale, Calif.). 
     Negative Stain EM of Purified SARS-CoV-2 Trimers 
     The trimers will be produced in Expi293 cells, purified using Agarose bound lectin beads (Agarose  Galanthus Nivalis  Lectin, Vector Laboratories) followed by size exclusion chromatography (GE Healthcare) using the Superose 6 Increase 10/300 GL column. The proteins will be further dialyzed into Tris-buffered saline (TBS). A total of 3 μL of purified proteins was adsorbed onto glow discharged carbon-coated Cu400 EM grids. The grids will be then stained with 3 μL of 2% uranyl acetate, blotted, and stained again with 3 μL of the stain followed by a final blot. Image collection and data processing will be performed on a FEI Tecnai T12 microscope equipped with a Oneview Gatan camera at 90,450× magnification at the camera and a pixel size of 1.66 Å. 
     Surface Plasmon Resonance (SPR) 
     Kinetics and affinities of antibody-antigen interactions will be measured on a Biacore 8K (GE/Cytiva) using CAP (GE/Cytiva) or Protein A (GE/Cytiva) chips and 1× HBS-EP+ pH 7.4 running buffer (20× stock from Teknova, Cat. No H8022) supplemented with BSA at 1 mg/ml. Typically, 100-200 RUs of antigen or antibody will be captured onto each flow cell and analytes will be passed over the flow cell at 50 μL/min for 3 min followed by a 5 min dissociation time. Regeneration is accomplished using 6M Guanidine-HCL in 02.5M NaOH or 10 mM glycine-HCl at pH 1.5 with 180 seconds contact time. Raw sensograms will be analyzed using Biacore evaluation software (GE/Cytiva), including flow cell and blank double referencing, and either Equilibrium fits or Kinetic fits with Langmuir model, or both, will be employed when applicable. Analyte concentrations will be measured on a NanoDrop 2000c Spectrophotometer using Absorption signal at 280 nm. 
     Differential Scanning Fluorimetry 
     The assay will employ a real-time PCR instrument to monitor changes in fluorescence of SYPRO Orange (or similar dye) and to determine melting temperatures. At least three temperature gradient scans will be run from room temperature to 120C at rate of 1-2C/min. Signals are normalized from 0 to 100. The SYPRO orange dye and the trimers added at appropriate concentration (2×-10× range and 100-1000 ug/ml, respectively) to optimize the experimental conditions. SYPRO orange has an excitation maximum near 500 nm and emission maximum near 600 nm. The real time system channel will be selected to optimize excitation and emission of SPYRO orange. 
     Western Blot 
     Proteins will be separated on a 4-12% BIS-TRIS gel (ThermoFisher Scientific), then following transfer, blots will be incubated with ACE2 or an anti-SARS-CoV spike protein polyclonal antibody (Novus Biologicals) then visualized with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (GE Amersham). 
     Immunofluorescence of Transfected 293T Cells 
     For in vitro staining of trimer protein expression 293T cells will be cultured on 4-well glass slides (Lab-Tek) and transfected with 3 μg per well of pDNA using TurboFectin8.0 (OriGene) transfection reagent following the manufacturer&#39;s protocol. Cells will be fixed 48 hrs after transfection with 10% Neutral-buffered Formalin (BBC Biochemical, Wash. State) for 10 min at room temperature (RT) and then washed with PBS. Before staining, chamber slides will be blocked with 0.3% (v/v) Triton-X (Sigma), 2% (v/v) donkey serum in PBS for 1 hr at RT. Cells will be stained with a rabbit anti-SARS-CoV spike protein polyclonal antibody (Novus Biologicals) diluted in 1% (w/v) BSA (Sigma), 2% (v/v) donkey serum, 0.3% (v/v) Triton-X (Sigma) and 0.025% (v/v) 1 g ml −1  Sodium Azide (Sigma) in PBS for 2 hrs at RT. Slides will be washed three times for 5 min in PBS and then stained with donkey anti-rabbit IgG AF488 (lifetechnologies) for 1 hr at RT. Slides will be washed again and mounted and covered with DAPI-Fluoromount (SouthernBiotech). 
     Example 2. Vaccine Delivery Systems 
     Recombinant Protein Vaccines 
     The SARS-CoV-2 Spike trimers described herein are amenable to delivery as a recombinant subunit vaccine. The trimers can be encoded into mammalian expression plasmids, such as pHLSEC. These plasmids can be employed to expressed and purified recombinant vaccines as described in this document. The recombinant proteins can be easily formulated with any number of adjuvant systems (such as aluminum phosphate) to enhance immunity. 
     DNA Plasmid Vaccines 
     The SARS-CoV-2 Spike trimers described herein are amenable to delivery as a transgene in a DNA plasmid (such as Inovio Pharmaceutical&#39;s synDNA platform). DNA vaccines are non-infectious and have a long record of safety in humans. DNA vaccines can induce high seroconversion rates in people. DNA vaccines can induce both B and T cell immunities. DNA plasmids can be formulated with adjuvating material to improve take-up, immune trafficking and resulting immune responses. 
     RNA Vaccines 
     The SARS-CoV-2 Spike trimers described herein are amenable to delivery as a transgene in an RNA vaccine (such as Moderna&#39;s mRNA platform). RNA vaccines are non-infectious, non-integrating and are naturally degrading. RNA vaccines have been shown to stimulate strong B cell responses to encoded transgenes. Naked RNA can be formulated with lipid nanoparticles (LNPs) to encapsulate RNA protecting the transgene from degradation. 
     Self-Replicating RNA Vaccines 
     The SARS-CoV-2 Spike trimers described herein are amenable to delivery as a transgene in a self-replicating RNA vaccine formulated as DNA. RNA replicons can be delivered by a DNA or mRNA to self-amplify resulting in higher transgene expression. 
     Adeno-Associated Virus Vaccines: 
     Modified versions of the SARS-CoV-2 Spike trimers described herein (such as ones which are capable of cell fusion by removal of key mutations impacting this function) are amenable to delivery as a transgene in AAV (or similar vector). AAV can be employed to obtain high expression of vaccine antigens in vivo. Numerous AAV variants exist to help target specific cell types and each can be explored with a SARS-CoV-2 Spike trimer. 
     REFERENCES 
     
         
         [1] L. C. Lambert, A. S. Fauci, N Engl J Med 2010, 363, 2036. 
         [2] Y. Gao, P. F. McKay, J. F. S. Mann, Viruses 2018, 10. 
         [3] S. Plotkin, Proc Natl Acad Sci USA 2014, 111, 12283. 
         [4] C. L. Trimble, M. P. Morrow, K. A. Kraynyak, et al., Lancet 2015, 386, 2078. 
         [5] A. E. Gregory, R. Titball, D. Williamson, Front Cell Infect Microbiol 2013, 3, 13. 
         [6] L. Zhao, A. Seth, N. Wibowo, et al., Vaccine 2014, 32, 327. 
         [7] S. Al-Halifa, L. Gauthier, D. Arpin, et al., Front Immunol 2019, 10, 22. 
         [8] W. Szmuness, C. E. Stevens, E. J. Harley, et al., N Engl J Med 1980, 303, 833. 
         [9] D. M. Harper, L. R. DeMars, Gynecol Oncol 2017, 146, 196. 
         [10] J. W. Stone, N. J. Thornburg, D. L. Blum, et al., Nanotechnology 2013, 24, 295102. 
         [11] K. Cheng, K. El-Boubbou, C. C. Landry, ACS Appl Mater Interfaces 2012, 4, 235. 
         [12] A. K. Giddam, M. Zaman, et al., Nanomedicine (Lond) 2012, 7, 1877. 
         [13] J. Fuenmayor, F. Godia, L. Cervera, N Biotechnol 2017, 39, 174. 
         [14] S. A. Kaba, C. P. Karch, L. Seth, K. M. B. Ferlez, et al., Vaccine 2018, 36, 906. 
         [15] Z. Xu, D. W. Kulp, Curr Opin Immunol 2019, 59, 49. 
         [16] J. Marcandalli, B. Fiala, S. Ols, M. Perotti, et al., Cell 2019, 176, 1420. 
         [17] K. Sliepen, G. Ozorowski, J. A. Burger, et al., Retrovirology 2015, 12, 82. 
         [18] S. Chattopadhyay, J. Y. Chen, H. W. Chen, C. J. Hu, Nanotheranostics 2017, 1, 244. 
         [19] N. Desai, AAPS J 2012, 14, 282. 
         [20] J. Feng, et al., Journal of Translational Medicine 2019, 17, 200. 
         [21] L. H. Lua, N. K. Connors, F. Sainsbury, et al., Biotechnol Bioeng 2014, 111, 425. 
         [22] A. Urakami, M. M. Ngwe Tim, M. L. Moi, et al., J Virol 2017, 91. 
         [23] Z. Jiang, G. Tong, B. Cai, Y. Xu, J. Lou, Protein Expr Purif 2011, 80, 203. 
         [24] A. C. Eifler, C. S. Thaxton, Methods Mol Biol 2011, 726, 325. 
         [25] B. S. Graham, M. S. A. Gilman, J. S. McLellan, Annu Rev Med 2019, 70, 91. 
         [26] T. Tokatlian, B. J. Read, C. A. Jones, et al., Science 2019, 363, 649. 
         [27] J. G. Jardine, T. Ota, D. Sok, M. Pauthner, et al., Science 2015, 349, 156. 
         [28] D. Sok, B. Briney, J. G. Jardine, D. W. Kulp, et al., Science 2016, 353, 1557. 
         [29] J. G. Jardine, D. W. Kulp, C. Havenar-Daughton, et al., Science 2016, 351, 1458. 
         [30] K. A. Dowd, S. Y. Ko, K. M. Morabito, et al., Science 2016, 354, 237. 
         [31] B. S. Davis, G. J. Chang, B. Cropp, J. T. Roehrig, et al., J Virol 2001, 75, 4040. 
         [32] B. Wang, K. E. Ugen, et al., Proc Natl Acad Sci USA 1993, 90, 4156. 
         [33] N. Y. Sardesai, D. B. Weiner, Curr Opin Immunol 2011, 23, 421. 
         [34] Z. Xu, M. C. Wise, H. Choi, A. Perales-Puchalt, et al., EBioMedicine 2018, 35, 97. 
         [35] M. Khoshnejad, A. Patel, K. Wojtak, et al., Mol Ther 2019, 27, 188. 
         [36] M. C. Wise, Z. Xu, E. Tello-Ruiz, C. Beck, et al., J Clin Invest 2019. 
         [37] P. Tebas, C. C. Roberts, K. Muthumani, E. L. Reuschel, et al., N Engl J Med 2017. 
         [38] P. Tebas, K. A. Kraynyak, A. Patel, J. N. Maslow, et al., J Infect Dis 2019. 
         [39] S. A. Kalams, S. D. Parker, M. Elizaga, B. Metch, et al., J Infect Dis 2013, 208, 818. 
         [40] K. Modjarrad, C. C. Roberts, K. T. Mills, et al., Lancet Infect Dis 2019. 
         [41] F. Brod, K. Miura, I. Taylor, Y. Li, A. Marini, et al., Front Immunol 2018, 9, 2780. 
         [42] K. Tomusange, D. Wijesundara, J. Gummow, et al., Sci Rep 2016, 6, 29131. 
         [43] P. Abbink, R. A. Larocca, R. A. De La Barrera, C. A. Bricault, E. T. Moseley, M. Boyd, M. Kirilova, Z. Li, D. Ng&#39;ang&#39;a, O. Nanayakkara, et al., Science 2016, 353, 1129. 
         [44] C. Bohannon, R. Powers, L. Satyabhama, et al., Nat Commun 2016, 7, 11826. 
         [45] B. Selander, U. Martensson, A. Weintraub, et al., J Clin Invest 2006, 116, 1425. 
         [46] A. Benoit, J. Beran, J. M. Devaster, et al., Open Forum Infect Dis 2015, 2, ofv067. 
         [47] M. Kanekiyo, M. G. Joyce, R. A. Gillespie, et al., Nat Immunol 2019, 20, 362. 
         [48] M. A. Kutzler, D. B. Weiner, Nat Rev Genet 2008, 9, 776. 
         [49] S. Lu, S. Wang, J. M. Grimes-Serrano, Expert Rev Vaccines 2008, 7, 175. 
         [50] D. Hobernik, M. Bros, Int J Mol Sci 2018, 19. 
         [51] M. Kanekiyo, C. J. Wei, H. M. Yassine, et al., Nature 2013, 499, 102. 
         [52] R. B. Zinyama-Gutsire, C. Chasela, et al., PLoS One 2015, 10, e0122659. 
         [53] M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, et al., J Exp Med 2004, 199, 1391. 
         [54] N. Zhang, M. J. Bevan, Immunity 2011, 35, 161. 
         [55] N. Van Braeckel-Budimir, J. T. Harty, Front Microbiol 2014, 5, 272. 
         [56] E. J. Grant, S. M. Quinones-Parra, et al., Curr Opin Virol 2016, 16, 132. 
         [57] M. Koutsakos, P. T. Illing, T. H. O. Nguyen, et al., Nat Immunol 2019, 20, 613. 
         [58] A. Durgeau, Y. Virk, S. Corgnac, F. Mami-Chouaib, Front Immunol 2018, 9, 14. 
         [59] S. Sasaki, R. R. Amara, A. E. Oran, et al., Nat Biotechnol 2001, 19, 543. 
         [60] M. A. Chattergoon, J. J. Kim, J. S. Yang, et al., Nat Biotechnol 2000, 18, 974. 
         [61] M. A. Chattergoon, T. M. Robinson, et al., J Immunol 1998, 160, 5707. 
         [62] O. Akbari, N. Panjwani, S. Garcia, R. Tascon, et al., J Exp Med 1999, 189, 169. 
         [63] J. Yan, M. P. Morrow, J. S. Chu, T. Racine, et al., Vaccine 2018, 36, 3079. 
         [64] P. M. Patel, C. H. Ottensmeier, et al., Oncoimmunology 2018, 7, e1433516. 
         [65] J. W. Labonte, J. Adolf-Bryfogle, et al., J Comput Chem 2017, 38, 276. 
         [66] D. W. Kulp, S. Subramaniam, J. E. Donald, et al., J Comput Chem 2012, 33, 1645. 
         [67] B. Briney, D. Sok, J. G. Jardine, D. W. Kulp, et al., Cell 2016, 166, 1459. 
         [68] E. K. Duperret, M. C. Wise, A. Trautz, et al., Mol Ther 2018, 26, 435. 
         [69] Torrents de la Pena A, et al. Cell Rep. 2017; 20(8):1805-17. 
         [70] Sanders R W, Moore J P. Immunol Rev. 2017; 275(1):161-82. 
         [71] Medina-Ramirez, M, et al., Journal of experimental medicine. 2017; 214(9):2573-90. 
         [72] F. Li, Annu. Rev. Virol., 2016, 3, 237-261. 
         [73] B. J. Bosch, R. van der Zee, et al., J. Virol., 2003, 77, 8801-8811. 
         [74] A. C. Walls, et al., Proc. Natl. Acad. Sci. U.S.A., 2017, 114, 11157-111629. 
         [75] M. Gui, et al., Cell Res., 2017, 27, 119-129. 
         [76] J. Pallesen, et al., Proc. Natl. Acad. Sci. U.S.A., 2017, 114, E7348-E7357. 
         [77] A. C. Walls, et al., Cell, 2019, 176, 1026-1039.e15. 
         [78] Y. Yuan et al., Nat. Commun., 2017, 8, 15092.